Annual Meeting

Transcription

Annual Meeting

EBMT 2014
40th Anniversary Edition of the
EBMT Annual Meeting
40th Annual Meeting of the European Society
for Blood and Marrow Transplantation
40th Meeting of the Physicians
30th Meeting of the Nurses Group
13th Meeting of the Data Management Group
6th Meeting of the Quality Management Group
3rd Cell Therapy Day
3rd Paediatric Day
8th Patient, Family & Donor Day - Sat 29 March
30 March - 2 April 2014 Milan, Italy
Congress
Overview
Content
Table of Content
Sponsors Supporting The EBMT Meeting.. . . . . .
Corporate Sponsors Supporting EBMT . . . . . . . .
Welcome Address. . . . . . . . . . . . . . . . . . .
8th EBMT Patient, Family & Donor Day Programme.
........................
........................
........................
........................
4
5
6
7
Programme Overview
......................................... 9
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
Organising Committee EBMT 2014. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
Contact Addresses EBMT 2014. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
Satellite Symposia - Sunday, 30 March 2014. . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
Opening Session - Sunday, 30 March 2014. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
Saturday - 29 March 2014.
Sunday - 30 March 2014. .
Monday - 31 March 2014. .
Tuesday - 1 April 2014. . .
Wednesday - 2 April 2014.
Scientific Programme: Physicians
3rd EBMT Cell Therapy Day - Monday, 31 March 2014. . . . .
Scientific Programme Physicians - Monday, 31 March 2014..
3rd Paediatric Day - Tuesday, 1 April 2014.. . . . . . . . . .
Scientific Programme Physicians - Tuesday, 1 April 2014. . .
Scientific Programme Physicians - Wednesday, 2 April 2014.
Posters: Physicians
Monday - 31 March 2014.
Tuesday - 1 April 2014.. .
...................
...................
...................
...................
...................
36
38
55
56
70
.....................................
.....................................
83
126
Scientific Programme: Nurses Group
Nurses Education Day - Sunday, 30 March 2014.. . . . . . . . .
Scientific Programme Nurses Group - Monday, 31 March 2014. .
Scientific Programme Nurses Group - Tuesday, April 1 2014. . .
Scientific Programme Nurses Group - Wednesday, 2 April 2014. .
Posters: Nurses Group
Monday, 31 March & Tuesday, 1 April 2014.
.................
.................
.................
.................
163
164
169
172
............................
174
Scientific Programme: Quality Management Group
Tuesday - 1 April 2014..
......................................
...............................
Posters: Quality Management Group.
Scientific Programme: Data Management Group
..................
..................
..................
Posters: Data Management. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Statistical Course - Saturday, 29 March & Sunday, 30 March 2014.
Data Management - Monday, 31 March 2014.. . . . . . . . . . . .
Data Management - Tuesday, 1 April 2014. . . . . . . . . . . . . .
General Information
General Information. . . . . . . . . .
Instructions For Speakers & Authors.
Networking Events. . . . . . . . . .
Registration Information. . . . . . .
Floor Plan. . . . . . . . . . . . . . .
...............................
...............................
...............................
...............................
...............................
Exhibition Floor Plan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Exhibitors And Sponsors. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
182
184
185
185
186
187
188
188
189
188
191
196
197
3
Sponsors
SPONSORS SUPPORTING THE EBMT MEETING
The organisers of the EBMT 2014 express their thanks and
appreciation to all those who are generously contributing to the
success of this meeting.
AABB Center for Cellular Therapies
Histogenics
Abbott Molecular
ICCBBA
ADIENNE Pharma & Biotech
Immudex
AIRINSPACE
International Myeloma Workshop
Alexion Pharma International
ITALFARMACO SpA.
AMGEN (EUROPE) GmbH
JANSSEN-CILAG SpA.
American Society for Blood and
Marrow Transplantation (ASBMT)
Kaneka Corporation
ASTELLAS PHARMA EUROPE LTD
Best Theratronics
Bioquell
BioRep Srl
Biosafe SA
Biotype Diagnostic GmbH
Celgene International
Cell Medica
CellGenix GmbH
Cesca Therapeutics, Inc.
CONSARTIC® GmbH
CTI Life Sciences
Eurocet128
European School of Haematology
Exem Consulting SA
4
Kiadis Pharma
Lophius Biosciences GmbH
MACOPHARMA
MAK-SYSTEM
MARCELL
medac GmbH
Miltenyi Biotec GmbH
MSD
MVE Chart
Neovii Biotech GmbH
Ontime Onboard Courier
OriGen Biomedical
PIERRE FABRE MÉDICAMENT
Remedy Informatics
Sanofi
Exprit Srl
Sanofi Oncology
French Society of Bone Marrow
Transplantation and Cell Therapies
(SFGM-TC)
SIAD Healthcare Spa
Fresenius Kabi Deutschland GmbH
Terumo BCT
GAM Farma
Teva Pharmaceuticals Europe B.V.
GE Healthcare
Therakos
Gentium
Gilead Sciences
Università Politecnica delle Marche
- Italy
HEMASOFT
Wisepress Medical Bookshop
Takeda Pharmaceutical International
GmbH
Congress
Overview
Sponsors
CORPORATE SPONSORS SUPPORTING EBMT
The EBMT would like to thanks its Corporate Sponsors for their
ongoing generous support:
Platinum
Gold
Silver
Bronze
5
Welcome Address
WELCOME ADDRESS
Dear friends,
On behalf of the EBMT and of the Local Organizing Committee, it is our pleasure to welcome you to
the 40th Annual Meeting of the EBMT, the 30th Meeting of the EBMT Nurses Group, the 13th Meeting of the EBMT Data Management Group, the 6th Meeting of the Quality Management Group, the
8th EBMT Patient & Family and the 1st Donor Day. This anniversary will be celebrated in Milan at the
same time as the Annual EBMT Meeting. The whole organisation is determined to make this historical
milestone a high-profile and unforgettable event.
EBMT has grown considerably in the last few years, and last year in London we celebrated the millionth transplant. EBMT has been a driving force of the biomedical and clinical history of hematopoietic
stem cell transplantation, and we are proud to be part of this history.
This anniversary is not only celebration. Looking forward to the next years, we are confronted with
new and exciting challenges such as new genome technologies, integration of targeted therapies into
transplant strategy, the emerging role of cell therapies, the choice of donor. These and many other
scientific issues will be included in the Scientific Programme that will integrate top-level science, high
technology, and clinical excellence; we also want to be close to the clinical needs of Centres. The EBMT
Nurses Group will celebrate its 30th anniversary with a program that will focus on the latest developments in patient care. Most of all, we consider transplant not as a stand-alone procedure, but as a
part of a complex therapeutic program, that needs contribution from different specialists and different
professional expertise. In this regard, EBMT is a unique society, in that it includes physicians, nurses,
allied health professionals, data managers, quality managers and now processing laboratory personnel. Several initiatives are planned to bring together nurses, physicians and other healthcare professionals who share the complex care of the transplant patient.
A peculiarity of 2014 program will be a new session format called “Cooperative Trials in Progress”,
in which national and international cooperative groups focused on a specific disease will present their
studies in progress, and will share their preliminary results. The Scientific Program this year will continue to offer, along with the main program, the second Paediatric Day, and a day dedicated to the various aspects of cell processing and therapy, organised in cooperation with ISCT (International Society
for Cellular Therapy). This year its name will change from “Cell Processing Day” to “Cell Therapy Day”.
Changing the name from “Processing” to “Therapy” implies a focus on clinical results of cell and gene
therapy, without disregarding procedures and regulatory issues. The target audience will be clinicians,
biologists involved in cell manipulation and processing, and basic scientists.
The 8th Patient and Family Day will take place as usual on the Saturday, March 29, 2014. This year we
would like to formally include donors as association and as single volunteers into the organization: its
name will change to “Patient, Family, and Donor Day”. The Italian Marrow Donor Association (ADMO)
will be involved, as well as patient and volunteer organizations.
We are happy to offer the opportunity to visit Milano to EBMT members. Milano is a cultural, economic, fashion European capital: it will host the meeting with its sophisticated atmosphere. The Milano
Convention Centre (MiCo) is the largest convention centre in Italy: it is located in the very heart of Milan
(5 min from Da Vinci’s Last Supper), surrounded by 2,000 hotel rooms within 1 km area, and easily
reachable from the three international airports.
Welcome to EBMT 2014 in Milan!
Marco Bregni, M.D.
Congress President
6
Paolo Corradini, M.D.
Scientific Chair
Aleksandra Babic, R.N.
Local Nurse
Congress
Overview
Patient, Family & Donor
8th EBMT Patient, Family & Donor Day Programme
Aula Magna, Università degli Studi di Milano - SATURDAY, 29 MARCH 2014
09:30 - 10:00 Welcome to the 8th Patient, Family and Donor Day
Chairs: Aleksandra Babic (Italy) & Marco Bregni (Italy)
Elisabeth Wallhult (Sweden)
Alejandro Madrigal (United Kingdom)
10:00 - 11:00 Plenary Session I: Donor issues - Safety, ethical and legal dilemmas
Chair: Alessandro Rambaldi (Italy)
JP Halter (Switzerland)
Annalisa Ruggeri (France)
Alessandro Nanni Costa (Italy)
Emanuela Imbrescia (Italy)
11:00 - 11:45 Plenary Session II: Transplant Issues in Thalassemia
Chair: Guido Lucarelli (Italy)
Giovanni Caocci (Italy)
Sarah Marktel
Guido Lucarelli (Italy)
11:45 - 13:00 Plenary Session III: Quality of Life After Transplant
Chair: Francesco Onida (Italy)
Clara Soliman (Italy)
11:55 - 12:15 Psychological problems after transplantation
Serena Giuliani (Italy)
12:15 - 12:35 Physician perspective
Rafael Duarte (Spain)
12:35 - 12:55 Nurse Perspective
Diana Greenfield (United Kingdom)
12:55 - 13:00 Pt’s experience: “Journey through Life and Music”
Manrico Mologni (Italy)
14:00 - 15:00 Round tables for specific disease oriented issues (ENG/ITA):
Autoimmune diseases
Chair: Riccardo Sacca rdi (Italy)
Marina Banfi (Italy)
GL Mancardi (Italy)
Nicoletta Del Papa (Italy)
Leukemia& MDS
Chair: Theo de Witte (Netherlands)
Michel van Gelder (Netherlands)
Ghulam Mufti (United Kingdom)
7
Patient, Family & Donor
8th EBMT Patient, Family & Donor Day Programme
Lymphoma & Multiple Myeloma
Chair: Laurent Garderet (France)
Massimiliano Vicini (Italy)
Laurent Garderet (France)
Stefan Schönland (Germany)
Paediatric Issues
Chair: Andrea Biondi (Italy)
Frederica Buzzi (Italy)
Attilio Rovelli (Italy)
Momcilo Jankovic (Italy)
15:00 - 16:00 Plenary Session IV Round table: Patient’s Associations. Patient
support and information; caregiver support
Chair: Franco Mandelli (Italy)
Michele Cevenini (Italy)
Franco Mandelli (Italy)
Franco Chianelli (Italy)
Francesco Onida (Italy)
16:30 - 17:00 Plenary Session V: Donor Associations, International Donor
Registries and Donor Centres
Chairs: Nicoletta Sacchi (Italy) & Anthony Nolan (Denmark)
17:00 - 17:15 Presentation of the DVD movie: Lulla’s Journey
Aleksandra Babic (Italy)
17:15 - 17:30 Closing remarks
Francesco Onida (Italy)
SUPPORTERS OF THE 8TH EBMT PATIENT, FAMILY & DONOR DAY
ADISCO
ADMO
Anthony Nolan
Sanofi
DMKS
Beat Leukemia
Pierre Fabre
Therakos
Comitato Maria Letizia Verga
Osteria Giulio Pane e Ojo
Associazione Italiana contro Leucemie-Linfomi e Mieloma (AIL)
Associazione Davide Soligo Onlus
Associazione Laura Coviello Onlus (ALC)
Associazione Malattie del Sangue Onlus
Associazione Italiana Lotta alla Sclerodermia Onlus (AILS)
Associazione Amici di Sabrina Fadini Onlus (ASFO)
8
Congress
Overview
Overview
PROGRAMME OVERVIEW - SATURDAY, 29 MARCH 2014
09:00
Suite 5 - Level M
Aula Magna, Università degli Studi di Milano
09:30
10:00
10:30
11:00
11:30
12:00
12:30
13:00
13:30
8TH EBMT PATIENT,
FAMILY & DONOR DAY
14:00
09:30 - 17:30
14:30
15:00
15:30
16:00
16:30
17:00
Statistical Course
15.00 - 18.00
17:30
18:00
18:30
19:00
19:30
20:00
9
Overview
PROGRAMME OVERVIEW - SUNDAY, 30 MARCH 2014
Gold Plenary
Level 2
Space 1
Level 0
Space 2
Level 0
Space 3
Level 0
Space 4
Level 0
09:00
SFGM-TC
Spotlight
Session
MSD
Satellite
Symposium
09:00 - 10:30
09:00 - 10:30
09:30
10:00
10:30
11:00
CTI
LIFESCIENCES
Satellite
Symposium
11:00 - 12:30
11:30
MEDAC
Satellite
Symposium
SANOFI
Satellite
Symposium
12:00
11:00 - 13:00
11:00 - 13:00
12:30
13:00
13:30
Gilead
Satellite
Symposium
SANOFI
Satellite
Symposium
13:30 - 15:30
13:30 - 15:30
14:00
14:30
15:00
15:30
16:00
PIERRE
FABRE
Satellite
Symposium
16:00 - 17:30
AMGEN
Satellite
Symposium
16:00 - 18:00
NEOVII
BIOTECH
Satellite
Symposium
16:00 - 18:00
16:30
KIADIS
Satellite
Symposium
17:00
16:00 - 18:00
17:30
18:00
18:30
Opening Session
19:00
18:30 - 20:00
19:30
20:00
10
Congress
Overview
Overview
PROGRAMME OVERVIEW - SUNDAY, 30 MARCH 2014
Brown 3
Level 2
Brown 1+2
Level 2
Amber 3+4
Level 2
Coffee & Registration
IFM-IUC
Spotlight Session
Suite 5
Level M
09:00
09:30
10:00
09:00 - 10:30
Statistical Course
10:30
09:00 - 12:00
11:00
Nurses
Education Day
11:30
09:30 - 17:00
12:00
12:30
13:00
Lunch
13:30
14:00
14:30
15:00
MILTENYI
BIOTEC Satellite
Symposium
13:30 - 15:30
Nurses
Education Day
cell medica
Satellite Symposium
Continued
13:30 - 15:30
15:30
Break
16:00
16:30
17:00
ASTELLAS
Satellite
Symposium
17:30
16:00 - 18:00
Nurses
Education Day
Continued
Takeda
Satellite Symposium
16:00 - 17:30
18:00
18:30
19:00
19:30
20:00
11
Overview
PROGRAMME OVERVIEW – MONDAY, 31 MARCH 2014
Gold Plenary
Level 2
Space 1+2
Level 0
Space 3
Level 0
Space 4
Level 0
Brown 3
Level 0
08:00
Educational 1
Immunogenics
in allogenic HCT:
Practical guidelines
for clinicians
08.00-09.30
NG
Workshop 3
Opening Session/
Keynote Lecture
Regenerative
Medicine
08.00-09.30
08.00-09.30
Educational 3
Conditioning
regimens for
aplastic anemia
08.00-09.30
08:30
09:00
09:30
NG
Presidential
Symposium
Quality of Life
09.45-11.00
09.45-11.15
10:00
Technology
Workshop /
Cell collection
and Processing
10:30
09.45-11.15
11:00
11:30
Working Party
Acute Leukemia
11.30-13.00
GENTIUM
Satellite
Symposia
Working Party
11.30-13.00
11.30-13.00
Lymphoma
Workshop 5
NG
Practical aspects in
cell therapy
GvHD
11.30-13.00
11.30-12.45
12:00
12:30
13:00
Lunch Controversy
SPECIAL LECTURE
Auto or allo in PTCL
13.10-14.00
Oral Session 1
Acute Leukemia/
MDS
14 :00 – 15 :30
13.10-14.00
Oral Session 2
Donor Issues
14 :00 – 15 :30
NG
Palliative Care
14.00-15.15
Oral Session 3
Cell & Gene
Therapy 1
14 :00 – 15 :30
Lunch Controversy
Treatment of RAEB
before transplant
13.10-14.00
Oral Session 4
Late Effects 1
14 :00 – 15 :30
13:30
14:00
14:30
15:00
15:30
16:00
Working Party
Workshop 6
Chronic
Malignancies
Cell Therapy
for GVHD
16.00-17.30
16.00-17.30
Oral Session 14
Paediatric Diseases 1
16:00 - 17:00
16:30
17:00
17:30
12
Congress
Overview
Overview
Brown 1
Level 2
Brown 2
Level 2
Amber 1+2
Level 2
Amber 3+4
Level 2
Workshop 1
Workshop 2
Education 2
Cooperative trials in
progress: adult ALL
Role of transplantation in
Myelofibrosis
08:00
08:30
09:00
08.00-9.30
08.00-09.30
Acute GVHD
08.00-09.30
09:30
10:00
10:30
NG
NG
Paediatric issues
Disease Update
09.45-11.00
09.45-11.00
11:00
11:30
12:00
12:30
Working Party
NG
Aplastic Anaemia
Make easy
11.30-13.00
11.30-13:00
Basic Science I
NG
Genomics application
and perspectives in
Hematology
Research Committee
11.30-12.45
11.30-13.00
13:00
13:30
Lunch Controversy
WMDA
Supported by Celgene
Lunch Controversy
13.10-14.00
13.00-14.00
13.10-14.00
NG
Oral Session 6
Oral Session 7
GVHD 1
Management Challenges
Infectious
Complications 1
14 :00 – 15 :30
14.00-15.30
Tolerance, Chimerism &
Immune Reconstitution
14 :00 – 15 :30
14 :00 – 15 :30
14:00
14:30
15:00
Oral Session 5
15:30
16:00
16:30
17:00
NG
NG
Working Party
CVAD
Symptom Management
Immunobiology
16.00-17.30
16.00-17.30
16.00-17.30
17:30
13
Overview
Amber 5
Level 2
Amber 6
Level 2
Amber 7
Level 2
Amber 8
Level 2
08:00
08:30
09:00
09:30
Data Management
Educational Session
NG
09.00 - 11.10
Oral Session 1
09.45-11.00
10:00
10:30
11:00
11:30
Nature
Publishing Group
11.30-13.00
Data Management
Workshop 4
Educational Session
Photoapheresis: for
selected pts only?
11.40 - 13.00
11.30-13.00
NG
12:00
Oral Session 2
11.30-13.00
12:30
13:00
Transplant
Immunology
13:30
13.10-14.00
14:00
Oral Session 9
Data Management
NG
Chronic Leukemia
Educational Session
14.00 - 15.25
14.00 - 15.25
Alternative
care environment
14.00-15.30
NG
14:30
Oral Session 3
14.00-15.30
15:00
15:30
16:00
NG
Data Management
Infection
Educational Session
NG
16.00-17.30
16.00 - 17.00
Oral Session 4
16.00-17.30
16:30
17:00
17:30
14
Congress
Overview
Overview
Suite 1+3
Level 2
Suite 4
Level 2
Suite 5
Level M
Suite 7, 8, 9
Level M
09:00
09:30
10:00
10:30
11:00
11:30
12:00
12:30
Data Management
EBMT Registry Database
13:00
Data Entry Training
Sessions
09.00 - 17.00
13:30
14:00
14:30
Oral Session 16
Regenerative Medicine
15:00
14.00 - 15.25
15:30
16:00
16:30
17:00
17:30
18:00
Nurses National Group Meetings
17:30 – 18:30
18:30
15
Overview
PROGRAMME OVERVIEW – TUESDAY, 1 APRIL 2014
Gold Plenary
Level 2
Space 1+2
Level 0
Space 3
Level 0
Educational 7
Educational 5
Chronic
Lymphocytic
Leukemia
Treatment of viral
infections in
children after
allo-HSCT
Cellular therapies
for severe
autoimmune
diseases
08.00-09.30
08.00-09.30
08.00-09.30
Space 4
Level 0
Brown 3
Level 2
08:00
Educational 4
Educational 6
Allogenic SCT in
AML
08.00-09.30
08:30
09:00
09:30
Plenary 1
Regulatory Aspects
in Stem Cell Transplantation & cellular
therapy: Between
Science & Ethics
Workshop 9
Plenary 2
Joint Session
Childhood GVHD
Cooperative Trials
in Progress: Mantle
Cell Lymphoma,
PTCL, CNS
Lymphoma
Nurses &
Physicians
09.30 - 11:00
09:45 - 11:15
09:00 - 11:00
Plenary 3
Safety and
Effectiveness of
Gene Therapy
09:45 - 11:15
09.45 - 11:15
10:00
10:30
11:00
11:30
Working Party
Infectious Diseases
11.30-13.00
Lunch Controversy
Role of ATG in
HLA-id sibling
transplants
13:10 - 140:00
Plenary 4
Joint Session with
Nurses Holistic Care
in Transplant
14.00-15.30
Workshop 11
Immunotherapy
of Childhood
Malignancies
11.30-13.00
Joint Session
with Nurses
Working Party
NG Patient
Autoimmune
Disease
Information &
“Patients Needs”
11.30-13.00
11.30-13.00
11.30-13.00
NG SYMPOSIUM
Basic Science
Session II
Lunch Controversy
Which children with
AML should be given
allo-HSCT in first CR
13:10-14:00
GENTIUM
13:00 - 14:00
Chronic GVHD
Inducible Pluripotent Stem Cells
Plenary 6
Plenary 5
Paediatrics &
Inborn Errors
Cord Blood
Transplantation
Infectious Diseases
14.00-15.30
14.00-15.30
Working Party
14.00-15.30
12:00
12:30
13:00
13:30
14:00
14:30
15:00
15:30
16:00
GENERAL
ASSEMBLY
16:30
15:45 - 16:45
16
Oral Session 11
Oral Session 13
Oral Session 10
Stem Cell
Mobilization &
Graft Engineering
Quality of Life &
Quality of Care
Hematopoietic
Tem Cells
16:45 – 17:45
16:45 – 17:45
16:45 – 17:45
17:00
17:30
Congress
Overview
Overview
Brown 1
Level 2
Brown 2
Level 2
Amber 1+2
Level 2
Amber 3+4
Level 2
08:00
Workshop 7
08:30
Unmanipulated HLA
haploidentical SCT
transplants
09:00
08.00-09.30
09:30
QUALITY MANAGEMENT
10:00
Interactive Workshop
(ROUND TABLES)
09.00-11.00
10:30
Workshop 8
Manipulated HLA
Haploididentical SCT
trnsplants
09:45 - 11:15
11:00
Joint Session
EBMT/WBMT
09:45 - 11:15
11:30
12:00
Workshop 10
Working Party
Transplantation in
Thalassemia
Solid Tumors
12:30
11.30-13.00
11.30-13.00
13:00
NAC Scientific
Lunch Controversy
13:30
14:00
Supported by SANOFI
13:00 - 14:00
13:10 - 14:00
Statistical
Symposium
14:30
15:00
Protection from Radiation in Major Radiation
Incidents
13.10 - 15.30
NG
Results in the
AHCTA Surveys
11:30 - 13:00
Making sense of...
15:30
JACIE Session
NG
Care of the carer
11.30-13:00
Lunch
Controversy Autografting
is the standard first line
treatment in all MCL
patients?
13:10 - 14:00
Working Party
Transplant Complications
14.00-15.30
14.15-15.45
16:00
16:30
17:00
17:30
Oral Session 15
Aplastic Anemia &
Autoimmune disease
16:45 – 17:45
Oral Session 8
Oral Session 12
Inborn errors
Cell & Gene Therapy 2
16:45 – 17:45
16:45 – 17:45
17
Overview
Amber 5
Level 2
Amber 6
Level 2
Amber 7
Level 2
Amber 8
Level 2
08:00
JACIE
Educational Session
08.00-09.00
08:30
09:00
09:30
NG
Disease update
09.30-11.00
Data Management
Educational Session
09.00 - 11.10
10:00
NG
Apheresis
10:30
09.30-11.00
11:00
11:30
NG
Data Management
NG
JACIE
Oral Session 5
Educational Session
Adolescent
Session
11.30-13.00
11.30 - 12.55
11.30-12.55
11.30-13.00
12:00
12:30
13:00
JACIE
Lunch Controversy
13.10-14.00
13:30
14:00
JACIE
Data Management
Solutions
NG
Educational Session
NG
Oral Session 6
14.00 - 15.25
New therapies
14.15-15.45
14.00-15.00
14:30
15:00
14.15-15.45
JACIE
Solutions
Data Management
15.20-16.20
16:00
16:30
Educational Session
16.00 - 17.00
15:30
Oral Sessions
16.30-17.30
17:00
17:30
18
Congress
Overview
Overview
Suite 1
Level 2
Suite 3+4
Level 2
Suite 5
Level M
Suite 7, 8, 9
Level M
08:00
08:30
NG
09:00
Annual Business Meeting
08.30-09.20
09:30
10:00
10:30
11:00
11:30
12:00
Data Management
12:30
Preview of the new EBMT
Registry system
13:00
Data Entry Training
Sessions
13:30
09.00 - 17.00
14:00
14:30
15:00
15:30
16:00
16:30
17:00
Nurses National
Nurses National
Group Meetings
Group Meetings
16.30-17.30
16.30-17.30
17:30
19
Overview
Programme Overview - Wednesday, 2 April 2014
Gold Plenary
Level 2
Space 1+2
Level 0
Space 3
Level 0
08:00
08:30
Educational 8
Educational 9
ALL: Decision to transplant
tailored on MRD
Clinical Management of
Transplant Complications
08:30-10.00
Special Lecture
Immune Tolerance
08.30-10.00
09:00
09:30
09:00 - 10:00
10:00
Oral Session 20
Oral Session 21
Stem Cell Source
Lymphoma
10:15 – 11:15
10:15 – 11:15
10:30
11:00
11:30
Plenary 7
Acute Myeloid
Leukemia Cooperative
Trials in Progress
11.30-13.00
Plenary 8
Workshop 14
Myeloma Cooperative Trials
in Progress
Novel Monoclonal antibody
in Hematology
11.30-13.00
11.30-13.00
12:00
12:30
13:00
CLOSING SESSION
13:00 – 13:15
13:30
14:00
20
Congress
Overview
Overview
Space 4
Level 0
Brown 3
Level 2
Brown 1
Level 2
Brown 2
Level 2
08:00
08:30
09:00
09:30
Outreach
Meeting
08:00 – 10:00
NG
09.00-10.30
Oral
Session 22
10:15 – 11:15
10:15 – 11:15
Closing Session
12:30
Oral
Session 18
Oral
Session 19
Acute Leukemia
10:15 – 11:15
NG
11:30
12:00
08:30-10.00
Paediatric & Adult
Solid Tumors
Pediatriac Disease
11:00
Allografting in
Hodgkin Lymphoma
Pre Transplant
Issues
10:00
10:30
Educational 11
Joint Session
11.00-12:45
Workshop 13
EBMT/ASBMT/EHA
Chronic Myeloid
Leukemia
11.30-13.00
11.30-13.00
13:00
13:30
14:00
21
Overview
Amber 1+2
Level 2
Amber 3+4
Level 2
Amber 6
Level 2
Amber 7
Level 2
08:00
08:30
09:00
Educational 10
Amyloidosis
08:30-10.00
(GITMO/EBMT)
NG
NG
Late Effects
Complications
09.00-10.30
09.00-10.30
Training Course on
European Approach to
the Medical Management
of Mass Radiation
Exposure
08.30 - 11.00
09:30
10:00
10:30
Oral Session 17
Multiple Myloma
10:15 - 11:30
11:00
11:30
12:00
12:30
13:00
13:30
14:00
22
Congress
Overview
Overview
Amber 8
Level 2
Suite 3
Level 2
Suite 4
Level 2
Suite 5
Level M
Oral Session 24
Oral Session
Oral Session 26
Oral Session 23
Late Effects 2
GVHD 2
10:15 - 11:30
10:15 - 11:30
08:00
08:30
09:00
09:30
10:00
10:30
11:00
Minimal Residual Disease
& reduced-intensity
Conditioning
10:15 - 11:30
25 Infectious
Complications 2
10:15 - 11:30
11:30
12:00
12:30
13:00
13:30
14:00
23
Organising Commitee
ORGANISING COMMITTEE EBMT 2014
Congress President
Marco Bregni (Milan)
Scientific Chair
Paolo Corradini (Milan)
Local Organising Committee
William Arcese (Rome)
Aleksandra Babic (Milan)
Andrea Bacigalupo (Genoa)
Andrea Biondi (Monza)
Stefano Cascinu (Ancona)
Luca Castagna (Rozzano)
Simone Cesaro (Verona)
Fabio Ciceri (Milan)
Francesco Lanza (Cremona)
Franco Locatelli (Rome)
Maura Massimino (Milan)
Enrica Morra (Milan)
Attilio Olivieri (Ancona)
Francesco Onida (Milan)
Antonio Palumbo (Turin)
Fabrizio Pane (Naples)
Paolo Pedrazzoli (Pavia)
Paolo Perseghin (Monza)
Luca Pierelli (Rome)
Alessandro Rambaldi (Bergamo)
Riccardo Saccardi (Florence)
Andrea Velardi (Perugia)
EBMT Board
Alejandro Madrigal (London). ..................... . . . . President
Mohamad Mohty (Paris). ........................... . . . President Elect
Anna Sureda (Cambridge).......................... . . . . Secretary
Fred Falkenburg (Leiden)............................ . . . Treasurer
Andreu Gusi (Barcelona). ............................ . . . Executive Director
Working Party Chair persons
Mohamad Mohty (Paris). ........................... . . . Acute Leukemia
Judith Marsh (London)............................... . . . Severe Aplastic Anaemia
Dominique Farge-Bancel (Paris)................... . . . Autoimmune Disease
Nicolaus Kröger (Hamburg). ........................ . . . Chronic Malignancies
Andrea Velardi (Perugia)............................ . . . Immunobiology
Andrew Grennery (Newcastle). .................... . . . . Inborn Errors
Simone Cesaro (Verona)............................. . . . Infectious Diseases
Rafael Duarte (Barcelona)........................... . . . Complications and Quality of Life
Peter Dreger (Heidelberg)........................... . . . . Lymphoma
Christina Peters (Vienna). . ......................... . . . . Paediatric Diseases
Francesco Lanza (Cremona)........................ . . . Solid Tumours
EBMT Nurses Group & Scientific Committee
Elisabeth Wallhult (Gothenburg)
Erik Aerts (Zürich)
Joachim Ahrens (Hamburg)
Inger Andersson (Gothenburg)
Aleksandra Babic (Milan)
Data Management Group
Carmen Ruiz de Elvira (London)
Ronald Brand (Leiden)
Myriam Labopin (Paris)
Richard Szydlo (London)
24
John Murray (Manchester)
Mairead NiChonghaile (Dublin)
Clara Soliman (Milano)
Simone van der Linden (Rotterdam)
Sara Zulu (London)
Quality Management Group
Renza Monteleone (Reggio Calabria)
Sylvia Haan (Groningen)
Phuong Huynh (Brussels)
Tuula Rintala (London)
Yvonne Schellekens (Amsterdam)
Congress
Overview
Contact
CONTACT ADDRESSES EBMT 2014
Congress President
Marco Bregni, M.D. Ospedale di Circolo,
Busto Arsizio
E-mail: bregni.marco@hsr.it
Physicians Scientific Secretariat
Paolo Corradini, M.D. Fondazione Istituto
Nazionale Tumori, Milano
E-mail: paolo.corradini@istitutotumorimi.it
Nurses Scientific Secretariat
Inger Em Andersson, Section of Hematology
and Coagulation, Sahlrenska University
Hospital, 413 45 Gothenburg / Sweden
Tel: +46 31 342 68 23
Fax: +46 31 825 73 6
E-mail: inger.em.andersson@vgregion.se
Data Management Group
Carmen Ruiz de Elvira, EBMT Central
Registry Office, Guy’s Hospital, 4th Floor
Tabard House, Talbot Yard, London, SE1 1YP,
United Kingdom
Tel: +44 207 188 8408
Exhibition & Sponsoring
EBMT 2014 c/o MCI Suisse SA, rue de Lyon
75, CP 502, 1211 Geneva / Switzerland
Tel: +41 22 33 99 639
Fax: +41 22 33 99 601
E-mail: Helene.barr@mci-group.com
ITALIAN PHARMACEUTICAL
COMPANIES / ITALIAN MINISTRY OF
HEALTH
MCI Italy has been chosen to collect all
applications from Italian Pharmaceuticals
Companies and file them with the
appropriate Italian Health Ministry officials.
For further information, please contact: MCI
Rome, Mrs Maria Grazia PAOLELLI, Via della
Ferratella in Laterano 41, 00184 Rome, Italy
Tel: +39 06 70495693
Fax: +39 06 7096292
E-mail: maria.paolelli-mci@mci-group.com
Hotel Accommodation
Fax: +44 207 188 8411
Tel: +41 22 33 99 581
E-mail: carmen.ruiz@kcl.ac.uk
Fax: +41 22 33 99 631
Quality Management Group
Eoin McGrath, EBMT Executive Office &
JACIE Office, Calle Rossello 140, 1o - 1a
08036 Barcelona / Spain
Tel: +34 93 453 87 11
Fax: +34 93 451 95 83
E-mail: eoin.mcgrath@EBMT.org
E-mail: EBMT2014.reg@mci-group.com
Congress Venue
MiCo
Piazzale Carlo Magno, 1
20149 Milano - ITALY
Web: www.micmilano.it
Organising Secretariat
Tel: +44 207 188 8408
Fax: +44 207 188 8411
E-mail: ebmt2014.reg@mci-group.com
25
Satellite Symposia
SATELLITE SYMPOSIA - SUNDAY, 30 MARCH 2014
09:00 - 10:30 French Society of Bone Marrow Transplantation and Cell Therapies
Space 3
Symposium: Allogeneic Stem Cell Transplantation in Patients with
Myelodysplastic Syndrome
Chairs: I Yakoub-Agha (France) & Marie Robin (France)
Welcome and Introduction
Indication of allo-SCT
Cytoreductive treatment before allo-SCT
Conditioning intensity
Treatment post allo-SCT
Marie Robin (France)
Theo de Witte (Netherlands)
I Yakoub-Agha (France)
Nicolaus Kröger (Germany)
Noël Milpied (France)
09:00 - 10:30 Merck Sharpe & Dohme Symposium (MSD)
Space 4
Chairs: Catherine Cordonnier (France) & Livio Pagano (Italy)
Welcome and Opening Remarks
Role of Observational Studies in Clinical Research
SEIFEM studies: Impact of real world Observations on current
practice
Catherine Cordonnier (France)
Livio Pagano (Italy)
Posaconazole Prophylaxis in Experimental Azole-resistant
Invasive Pulmonary Aspergillosis
P. Verweij (Netherlands)
Empiric therapy for Invasive Fungal Infections- Candida &
Aspergillus
Johan Maertens (Belgium)
Q&A
26
Closing Remarks
Satellite Symposia
09:00 - 10:30 Spotlight on the latest advances in multiple myeloma: the IFM
perspective Session supported by the “Intergroupe Francophone du
Myelome”(IFM) and the Institut Universitaire de Cancerologie (IUC),
Paris, France
Satellite
Symposia
Amber 3+4
Chairs: Michel Attal (France) & Mohamad Mohty (France)
Biology update
The optimal induction
Conditioning prior to auto-transplant: what’s new?
Consolidation and maintenance strategies
Treatment of the elderly: an update
Round table discussion : future of alkylating agents in myeloma
Michel Attal (France)
Mohamad Mohty (France)
Hervé Avet-Loiseau (France)
Philippe Moreau (France)
Thierry Facon (France)
All Speakers
11:00 - 13:00 CTI Life Sciences Symposium: Is Salvage Therapy Possible in Patients
Space 1
with DLBCL After Failure of Standard Second Line Regimens?
Chair: Anna Sureda (Spain)
Outcome of patients who failed R-DHAP or R-ICE in CORAL study
Christian Gisselbrecht (France)
Outcome of chemo-insensitive patients on PIX301 and, late stage
salvage with pixantrone - the German experience
Norbert Schmitz (Germany)
Role of allo-SCT in DLBCL, and potential registry study for EBMT
in chemo-insensitive transplant eligible patients
Anna Sureda (Spain)
27
Satellite Symposia
11:00 - 13:00 Medac Symposium: TREOSULFAN - A Conditioning Agent On Its Way to
Space 3
an Established Alternative in Stem Cell Transplantation
Chairs: Fabio Ciceri (Italy) & Franco Locatelli (Italy)
Treosulfan in Adult Patients with AML and MDS
Treosulfan Based Conditioning pre Allo-SCT for Lymphatic Malignancies
8 Years Italian Experience in Haploidentical HSCT
Treosulfan Based Conditioning in the US for Patients Undergoing
Umbilical Cord Blood Transplantation
Fabio Ciceri (Italy)
Dietrich Beelen (Germany)
Arnon Nagler (Israel)
Jacopo Peccatori (Italy)
Filippo Milano (United States)
Treosulfan Based Conditioning in Children with Primary
Immunodeficiency
Mary Slatter (United Kingdom)
Myeloablation & Low Toxicity in SCT - A Contradiction?
Christina Peters (Austria)
Conclusions/Summary
Franco Locatelli (Italy)
11:00 - 13:00 Sanofi Symposium: Progress in GVHD Prophylaxis
Space 4
Chair: Mohamad Mohty (France)
Impact of ATG on outcome after reduced-intensity conditioning &
Clinical case discussion
Frederic Baron (Belgium)
ATG reduces GVHD without increasing relapse & Clinical case
discussion
Jan Storek (Canada)
Long term side effects of chronic GVHD & Clinical case discussion
Bipin Savani (United States)
Pulmonary Function after Flu-Bu-ATG Conditioning & Clinical
case discussion
Discussion/Conclusions
28
All
Satellite Symposia
13:30 - 15:30 Gilead Sciences Symposium: Considering the host: Risk factors for
fungal infectionsS
Satellite
Symposia
Space 1
Chair: Johan Maertens (Belgium)
Host factors: primary immune deficiencies and the risk of fungal
infections
Emmanuel Roilides (United Kingdom)
Genetic risk factors for fungal infections
Host factors - secondary immune deficiencies and
immunomodulatory treatments
Anne Puel (France)
Georg Maschmeyer (Germany)
Immune deficiency - elucidation of patient cases
Summary and Close
13:30 - 15:30 Sanofi symposium: Stem Cell Mobilization: from science to clinical
Space 3
practice
Chair: Kai Huebel (Germany)
Welcome and introduction
Stem cells, quality matters
T cell and dendritic cells subsets inautologous grafts
Mega stem cells dose and haplo-transplant
Case report: pre-emptive mobilization approach
Pharmaco-economic aspects of stem cell mobilization
Panel discussion based on a clinical case
Kai Huebel (Germany)
Stefan Fruehauf (Germany)
Kai Huebel (Germany)
Richard Clark (United Kingdom)
All
29
Satellite Symposia
13:30 - 15:30 Miltenyi Biotec Symposium: Cellular therapy: Facts, developments,
Brown 3
and future visions
Chair: Franco Aversa (Italy)
Enabling novel therapies
Stem cell boost as a rescue therapy for patients with poor graft
function after allogeneic HSCT
Stefan MILTENYI (Germany)
Cord blood transplantation supported by third party donor cells
An update on engraftment kinetics and long-term outcomes
Koen van Besien (United States)
Ex vivo TCR / /and CD19 depletion in haploidentical SCT for
children with hematological disease: Results from a single-center
trial
Ex vivo TCR / /CD19 T and B cell depletion in HSCT for treatment
of adult patients with hematological disease
Franco Aversa (Italy)
Multi-virus specific T cells to manage viral reactivation after stem
cell transplantation
Tobias Feuchtinger (Germany)
Concluding Remarks
Franco Aversa (Italy)
13:30 - 15:00 Cell Medica Symposium: T Cell Therapy - What Does the Future Hold?
Amber 3+4
Chair: Hermann Einsele (Germany)
Modified T cells for Cancer Treatment
Viral Reactivation in High-Risk Paediatric Transplant Patients
EBV Positive Lymphoma - Point of Attack
Panel discussion and concluding remarks - T cell therapy - what
does the future hold?
Chair
Hans Stauss (United Kingdom)
Waseem Qasim (United Kingdom)
All Speakers
30
Satellite Symposia
16:00 - 17:30 Pierre-Fabre Symposium: Hematological malignancies : from allo
transplant to life after transplant
Satellite
Symposia
Space 1
Chair: James Russell (Canada)
James Russell (Canada)
Busulfan based conditioning for adult lymphoid malignancies:
What have we learned?
James Russell (Canada)
Allogeneic SCT as a promising curative approach in T-Cell and
B-Cell-Lymphoma
Cell
Bertram Glass (Germany)
Latest improvement in quality of life after transplant in adults
after reduced toxicity conditionings
Didier Blaise (France)
Allogeneic Hematopoietic Stem Cell Transplantation for paediatric
ALL: challenging approaches
Marta Gonzalez-Vicent (Spain)
16:00 - 18:00 Amgen Symposium: Harnessing the immune system in ALL: the role of
Space 2
T-cell engagement
Chair: Renato Bassan (Italy)
Welcome
Renato Bassan (Italy)
Unmet needs in relapsed/refractory ALL
Incorporating minimal residual disease into treatment decisions
in adult ALL
Dieter Hoelzer (Germany)
Monika Brüggemann (Germany)
Engaging T cells to fight cancer: the potential of BiTE® antibodies
in haematology
Matthias Klinger (Germany)
Clinical development of the BiTE® antibody blinatumomab
Panel Discussion
Meeting Close
Max Topp (Germany)
All Speakers
31
Satellite Symposia
16:00 - 18:00Neovii-Biotech Symposium: Monitoring and managing of acute
Space 3
leukemia relapse after T-cell depleted allogeneic SCT
Chairs: Hans Kolb (Germany) & Arnon Nagler (Israel)
Risk factors of relapse
Hans Kolb (Germany)
Registry data EBMT
Jordi Esteve (Spain)
Monitoring of minimal residual disease
By flow cytometry
Adriano Venditti (Italy)
By molecular biology
Andrea Biondi (Italy)
By chimerism
Management of relapse
By pre-emptive therapy
Christoph Schmid (Germany)
By new drugs
Jakob Passweg (Switzerland)
By second SCT
Jurgen Finke (Germany)
Summary
16:00 - 18:00Kiadis Pharma Symposium: Effective T-cell immunotherapy with
Space 4
ATIR™ after haploidentical HSCT: Excellent OS with low GvHD
Chair: Armand Keating
Welcome and general introduction
Challenges of alternative donor transplantation
Selective depletion to overcome challenges in allogeneic
transplants
Armand Keating
Irwin Walker(Canada)
Stephan Mielke (Germany)
Excellent OS and low GvHD following ATIR™ treatment in patients
with hematological malignancies
Denis-Claude Roy (Canada)
32
Satellite Symposia
Change control during process development: How the application
of Quality by Design (QbD) resulted in stable and robust ATIR™
manufacturing
Robert Preti (United States)
Can ATIR™ compete with MUD transplants?
Closing Remarks
John Barrett (United States)
Armand Keating (Canada)
16:00 - 18:00 Astellas Symposium: Viewpoints on the management of infectious
Brown 3
complications
Chair: Michael von Bergwelt-Baildon (Germany)
Introduction
Michael von Bergwelt-Baildon (Germany)
Clinical perspectives on invasive fungal disease (IFD)
Approaches to preventing IFD in the challenging patient
Real-world approaches to echinocandin-based antifungal
prophylaxis
Michel un Bergwelt-Baildon (Germany)
Noël Milpied (France)
Approaches to treating suspected IFD in the high-risk patient
Zdenek Racil (Czech republic)
Panel discussion: Management measures for IFD in the
challenging patient - strategies for optimising outcomes
All Speakers
Curtailing the far reaching consequences of Clostridium difficile
infection (CDI)
Practical and health economic perspectives
The clinical viewpoint
Panel discussion: Are the clinical needs of haematology patients
with CDI being met - what still needs to be done?
Nicola Petrosillo (Italy)
All Speakers
Chair’s summary
Michael von Bergwelt-Baildon (Germany)
33
Satellite
Symposia
Satellite Symposia
16:00 - 18:00 Takeda Symposium: Managing the relapsed/refractory lymphoma
Amber 3+4
patient in the era of targeted therapies
Welcome and faculty introduction
Current state of the art: SCT in lymphoma
Targeted therapies and their impact on relapsed/refractory
lymphoma treatment
Peter Dreger (Germany)
Transplant-ineligible patients: Has any progress been made in
their management?
Simonetta Viviani (Italy)
Panel discussion: Where do targeted therapies fit in the
management of lymphoma?
All
Satellite symposia - Monday, 31 March 2014
11:30 - 13:00 Gentium Symposium: CCan severe hepatic veno-occlusive disease
Space 1 & 2
(VOD) ever be treated effectively? Exploring the data behind a new
treatment approach
Chairs: Enric Carreras (Spain) & Mike Potter (United Kingdom)
Severe VOD: Do you see it…do you treat it?
The benefits of active treatment for severe VOD: evidence from
the defibrotide T-IND study
Enric Carreras (Spain)
Paul Richardson (United States)
Mike Potter (United Kingdom)
Endothelial cells: the protective effect of defibrotide
Maribel Diaz-Ricart (Spain)
You vs the experts: how would you identify and treat severe VOD?
Panel:
Tony Pagliuca (United Kingdom)
Selim Corbacioglu (Germany)
Fiona Dignan (United Kingdom)
34
Summary and close
Enric Carreras (Spain)
//////////////
Satellite
Symposia
SATELLITE SYMPOSIA - MONDAY, 31 MARCH 2014
Come and visit Gentium, a Jazz Pharmaceutical Company,
at stand 205 to meet the team
and to discover more about
severe Veno-Occlusive Disease
We are committed to continuing
our investment into research and
medical education.
Join us at our medical and nurse
satellite symposia at EBMT.
A Jazz Pharmaceuticals Company
DEF/INT/051/0201-01
Date of preparation: February 2014
35
Physicians Programme
OPENING SESSION – SUNDAY, 30 MARCH 2014
18:30 - 20:00Opening Session
Gold Plenary
18:30 - 18:45
Welcome
18:45 - 19:00
Van Bekkum Award
PH-O001 - T CELLS ENGINEERED WITH A CHIMERIC ANTIGEN
RECEPTOR (CAR) TARGETING CD19 (CTL019 CELLS) PRODUCE
SIGNIFICANT IN VIVO PROLIFERATION, COMPLETE RESPONSES
AND LONG-TERM PERSISTENCE WITHOUT GVHD IN CHILDREN AND
ADULTS WITH RELAPSED, REFRACTORY ALL
Marco Bregni (Congress President)
Alejandro Madrigal (EBMT President)
Elisabeth Wallhult (President, Nurses Group)
Frey N., Aplenc R., Levine B., Maude S., Rheingold S., Barker C. S., Teachey D.,
Porter D., June C., Mahnke Y., Grupp S.* (Philadelphia, United States)
19:00 - 19:15
Basic Science Award
PH-O007 - TRACKING T CELL DYNAMICS IN THE FIRST MONTH AFTER
ALLOGENEIC HSCT OFFERS A UNIQUE OPPORTUNITY TO UNVEIL THE
MECHANISM OF MEMORY STEM T CELL FORMATION IN HUMANS
Oliveira G., Greco R., Taccioli C., Forcato M., Valtolina V., Noviello M., Morelli
M., Lunghi F., Marktel S., Bellio L., Bicciato S., Peccatori J., Ciceri F., Bonini C.,
Bondanza A., Cieri N.* (Milan, Italy)
19:15 - 19:45
EBMT Lecture - Medicine as an art: Past and Present
19:45 - 19:50
Outstanding Contribution to EBMT Award
19:50 - 20:00
Happy Birthday, EBMT!
Giorgio Bordin (Italy)
Roland Brand
Marco Bregni (Italy)
Cell Therapy Day - Monday, 31 March 2014
08:00 - 09:30 Workshop 3: Regenerative Medicine
Space 4
Chairs: Kurt Gunter (United States) & Francesco Dazzi (United Kingdom)
08:00 - 08:30 Tissue engineering and the road to whole organs
Harald Ott (United States)
08:30 - 09:00 Heart regeneration
Gustav Steinhoff (Germany)
09:00 - 09:30 NK and CIK therapy in haematological malignancies
Mickey Koh (United Kingdom)
36
3rd EBMT Cell Therapy Day - Monday, 31 Mar 2014
09:45 - 11:15 Technology Workshop: Cell Collection and Processing
Space 4
Chair: Christian Chabannon (France)
09:45 - 10:15 Apheresis technology
Luca Pierelli (Italy)
10:15 - 10:30 Cryopreservation
Boris Calmels (France)
Scientific
Programme
Physicians
10:30 - 10:45 Cell washing
Riccardo Saccardi (Italy)
11:30 - 13:00 Workshop 5: Practical aspects in cell therapy
Space 4
Chair: Francesco Lanza (Italy)
11:30 - 12:00 Evolution of regulatory issues in cell therapy
Stefan Scheding (Sweden)
12:00 - 12:30 Cord Blood Banking
Sergio Querol (Spain)
12:30 - 13:00 Stem cell enumeration and quality control in cryopreserved
material
Francesco Lanza (Italy)
13:10 - 14:00 Special Lecture: New frontiers in cellular therapy for lymphoid
Gold Plenary
malignancies
Stephan Grupp (United States)
14:00 - 15:30Oral Session 3: Cell and Gene Therapy 1
Space 4
Chairs: Edwin Wagena (Canada) & T. Ladidot
14:06 - 14:18 PH-O027 - Cytokine-Induced Killer (CIK) cells enable elimination
of Minimal Residual Disease (MRD) in patients with haematological malignancies after allogeneic stem cell transplantation
Hünecke S., Pfirrmann V., Willasch A., Lucchini G., Jarisch A., Soerensen
J., Klingebiel T., Bader P., Boenig H., Bug G., Rettinger E.* (Frankfurt/Main,
Germany)
14:18 - 14:30 PH-O028 - Multi-Virus-Specific T-Cell therapy for patients after
Hematopoietic Stem Cell and Cord Blood Transplantation.
Hanley P., Krance R., Brenner M. K., Leen A. M., Rooney C. M., Shpall E. J.,
Heslop H. E., Bollard C.* (Washington , United States)
14:30 - 14:42 PH-O029 - Gene-Modified Human alpha/beta-T cells expressing
a Chimeric CD16-Cd3ZETA receptor as adoptively Transferable
Effector Cells for anticancer Monoclonal Antibody Therapy
Ochi F., Tanimoto K., Asai H., Miyazaki Y., Okamoto S., Mineno J., Kuzushima
K., Barrett J., Ishii E., Yasukawa M., Fujiwara H.* (Toon, Japan)
37
3rd EBMT Cell Therapy Day - Monday, 31 Mar 2014
14:42 - 14:54
PH-O030 - High-Affinity CD20-Specific TCRS suitable for adoptive
immunotherapy can be readily isolated from the allo-repertoire
using reverse immunology
Jahn L., Hombrink P., Kester M. G., Schoonakker M. P., Falkenburg J. F., van
Veelen P. A., Heemskerk M. H.* (Leiden, Netherlands)
14:54 - 15:06
PH-O031 - Off-Tumor target expression levels do not predict
CAR-T Cell killing: A foundation for the safety of CD44V6-targeted T
Cells
Nicolis di Robilant B., Falcone L., Camisa B., Norelli M., Gentner B., Genovese
P., Ponzoni M., Saudemont A., Bordignon C., Naldini L., Ciceri F., Dotti G.,
Bonini C., Bondanza A., Casucci M.* (Milano, Italy)
15:06 - 15:18
PH-O032 - Donor T-Cells for Hematopoietic restricted minor
histocompatibility antigens are induced in patients with combined
GVL and GVHD
Lurvink E. G., van Bergen C. A., Honders M. W., van Luxemburg-Heijs S. A.,
Kester M. G., Falkenburg J. F., Griffioen M., Pont M. J.* (Leiden, Netherlands)
15:18 - 15:30
PH-O033 - A new fully humanized transgenic mouse model for
predicting the hematological toxicities of genetically targeted T
Cells
Casucci M., Camisa B., Falcone L., Saudemont A., Genovese P., Naldini L.,
Dotti G., Bonini C., Bondanza A., Norelli M.* (Milano, Italy)
16:00 - 17:30 Workshop 6: Cell therapy for GVHD
Space 4
Chairs: Katarina LeBlanc (Sweden) & Willem Fibbe (Netherlands)
16:00 - 16:30 GVHD: Biology and animal models
Marcel van den Brink (United States)
16:30 - 17:00 IL2 administration to treat chronic GVHD
Robert Soiffer (United States)
17:00 - 17:30 Use of MSC for the treatment of GVHD
Willem Fibbe (Netherlands)
PHYSICIANS Programme - Monday, 31 March 2014
08:00 - 09:30 Educational 1: Immunogenetics in allogeneic HCT: Practical
Gold Plenary
guidelines for clinicians
Chair: Alberto Bosi (Italy)
08:00 - 08:30
Polymorphic Gene Systems: HLA and beyond
08:30 - 09:00
All you need to know about HLA Typing
09:00 - 09:30
Hematopoietic Chimerism: New Challenges and Clinical
Significance
Steven Marsh (United Kingdom)
Gottfried Fischer (Austria)
Katharina Fleischhauer (Germany)
38
08:00 - 09:30 Educational 3: Conditioning regimens for aplastic anemia
Chair: Hubert Schrezenmeier (Germany)
08:00 - 08:30
ATG based
08:30 - 09:00
Campath based
09:00 - 09:30
Haplo in paediatric patients
Judith Marsh (United Kingdom)
Selim Corbacioglu (Germany)
Scientific
Programme
Physicians
Brown 3
08:00 - 09:30 Workshop 1: Cooperative trials in progress: adult ALL
Brown 1
Chair: Fabrizio Pane (Italy)
08:00 - 08:30 AlloSCT in adult and adolescent Ph negative ALL
Herve’ Dombret (France)
08:30 - 09:00
Novel long term treatment strategies for adult and elderly Ph+ ALL
09:00 - 09:30
Rescue therapy of adult ALL in relapse after chemotherapy or
AlloSCT
Oliver Ottmann (Germany)
Jose Maria Ribera Santasusana (Spain)
08:00 - 09:30 Workshop 2: Role of transplantation in myelofibrosis
Amber 1+2
Chair: Alessandro Vannucchi (Italy)
08:00 - 08:30 Defining clinical and biological risk factors
F. Cervantes (Spain)
08:30 - 09:00 Conventional therapy and role of splenectomy
Francesco Passamonti (Italy)
09:00 - 09:30 Indications to allografting in myelofibrosis
08:00 - 09:30 Educational 2: Acute GVHD
Amber 3+4
Chair: Ernst Holler (Germany) & Tamas Masszi (Hungary)
08:00 - 08:30 Proteomic profiling for pre-emptive treatment GVHD
Eva Mischak-Weissinger
08:30 - 09:00 Treatment of steroid refractory GVHD
Alessandro Rambaldi (Italy)
09:00 - 09:30 The role of APC in GVHD and GVL
R. Chakraverty (United Kingdom)
39
09:45 - 11:15 Presidential Symposium
Gold Plenary
Chair: Alejandro Madrigal (United Kingdom)
09:45 - 09:50 Introduction
09:50 - 09:55 Honorary Member Award
Massimo F. Martelli
09:55 - 10:00 Honorary Member Award
Shaun McCann
10:00 - 10:05 Clinical Achievement Award
Rose-Marie Hamladji
10:03 - 10:15 PH-O002 - RESULTS OF AN OPEN-LABEL, PROSPECTIVE, RAN-
DOMIZED CLINICAL TRIAL ON TWO DIFFERENT DOSAGES OF
RABBIT ANTI-THYMOCYTE GLOBULIN (RATG) IN CHILDREN WITH
HEMATOLOGICAL MALIGNANCIES GIVEN ALLOGENEIC HSCT
FROM AN UNRELATED VOLUNTEER
Bernardo M. E., Rognoni C., Giorgiani G., Rovelli A., Pession A., Fagioli F.,
Favre C., Lanino E., Comoli P., Bertaina A., Prete A., Zecca M., Locatelli F.*
(Rome, Italy)
10:15 - 10:27 PH-O003 - GENE THERAPY OF ACUTE LEUKEMIAS WITH
CHIMERIC ANTIGEN RECEPTORS (CARS)-ENGINEERED CYTOKINE
INDUCED KILLER (CIK) CELLS BY SLEEPING BEAUTY SYSTEM
Turazzi N., Benedicenti F., Tettamanti S., Giordano Attianese G. M. P.,
Montini E., Cooper L. J. N., Aiuti A., Biondi A., Biagi E., Rossi V., Magnani C.
F.* (Monza, Italy)
10:27 - 10:39 PH-O004 - UPFRONT MATCHED AND MISMATCHED UNRELATED
TRANSPLANTATION IN PAEDIATRIC APLASTIC ANAEMIA: A
UNITED KINGDOM MULTICENTRE RETROSPECTIVE EXPERIENCE
Samarasinghe S., Wynn R., Velangi M., Vora A., Bonney D., Gibson B., Skinner
R., Ewins A.-M., Amrolia P., De La Fuente J., Shaw A., Steward C., Veys P.,
Hough R., Bhatnagar N.* (London, United Kingdom)
10:39 - 10:51 PH-O005 - A NEW ANN ARBOR GRADING SYSTEM USES BIO-
MARKERS TO RISK STRATIFY PATIENTS FOR NON RELAPSE MORTALITY AT THE ONSET OF ACUTE GRAFT VERSUS HOST DISEASE
Braun T. M., Harris A. C., Taylor A., Miller H., Ferrara J. L., Magenau J., Holler
E., Weisdorf D. J., Ho V. T., Bolanos-Meade J., Alousi A. M., Levine J. E.* and
Blood and Marrow Transplant Clinical Trials Network (Ann Arbor, United
States)
10:51 - 11:03 PH-O006 - AUTOLOGOUS HAEMOPOETIC STEM CELL TRANSPLAN-
TATION FOR RESISTANT CROHN’S DISEASE: FINAL RCT EFFICACY
DATA: SPONSORED BY THE AUTOIMMUNE DISEASES WORKING
PARTY AND THE EUROPEAN CROHN’S AND COLITIS ORGANISATION
40
Hawkey C.* and The ASTIC Trialists (Nottingham, United Kingdom)
11:30 - 13:00 Working Party: Acute Leukaemia
Gold Plenary
11:30 - 11:40 Introduction and update on the EBMT Acute Leukaemia Working
Party activities
Scientific
Programme
Physicians
Myriam Labopin (France)
Norbert Gorin (France)
Sebastian Giebel (Poland)
11:40 - 11:50 Comorbidities and allo-SCT for AML: where do we stand?
Roni Shouval (Israel)
11:50 - 12:00 Molecular markers and allo-HSCT for AML: an update
Jordi Esteve (Spain)
12:00 - 12:20 Conditioning for haploidentical allo-SCT: what’s new?
Borje Andersson (United States)
12:20 - 13:00 Treatment of ALL: State of the art
Jacob Rowe (Israel)
Working Party Abstracts
Full content of abstract available in the EBMT Abstract Book
BONES, MOANS AND GROANS IN ACUTE LEUKEMIA.
INTRODUCTION AND UPDATE ON THE EBMT ACUTE LEUKAEMIA
WORKING PARTY ACTIVITIES
COMORBIDITIES AND ALLO-SCT FOR AML: WHERE DO WE STAND?
MOLECULAR MARKERS AND ALLO-HSCT FOR AML: AN UPDATE
Mahesh Deshmukh (India)
41
11:30 - 13:00 Working Party: Lymphoma
Space 3
Chair: Peter Dreger (Germany)
11:30 - 11:40 Trends in Lymphoma transplants and LWP Activity report
advertise NIS / MTD survey
11:40 - 11:45 The LWP Educational Course 2014 in Cyprus
Charalampia Kyriakou (United Kingdom)
11:45 - 11:50 Presentation of Jian-Jian-Luan Award winner
11:50 - 12:05 Lecture of the Jian-Jian-Luan Award winning abstract
EFFECT OF IMMUNOMODULATION FOR PERIPHERAL T-CELL LYMPHOMA IN
RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT : A
SFGM-TC STUDY ON 64 PATIENTS
AC Mamez et al
12:05 - 12:15 European MCL Transplant Consensus
Steve Robinson (United Kingdom)
Olivier Hermine (France)
12:15 - 13:00 LWP Keynote Debate: BTK inhibitors, BH3 mimetics, new
antibodies & co: Still a place for transplantation in follicular
lymphoma in 2014?
Robert Marcus (United Kingdom)
Silvia Montoto (United Kingdom)
ALK POSITIVE LARGE B-CELL LYMPHOMA WITH DETAILED
IMMUNOHISTOCHEMICAL AND FLOW CYTOMETRIC FEATURES.
Komal Galani (India)
11:30 - 13:00 Working Party: Aplastic Anaemia
Brown 1
Chair: Judith Marsh (United Kingdom)
11:30 - 11:40 Treatment Options for Refractory SAA: Haplo HSCT
11:40 - 11:50 Treatment Options for Refractory SAA: Cord Blood
Regis De la Tour (France)
11:50 - 12:00 Treatment Options for Refractory SAA: Best supportive treatment
12:00 - 12:10
Is this the time to move to Eltrombopag? Background
Alicia Rovo (Switzerland)
12:10 - 12:20 Is this the time to move to Eltrombopag? The Race Study
42
A. Risitano (Italy)
12:20 - 12:40 Is this the time to move to Eltrombopag? The moderate AA study
Britta Hochsmann (Germany)
THROMBOPOIETIN MIMETIC AS THERAPY OPTION FOR APLASTIC
ANEMIA
HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION
IS A THERAPEUTIC OPTION IN PATIENTS WITH REFRACTORY
ACQUIRED SEVERE APLASTIC ANEMIA: A SURVEY BY THE SEVERE
APLASTIC ANEMIA WORKING PARTY (SAAWP) AND PAEDIATRIC
DISEASES WORKING PARTY (PDWP) OF THE EU
Maria Teresa Lupo Stanghellini (Italy)
EFFICIENCY AND SAFETY OF THROMBOPOETIN IN MODERATE
APLASTIC ANEMIA - EMAA TRIAL
Britta Höchsmann (Germany)
11:30 - 13:00 Basic Science I: Genomics application and perspectives in
Amber 1+2
Hematology
Chairs: Alexander Kohlmann (Germany)
11:30 - 12:00 Next generation sequencing
Alexander Kohlmann (Germany)
12:00 - 12:30 MicroRNAs, regulators of bone marrow hemeostasis and future
biomarkers
Florian Kuchenbauer (Germany)
12:00 - 13:00 Gene expression profiling
Pier Paolo Piccaluga (Italy)
11:30 - 13:00Nature Publishing Group: How to get your paper published
Amber 5
Chair: Hillard Lazarus (United States)
Hillard Lazarus (United States)
Robert Peter Gale (United States)
11:30 - 13:00 Workshop 4: Photoapheresis: for selected pts only?
Amber 7
Chair: Miguel Lozano (Spain)
11:30 - 12:00 ECP: technical issues
Paolo Perseghin (Italy)
12:00 - 12:30 Indications for ECP in the paediatric setting
Justyna Kanold (France)
12:30 - 13:00 Indications for ECP in the adult setting
Hildegard Greinix (Austria)
43
Scientific
Programme
Physicians
Alicia Rovo (Switzerland)
13:10 - 14:00Lunch Controversy Auto or allo in PTCL
Space 4
Chair: Christian Gisselbrecht (France)
13:10 - 14:00 Allo transplantation in T-cell lymphoma
13:10 - 14:00 Auto
Peter Reimer (Germany)
13:10 - 14:00Lunch Controversy: Treatment of RAEB before transplant
Brown 3
Chair: Norbert Gorin (France)
13:10 - 14:00 Chemo
Ghulam Mufti (United Kingdom)
13:10 - 14:00 Epigenetic therapy
Pierre Fenaux (France)
13:10 - 14:00WMDA
Brown 1
Chair: Bronwen Shaw (United Kingdom)
13:00 - 14:00Lunch Controversy: Post-allogeneic HSCT treatment with
Amber 1+2
hypomethylators in AML patients: before or after relapse?
Chair: Jan Cornelissen (Netherlands)
13:00 - 13:25
Before relapse
13:25 - 13:50
After relapse
13:50 - 14:00
Q&A
Charles Craddock (United Kingdom)
Guido Kobbe (Germany)
Jan Cornelissen (Netherlands)
Support provided by Celgene
13:10 - 14:00Lunch Controversy: Autografting is the tandard first line
Amber 3+4
treatment in all myeloma patients?
Chair: Hermann Einsele (Germany)
13:10 - 14:00
No
13:10 - 14:00
Yes
Antonio Palumbo (Italy)
13:10 - 14:00 Transplant Immunology
Amber 5
Chair: Fred Falkenburg (Netherlands)
13:10 - 13:25 Identification and isolation of high avidity T-cells for immunotherapy
44
Dirk Busch (Germany)
13:25 - 13:40 Use of genetically modified Lymphocytes in allogeneic stem cell
transplantation
Chiara Bonini (Italy)
13:40 - 13:55 Inflammatory circumstances shifting the balance from CVL to
GVHD
Fred Falkenburg (Netherlands)
Gold Plenary
Chairs: Jordi Esteve (Spain) & Felicetto Ferrara (Italy)
14:06 - 14:18
ALLOGENEIC AND AUTOLOGOUS HSCT FOR ELDERLY PATIENTS
WITH ACUTE LYMPHOBLASTIC LEUKEMIA. AN ANALYSIS FROM
ACUTE LEUKEMIA WORKING PARTY OF THE EBMT
14:18 - 14:30
AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
FOLLOWED BY PROLONGED MAINTENANCE PROVIDES SURVIVAL
BENEFIT OVER ONLY CHEMOTHERAPY IN T-CELL ACUTE
LYMPHOBLASTIC LEUKEMIA: RESULTS OF THE RALL STUDY GROUP
Elena Parovichnikova (Russian Federation)
14:30 - 14:42 TREOSULFAN BASED CONDITIONING PRIOR TO ALLOGENEIC STEM
CELL TRANSPLANTATION (HSCT) FOR ACUTE MYELOGENOUS
LEUKEMIA (AML): A RETROSPECTIVE ANALYSIS FROM THE ALWP
OF THE EBMT.
14:42 - 14:54 GENOMIC EVOLUTION AND GENETIC ALTERATIONS IN ADULT
PATIENTS WITH PHILADEPHIA CHROMOSOME- NEGATIVE
ACUTE LYMPHOBLASTIC LEUKEMIA FROM DIAGNOSIS TO
RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Haowen Xiao (China)
14:54 - 15:06 IMPACT OF CYTOGENETIC USING THE IPSS REVISED CYTOGENETIC
CLASSIFICATION ON OUTCOME AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION FOR MDS OR AML EVOLVING FROM MDS:
A RETROSPECTIVE MULTICENTER STUDY OF THE CHRONIC
MALIGNANCIES WORKING PARTY OF THE EBMT
Christian Koenecke (Germany)
15:06 - 15:18
ALLOGENEIC TRANSPLANTS FOR MYELODISPLASTIC
SYNDROMES: STRONG REDUCTION OF TRANSPLANT MORTALITY
IN RECENT YEARS
Andrea Bacigalupo (Italy)
15:18 - 15:30 NON-LINEAR CLONAL EVOLUTION OF LEUKEMIA DRIVEN BY THE
SELECTIVE IMMUNE PRESSURE OF ALLOGENEIC HSCT
Luca Vago (Italy)
45
Scientific
Programme
Physicians
14:00 - 15:30Oral Session 1: Acute Leukemia / MDS
14:00 - 15:30Oral Session 2: Donor Issues
Space 1 & 2
Chairs: Alberto Bosi (Italy) & Ghosta Gahrton (Sweden)
14:06 - 14:18 PH-O048 - INTERACTION BETWEEN HLA COMPATIBILITY
AND AGE ASSOCIATED RISK IN HEMATOPOETIC STEM CELL
TRANSPLANTATION (HSCT)
Zollikofer C., Müller C., Niederwieser D., Bunjes D., Meyer R. G., Gramatzki
M., Wulf G., Arnold R., Einsele H., Glass B., Stuhler G., Pfreundschuh M.,
Schrezenmeier H., Mytilineos J., Fürst D.* (Ulm, Germany)
14:18 - 14:30 PH-O049 - RELATED HPC DONOR SAFETY AND MANAGEMENT
HAS BEEN ENHANCED BY ADHERENCE TO IMPROVED JACIE
STANDARDS
Ethell M. E., Potter M. N., Madrigal A., Shaw B. E., Anthias C.* (London, United
Kingdom)
14:30 - 14:42 PH-O050 - IMPACT OF HLA-MISMATCH ON OUTCOME AFTER
ATG-CONTAINING MYELOABLATIVE AND REDUCED-INTENSITY
UNRELATED DONOR TRANSPLANTATION
Ayuk F., Zabelina T., Wolschke C., Stübig T., Alchalby H., Müller I., Zander A.,
Kröger N., Janson D.* (Hamburg, Germany)
14:42 - 14:54 PH-O051 - PROFOUND T-CELL RESPONSE AGAINST HLA-DRB3
ASSOCIATED WITH SEVERE GVHD AFTER PURIFIED CD4+ T-CELL
INFUSION FROM AN HLA 10/10 MATCHED UNRELATED DONOR.
van Luxemburg-Heijs S. A., van Bergen C. A., Halkes C. J., Jedema I.,
Falkenburg J., van Balen P.* (Leiden, Netherlands)
14:54 - 15:06 PH-O052 - RAPID DONOR IDENTIFICATION AND SHORTER
TIME TO TRANSPLANT USING A REGISTRY-BASED GRAFT
IDENTIFICATION AND ADVISORY SERVICE (GIAS)
Marsh S. G., Blake H., Evseeva I., MacKinnon S., Pagliuca A., Potter M. N.,
Russell N. H., Craddock C. F., Madrigal A. J., Shaw B. E., Lown R.* (London,
United Kingdom)
15:06 - 15:18 PH-O053 - PROSPECTIVE EVALUATION OF T-CELL-REPLETE
HAPLOIDENTICAL HSCT WITH LOW-DOSE ANTI-T-LYMPHOCYTE
GLOBULIN COMPARED WITH CONTEMPORANEOUS MATCHED
SIBLING HSCT AND UNRELATED HSCT: RESULTS FROM AN OPENLABEL TRIAL
Xiao H., Lai X., Shi J., Tan Y., He J., Xie W., Zheng W., Cai Z., Lin M., Huang H.,
Luo Y.* (Hangzhou, China)
15:18 - 15:30 PH-O054 - G-CSF AND PLERIXAFOR SUCCESSFULLY MOBILIZE
MEGA-DOSES OF DONOR CD34+ HEMATOPOIETIC STEM CELLS
(HSC) FOR T-CELL RECEPTOR (TCR)-AB/CD19-DEPLETED
HAPLOIDENTICAL TRANSPLANTATION
Locatelli F., Filippini P., Li Pira G., Ceccarelli S., Del Principe G., Leone G.,
Brescia L. P., Bertaina A., Palumbo G., Merli P., Pagliara D., Altomare L.,
Girolami E., Lucarelli B., Rutella S.* (Rome, Italy)
46
14:00 - 15:30Oral Session 4: Late Effects 1
Brown 3
Chairs: Tapani Ruutu (Finland) & Andre Tichelli (Switzerland)
14:06 - 14:18 PH-O055 - PROSPECTIVE OBSERVATIONAL STUDY ON THE
OCCURRENCE OF METABOLIC SYNDROME IN PATIENTS
UNDERGOING AUTOLOGOUS OR ALLOGENEIC HSCT.
Airaghi L., Saporiti G., Orsatti A., Tagliaferri E., Grifoni F., Motta B., Galassi G.,
Cortelezzi A., Onida F., Cavalieri S., Annaloro C., Mometto G.* (Milano, Italy)
Scientific
Programme
Physicians
14:18 - 14:30 PH-O056 - BONE HEALTH IN LONG TERM SURVIVORS OF
ALLOGENEIC BONE MARROW TRANSPLANTATION
Lowdon A., O’ Boyle F., Apperley J., Szydlo R., Todd J., Salooja N., Deplano S.*
(London, United Kingdom)
14:30 - 14:42 PH-O057 - EFFICACY OF ECULIZUMAB IN ALLOGENIC
STEM CELL TRANSPLANTATION ASSOCIATED THROMBOTIC
MICROANGIOPATHY: A RETROSPECTIVE STUDY ON BEHALF THE
SOCIETE FRANCAISE DE GREFFE DE MOELLE ET DE THERAPIE
CELLULAIRE (SFGM-TC)
Galambrun C., Sirvent A., Huynh A., Faguer S., Nguyen Quoc S., Bay J. O.,
Neven B., Moussi-Frances J., Lioure B., Xhaard A., Fremeaux-Bacchi V.,
Veyradier A., Coppo P., Socié G., Peffault de Latour R., Sicre De Fontbrune F.*
and SFGM-TC (Paris, France)
14:42 - 14:54 PH-O058 - QUALITY OF LIFE AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION IN PATIENTS WITH MYELOFIBROSIS
Alchalby H., Wulf G., Zabelina T., Sehner S., Wolff D., Kobbe G., Bornhäuser
M., Baurmann H., Bethge W., Zander A., Kröger N., Machate N.* (Hamburg,
Germany)
14:54 - 15:06 PH-O059 - MAJOR AND BIDIRECTIONAL ABO INCOMPATIBILITY
RELATED PURE RED CELL APLASIA DOES NOT COMPROMISE
THE OUTCOME POST ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Bousiou Z., Mallouri D., Abela E., Kaloyannidis P., Apostolou C., Yannaki E.,
Batsis I., Smias C., Kynigopoulou P., Fitili C., Sotiropoulos D., Ganidou M.,
Bamihas G., Anagnostopoulos A., Sakellari I.* (Thessaloniki, Greece)
15:06 - 15:18 PH-O060 - HETEROGENEITY OF MYELOABLATIVE TOTAL BODY
IRRADIATION TECHNIQUES IN CURRENT CLINICAL PRACTICE. A
SURVEY OF ACUTE LEUKEMIA WORKING PARTY OF THE EBMT
Miszczyk L., Slosarek K., Moukhtari L., Ciceri F., Esteve J., Gorin N. C., Labopin
M., Nagler A., Schmid C., Mohty M., Giebel S.* (Gliwice, Poland)
15:18 - 15:30 PH-O061 - HIGH IMPACT OF NEUROLOGICAL COMPLICATIONS
IN ALLOGENIC STEM CELL TRANSPLANTATION IN THE OVERALL
SURVIVAL
Gutiérrez L., Iglesias M., Ormazabal I., Bermúdez A., Yáñez L., MontesGaisán C., De Miguel C., Richard C., Insunza A., Conde E., Ibarrondo P.*
(Santander, Spain)
47
14:00 - 15:30Oral Session 5: GVHD 1
Brown 1
Chairs: Ignazio Majolino (Italy) & Olle Ringden (Sweden)
14:06 - 14:18 PH-O034 - CD4+ T CELL FUNCTIONS ARE POTENTLY SUPPRESSED
BY THE JANUS KINASE 1/2 (JAK1/JAK2) INHIBITOR RUXOLITINIB
Cornez I., Brossart P., Wolf D., Heine A., Schönberg K., Parampalli
Yajnanarayana S.* (Bonn, Germany)
14:18 - 14:30 PH-O035 - TREATMENT OF STEROID RESISTANT GRADE II TO IV
ACUTE GVHD BY INFUSION OF MESENCHYMAL STROMA CELLS
EXPANDED WITH PLATELET LYSATE - A PHASE I/II STUDY
te Boome L., Mansilla C., Lindemans C., Cuijpers M., Westinga K., Petersen
E., Spierings E., Bierings M., Boelens J. J., Slaper-Cortenbach I., Kuball J.,
Wulffraat N., Van Der Wagen L.* (Utrecht, Netherlands)
14:30 - 14:42 PH-O036 - TARGETING THE ARYL HYDROCARBON
RECEPTOR WITH AN ORAL INDOLE DERIVATIVE TO PREVENT
GASTROINTESTINAL GVHD.
Giver C. A., Rangaraju S., Swimm A., Sharma A., Quayed M., Kalman D.,
Waller E. K.* (Atlanta, United States)
14:42 - 14:54 PH-O037 - IMPAIRED THYMIC EXPRESSION OF A TISSUE-
RESTRICTED ANTIGEN LICENSES THE DE NOVO GENERATION OF
AUTOREACTIVE CD4+ T CELLS DURING MURINE ACUTE GRAFTVERSUS-HOST DISEASE
Hauri-Hohl M., Holländer G. A., Krenger W., Dertschnig S.* (Basel,
Switzerland)
14:54 - 15:06 PH-O141 - CO-DEVELOPMENT OF GVHD WITH GVL IS
DETERMINED BY MAGNITUDE, STRENGTH AND TISSUE
RESTRICTION OF THE ALLOREACTIVE T CELL RESPONSE.
van Luxemburg-Heijs S. A., de Wreede L. C., Eefting M., Jedema I., Halkes C.
J., Griffioen M., Falkenburg J. F., van Bergen C. A.* (Leiden, Netherlands)
15:06 - 15:18 PH-O039 - PROINFLAMMATORY HUMAN 6-SULFO LACNAC+
DENDRITIC CELLS ACCUMULATE IN INTESTINAL ACUTE GRAFTVERSUS-HOST DISEASE
Sommer U., Larsson B., Wehner R., Zimmermann N., Kramer M., Kloss
A., Günther C., Babatz J., Schmelz R., Brückner S., Schetelig J., Bornhäuser
M., Schäkel K., Bachmann M., Aust D., Barreton G., Schmitz M., Tuve S.*
(Dresden, Germany)
15:18 - 15:30 PH-O040 - NEOVASCULARIZATION PRECEDES LYMPHOCYTE
INFILTRATION AND TARGET ORGAN DAMAGE DURING ACUTE
GVHD
Penack O., Shi Y., Mengwasser J., Cordes S., Riesner K.* (Berlin, Germany)
48
14:00 - 15:30Oral Session 6: Tolerance, Chimerism and Immune Reconstitution
Amber 1+2
Chairs: A. Elmaagacli (Germany) & Loredana Ruggeri (Italy)
14:06 - 14:18 PH-O041 - ADOPTIVE IMMUNOTHERAPY WITH TREG AND TCON
SEPARATES GVL FROM GVHD IN HLA-HAPLOIDENTICAL STEM
CELL TRANSPLANTATION
14:18 - 14:30 PH-O042 - AGONISTIC CO-STIMULATION SYNERGIZES WITH CO-
INHIBITORY BLOCKADE TO REVERSE EXHAUSTION OF HELPLESS
CD8 T CELLS
Buchan S., Flutter B., Zhang L., Bennett C., Freeman G. J., Croft M., SYKES M.,
Al-Shamkhani A., Chakraverty R., Manzo T.* (London, United Kingdom)
14:30 - 14:42 PH-O043 - HIGH FREQUENCY OF T MEMORY STEM CELLS
PRECEDES T CELL IMMUNE-RECONSTITUTION FOLLOWING
HUMAN BONE MARROW TRANSPLANTATION
Mavilio D., Castagna L., Roederer M., Tentorio P., Zanon V., Gandolfi S.,
Roberto A., Lugli E.* (Rozzano (MI), Italy)
14:42 - 14:54 PH-O044 - PLASMA INTERLEUKIN-7 LEVELS PREDICT THE RATE
OF IMMUNORECONSTITUTION IN MYELOABLATIVE ALLOGENEIC
STEM CELL TRANSPLANTATION
Shamim Z., Jordan K., Pontoppidan P. L., Hylland H., Ifversen M., Heilmann
C., Nielsen C. H., Sengeløv H., Ryder L. P., Müller K., Kielsen K.* (Copenhagen,
Denmark)
14:54 - 15:06 PH-O045 - PREDICTABLE PATTERNS OF VARIABILITY IN
STABLE MIXED CHIMERISM: IMMUNOBIOLOGIC AND PATIENT
MANAGEMENT IMPLICATIONS OF LONG-TERM GRAFT BEHAVIOR
IN MALIGNANT AND NON-MALIGNANT DISEASE
Stein J., Kenett R., Stepensky P., Or R., Israel S., Hazan O., Abed El-Latif M.,
Klein T., Kristt D.* (Jerusalem, Israel)
15:06 - 15:18 PH-O046 - MISSING HLA C GROUP 1 LIGAND IN PATIENTS WITH
AML AND MDS IS ASSOCIATED WITH REDUCED RISK OF RELAPSE
AND IMPROVED SURVIVAL AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION WITH FLUDARABINE AND TREOSULFAN
REDUCED TOXICITY CONDITIONING
Bernardi M., Yerushalmi R., Peccatori J., Shem-Tov N., Lo Russo A., Volchek
Y., Vago L., Bonini C., Lupo Stanghellini M. T., Nagler A., Ciceri F., Shimoni A.*
(Tel-Hashomer, Israel)
15:18 - 15:30 PH-O047 - CD39+ T REGULATORY CELLS AS A BIOMARKER OF
IMMUNE RECONSTITUTION AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION.
Nikolova M., Avramova B., Konstantinov D., Yordanova M. N.* (Sofia,
Bulgaria)
49
Scientific
Programme
Physicians
Ruggeri L., Falzetti F., Carotti A., Terenzi A., Massei M. S., Amico L., Pierini A.,
Velardi A., Martelli M. F., Di Ianni M.* (Perugia, Italy)
14:00 - 15:30Oral Session 7: Infectious Complications 1
Amber 3+4
Chairs: Bobby Gaspar (United Kingdom) & Olaf Penack (Germany)
14:06 - 14:18 PH-O020 - SEVERE INFECTIONS AFTER SINGLE UMBILICAL CORD
BLOOD TRANSPLANTATION IN ADULTS WITH OR WITHOUT THE
CO-INFUSION OF CD34+ CELLS FROM A THIRD PARTY DONOR:
RESULTS OF A MULTICENTER STUDY FROM THE GRUPO ESPAÑOL
DE TRASPLANTE HEMATOPOYÉTICO (GETH)
Martino R., Parody R., Esquirol A., Rovira M., Barba P., Vazquez L., Serrano
D., Cabrera J., Regidor C., Fores R., García-Marco J., Sánchez-Ortega I., de la
Cámara R., García-Cadenas I.* and Infectious/Non-infectious Complications
Subcommittee of the Grupo Español de Trasplante Hematopoyético (GETH)
(Barcelona, Spain)
14:18 - 14:30 PH-O021 - CYTOMEGALOVIRUS PEPTIDE VACCINATION RESULTS
IN CLEARANCE OF THE VIRUS LOAD
Schmitt A., Hofmann S., Götz M., Michels B., Malcherek G., Maccari B.,
Lindner D., Wuchter P., Mertens T., Döhner H., Ho A. D., Bunjes D. W., Dreger
P., Schrezenmeier H., Schauwecker P., Wiesneth M., Greiner J., Michael S.*
(Heidelberg, Germany)
14:30 - 14:42 PH-O022 - UPDATE OF THE PROSPECTIVE STUDY ON THE ROLE
OF BED-SIDE ULTRASOUND IN NEUTROPOENIC ENTEROCOLITIS:
72 EPISODES OUT OF 1499 PATIENTS ENROLLED. EARLY
DIAGNOSIS REDUCE MORTALITY AND CHANGE DIAGNOSTIC
CRITERIA
Bruno B., Lippolis P., Caracciolo F., Orciuolo E., Buda G., Cerri F., Caramella D.,
Petrini M., Benedetti E.* (Pisa, Italy)
14:42 - 14:54 PH-O023 - PRE-ENGRAFTMENT BLOODSTREAM INFECTIONS IN
489 HAEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS:
AETIOLOGY, RISK FACTORS AND IMPACT ON MORTALITY.
Mikulska M., Varaldo R., Ghiso A., GUALANDI F., Dominietto A., Bregante S.,
di Grazia C., Borghesi M. L., BALLETTO E., Del Bono V., Bacigalupo A., Viscoli
C., Galaverna F.* (Genoa, Italy)
14:54 - 15:06 PH-O024 - HUMAN HERPESVIRUS-6 DETECTION IN
CEREBROSPINAL FLUID AFTER ALLOGENEIC HEMATOPOIETIC
CELL TRANSPLANTATION: FREQUENCY AND SIGNIFICANCE
Boeckh M. J., Zerr D., Jerome K. R., Sedlak R. H., Hill J. A.* (Seattle, United
States)
15:06 - 15:18 PH-O025 - RAPID SALVAGE TREATMENT OF PATIENTS
AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL
TRANSPLANTATION USING GOOD MANUFACTURING PRACTICE
(GMP)-COMPLIANT POLYPEPTIDE-EXPANDED ADENOVIRUSSPECIFIC T-CELLS
50
Freimüller C., Stemberger J., Artwohl M., Witt V., Lion T., Fischer G.,
Lawitschka A., Ritter J., Hummel M., Holter W., Fritsch G., Matthes-Martin S.,
Geyeregger R.* and Infectious disease (Vienna, Austria)
15:18 - 15:30 PH-O026 - VIRAL INFECTIONS AFTER ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM
UNRELATED DONORS: ON BEHALF OF COMPLICATIONS WORKING
GROUP OF THE JAPAN SOCIETY FOR HEMATOPOIETIC CELL
TRANSPLANTATION (JSHCT)
Nishida T., Nakazawa Y., Hayashi Y., Takenaka K., Nakasone H., Oshima K.,
Uchida N., Kakihana K., Eto T., Morishima Y., Kato K., Suzuki R., Fukuda T.,
Asano-Mori Y.* (Tokyo, Japan)
Amber 5
Scientific
Programme
Physicians
14:00 - 15:30Oral Session 9: Chronic leukemia
Chairs: Marie Robin (France) & Gianantonio Rosti (Italy)
14:06 - 14:18 PH-O062 - SEVEN YEARS FOLLOW-UP OF THE PROSPECTIVE
MULTICENTER STUDY OF REDUCED-INTENSITY ALLOGENEIC
STEM CELL TRANSPLANTATION FOR PRIMARY OR POST ET/PV
MYELOFIBROSIS
Zabelina T., Wolff D., Kobbe G., Bornhäuser M., Baurmann H., Nagler A.,
Bethge W., Schaefer-Eckert K., Corradini P., Dreger P., Stuhler G., Zander A.
R., Kröger N., Alchalby H.* and Chronic leukemias (Hamburg, Germany)
14:18 - 14:30 PH-O063 - LONG-TERM FOLLOW-UP DATA SUPPORT THE
CURATIVE POTENTIAL OF ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANTATION IN PATIENTS WITH CHRONIC LYMPHOCYTIC
LEUKEMIA: A RETROSPECTIVE ANALYSIS FROM THE CHRONIC
MALIGNANCIES WORKING PARTY OF THE EBMT
van Gelder M., de Wreede L., Henseler A., van Biezen A., Niederwieser D.,
Karas M., Andersen N. S., Gramatzki M., Dreger P., Bunjes D., Petersen E.,
Potter M., Beelen D., Yakoub-Agha I., Cornelissen J. J., Russell N. H., Finke J.,
Maertens J., Blaise D., Paneesha S., Vitek A., Bornhäuser M., Schoenland S.,
Kröger N., Schetelig J.* (Dresden, Germany)
14:30 - 14:42 PH-O064 - PROGNOSTIC SIGNIFICANCE OF EBMT SCORE FOR
CHRONIC MYELOID LEUKAEMIA PATIENTS IN THE ERA OF
TYROSINE KINASE INHIBITOR THERAPY: A RETROSPECTIVE
STUDY FROM THE CHRONIC MALIGNANCY WORKING PARTY
OF THE EUROPEAN GROUP FOR BLOOD AND MARROW
TRANSPLANTATION (EBMT)
Szydlo R., Hoek J., Beelen D., Hamladji R., Kyrcz-Krzemien S., Bacigalupo A.,
Niederwieser D., Tischer J., Schwerdtfeger R., Volin L., Greinix H., Chalandon
Y., Kroeger N., Olavarria E., Gurman G., Milojkovic D.* (London, United
Kingdom)
14:42 - 14:54 PH-O065 - R-DHAP IMMUNO-CHEMOTHERAPY IS AN EFFECTIVE
REMISSION-INDUCTION TREATMENT FOR FLUDARABINE
REFRACTORY CLL PATIENTS AND ALLOWS THE MAJORITY TO
PROCEED TO ALLOGENEIC STEM CELL TRANSPLANTATION RESULTS OF THE PROSPECTIVE MULTICENTER HOVON 88 TRIAL
Ghidey W., Cornelissen J., Zachée P., Hoogendoorn M., Daenen S., Petersen
E., Beker A., Timmers G.-J., Kater A., van Oers R., Van Gelder M.* (Maastricht,
Netherlands)
51
14:54 - 15:06 PH-O066 - EBMT PROSPECTIVE NON-INTERVENTIONAL STUDY
ON ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
IN T-PROLYMPHOCYTIC LEUKEMIA (T-PLL). PRELIMINARY
ANALYSIS OF 43 PATIENTS.
Iacobelli S., Hoek J., Drozd-Sokolowska J. M., Potter M., Wulf G., Chevallier P.,
Ljugman P., Koc Y., Schetelig J., DeWitte T., Kroeger N., Dreger P., WiktorJedrzejczak W.* and Chronic Malignancies Working Party (Warsaw, Poland)
14:00 - 15:30Oral Session 16: Regenerative Medicine
Suite 4
Chairs: Francesco Dazzi (Italy) & Mauro Krampera (Italy)
14:06 - 14:18 PH-O015 - MODELING ADOPTIVE IMMUNOTHERAPY IN MOUSEHUMANS CHIMERAS TO IDENTIFY NOVEL MECHANISMS OF
LEUKEMIA IMMUNOEDITING
Lazarevic D., Toffalori C., Bernardi M., Peccatori J., Bordignon C., Bonini
C., Fleischhauer K., Ciceri F., Stupka E., Garcia-Manteiga J. M., Camisa B.,
Caserta C., Crucitti L., Greco R., Bondanza A., Vago L., Oliveira G.* (Milano,
Italy)
14:18 - 14:30 PH-O016 - DISTINCT MOLECULAR SIGNATURE AND POTENT
HEMATOPOIESIS-SUPPORTING FUNCTION OF HIGHLY ENRICHED
PRIMARY HUMAN BONE MARROW LINEAGE NEG/CD45 NEG/
CD271 POS/PDGFR-ΑLPHA LOW/NEG STROMA STEM CELLS
Li H., Ghazanfari R., Zacharaki D., Ekblom M., Méndez-Ferrer S., Scheding
S.* (Lund, Sweden)
14:30 - 14:42 PH-O017 - FUNCTIONAL RECONSTITUTION OF BONE/
BONE MARROW MICROENVIRONMENT FOLLOWING IN VIVO
IMPLANTATION OF CARTILAGE PELLETS DIFFERENTIATED
FROM HUMAN BONE MARROW- AND CORD BLOOD- DERIVED
MESENCHYMAL STEM CELLS (MSCS)
Azario I., Rambaldi B., Biondi A., Riminucci M., Bianco P., Sacchetti B.,
Pievani A., Serafini M.* (Monza, Italy)
14:42 - 14:54 PH-O018 - DEFINING MOLECULAR ROADBLOCKS THROUGH AN
INTERMEDIATE STANDSTILL DERIVED DURING REPROGRAMMING
HUMAN FIBROBLAST TO IPS CELL
Zhang L., Liu S., He H., Wang Y.* (Hangzhou, China)
14:54 - 15:06 PH-O019 - BONE MARROW MESENCHYMAL STROMAL CELLS
PROTECT ACUTE LEUKEMIA CELLS FROM CYTOTOXIC AGENTS VIA
GALECTIN-3 MEDIATED WNT/Β-CATENIN SIGNALING
Lou L., Liu L., Hu Y., Gu Y., Huang H., Hu K.* (Hangzhou, China)
52
16:00 - 17:30 Working Party: Chronic Malignancies
Gold Plenary
Chair: Nicolaus Kröger (Germany)
16:00 - 16:10 Introduction and trends in CMWP
16:10 - 16:25 Autologous Stem Cell Transplantation in Amyloidosis
Scientific
Programme
Physicians
AGE-RELATED TRENDS IN UTILISATION AND OUTCOME OF AUTOLOGOUS
HAEMATOPOIETIC CELL TRANSPLANTATION FOR MULTIPLE MYELOMA - A
STUDY BY THE PLASMA CELL SUBCOMMITTEE OF THE EBMT CHRONIC
MALIGNANCIES WORKING PARTY
Holger Auner (United Kingdom)
AUTOLOGOUS TRANSPLANT (AHCT) FOR OLDER PATIENTS WITH MULTIPLE
MYELOMA (MM) - LOW NON-RELAPSE MORTALITY (NRM) AND SIMILAR
BENEFIT AS IN YOUNGER PATIENTS (PTS)
Parameswaran Hari (United States)
16:25 - 16:55 Autologous Stem Cell Transplantation for older patients with
Multiple Myeloma (EBMT and CIBMTR experience)
THE REVISED IPSS (IPSS-R) AT TRANSPLANT PREDICTS OVERALL
AND RELAPSE-FREE SURVIVAL AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION IN MDS/SAML: A RETROSPECTIVE ANALYSIS OF THE
EBMT CHRONIC MALIGNANCIES WORKING PARTY
Christof Scheid (Germany)
PREVENTION AND TREATMENT OF MDS RELAPSE AFTER ALLOGENEIC STEM
CELL TRANSPLANTATION (SCT)
16:55 - 17:30 Allogeneic SCT in MDS:
ONE-YEAR SURVIVAL AFTER AUTOLOGOUS PERIPHERAL BLOOD
TRANSPLANTATION CENTER IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS
HAS STEADILY IMPROVED FROM 1997 TO 2010 IN EBMT CENTERS.
Stefan Shoenland (Germany)
16:00 - 17:00Oral Session 14: Paediatric Diseases 1
Brown 3
Chairs: Peter Bader (Germany) & Franca Fagioli (Italy)
16:00 - 16:12 PH-O097 - CLINICAL IMPACT OF POST-TRANSPLANT CHIMERISM
MONITORING IN CD33/34 BONE MARROW SUBPOPULATIONS
AND WHOLE PERIPHERAL BLOOD IN PAEDIATRIC AML:
PROSPECTIVE COMPARISON OF HIGHLY SENSITIVE REAL TIME
SEQUENCE POLYMORPHISM PCR VERSUS GOLD-STANDARD STRPCR
Rettinger E., Zabel M., Kreyenberg H., Meyer V., Borkhardt A., Metzler
M., Kremens B., Strahm B., Woessmann W., Mauz-Koerholz C., Gruhn B.,
Burdach S., Albert M., Schlegel P.-G., Klingebiel T., Bader P., Merker M.,
Willasch A. M.* (Frankfurt am Main, Germany)
53
16:12 - 16:24
PH-O098 - UNRELATED DOUBLE CORD BLOOD TRANSPLANTATION
IN CHILDREN: A RETROSPECTIVE ANALYSIS ON BEHALF OF
EUROCORD AND PDWP-EBMT ruggeri
A., michel G., dalle J.-H., O’Brien T., seraihy A., Hough R., Deconinck E., Jubert
C., Bittencourt H., Gandemer V., Chastagner P., Skorobogatova E., Fegueux
N., Rialland F., Lawson S., Lioure B., Veys P., Shaw P. J., Passweg J., Xavier E.,
Volt F., Gluckman E., peters C., rocha V., Giannotti F.* (paris, France)
16:24 - 16:36
PH-O099 - MONITORING OF MINIMAL RESIDUAL DISEASE AFTER
ALLOGENEIC STEM CELL TRANSPLANTATION IN RELAPSED
CHILDHOOD ALL ALLOWS THE IDENTIFICATION OF IMPENDING
RELAPSE - RESULTS OF THE ALL BFM SCT 2003 TRIAL
Kreyenberg H., von Stackelberg A., Eckert C., Salzmann-Manrique E., Meisel
R., Poetschger U., Stachel D., Schrappe M., Schrauder A., Schulz A., Lang P.,
Mueller I., Albert M., Willasch A., Klingebiel T., Peters C., Bader P.* (Frankfurt,
Germany)
16:36 - 16:48
PH-O100 - THE ROLE OF MEGATHERAPY (MGT) AND STEM CELL
TRANSPLANTATION (SCT) IN HIGH RISK EWING TUMOURS: MORE
THAN 30 YEARS OF EBMT ACTIVITY.
Poetschger U., Luksch R., Yaniv I., Valteau-Couanet D., Glokova E., Jürgens
H., Dirksen U., Michon J., Oberlin O., van der Berg H., Wheelan J., Lewis I.,
Bregni M., Peters C., Lanza F., Ladenstein R.* and for the EBMT Paediatric
and Solid Tumor Working Groups (Vienna, Austria)
16:48 - 17:00
PH-O101 - OPTIMIZATION OF ECULIZUMAB THERAPY IN
CHILDREN TREATED FOR HSCT-ASSOCIATED THROMBOTIC
MICROANGIOPATHY
Fukuda T., Vinks A., Mizuno K., Laskin B. L., Goebel J., Myers K. C., Bleesing
J., Grimley M., Chandra S., Dandoy C. E., Davies S. M., Jodele S.* (Cincinnati,
United States)
16:00 - 17:30 Working Party: Immunobiology
Amber 3+4
Chairs: Antoine Toubert (France) & Andrea Velardi (Italy)
16:00 - 16:05 Introduction of the Jon van Rood Award
Hans Kolb (Germany)
16:05 - 16:15 Jon J. van Rood Award
HLA class II upregulation during viral infection leads to HLA-DP–directed
graft-versus-host disease after CD41 donor lymphocyte infusion
Sanja Stevanovic (Netherlands)
16:15 - 16:40 Novel perforin positive regulatory dendritic cells in metabolic
syndrome and autoimmunity
Yair Resiner (Israel)
16:40 - 17:05 Balancing immunity and tolerance through metabolic pathways
Francesca Fallarino (Italy)
17:05 - 17:30 Immunoregulatory loops in intestinal GvHD: Focus on microbiome
and IDO
Ernst Holler (Germany
54
3RD Paediatric DAY - TUESDAY, 1 APRIL 2014
08:00 - 09:30 Educational 7: Treatment of viral infections in children after allo-HSCT
Space 1 & 2
Chairs: Jean Hugues Dalle (France) & Paul Veys (United Kingdom)
08:00 - 08:30 CMV
Giuseppe Gerna (Italy)
08:30 - 09:00 HAdV
Thomas Lion (Austria)
Scientific
Programme
Physicians
09:00 - 09:30 Impact of the respiratory viruses on the outcomes of HCT
Jaap Jan Boelens (Netherlands)
09:30 - 11:00 Workshop 9: Childhood GVHD
Space 1 & 2
Chairs: Attilio Rovelli (Italy) & Arian Lankester (Netherlands)
09:30 - 10:00 Biomarkers predictive of GVHD occurrence
James Ferrara (United States)
10:00 - 10:30 Pentraxin and GVHD
Cecilia Garlanda (Italy)
10:30 - 11:00 How to design a randomized clinical trial for childhood acute GVHD
Anita Lawitschka (Austria)
11:30 - 13:00 Workshop 11: Immunotherapy of childhood malignancies
Space 1 & 2
Chairs: Roberto Luksch (Italy) & Peter Bader (Germany)
11.30 - 12.00 Chimeric antigen receptors for Paediatric leukemia: new
advancements for ALL and AML
Ettore Biagi (Italy)
12.00-12.30 Monoclonal antibody for ALL
M. Zwaan (Netherlands)
12.30-13.00 Monoclonal antibodies for Hodgkin lymphoma
Gerhard Zugmaier (Germany)
13:10 - 14:00Lunch Controversy: Which children with AML should be given Space 1 & 2
allo-HSCT in first CR?
Chairs: Gérard Michel (France) & Brenda Gibson (United Kingdom)
13:10 - 14:00 The chemo point of view
Ursula Creutzig (Germany)
13:10 - 14:00 The transplant point of view
55
3RD Paediatric DAY - TUESDAY, 1 APRIL 2014
14:00 - 15:00 Working Party: Paediatrics & Inborn Errors
Space 1 & 2
Chairs: Christina Peters (Austria) & Andrew Gennery (United Kingdom)
14:00 - 14:15 Adrenoleukodystrophy project - update proposal
Jaap Jan Boelens (Netherlands)
14:15 - 14:30 SCETIDE - latest results and outcomes
Nizar Mahlaoui (France)
14:30 - 14:45 DNA Repair defects - outcome of HSCT IEWP/CIBMTR study
Andrew Gennery (United Kingdom)
TECHNICAL ASPECTS OF EXTRACORPOREAL PHOTOPHERESIS FOR
THE TREATMENT OF Paediatric PATIENTS. SUMMARY OF AN
INTERNATIONAL EBMT PAEDIATRIC DISEASES WORKING PARTY
WORKSHOP
Volker Witt (Austria)
PHYSICIANS Programme - Tuesday, 1 April 2014
08:00 - 09:30 Educational 4: Chronic lymphocytic leukemia
Gold Plenary
Chairs: Mauricette Michallet (France) & Claire Dearden (United Kingdom)
08:00 - 08:30 New biological markers
Stephan Stilgenbauer (Germany)
08:30 - 09:00 New drugs for CLL
Claire Dearden (United Kingdom)
09:00 - 09:30 Lost in transition? Transplant indication during transition to a
new era of CLL treatment
Johannes Schetelig (Germany)
08:00 - 09:30 Educational 5: Cellular therapies for severe autoimmune diseases
Space 3
Chairs: Renate Arnold (Germany) & Riccardo Saccardi (Italy)
08:00 - 08:30 Cellular therapy for Multiple Sclerosis
Antonio Uccelli (Italy)
08:30 - 09:00 Epigenetic alterations and HSCT in crohn’s disease
Jack Satsangi (United Kingdom)
09:00 - 09:30 Pharmacoeconomy of HSCT in Ads
Alice Bessey (United Kingdom)
56
08:00 - 09:30 Educational 6: Allogeneic SCT in AML
Brown 3
Chairs: Jan Cornelissen (Netherlands) & Mohamad Mohty (France)
08:00 - 08:30 Age, comorbidities and donor selection
Antonio Pagliuca (United Kingdom)
08:30 - 09:00 Indication to SCT
Jorge Sierra (Spain)
Scientific
Programme
Physicians
09:00 - 09:30 Conditioning regimen
08:00 - 09:30 Workshop 7: Unmanipulated HLA haploidentical SCT transplants
Amber 1+2
Chairs: Fabio Ciceri (Italy) & Xiao-Jun Huang (China)
08:00 - 08:30
Improving outomes of unmanipulated Haploidentical Stem Cell
Transplantation or Unmanipulated Haploidentical Stem Cell
Tramsplantation: Theory and Practice
08:30 - 09:00
Bone Marrow
09:00 - 09:30
Primed BM
Xiao-Jun HUANG (China)
William Arcese (Italy)
09:30 - 11:00 Joint Session Physicians / Nurses: CLABSI project
Space 4
Emilian Snarski (Poland)
Arno Mank (Netherlands)
09:45 - 11:15 Plenary 1: Regulatory aspects in stem cell transplantation and
Gold Plenary
cellular therapy: between science and ethics
Chairs: Alejandro Madrigal (United Kingdom), Mohamad Mohty (France) &
09:45 - 10:00 Advanced therapy medicinal products (ATMP): current challenges
Christian Chabannon (France)
10:00 - 10:15 Defibrotide: A case study
Khalid Islam (Italy)
10:15 - 10:30 Drug approval: the physician perspective
10:30 - 10:45 Drug approval: the EMA perspective
10:45 - 11:00 HHow to transfer scientific results into innovative drugs
Claudio Bordignon (Italy)
57
09:45 - 11:15 Plenary 2: Cooperative trials in progress: Mantle Cell Lymphoma,
Space 3
PTCL, CNS lymphoma
Chair: M. Trney (Czech Republic) & Umberto Vitolo (Italy)
09:45 - 10:15 MCL
Olivier Hermine (France)
10:15 - 10:45 Which treatment of PTCL in 2014?
Bertrand Coiffier (France)
10:45 - 11:15 Ongoing randomized trials in primary CNS lymphoma
Andres Ferreri (Italy)
09:45 - 11:15 Plenary 3: Safety and effectiveness of gene therapy
Brown 3
Chairs: Chiara Bonini (Italy) & Marina Cavazzana Calvo (France)
09:45 - 10:15 Gene therapy for primary immunodeficiencies
Alain Fischer (France)
10:15 - 10:45 Gene therapy for Wiskott-Aldrich Syndrome
Alessandro Aiuti (Italy)
10:45 - 11:15 Gene therapy for phagocytic cell defects and hemophagocytic
lymphohistiocytosis
Claire Booth (United Kingdom)
09:45 - 11:15 Workshop 8: Manipulated HLA haploidentical SCT transplants
Amber 1 & 2
Chairs: Massimo Fabrizio Martelli (Italy) & Yair Reisner (Isreal)
09:45 - 10:15 Selected CD34 cells
Andrea Velardi (Italy)
10:15 - 10:45 T-depleted grafts
Rupert Handgretinger (Germany)
10:45 - 11:15 Split DLI/Cy/CD34
Steve Mackinnon (United Kingdom)
58
09:45 - 11:15 EBMT-WBMT Joint Session - A Scientific Symposium: Hematopoietic
Amber 3+4
Stem Cell Transplantation: Access and Affordability
Chair: Dietger Niederweiser (Germany), Yoshihisa Kodera (Japan), Dennis
Confer (United States), Hildegard Greinix (Austria) & Daniel Weisdorf (United
States)
Dietger Niederweiser (Germany)
09:50 - 10:10 Non-Government Organization (NGO): Status Significance and
Scientific
Programme
Physicians
opportunities of NGO
José Nunez (Switzerland)
10:10 - 10:35
Cost of non-transplant therapy for hematologic malignancies
Jane Apperley (United Kingdom)
10:35 - 10:55 Alternative donor selection: Haploidentical donor
Leo Luznik (United States)
10:55 - 11:15 Cord blood stem cell transplantation
Mary Eapen (United States)
11:30 - 13:00 Working Party: Infectious Diseases
Gold Plenary
Chairs: Simone Cesaro (Italy) & Jan Styczynski (Poland)
11:30 - 11:35
The CMV debate: introduction
11:35 - 11:50
Is pre-emptive therapy still the gold standard for CMV infection
or should be moved to chemo prophylaxis, vaccination or adoptive
immunotherapy? PROS
11:50 - 12:05
Is pre-emptive therapy still the gold standard for CMV infection
or should be moved to chemo prophylaxis, vaccination or adoptive
immunotherapy? CONS
Simone Cesaro (Italy)
Per Ljungman (Sweden)
Hermann Einsele (Germany)
12:15 - 12:30 Must we still fear infection by zygomycetes?
12:30 - 12:45
ECIL 5: new guidelines for Pneumocystis prophylaxis, viral
hepatitis, and update of prophylaxis and treatment fungal infection
12:45 - 12:55
Incidence of Gram Negative bacteremia among EBMT centers: an
IDWP study
Dina Averbuch (Israel)
NON-INTERVENTIONAL PROSPECTIVE MULTICENTER STUDY ON THE
RESISTANCE PATTERN OF GRAM-NEGATIVE BACTERIA ISOLATED
FROM BLOOD FROM HSCT RECIPIENTS, ON BEHALF OF THE IDWP
Diana Averbuch (Israel)
59
11:30 - 13:00 Working Party: Autoimmune Disease
Space 3
11:30 - 11:40
Chairs: John Snowden (United Kingdom) & Dominique Farge (France)
Update of the activity of the EBMT Autoimmune Diseases Working
Party (ADWP)
John Snowden (United Kingdom)
Manuela Badoglio (France)
Dominique Farge (France)
11:40 - 11:55
Cell therapy for Scleroderma the next steps?
11:55 - 12:10
Rationale and results from use of mesenchymal stem cell in lupus
the chinese experience
Prof. Sun (China)
12:10 - 12:25 Stem cell therapy for NMO, CIDP and other rare neurological disease
Raphaela Greco (Italy)
Attilio Bondanza (Italy)
12:25 - 12:40 Mesenchymal Stem Cell for autoimmune Diseases what have we
learned from GVHD?
Katarina LeBlanc (Sweden)
STEM CELL THERAPY FOR NEUROMYELITIS OPTICA, CHRONIC
INFLAMMATORY DEMYELINATING POLYNEUROPATHY AND OTHER
IMMUNE-MEDIATED NEUROLOGICAL DISEASES
UPDATE OF THE ACTIVITY OF THE EBMT AUTOIMMUNE DISEASES
WORKING PARTY (ADWP)
RATIONALE AND RESULTS FROM USE OF MESENCHYMAL STEM CELL IN
LUPUS: THE CHINESE EXPERIENCE
CELL THERAPY FOR SCLERODERMA: THE NEXT STEPS?
BRINGING MESENCHYMAL STEM CELLS INTO THE CLINIC
Raffaela Greco (Italy)
Lingyun SUN (China)
Dominique FARGE (France)
Leblanc Katarina (Sweden)
11:30 - 13:00 Joint session with nurses: Chronic GVHD
Brown 3
Chair: Olle Ringden (Sweden)
11:30 - 12:00 Pathophysiology
Gerard Socié (France)
12:00 - 12:30 Results of the international survey of EBMT-NCI task force
12:30 - 13:00 TKI based treatment
60
Attilio Olivieri (Italy)
11:30 - 13:00 Working Party: Solid Tumours
Brown 1
Chairs: Marco Bregni (Italy) & Francesco Lanza (Italy)
11:30 - 11:45 Role of autologous transplantation in Germ cell Tumor (GCT).
Tiger study
Thomas Powles (United Kingdom)
11:45 - 12:00 EBMT retrospective studies in germ cell tumors
U. De Giorgi (Italy)
Scientific
Programme
Physicians
12:00 - 12:15 Outcome of breast cancer undergoing HDC with autologous
support: data of the Italian registry (GITMO) on 1600 patients
P. Pedrazzoli (Italy)
12:15 - 12:30 Presentation of two clinical protocols of HDC for breast cancers
D. Generali (Italy)
12:30 - 12:45 Stem Cell Trasplantation in pancreatic carcinoma
B. Omazic (Sweden)
12:45 - 13:00 Cell therapy in solid tumors
PRESENTATION OF TWO CLINICAL PROTOCOLS OF HDC FOR
BREAST CANCERS
Daniele Generali (Italy)
GENERATION OF TUMOR-SPECIFIC CYTOTOXIC T-LYMPHOCYTES
FROM PERIPHERAL BLOOD FOR ADOPTIVE T-CELL TRANSFER IN
COLORECTAL CANCER PATIENTS
ROLE OF AUTOLOGOUS TRANSPLANTATION IN GERM CELL TUMOR
(GCT). OVERVIEW OF TIGER STUDY.
FROM PERIPHERAL BLOOD OF COLORECTAL CANCER PATIENTS
FOR ADOPTIVE T-CELL TRANSFER
EBMT RETROSPECTIVE STUDIES IN GERM CELL TUMORS
ALLOGENEIC STEM CELL TRANSPLANTATION IN PANCREATIC
CARCINOMA.
Paolo Pedrazzoli (United Kingdom)
OUTCOME OF BREAST CANCER UNDERGOING HDC WITH
AUTOLOGOUS SUPPORT: DATA OF THE ITALIAN REGISTRY (GITMO)
ON 1600 PATIENTS
61
11:30 - 13:00 Workshop 10: Transplantation in Thalassemia
Amber 1+2
Chairs: Cristina Hereda Diaz (Spain) & Emanuele Angelucci (Italy)
11:30 - 12:00 Long-term follow up
Giovanni Caocci (Italy)
12:00 - 12:30 Transplantation in developing countries
Ardeshir Ghavamzadeh (Iran, Islamic Republic Of)
12:30 - 13:00 No transplant
Maria Domenica Cappellini (Italy)
13:10 - 14:00Lunch Controversy : Role of ATG in HLA-id sibling transplants
Gold Plenary
Chair: Eduardo Olavarria (Spain)
13:10 - 14:00
No
13:10 - 14:00
Yes
Dolores Caballero (Spain)
Didier Blaise (France)
13:10 - 14:00 Basic Science Session II: Inductible Pluripotent Stem Cells
Brown 3
Chairs: Attilio Bondanza (Italy) & Roberto Lemoli (Italy)
13:10 - 13:35
Generating hematopoietic stem cells from human pluripotent stem
cells
13:35 - 14:00
Reprogramming technologies for a better understanding and
treatment of human diseases
Sergei Doulatov (United States)
Juan Carlos Izpisua Belmonte (United States)
13:00 - 14:00Lunch Controversy Support Provided by Sanofi Oncology: Is chemoBrown 1
13:00-13:10
therapy needed for stem cell mobilization in multiple myeloma?
Chair: Francesco Lanza (Italy)
Autolougous Hematopoietic Stem Cell mobilization
13:10-13:50
Yes – chemotherapy is needed for stem cell mobilization in
multiple myeloma
Hermann Einsele (Germany)
No – chemotherapy is not needed for stem cell mobilization in
multiple myeloma
13:50-14:00
Summary and conclusions
Financial support provided by Sanofi
62
13:10 - 14:00NAC Scientific Workshop Protection from Radiation in Major
Amber 1+2
Radiation Incidents
Chair: Bhawna Sirohi (India)
13:10 - 13:25 Benefit of Radio-protectors prior to radiation exposure
Nick Gent (United Kingdom)
13:25 - 13:40 Evidence-based Support in the Nonhuman Primate for Mitigation
of the Acute Radiation Syndrome
Ann Farese (United States)
EBMT NAC Radiation Preparedness
Scientific
Programme
Physicians
13:40 - 13:55
Ray Powles (United Kingdom)
13:10 - 14:00Lunch Controversy: Autografting is the standard first line
Amber 3+4
13:10 - 14:00
treatment in all MCL patients?
Chair: Olivier Hermine (France)
There is no good evidence in favour of transplantation in mantle
cell lymphoma
Robert Marcus (United Kingdom)
13:10 - 14:00
Yes
Stephen Robinson (United Kingdom)
14:00 - 15:30 Plenary 4: Joint session with nurses: Holistic care in transplant
Gold Plenary
Chairs: Elisabeth Wallhult (Sweden) & Alejandro Madrigal (United Kingdom)
14:00 - 14:20 Outcomes in the transplant recipient-caregiver team during
allogeneic transplantation
Moira Stephens (Australia)
14:20 - 14:40 Care of the older patient undergoing transplantation
Margot Gosney (United Kingdom)
14:40 - 15:00 Physical therapy Spiritual care and the role of hope
Tullio Proserpio (Italy)
15:00 - 15:20 Palliative care and end-of-life in the transplant patient
Augusto Caraceni (Italy)
14:00 - 15:00 Plenary 6: Cord Blood Transplantation
Space 3
Chairs: Eliane Gluckman (France) & Guillermo Sang (Spain)
14:00 - 14:30 The selection of the best CB unit
Mary Eapen (United States)
14:30 - 15:00 The best conditioning regimen for single and double CB
transplant
Vanderson Rocha (United Kingdom)
15:00 - 15:30 New modalities of CB transplant (intrabone, expansion, CB+Haplo)
Francesco Frassoni (Italy)
63
14:00 - 15:30 Plenary 5: Infectious Diseases
Brown 3
Chairs: Anna Locasciulli (Italy) & Catherine Cordonnier (France)
14:00 - 14:30 Virology: adenovirus
14:30 - 15:00 ECIL
15:00 - 15:30 Current causes of infection
P. Donnelly (Netherlands)
14:00 - 15:00 JACIE Workshop
Amber 1+2
Chairs: Alessandro Rambaldi (Italy) & Tamer Demirer (Turkey)
14:00 - 15:30 Working Party: Complications and Quality of Life
Amber 3+4
Chairs: Rafael F. Duarte (Spain) & Grzegorz Basak (Poland)
14:00 - 14:10 Chairman’s report
Rafael F. Duarte (Spain)
14:10 - 14:20 Prospective Observational Registry to Collect Safety and
Outcome Data in Patients Diagnosed with Severe VOD Following
Hematopoietic Cell Transplantation and Treated with Defitelio® or
Supportive Care
Rafael F. Duarte (Spain)
14:20 - 14:30 Prospective Non-Interventional Study on Second Line Treatment
of Acute Corticosteroid-Refractory GVHD
Emma das Gupta (India)
14:30 - 14:40 Prospective Non-Interventional Study on the Impact of Uric Acid
Levels Prior to Allogeneic Transplantation and Acute GVHD
Olaf Penack (Germany)
14:40 - 14:50 Graft-Versus-Host Disease: Incidence, Risk Factors and Organ
Involvement after Unrelated Double Cord Blood Transplantation
in Adult Patients with Malignant Hematologic Disorders. A
Retrospective Analysis on Behalf of Eurocord, SFGM-TC and
CQLWP- EBMT.
Vanderson Rocha (United Kingdom)
14:50 - 15:00 Bronchiolitis Obliterans Syndrome: an EBMT Retrospective Study
Mutlu Arat (Turkey)
15:00 - 15:30 Long-Term Follow Up after Transplant: From Guidelines to
Clinical Practice
Bipin Savani (United States)
64
16:45 - 17:45Oral Session 11: Stem Cell Mobilization and Graft engineering
Space 1 & 2
Chairs: Vanderson Rocha (United Kingdom) & Corrado Tarella (Italy)
16:45 - 16:57 PH-O087 - MONONUCLEAR CELL COLLECTION FOR
EXTRACORPOREAL PHOTOCHEMOTHERAPY: PROSPECTIVE
STUDY COMPARING TWO APHERESIS SYSTEMS
Lopez V., Castilla-Llorente C., Iniesta P., Heras I., Nieto J. B., De Arriba F.,
Vicente V., Lozano M. L.* (Murcia, Spain)
Scientific
Programme
Physicians
16:57 - 17:09 PH-O088 - FEASIBILITY AND EFFICACY OF ALLOGENEIC
PERIPHERAL BLOOD PROGENITOR CELL COLLECTIONS ON THE
FOURTH VERSUS THE FIFTH DAY OF G-CSF ADMINISTRATION
Friedrich G., Wachtel A., Loechelt C., Bein G., Sachs U. J., Flommersfeld S.*
(Marburg, Germany)
17:09 - 17:21 PH-O089 - VALIDATION IN A MULTICENTER SETTING OF GITMO
CRITERIA FOR IDENTIFICATION OF THE POOR MOBILIZER
IN MULTIPLE MYELOMA (MM) AND LYMPHOMA PATIENTS:
PRELIMINARY ANALYSIS ON 312 PATIENTS
Di Nardo E., Nuccorini R., Chiarucci M., Nassi L., Mengarelli A., Capria S.,
Ciceri F., Martino M., Piccirillo N., Pascale S., Pizzuti M., Olivieri A., Attolico I.*
(Potenza, Italy)
17:21 - 17:33 PH-O090 - COLLECTION AND TRANSPLANTATION OF
AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS IN PATIENTS
WITH MULTIPLE MYELOMA TREATED WITH LENALIDOMIDE
Alavi A., Schiller G. J., Grubovic R. M.* (Skopje, Macedonia, The Former Yugoslav
Republic Of)
17:33 - 17:45 PH-O091 - THE KINETICS OF NICHE CYTOKINES AND THEIR
INFLUENCE ON MOBILIZATION EFFICACY AND TIMING IN
PATIENTS WITH HEMATOLOGICAL MALIGNANCIES.
Krawczynska A., Czemerska M., Pluta A., Cebula-Obrzut B., Wierzbowska A.,
Robak T., Robak M., Szmigielska K., Grzybowska-Izydorczyk O., SzmigielskaKaplon A.* (Lodz, Poland)
16:45 - 17:45Oral Session 13: Quality of life and quality of care
Space 3
Chairs: Nina Salooja (United Kingdom) & Diana Greenfield (United Kingdom)
16:45 - 16:57 PH-O072 - MACHINE LEARNING BASED PREDICTIVE MODELING
FOR MORTALITY 100 DAYS POST ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTATION (ALLO-HSCT) IN ACUTE
LEUKEMIA: AN EBMT- ACUTE LEUKEMIA WORKING PARTY
(ALWP) REGISTRY STUDY
Labopin M., Bondi O., Mishan-Shamay H., Shimoni A., Ciceri F., Esteve J.,
Giebel S., Gorin N.-C., Schmid C., Zakaria I., Moukhtari L., Polge E., Aljurf
M., Kroger N., Craddock C., Bacigalupo A., Cornelissen J., Baron F., Unger R.,
Nagler A., Mohty M., Shouval R.* and Acute Leukemia Working Party of the
EBMT (Ramat- Gan, Israel)
65
16:57 - 17:09 PH-O073 - SURVIVAL ADVANTAGE FOR PATIENTS WITH AML/
MDS GIVEN ALLOGENEIC SCT USING MYELOABLATIVE VERSUS
REDUCED INTENSITY CONDITIONING (RIC) MAY BECOME
APPARENT 5-10 YEARS AFTER TRANSPLANTATION: RIC STUDIES
MAY NEED TO BE REVISITED AFTER LONG-TERM FOLLOW-UP.
Volchek Y., Danylesko I., Nagler A., Shem-Tov N., Shimoni A.*, Yerushalmi R.
17:09 - 17:21 PH-O074 - CHEMOTHERAPY DOSE ADJUSTMENT FOR
OBESE PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL
TRANSPLANTATION (HSCT): A SURVEY ON BEHALF OF THE ALWP
OF THE EBMT
Labopin M., Shimoni A., Ciceri F., Mohty M., Shem-Tov N., Moukhtari L.,
Esteve J., Giebel S., Gorin N.-C., Schmid C., Nagler A.* (Tel Hashomer, Israel)
17:21 - 17:33 PH-O075 - “JACIE” ACCREDITATION STATUS OF THE TRANSPLANT
TEAM AND OUTCOME AFTER HEMATOPOIETIC STEM CELL
TRANS¬PLANTATION
Brand R., McGrath E., van Biezen A., Baldomero H., Sureda A., Ljungman
P., Chabannon C., Apperley J., Rambaldi A., Gratwohl A.* and for the Joint
Ac¬creditation Committee (JACIE) of the International Society for Cellular
Therapy (ISCT) and the European Group for Blood and Marrow Transplantation
(EBMT), and the European Leukemia Net (ELN). (Basel, Switzerland)
17:33 - 17:45 PH-O076 - INCIDENCE AND RISK FACTORS FOR LIFE-
THREATENING BLEEDING AFTER ALLOGENEIC STEM CELL
TRANSPLANT
Sánchez-Barba M., López-Corral L., Vázquez L., Sánchez-Guijo F., PérezLópez E., Cabrero-Calvo M., López-Godino O., Guerrero C., Alberca I., del
Cañizo C., Caballero D., González-Porras J.-R., Labrador J.* (Salamanca, Spain)
16:45 - 17:45Oral Session 10: Hematopoietic Stem Cells
Brown 3
Chairs: Fabio Benedetti (Italy) & Arnon Nagler (Israel)
16:45 - 16:57 PH-O082 - TREOSULFAN, FLUDARABINE AND
ALEMTUZUMAB CONDITIONING FOR HEMATOPOIETIC STEM
CELL TRANSPLANTATION IN CHILDREN WITH PRIMARY
IMMUNODEFICIENCY: UK EXPERIENCE
Abinun M., Rao K., Nademi Z., Chiesa R., Flood T., Cant A., Hambleton S.,
Amrolia P., Allwood Z., Nikolajeva O., Qasim W., Gaspar H., Veys P., Skinner
R., Samarasinghe S., Gennery A., Slatter M.* (Newcastle upon Tyne, United
Kingdom)
16:57 - 17:09 PH-O083 - OUTCOMES OF HAEMATOPOIETIC STEM CELL
TRANSPLANTATION (HSCT) FOR SEVERE CONGENITAL
NEUTROPENIA PRELIMINARY RESULTS
Fioredda F.* and Aplastic Anemia Working Party, Inborns Error Working
Party, Paediatric Diseases Working Party (Genova, Italy)
66
17:09 - 17:21 PH-O084 - T CELL DEPLETED HAPLOIDENTICAL STEM CELL
TRANSPLANTATION FOLLOWED BY ADD-BACKS OF SUICIDEGENE MODIFIED DONOR T-CELLS OFFERS LONG TERM SURVIVAL
FREE OF IMMUNE SUPPRESSION TREATMENT: A 7 YEARS
FOLLOW-UP IN 56 PATIENTS
Greco R., Oliveira G., Peccatori J., Marcatti M., Guggiari E., Lunghi F.,
Marktel S., Giglio F., Bondanza A., Malerba A., Trinca S., Corti C., Bernardi
M., Lambiase A., Bordignon C., Bonini C., Ciceri F., Lupo-Stanghellini M. T.*
(Milan, Italy)
Scientific
Programme
Physicians
17:21 - 17:33 PH-O085 - CLINICAL IMPACT OF THE NON-USE OF
GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) DURING
THE APLASIA OF AUTOLOGOUS STEM CELL TRANSPLANTATION
(ASCT) IN PATIENTS WITH MULTIPLE MYELOMA (MM)
Andrade Gonzalez X., Correa J. G., Martinez cibrian N., Suarez-Lledó M.,
Ardila A., Martinez C., Urbano-Izpizua A., Rovira M., Rosiñol L., Fernándezaviles F., Gutierrez-Garcia G., Magnano L. C.* (Barcelona, Spain)
17:33 - 17:45 PH-O086 - BLOOD-BRAIN BARRIER PENETRATION OF
TREOSULFAN AND ITS BIOLOGICALLY ACTIVE EPOXIDES IN
JUVENILE AND YOUNG ADULT RATS
Główka F., Baumgart J., Böhm S., Romański M.* (Poznan, Poland)
16:45 - 17:45Oral Session 15: Aplastic Anemia and Autoimmune Diseases
Brown 2
Chairs: Antonio Risitano (Italy) & Monstserrat Rovires (Spain)
16:45 - 16:57 PH-O077 - AUTOLOGOUS HEMATOPOIETIC STEM CELL
TRANSPLANTATION FOR MULTIPLE SCLEROSIS: THE SWEDISH
EXPERIENCE
Fagius J., Iacobaeus E., Svenningsson A., Lycke J., Gunnarsson M., Nilsson
P., Vrethem M., Fredrikson S., Martin C., Sandstedt A., Uggla B., Lenhoff S.,
Johansson J.-E., Isaksson C., Carlson K., Burman J., Hägglund H. G.* (Uppsala,
Sweden)
16:57 - 17:09 PH-O078 - SIMILAR LONG TERM OVERALL SURVIVAL AFTER
ALLOGENEIC HCT FOR SEVERE APLASTIC ANEMIA IN PATIENTS
TRANSPLANTED WITH A RELATED DONOR COMPARED TO AN
UNRELATED DONOR
Jacobsen N., Heilmann C., Sengeløv H., Mortensen B.* (Copenhagen Ø,
Denmark)
17:09 - 17:21 PH-O079 - INCIDENCE AND RISK FACTORS FOR HEMOLYTIC
PAROXYSMAL NOCTURNAL HEMOGLOBINUREA (PNH) IN
APLASTIC ANEMIA (AA) PATIENTS
Golubovskaya I., Ivanova M., Babenko E., Pronkina N., Kruchkova I., Lisukov
I., Afanasyev B., Kulagin A.* (St. Petersburg, Russian Federation)
67
17:21 - 17:33 PH-O080 - EVOLUTION, TRENDS AND LONG TERM OUTCOMES
IN HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN
AUTOIMMUNE DISEASES (ADS): A RETROSPECTIVE STUDY FROM
THE AUTOIMMUNE DISEASES WORKING PARTY (ADWP) OF THE
EBMT 1996-2013
Marjanovic Z., Badoglio M., Saccardi R., Farge D., Snowden J.* and EBMT
Autoimmune Disease Working Party (ADWP) (Sheffield, United Kingdom)
17:33 - 17:45 PH-O081 - NORMALIZATION OF TYPE I INTERFERON (IFN)
SIGNATURE AFTER “IMMUNE RESET” WITH IMMUNOABLATION
AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN SYSTEMIC
LUPUS ERYTHEMATOSUS (SLE)
Biesen R., Kyogoku C., Grün J., Burmester G.-R., Grützkau A., Radbruch A.,
Hiepe F., Arnold R., Alexander T.* (Berlin, Germany)
16:45 - 17:45Oral Session 8: Inborn errors
Amber 1+2
Chairs: Michael Albert (Germany) & Arjan Lankester (Netherlands)
16:45 - 16:57 PH-O067 - UNRELATED UMBILICAL CORD BLOOD
TRANSPLANTATION FOR CHILDREN WITH OSTEOPETROSIS: AN
EUROCORD AND INBORN ERRORS WORKING PARTY (IEWP)EBMT STUDY
Ruggeri A., Zecca M., Gonzales-Vincent M., Bordon V., Yaniv I., Lawson S.,
Poire X., Dini G., Abecasis M., Al-Seraihy A., Kenzey C., Xavier E., Bierings M.,
Gluckman E., Locatelli F., Schulz A., Gennery A., Rocha V., Chiesa R.* (London,
United Kingdom)
16:57 - 17:09 PH-O068 - HAEMATOPOIETIC STEM CELL TRANSPLANTATION
FOR SICKLE CELL DISEASE: AN INTERNATIONAL SURVEY ON
BEHALF OF EUROCORD-MONACORD, EBMT PAEDIATRIC DISEASE
WORKING PARTY AND CIBMTR
Volt F., Locatelli F., Rocha V., Peters C., Labopin M., Devergie A., Cavazzana
M., Cappelli B., Eapen M., Simoes B., Matthes S., Ramanan V., Roberts I., de
la Fuente J., Bernaudin F., Ruggeri A.*, Dalle J. H., Gluckman E. (Paris, France)
17:09 - 17:21 PH-O069 - OUTCOMES OF ALLOGENEIC CORD BLOOD
TRANSPLANTATION FOR LEUKODYSTROPHIES; A JOINT STUDY OF
EUROCORD AND “INBORN ERRORS WP-EBMT”
Ruggeri A., Rocha V., Michel G., Ayas M., O’Brien T., Krivan G., Bordon V.,
Schots R., Rovelli A., Elorza I., Moraleda J. M., Shaw P. J., Renard M., Sykora
K.-W., Or R., Zuckerman T., Abecasis M., Bredius R., Yesilipek A., Diaz M. A.,
Gennery A., Gluckman E., Boelens J. J., Hol J.* and Inborn Errors WP-EBMT
(Utrecht, Netherlands)
17:21 - 17:33 PH-O070 - OUTCOMES OF THALASSEMIA PATIENTS UNDERGOING
TRANSPLANT BY USING MYELOABLATIVE VERSUS REDUCED
TOXICITY CONDITIONING REGIMENS
Pakakasma S., Anurathapan U., Sirachainan N., chuansumrit A., Hongeng
S.* (Bangkok, Thailand)
68
17:33 - 17:45 PH-O071 - SUCCESSFUL HEMATOPOIETIC STEM CELL
TRANSPLANTATION FOR THALASSEMIA MAJOR USING
PREIMPLANTATION GENETIC DIAGNOSIS FOR HLA-MATCHED
DONOR: REPORT OF FOUR Paediatric CASES FROM A SINGLECENTRE
BABACAN O., ATAY A., KUREKCİ A. E., EKER I., GURSEL O.* (Ankara, Turkey)
16:45 - 17:45Oral Session 12: Cell and Gene Therapy 2
Chairs: Martino Introna (Italy) & Fabio Ciceri (Italy)
16:45 - 16:57 PH-O092 - LONG-TERM IMMUNOLOGICAL PROFILE AND T
CELL DYNAMICS IN PATIENTS TREATED WITH ALLOGENEIC
TRANSPLANTATION AND TK-CELLS FOR HEMATOLOGICAL
MALIGNANCIES.
Lupo Stanghellini M. T., Cieri N., Greco R., D’Agostino M., Noviello M.,
Valtolina V., Vago L., Bondanza A., Traversari C., Ruggiero E., Paruzynski A.,
Schmidt M., Von Kalle C., Ciceri F., Bordignon C., Bonini C., Oliveira G.* (Milan,
Italy)
16:57 - 17:09 PH-O093 - THE ARYL HYDROCARBON RECEPTOR ANTAGONIST
STEMREGENIN 1 IMPROVES IN VITRO GENERATION OF HIGHLY
FUNCTIONAL NK CELLS FROM HEMATOPOIETIC PROGENITOR
CELLS
Cany J., Maas F., Jansen J., Blijlevens N., Schaap N., Dolstra H., Roeven M.*
(Nijmegen, Netherlands)
17:09 - 17:21 PH-O094 - TCR TRANSGENIC ALLO-RESTRICTED T CELLS
DIRECTED AGAINST EWING SARCOMA ASSOCIATED ANTIGENS
EZH2 AND CHM1
Thiede M., Kirschner A., Grunewald T., Mall S., Klar R., Niemeyer M.,
Leisegang M., Ridell S., Busch D., Uckert W., Krackhardt A., Burdach S., Thiel
U., Richter G., Blaeschke F.* (Munich, Germany)
17:21 - 17:33 PH-O095 - NK-CELL PRECONDITIONING BEFORE
HAPLOIDENTICAL TRANSPLANTATION IN REFRACTORY ACUTE
MYELOID LEUKEMIA IN CHILDREN
Shelikhova L., Tatarinova O., Kurnikova E., Boyakova E., Shekhovtsova Z.,
Novichkova G., Maschan A., Levadnyi A., Muzalevskii Y., Kazachenok A.,
Baidildina D., Kalinina I., Maschan M.* (Moscow, Russian Federation)
17:33 - 17:45 PH-O096 - NY-ESO-1-SPECIFIC SINGLE EDITED T CELLS ENSURE
TUMOR REJECTION WITHOUT INDUCING XENOGENEIC GVHD
Genovese P., Magnani Z., Landoni E., Provasi E., Lombardo A., Reik A., Cieri
N., Ponzoni M., Ciceri F., Bordignon C., Holmes M., Gregory P., Naldini L.,
Bonini C., Camisa B., Mastaglio S.* (Milan, Italy)
69
Scientific
Programme
Physicians
Amber 3+4
PHYSICIANS Programme - Wednesday, 2 April 2014
08:30 - 10:00 Educational 8: ALL: decision to transplant tailored on MRD
Gold Plenary
Chairs: Dieter Hoelzer (Germany) & Enrica Morra (Itally)
08:30 - 09:00 Philadelphia neg
09:00 - 09:30 Philadelphia + ALL
Oliver Ottmann (Germany)
09:30 - 10:00 The experience in paediatric setting
Christina Peters (Austria)
09:00 - 10:00 Special Lecture: Immune Tolerance
Space 1 & 2
Chairs: Hemann Einsele (Germany)
Speaker: Maria Grazia Roncarolo (Italy)
08:30 - 10:00 Educational 9: Clinical management of Transplant complications
Space 3
Chair: Alessandro Rambaldi (Italy) & Rafael Duarte (Spain)
08:30 - 09:00 The Metabolic Syndrome:Inflammation, Oxidative Stress and
Nutrigenomics for HCT Recipients
Jose Lopez-Miranda (Spain)
09:00 - 09:30 Diagnosis, Prevention and Treatment of Osteoporosis and
Alterations of the Bone Metabolism after HCT
09:30 - 10:00 Mucositis: should we care?
Nicole Blijlevens (Netherlands)
08:30 - 10:00 Educational 11: Allografting in Hodgkin Lymphoma
Brown 1
Chairs: Steve Mackinnon (United Kingdom) & Anna Sureda (Spain)
08:30 - 09:00 Indications and Bridging to transplant
Anna Sureda (Spain)
09:00 - 09:30 SCT strategies
Steve Mackinnon (United Kingdom)
09:30 - 10:00 Treatment of relapse after allogeneic transplantation
Luca Castagna (Italy)
70
08:30 - 10:00 Educational 10: Amyloidosis
Amber 1+2
Chair: Christian Straka (Germany)
08:30 - 09:00 Biology and new drugs
Giampaolo Merlini (Italy)
09:00 - 09:30 Transplantation in Waldenstrom’s macroglobulinemia.
Prognostic factors in high risk.
Scientific
Programme
Physicians
Charalampia Kyriakou (United Kingdom)
08:30 - 11:00 Advanced GITMO/EBMT Training Course
Amber 7
European Approach to the Medical Management of Mass Radiation Exposure
Chairs: Francesco Frassoni (Italy) & Elisabeth Wallhult (Sweden)
08:35 - 08:45 Basic Irradiation Physics for “beginners”
Duncan Cox (United Kingdom)
08:45 - 09:00 Previous incidents / Effects of irradiation
Leif Stenke (Sweden)
09:00 - 09:15 Fukushima
09:15 - 09:30 Scenarios - Hidden Sources/Overt
Duncan Cox (United Kingdom)
09:30 - 09:45 Primary Triage
Tony Bleetman (United Kingdom)
09:45 - 10:00 Secondary Triage METREPOL EBMT Pocket Guide & Closing Remarks
10:00 - 10:10 Secondary Triage Korea
Hyo Rak Lee (Korea, Republic Of)
10.10-10.20 Supportive Therapy to Neuropenic Patients
10:20 - 10:30 BMT protocols /BMT triage
Antonio Pagliuca (United Kingdom)
10:30 - 10:40 Multi-organ dysfunction syndrome
Bhawna Sirohi (India)
10:40 - 10:50 Website support REMM
Dennis Confer (United States)
10:50 - 11:00 Specialist Nursing
71
10:15 - 11:30Oral Session 20: Stem Cell Source
Space 1 & 2
10:18 - 10:30
Chairs: Luca Castagna (Italy) & Francesca Patriarca (Italy)
PH-O102 - CD34 CELL DOSE IS CORRELATED WITH HEMATOLOGIC
RECOVERY BUT NOT CHRONIC GVHD: RESULTS OF THE CBMTG
TRIAL COMPARING G-CSF-MOBILIZED PERIPHERAL BLOOD(GPB) VS G-CSF STIMULATED BONE MARROW(G-BM) IN SIBLING
ALLOGRAFTS FOR HEMATOLOGIC MALIGNANCIES
Aljurf M., Lachance S., Walker I., Toze C., Rubinger M., Lipton J., Lee S., Szer
J., Doocey R., Lewis I., Huebsch L., Howson-Jan K., Lalancette M., Almohareb
F., Chaudhri N., Ivison S., Kariminia A., Fairclough D., Devins G., Szwajcer
D., Foley R., Smith C., Panzarella T., Kerr H., Schultz K., Couban S.* (Halifax,
Canada)
10:30 - 10:42
PH-O103 - SINGLE HIGH-RESOLUTION HLA MISMATCH HAS
SIMILAR ADVERSE IMPACT ON THE OUTCOME OF RELATED
HEMATOPOIETIC STEM CELL TRANSPLANTATION COMPARED WITH
SINGLE LOW-RESOLUTION HLA MISMATCH
Kanda J., Miyamura K., Kubo K., Hidaka M., Adachi S., Ichinohe T., Atsuta
Y., Kanda Y., Fuji S.* and HLA Working Group of the Japan Society for
Hematopoietic Cell Transplantation (Tokyo, Japan)
10:42 - 10:54
PH-O104 - EFFECT OF CD8+ CELL CONTENT ON UMBILICAL CORD
BLOOD TRANSPLANTATION IN ADULTS WITH HEMATOLOGICAL
MALIGNANCIES
Moscardó F., Sanz J., Carbonell F., Larrea L., Montesinos P., Lorenzo I.,
Vera B., Boluda B., Salazar C. J., Cañigral C., Planelles D., Jarque I., Solves P.,
Martín-Aragonés G., López-Chuliá F., Martínez J. A., de la Rubia J., Carpio N.,
Martínez-Cuadrón D., Puig N., Montoro J. A., Roig R., Sanz M. A., Sanz G. F.*
(Valencia, Spain)
10:54 - 11:06
PH-O105 - COMPARATIVE STUDY OF UNRELATED CORD BLOOD
AND NON T-CELL DEPLETED HAPLOIDENTICAL STEM CELL
TRANSPLANTATION IN ADULTS WITH ACUTE LEUKEMIA
Myriam L., Piemontese S., Arcese W., Bacigalupo A., Blaise D., Bosi A.,
Huang H., Karakasis D., Koc Y., Michallet M., Sanz J., Santarone S., Sengelov
H., Sierra J., Vincent L., Sanz G., Gluckman E., Ciceri F., Rocha V., Mohty M.,
Ruggeri A.* and A EUROCORD, ALWP-EBMT STUDY (Paris, France)
11:06 - 11:18
PH-O106 - RESULTS OF HLA-HAPLOIDENTICAL STEM CELL
TRANSPLANTATION AFTER REMOVAL OF ALPHA/BETA+ T CELLS
AND OF CD19+ B CELLS IN CHILDREN WITH ACUTE LEUKEMIA
Pagliara D., Pende D., Rutella S., Falco M. E., Bauquet A., Spagnoli A.,
Lucarelli B., Brescia L. P., Merli P., Andreani M., Li Pira G., Ceccarelli S.,
Grapulin L., Palumbo G., Bernardo M. E., Biagini S., Moretta F., Milano G. M.,
Airoldi I., Moretta A., Moretta L., Locatelli F., Bertaina A.* (Rome, Italy)
11:18 - 11:30
PH-O107 - UNRELATED CORD BLOOD TRANSPLANTATION IN
ADULTS WITH PRIMARY AND SECONDARY MYELOFIBROSIS: A
RETROSPECTIVE STUDY ON BEHALF OF EUROCORD AND CMWPEBMT
Ruggeri A., Deconinck E., Mohty M., Michallet M., Sanz G., Chevallier P., Cahn
J.-Y., Legrand F., Rovira M., Passweg J., Cornelissen J. J., Sierra J., Nguyen S.,
Maillard N., Yakoub-Agha I., Linkesch W., Cannell P., Marcatti M., Bay J.-O.,
Rocha V., Kröger N., Gluckman E., Olavarria E., Robin M., Giannotti F.* (paris,
72
France)
10:15 - 11:30Oral Session 21: Lymphoma
Space 3
Chairs: Maurizio Martelli (Italy) & Harry Shouten (Netherlands)
10:18 - 10:30 PH-O108 - REDUCED INTENSITY ALLOGENEIC SCT ACHIEVES
Boumendil A., Finel H., Schouten H., Maertens J., Sureda A., Rambaldi A.,
Wahlin A., Blaise D., Deconinck E., Cordonnier C., Yakoub-Agha I., Volin
L., Vitek A., Russell N., Ganser A., Veelken J., Vandenberghe E., Faber E.,
Montoto S., Dreger P., Robinson S. P.* and Lymphoma Working Party Of The
EBMT (Bristol, United Kingdom)
10:30 - 10:42 PH-O109 - ALLOGENEIC AND AUTOLOGOUS STEM CELL
TRANSPLANTATION FOR HEPATOSPLENIC T CELL (HSTL)
LYMPHOMA: A RETROSPECTIVE STUDY OF THE EBMT
LYMPHOMA WORKING PARTY.
Schmitz N., Stein H., Finel H., Boumendil A., Vitek A., Avivi I., Bazarbachi
A., Bethge W., Castagna L., Faber E., Fegueux N., Ifrah N., Ljungman P.,
Michallet M., Milpied N., Or R., Poire X., Pretnar J., Rambaldi A., Thomson K.,
Vernant J., Wahlin A., Yeshurun M., Dreger P., Tanase A.* and on behalf of
Lymphoma Working Party (Bucharest, Romania)
10:42 - 10:54 PH-O110 - IMPROVED RESULTS OF MYELOABLATIVE
ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT)
VS REDUCED INTENSITY ALLO-SCT IN MULTIPLY RELAPSED
HODGKIN’S LYMPHOMA (HL) IN RECENT YEARS. AN ANALYSIS ON
BEHALF OF THE LWP OF THE EBMT
Boumendil A., Finel H., Thomson K., Craddock C., Abdel-Rahman F., Cagirgan
S., Mackinnon S., Potter M., Greinix H., Bandini G., Brown P., Colin M., Dreger
P., Sureda A., Stavrik S.* and on behalf of the LWP of the EBMT (Skopje ,
Macedonia, The Former Yugoslav Republic Of)
10:54 - 11:06 PH-O111 - AUTOLOGOUS STEM CELL TRANSPLANTATION FOR
PRIMARY MEDIASTINAL B CELL LYMPHOMA IN THE RITUXIMAB
ERA: A RETROSPECTIVE STUDY OF THE EBMT LYMPHOMA
WORKING PARTY
Boumendil A., Finel H., Nagler A., De Souza C., Ünal A., Botelho de Sousa
A., Ribera Santasusana J. M., Dreger P., Vandenberghe E., Afanasyev B.,
Bordessoule D., Moraleda J. M., Conde E., Pohlreich D., Avivi I.* (Haifa, Israel)
11:06 - 11:18 PH-O112 - EFFECT OF IMMUNOMODULATION FOR PERIPHERAL
T-CELL LYMPHOMA IN RELAPSE AFTER ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANT : A SFGM-TC STUDY
ON 64 PATIENTS.
Levy V., Chevallier P., Vigouroux S., Xhaard A., Contentin N., Mohty M.,
Yakoub-Agha I., Bulabois C. E., Deconink E., Lamy T., huynh A., Fegueux N.,
Turlure P., Maury S., Beguin Y., Bourhis J.-H., Bilger K., Bay J.-O., Guillerm G.,
Suarez F., Maillard N., Rialland F., Jubert F., Nguyen Quoc S., Mamez A.-C.*
(Paris, France)
73
Scientific
Programme
Physicians
LONG TERM DISEASE CONTROL IN PATIENTS WITH FOLLICULAR
LYMPHOMA RELAPSING AFTER A PRIOR AUTOLOGOUS SCT AND
MAY OVERCOME THE ADVERSE IMPACT OF EARLY RELAPSE POST
AUTOSCT. AN EBMT LYMPHOMA WORKING PARTY ANALYSIS
11:18 - 11:30 PH-O113 - AUTOLOGOUS HEMATOPOIETIC STEM CELL
TRANSPLANTATION (HCT) WITH OR WITHOUT TOTAL BODY
IRRADIATION (TBI) IN NEWLY DIAGNOSED MANTLE CELL
LYMPHOMA (MCL) PATIENTS. A RETROSPECTIVE EVALUATION OF
132 PATIENTS FROM THE POLISH LYMPHOMA RESEARCH GROUP
(PLRG).
Romejko-Jarosinska J., Jurczak W., Krawczyk K., Giza A., Czerw T., Giebel
S., Czyz A., Kopinska A., Spychalowicz W., Drozd-Sokolowska J., DerenWagemann I., Wrobel T., Subocz E., Halaburda K., Chmielowska E., Osiadacz
W., Brzeska B., Walewski J., Szymczyk M.* (Warsaw, Poland)
10:15 - 11:30Oral Session 22: Paediatric Diseases 2
Space 4
Chairs: Andrea Biondi (Italy) & Isaac Yaniv (Israel)
10:18 - 10:30 PH-O114 - OUTCOMES OF UNRELATED CORD BLOOD
TRANSPLANTATION FOR PATIENTS WITH INFANT LEUKEMIA
Volt F., Michel G., Diaz de Heredia C., Abecasis M., Zecca M., Locatelli F.,
Vora A., Yakouben K., Gluckman E., Rocha V., O’Obrien T., Cornish J., Peters
C., Lanino E., Ruggeri A., Dalle J. H.* and Eurocord and PDWP-EBMT (Paris,
France)
10:30 - 10:42 PH-O115 - “WE CAN WORK IT OUT” - THE DEVELOPMENT
OF A CONSENSUS APPROACH TO PAEDIATRIC STEM CELL
TRANSPLANTATION IN THE UK
Veys P., Steward C. G., Vora A., Gibson B., Skinner R., Shenton G., Campbell
H., Velangi M., Hough R., de la Fuente J., Connor P., O’Marcaigh A., Amrolia
P., Potter M., Wynn R. F.* (Manchester, United Kingdom)
10:42 - 10:54 PH-O116 - ALEMTUZUMAB CONCENTRATIONS AFTER STEM
CELL TRANSPLANTATION IN CHILDREN: IMPACT ON IMMUNE
RECOVERY
Clemens E., Jansen-Hoogendijk A. M., Hale G., Lankester A. C., Bredius R. G.,
van Tol M. J., Jol-van der Zijde C. M.* (Leiden, Netherlands)
10:54 - 11:06 PH-O117 - ALLOGENIC STEM CELL TRANSPLANTATION IN
AMEGACARYOCYTOSIS : RESULTS OF A RETROSPECTIVE STUDY IN
EBMT CENTERS
DALISSIER A., ALAHMARI A. A., CORNISH J., SEDLACEK P., YANIV I., PETERS
C. P., Mony F., Jean-Hugues D.* (PARIS, France)
11:06 - 11:18 PH-O118 - “UNLICENSED” KILLER IMMUNOGLOBULIN-LIKE
RECEPTOR (KIR)-NEGATIVE NK CELLS MEDIATE GRAFT VERSUS B
CELL PRECURSOR LEUKEMIA ALLOREACTIVITY IN VIVO.
Kübler A., Woiterski J., Handgretinger R., Hartwig U., Herr W., Witte K.,
Mezger M., Oevermann L., Andre M. C.* (Tuebingen, Germany)
11:18 - 11:30 PH-O119 - HLA-HAPLOIDENTICAL T-CELL DEPLETED
HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN
WITH FANCONI ANEMIA
74
Strocchio L., Pagliara D., Comoli P., Bertaina A., Giorgiani G., Perotti C.,
Corbella F., Brescia L., Locatelli F., Zecca M.* (Pavia, Italy)
10:15 - 11:30Oral Session 18: Paediatric and Adult Solid tumors
Brown 1
Chairs: Brigitta Omazic (Sweden) & Paolo Pedrazzoli (Italy)
10:18 - 10:30 PH-O120 - RISK FACTORS WITHIN THE EUROPEAN HIGH RISK
NEUROBLASTOMA HR-NBL1/SIOPEN TRIAL.
Scientific
Programme
Physicians
Poetschger U., Luksch R., Brock P., Castel V., Yaniv I., Papadakis V., Laureys
G., Malis J., Balwierz W., Ruud E., Kogner P., Schroeder H., Forjaz De Lacerda
A., Beck-Popovic M., Bician P., Garami M., Trahair T., Ambros P., Holmes K.,
Gaze M., Pearson A. D., Valteau-Couanet D., Ladenstein R.* and For the
SIOP Europe Neuroblastoma Group (Vienna, Austria)
10:30 - 10:42 PH-O121 - REDUCED INTENSITY CONDITIONING REGIMEN AND
ALLOGENEIC STEM CELL TRANSPLANTATION FROM RELATED
OR UNRELATED HLA IDENTICAL DONOR IN ADVANCED SOLID
TUMOURS.
Rondelli R., Caselli D., Lanino E., Messina C., Luksch R., Pession A., Zecca
M., Favre C., Rabusin M., Locatelli F., Fagioli F., Prete A.* and On behalf of
AIEOP-HSCT, GITMO and ISG Working Group (Bologna, Italy)
10:42 - 10:54 PH-O122 - LONG-TERM FOLLOW UP OF PATIENTS UNDERGOING
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AS
TREATMENT FOR SOLID TUMORS.
Mattsson J., Remberger M., Ringdén O., Omazic B.* (Stockholm, Sweden)
10:54 - 11:06 PH-O123 - ADJUVANT HIGH-DOSE CHEMOTHERAPY WITH
AUTOLOGOUS HEMATOPOIETIC STEM CELL SUPPORT FOR 1183
HIGH-RISK PRIMARY BREAST CANCER PATIENTS: FINAL RESULTS
FROM THE ITALIAN NATIONAL REGISTRY
Castagna L., Martino M., Pedrazzoli P.* and on behalf of Gruppo Italiano
per il Trapianto di Midollo Osseo, Cellule staminali emopoietiche e terapia
cellulare (GITMO) - Sezione Tumori Solidi (Pavia, Italy)
11:06 - 11:18 PH-O124 - IMPACT OF DISEASE RESPONSIVENESS PRE-
TRANSPLANT ON SURVIVAL IN ADULT MALES WITH GERM CELL
TUMORS (GCT). EARLY RESULTS AND IMPLICATIONS FOR THE
SALVAGE TREATMENT STRATEGY.
Secondino S., Giannatempo P., Lo Vullo S., Farè E., Di Nicola M., Magni
M., Raggi D., Paternò E., Nicolai N., Salvioni R., Mariani L., Gianni A. M.,
Pedrazzoli P., Necchi A.* (Milano, Italy)
11:18 - 11:30 PH-O125 - CYTOKINE-INDUCED KILLER (CIK) CELLS EFFECTIVELY
KILL CHEMO-RESISTANT MELANOMA INCLUDING PUTATIVE
CANCER STEM CELLS
Giraudo L., Leuci V., Mesiano G., Todorovic M., Cangemi M., Zaccagna
A., Pisacane A., Gallo S., Carnevale-Schianca F., Aglietta M., Sangiolo D.,
Gammaitoni L.* (Candiolo (Torino), Italy)
75
10:15 - 11:30Oral Session 19: Acute Leukemia
Brown 2
10:18 - 10:30
Chairs: Frederic Baron (Belgique) & Arnon Nagler (Israel)
PH-O126 - UNMANIPULATED HAPLOIDENTICAL TRANSPLANTS
FOR ACUTE MYELOID LEUKEMIA (AML) AND REFRACTORY ANEMIA
WITH EXCESS BLASTS (RAEB)
Gualandi F., Dominietto A., Varaldo R., van Lint M. T., Ghiso A., Bregante S.,
Di Grazia C., Galaverna F., Stasia A., Lamparelli T., Bacigalupo A., Raiola A.
M.* (Genoa, Italy)
10:30 - 10:42
PH-O127 - ALLOGENEIC STEM CELL TRANSPLANTATION FOR
ACUTE MYELOID LEUKEMIA WITH NORMAL CYTOGENETICS
(CN-AML): OUTCOME, RISK FACTORS AND ROLE OF MOLECULAR
SUBGROUPS IN 1006 PATIENTS - A REPORT FROM THE ACUTE
LEUKEMIA WORKING PARTY OF EBMT
Labopin M., Socie G., Rambaldi A., Schwerdtfeger R., Vigouroux S., Deconinck
E., Huynh A., Volin L., Bourhis J.-H., Maertens J., Chevalier P., Jindra P.,
Schlimok G., Cornelissen J., Ifrah N., Nagler A., Polge E., Esteve J., Mohty
M., Schmid C.* and Acute Leukaemia Working Party of EBMT (Augsburg,
Germany)
10:42 - 10:54
PH-O128 - PHASE I TRIAL OF ESCALATED DOSES OF TARGETED
MARROW/LYMPHOID IRRADIATION (TMLI) DELIVERED
BY TOMOTHERAPY COMBINED WITH ETOPOSIDE AND
CYCLOPHOSPHAMIDE; AN ALLOGENEIC HCT PREPARATIVE
REGIMEN FOR PATIENTS WITH REFRACTORY LEUKEMIA.
Palmer J., O’Donnell M., Snyder D., Tsai N.-C., Parker P., Farol L., Spielberger
R., Sahebi F., Murata-Collins J. L., Senitzer D., Radany E., Schultheiss T., Liu
A., Wong J., Forman S. J., Stein A. S.* (Duarte, United States)
10:54 - 11:06
PH-O129 - CIITA-DEPENDENT TRANSCRIPTIONAL
DOWNREGULATION OF HLA CLASS II RESULTS IN LEUKEMIA
IMMUNE ESCAPE AND RELAPSE AFTER ALLOGENEIC HSCT
Cittaro D., Lazarevic D., Bernardi M., Peccatori J., Bonini C., Fleischhauer
K., Ciceri F., Stupka E., Riba M., Zito L., Barcella M., Spinelli O., Crucitti L.,
Rambaldi A., Barlassina C., Vago L., Toffalori C.* (Milano, Italy)
11:06 - 11:18
PH-O130 - UNMANIPULATED GRAFT HAPLOINDENTICAL
ALLOGENEIC STEM CELL TRANSPLANTATION (HAPLO-SCT) IN
ACUTE LEUKEMIA: A LONG-TERM FOLLOW-UP SURVEY ON
BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY (ALWP)
OF THE EUROPEAN GROUP FOR BLOOD AND MARROW
TRANSPLANTATION (EBMT).
Ciceri F., Labopin M., Gorin N. C., Huang H., Di Bartolomeo P., Depei W.,
Beelen D., Koc Y., Afanasyev B., Bacigalupo A., Tischer J., Arcese W., Mohty
M., Piemontese S.* and Acute Leukemia Working Party (ALWP) of the
European Group for Blood and Marrow Transplantation (EBMT). (Milano, Italy)
11:18 - 11:30
PH-O131 - MOBILIZATION-DRIVEN POST-CONSOLIDATION
THERAPY IN 72 ELDERLY AML PATIENTS: FEASIBILITY AND
EFFICACY OF ASCT VS LOW DOSE GEMTUZUMAB-OZOGAMICIN
Capelli D., Chiarucci M., Poloni A., Saraceni F., Mancini G., Trappolini S.,
Montanari M., Scortechini I., Rupoli S., Offidani M., Scortechini A. R., Gini G.,
Discepoli G., Leoni P., Olivieri A.* (Ancona, Italy)
76
10:15 - 11:45Oral Session 17: Multiple Myeloma
16:45 - 16:57
Chairs: M. Boccadoro (Italy) & Laurent Garderet (France)
PH-O132 - CYCLOPHOSPHAMIDE-LENALIDOMIDEDEXAMETHASONE VS ASCT, FOLLOWED BY MAINTENANCE WITH
LENALIDOMIDE-PREDNISONE VS LENALIDOMIDE ALONE IN
NEWLY DIAGNOSED MM PATIENTS: A PHASE 3 RANDOMIZED EMN
TRIAL
Palumbo A., Spencer A., Di Raimondo F., Zdenek A., Larocca A., Falcone A.
P., Catalano L., Finsinger P., Scudla V., Aschero S., Offidani M., Liberati A. M.,
Carella A. M., Maisnar V., Donato F., Caravita T., Corradini P., Ria R., Pulini
S., Stocchi R., Conticello C., Petrucci M. T., Hajek R., Boccadoro M., Gay F.*
(Torino, Italy)
16:57 - 17:09
PH-O133 - SUPERIOR DURABILITY OF RESPONSE WHEN A
SECOND AUTOLOGOUS STEM CELL TRANSPLANT CONSOLIDATES
BORTEZOMIB-CONTAINING RE-INDUCTION THERAPY FOR
RELAPSED MULTIPLE MYELOMA (MM): FINAL RESULTS FROM THE
BSBMT/UKMF MYELOMA X (INTENSIVE) TRIAL.
Williams C., Cairns D. A., Chalmers A., Cavenagh J., Snowden J., Parrish C.,
Ashcroft J., Yong K., Cavet J., Hunter H., Bird J., O’Connor S., Brown J., Morris
T., Cook G.* and National Cancer Research Institute UK, Myeoma Sub-group
(Leeds, United Kingdom)
17:09 - 17:21
PH-O134 - HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM
CELL TRANSPLANTATION (ASCT) INDUCES DURABLE REMISSIONS
IN PATIENTS WITH POEMS SYNDROME: A RETROSPECTIVE STUDY
OF THE PLASMA CELL DISORDERS SUBCOMMITTEE OF THE
CHRONIC MALIGNANCY WORKING PARTY OF THE EBMT.
Garderet L., Iacobelli S., van Biezen A., Hoek J., Rovira M., Byrne J.,
Bordessoule D., Leone G., Nagler A., Castagna L., Cook M., Legros L.,
Ossenkoppele G., Leblond V., Morris T., Kroger N., Cook G.* and Plasma
Cell Disorders Sub-group, Chronic Malignancy Work Party (Leeds, United
Kingdom)
17:21 - 17:33
PH-O135 - STEM CELL HARVESTING AFTER RE-INDUCTION WITH
A BORTEZOMIB-BASED REGIMEN FOR MULTIPLE MYELOMA
RELAPSING AFTER AUTOLOGOUS STEM CELL TRANSPLANT IS
FEASIBLE, SAFE AND EFFECTIVE: RESULTS FROM THE BSBMT/
UKMF MYELOMA X (INTENSIVE) TRIAL.
Cook G., Williams C., Cairns D., Cavenagh J., Snowden J. A., Ashcroft J., Cavet
J., Hunter H., Bird J. M., Chalmers A., Brown J., Yong K., Schey S., Morris T.,
Chown S., Parrish C.* and National Cancer Research Institute Haematooncology Clinical Studies Group (Leeds, United Kingdom)
17:33 - 17:45
PH-O136 - TANDEM AUTOHSCT WITH SEQUENTIAL USE OF
TOTAL MARROW IRRADIATION AND HIGH-DOSE MELPHALAN IN
MULTIPLE MYELOMA. INTERIM ANALYSIS OF A PHASE II CLINICAL
TRIAL
Kruzel T., Sadus-Wojciechowska M., Najda J., Czerw T., Mendrek W., Blamek
S., Glowacki G., Jochymek B., Matulewicz L., Radwan M., Leszczynski W.,
Dolla L., D’Amico A., Slosarek K., Holowiecki J., Miszczyk L., Giebel S.* (Gliwice,
Poland)
77
Scientific
Programme
Physicians
Amber 1+2
10:15 - 11:30Oral Session 24: Minimal Residual Disease and Reduced-Intensity
Amber 8
Conditioning
Chairs: Marco Ladetto (Italy) & Renato Bassan (Italy)
10:18 - 10:30 PH-O143 - IMPACT OF RABBIT ANTI-THYMOCYTE GLOBULIN-
CONTAINING REDUCED-INTENSITY CONDITIONING REGIMENS ON
OUTCOMES OF ADULTS UNDERGOING UNRELATED CORD BLOOD
TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCIES
Ruggeri A., Blaise D., Mohty M., Fegueux N., Chevallier P., Cornelissen J.,
Maillard N., Milpied N., Petersen E., Linkesch W., Sengeloev H., Kenzey
C., Gluckman E., Rocha V., Yakoub-Agha I., Pascal L., Tucunduva L.* and
EUROCORD and EBMT (Paris, France)
10:30 - 10:42 PH-O144 - REDUCED INTENSITY ALLOGENEIC STEM CELL
TRANSPLANT IN PATIENTS WITH MULTIPLE MYELOMA: A
COMPARISON OF TANDEM AUTO-ALLOGRAFT TO EARLY
REDUCED INTENSITY ALLOGRAFT AS UPFRONT TRANSPLANT: AN
EBMT ANALYSIS ON BEHALF OF THE PLASMA CELL DISORDERS
Iacobelli S., Van Biezen A., Volin L., Dreger P., Michallet M., Ljungman P. T.,
Morris C. T., Schonland S., de Witte T., Garderet L., Henseler A., Schaap N. P.,
López-Corral L., Poire X., Passweg J., Hamljadi R. M., Kroeger N., Gahrton G.,
Sahebi F.* (Duarte, United States)
10:42 - 10:54 PH-O145 - MINIMAL RESIDUAL DISEASE (MRD) ASSESSMENT IN
POST-FIRST RELAPSE RE-INDUCTION IS PREDICTIVE FOR TIME
TO PROGRESSION (TTP): RESULTS FROM THE BSBMT/UKMF
MULTIPLE MYELOMA (MM) X INTENSIVE TRIAL
De Tute R. M., Cairns D. A., Fletcher M., Owen R. G., Williams C., Cavanagh J.
D., Snowden J. A., Rawstron A. C., Parrish C., Morris T. C., Brown J. M., Cook
G., Ashcroft J.* (Wakefield, United Kingdom)
10:54 - 11:06 PH-O146 - PREDICTIVE SCORES FOR NON-RELAPSE MORTALITY
FOLLOWING ALLOGENEIC HSCT: ONE SIZE FITS ALL OR A
TAILORED SCORE FOR RECIPIENTS OF REDUCED INTENSITY
CONDITIONING WITH AML IN CR1? - A STUDY FROM THE EBMT
ACUTE LEUKEMIA WORKING PARTY.
Labopin M., Niederwieser D., Schlenk R. F., Socié G., Milpied N., Nagler
A., Blaise D., Rocha V., Cornelissen J. J., Mohty M., Versluis J.* (Rotterdam,
Netherlands)
11:06 - 11:18 PH-O147 - IMPACT OF THE INTENSITY OF THE PROPHYLACTIC
IMMUNOSUPRESSIVE THERAPY IN HLA IDENTICAL ALLOGENEIC
STEM CELL TRANSPLANTATION FOR CR1 AML CONDITIONED
WITH A FLUDARABINE- IV BUSULFAN REGIMEN: A
RETROSPECTIVE STUDY OF THE ALWP OF THE EBMT
Labopin M., Blaise D., Socié G., Huynh A., Chevallier P., Vigouroux S., Dulabois
C. E., Fegueux N., Nguyen-Quoc S., Lioure B., Caballero D., Lemasle E., Nagler
A., Mohty M., Rubio M. T.* (PARIS CEDEX 12, France)
78
11:18 - 11:30
PH-O148 - CONDITIONING INTENSITY IN MIDDLE AGED PATIENTS
WITH AML IN CR1. NO ADVANTAGE FOR MYELOABLATIVE REGIMENS IRRESPECTIVE OF THE RISK GROUP. AN OBSERVATIONAL
ANALYSIS BY THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT
Labopin M., Cornelissen J., Volin L., Socié G., Huynh A., Tabrizi R., Wu
D., Craddock C., Schaap N., Kuball J., Chevallier P., Cahn J.-Y., Blaise D.,
Ghavamzadeh A., Bilger K., Ciceri F., Nagler A., Schmid C., Giebel S., Mohty
M., Passweg J. R.* and Acute Leukemia Working Party of the European
Blood and Marrow Transplant Group (EBMT) (Basel, Switzerland)
Suite 3
10:18 - 10:30
Scientific
Programme
Physicians
10:15 - 11:30Oral Session 25: Infectious Complications 2
Chairs: Dina Averbuch (Israel) & Rafael de la Cámara (Spain)
PH-O149 - PROSPECTIVE MULTICENTER RANDOMIZED TRIAL
COMPARING ANTIFUNGAL EFFECT OF GM-CSF, G-CSF, OR
COMBINATION OF GM-CSF AND G-CSF FOR NEUTROPENIC
RECIPIENTS OF ALLOGENEIC STEM CELL TRANSPLANTATION
Zhou J., Lai Y., Jiang M., Song Y., Wan L., Wang C.* (shanghai, China)
10:30 - 10:42 PH-O150 - T-CELL DONOR REGISTRY FOR THIRD PARTY
ADOPTIVE IMMUNOTHERAPY IN HEMATOPOIETIC CELL AND
SOLID ORGAN TRANSPLANTATION
Maecker-Kolhoff B., Tischer S., Sukdolak C., Bunse C., Figuieiredo C.,
Goudeva L., Immenschuh S., Heuft H.-G., Blasczyk R., Eiz-Vesper B.*
(Hannover, Germany)
10:42 - 10:54
PH-O151 - IMMUNOGENICITY AND SAFETY OF 4 DOSES OF
13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE FOLLOWED
BY 1 DOSE OF 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE
VACCINE IN ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANT RECIPIENTS AGED ≥2 YEARS: AN OPEN LABEL
CLINICAL TRIAL
Ljungman P., Juergens C., Maertens J., Selleslag D., Sundaraiyer V., Clarke K.,
Gruber W. C., Scott D. A., Schmoele-Thoma B., Cordonnier C.* (Créteil, France)
10:54 - 11:06
PH-O152 - PROPHYLACTIC SINGLE DONOR GRANULOCYTE
TRANSFUSIONS IMPROVE THE OUTCOME OF HIGH
RISK PAEDIATRIC PATIENTS UNDERGOING STEM CELL
TRANSPLANTATION WITH KNOWN BACTERIAL AND FUNGAL
INFECTIONS: A 10-YEAR SINGLE CENTRE EXPERIENCE.
Mijovic A., Veys P., Bagkeris M., Amrolia P., Rao K., Chiesa R., Silva J., Finch
M., Nikolajeva O.* (London, United Kingdom)
11:06 - 11:18
PH-O153 - A MATCHED-PAIR ANALYSIS OF INFECTIONS AND
RELATED MORTALITY IN HAPLOIDENTICAL VS HLA IDENTICAL
TRANSPLANTATION.
Maffongelli G., Tatarelli P., De Angelis G., Cerretti R., Picardi A., Cudillo L.,
Di Piazza F., Benedetta M., Gentile G., Andreoni M., Arcese W., Sarmati L.*
(Roma, Italy)
11:18 - 11:30
PH-O154 - CHARACTERIZATION OF POLYOMAVIRUS VP1 SPECIFIC
CD8+ T CELLS
Malcherek G., Dreger P., Ho A. D., Mani J., Gedvilaite A., Wang L., Schmitt A.,
Michael S.* (Heidelberg, Germany)
79
10:15 - 11:30Oral Session 26: Late Effects 2
Suite 4
Chairs: Alois Gratwhol (Switzerland) & Franco Aversa (Italy)
10:18 - 10:30 PH-O155 - CAPILLARY LEAK SYNDROME IN THE Paediatric
POPULATION: INCIDENCE, RISK FACTORS AND PROGNOSTIC
VALUE.
Daniel J., Sörensen J., Jarisch A., Rettinger E., Willasch A., Klingebiel T., Bader
P., Lucchini G.* (frankfurt am main, Germany)
10:30 - 10:42 PH-O156 - INFLUENCE OF GRAFT-VERSUS-HOST DISEASE
ON LATE RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCIES:
A NATIONWIDE RETROSPECTIVE STUDY FROM THE LATE
COMPLICATIONS AND QUALITY-OF-LIFE WORKING GROUP OF
JSHCT
Kuwabara H., Ohashi K., Uchida N., Fukuda T., Miyamura K., Mori S.-I., Kato
K., Tanaka J., Adachi S., Atsuta Y., Yamashita T.* (Tokyo, Japan)
10:42 - 10:54 PH-O157 - IMPROVED NON-RELAPSE MORTALITY AFTER
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
OVER 3 DECADES: A SINGLE-INSTITUTION HISTORICAL
EXPERIENCE
Chevallier P., Guillaume T., Delaunay J., Legouill S., Harrousseau J.-L.,
Moreau P., Milpied N., Mohty M., Malard F.* (Nantes, France)
10:54 - 11:06 PH-O158 - CAUSES OF MORTALITY AFTER ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION IN 2126
CONSECUTIVE PATIENTS: COMPARISON AMONG HLA-MATCHED
RELATED, UNRELATED AND HAPLOIDENTICAL HSCT
Wang F., Wang Y., Liu D., Xu L., Liu K., Huang X., Yan C. H.* (Beijing, China)
11:06 - 11:18 PH-O159 - BONE LOSS IS SEEN AS EARLY AS 100 DAYS IN
PATIENTS POST ALLOGENEIC HAEMATOPOIETIC STEM CELL
TRANSPLANT
Kendler D., Pajerski B., Broady R.* (VANCOUVER, Canada)
11:18 - 11:30 PH-O160 - RECOMBINANT THROMBOMODULIN FOR
THE TREATMENT OF TRANSPLANTATION-ASSOCIATED
COAGULOPATHY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Nomura S., Ito T., Katayama Y., Kyo T., Ota S., Seki M., Chiba S., Maeda Y.,
Tanimoto M., Ikezoe T., Yagi H., Ishida Y., Fujishima N., Sawada K., Ishii K.*
and SIGHT Study Group (Hirakata, Japan)
80
10:15 - 11:30Oral Session 23: GVHD 2
Suite 5
Chairs: Ernst Holler (Germany) & Enric Carreras (Spain)
10:18 - 10:30 PH-O137 - THE JAK1/JAK2 INHIBITOR, RUXOLITINIB
SUBSTANTIALLY AFFECTS NK CELL BIOLOGY
Janna R., Cornez I., Brossart P., Wolf D., Schönberg K.* (Bonn, Germany)
10:30 - 10:42 PH-O138 - SNPS IN THE PROMOTER REGION OF THE IL17A GENE
Scientific
Programme
Physicians
ALLOW ANTICIPATION OF COMPLICATIONS AFTER SIBLING HLAIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION (ALLOSCT).
Martínez-Laperche C., González-Rivera M., Bosch-Vizcaya A., MartínAntonio B., Guillem V., Nieto J., González M., de la Cámara R., Brunet S.,
Jiménez-Velasco A., Espigado I., Vallejo C., Sampol A., Serrano D., Kwon
M., Gayoso J., Balsalobre P., Urbano-Izpizua A., Solano C., Gallardo D.,
Díez-Martín J., Buno I., Buces E.* and on behalf of the Spanish Group for
Hematopoietic Transplantation (GETH) (Madrid, Spain)
10:42 - 10:54 PH-O139 - LACK OF DONOR DERIVED IL-17A AND IL-17F ACCELERATES GVHD BY ALTERATION OF RECIPIENT’S INTESTINAL BARRIER
Hoffmann K., Mottok A., Ganser A., Förster R., Prinz I., Koenecke C., Schreder
A.* (Hannover, Germany)
10:54 - 11:06 PH-O140 - DOUBLE CORD BLOOD TRANSPLANTATION:
INCIDENCE, ORGAN INVOLVEMENT AND RISK FACTORS OF ACUTE
GRAFT VERSUS HOST DISEASE. A RETROSPECTIVE ANALYSIS ON
BEHALF OF EUROCORD-EBMT
Ruggeri A., Rocha V., Gluckman E., Chevallier P., Deconinck E., Cornelissen
J. J., Blaise D., Cahn J.-Y., Milpied N., Mohty M., Michallet M., Bourhis J.-H.,
Fegueux N., Socié G., Labopin M., Sengeloev H., Karakasis D., Mannone L.,
Nagler A., Guilhot F., Clement L., Bay J.-O., Lamy T., Petersen E., McQuaker
G., Craddock C., Tischer J., Kenzey C., Giannotti F., Xavier E.* (Paris, France)
11:18 - 11:30 PH-O142 - COULD PROPHYLACTIC ANTITHYMOCYTE GLOBULIN BE-
FORE ALLOGENEIC STEM CELL TRANSPLANTATION REDUCE RISK OF
PULMONARY GVHD IN ADULT PATIENTS WITH ACUTE LEUKEMIA?
Lin C.-T., Tang J.-L., Yao M., Li C.-C., Ko B.-S., Huang S.-Y., Wu S.-J., Liu J.-H.,
Liao X.-W.* (Taipei, Taiwan, Province of China)
11:30 - 13:00 Plenary 7: Acute Myeloid Leukemia Cooperative Trials in Progress
Gold Plenary
Chairs: Guillermo Sanz (Spain) & Alan Burnett (United Kingdom)
11:30 - 12:00 MRC
Alan Burnett (United Kingdom)
12:00 - 12:30 GIMEMA - AML trials
Adriano Venditti (Italy)
12:30 - 13:00 Polish leukemia group
81
11:30 - 13:00 Plenary 8: Myeloma Cooperative Trials in Progress
Space 1 & 2
Chairs: Michele Cavo (Italy) & Roman Hajek (Czech Republic)
11:30 - 12:00
EMN
12:00 - 12:30
MRC
12:30 - 13:00
IFM
Pieter Sonneveld (Netherlands)
G. Morgan (United Kingdom)
11:30 - 13:00 Workshop 14: Novel Monoclonal antiboby in hematology
Space 3
Chairs: I Yakoub-Agha (France) & Mohamad Mohty (France)
11:30 - 12:00
Acute lymphoblastic leukemia
12:00 - 12:30
Multiple myeloma
12:30 - 13:00
B-cell lymphomas
Max Topp (Germany)
Umberto Vitolo (Italy)
11:30 - 13:00 EBMT / ASBMT / EHA Joint Session
Space 4
Chairs: EBMT-Alejandro Madrigal (United Kingdom), ASBMT-Ginna Laport
(United States), EHA-Jorge Sierra (Spain)
11.30-12.00
Multicentre controlled study on the impact of stem cell donation
either after mobilization with G-CSF or bone marrow harvest on
unrelated donors.
12.00-12.30
Allogeneic hematopoietic transplantation after reduced intensity
conditioning: Factors influencing the outcome
Elisabeth Nacheva (United Kingdom)
Jorge Sierra (Spain)
11:30 - 13:00 Workshop 13: Chronic myeloid leukemia
Brown 1
Chair: Angelo Michele Carella (Italy) & Jane Apperley (United Kingdom)
11:30 - 12:00 Treatment free remission, a reality?
Philippe Rousselot (France)
12:00 - 12:30 Sustainability of TKI treatment
Jiri Mayer (Czech Republic)
12:30 - 13:00 Indications for Transplant
Jane Apperley (United Kingdom)
13:00 - 13:15 Closing Session
Gold Plenary
82
Physicians Posters
Acute leukaemia - MONDAY, 31 MARCH 2014
PH-P001
FACTORS AFFECTING INITIAL CYCLOSPORINE A LEVEL AND
ITS CORRELATION WITH CLINICAL OUTCOME IN ACUTE
LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC STEM CELL
TRANSPLANTATION
Punatar S., Gawande J., Bagal B., Mathew L., Kannan S., Khattry N., Gupta
A.* (Mumbai, India)
SECONDARY AML IN CHILDREN SUFFERING FROM FANCONI
ANEMIA IN GERMANY: A 20 YEARS EXPERIENCE
Hoseini S., Maecker-Kolhoff B., Schneppenheim R., Ebell W., Schmid H.,
Bader P., Ehlert K., Sykora K.-W., Creutzig U., Kratz C., Chao M. M., Reinhardt
D., Sauer M., Beier R.* (Hannover, Germany)
PH-P003
THIOTEPA-BASED CONDITIONING PRIOR TO ALLOGENEIC STEM
CELL TRANSPLANTATION (HSCT) FOR ACUTE MYELOID LEUKEMIA
(AML) - A SURVEY FROM THE ALWP OF THE EBMT
Labopin M., Finke J., Bunjes D., Olivieri A., Santarone S., Rambaldi A., Kanz
L., Messina G., Nagler A., Mohty M., Eder S.* and Acute Leukemia Working
Party (Paris, France)
PH-P004
T REPLETED HAPLOIDENTICAL MISMATCH ALLOGENEIC VERSUS
IN ADULT PATIENTS WITH ACUTE LEUKEMIA IN COMPLETE
REMISSION: A PAIR-MATCHED ANALYSIS FROM THE ALWP.
Labopin M., Ciceri F., Piemontese S., Arcese W., Di Bartolomeo P., Blaise D.,
Meloni G., Huang H., Depei W., Chen J., Bacigalupo A., Olivieri A., Mohty M.,
Gorin N. C.* and Acute Leukemia working party of EBMT (Paris, France)
PH-P005
PRE-TRANSPLANT WEIGHT LOSS AND TOTAL SERUM PROTEIN
PREDICT RELAPSE OF ACUTE MYELOID LEUKAEMIA AFTER
ALLOGENEIC STEM CELL TRANSPLANTATION
Dietrich S., Radujkovic A., Stölzel F., Falk C. S., Benner A., Schaich M.,
Bornhäuser M., Krämer A., Hegenbart U., Dreger P., Luft T.* (Heidelberg,
Germany)
PH-P006
LEVELS OF MINIMAL RESIDUAL DISEASE AS AN INDICATOR FOR
ASSESSMENT OF THE RISK IN PATIENTS WITH ACUTE LEUKEMIAS
AFTER INDUCTION THERAPY AND ALLOGENEIC HEMATOPOIETIC
STEM CELLS TRANSPLANTATION (CIC859)
Balazenko G., Michova A., Spassov B., Varbanova V., Mihaylov G. G.,
Arnaudov G., Guenova M.*, Ganeva P. (Sofia, Bulgaria)
PH-P007
NKP46 EXPRESSION AT DIAGNOSIS PREDICTS POST-GRAFT
OUTCOME IN AML PATIENTS
Zemmour C., Fauriat C., Harbi S., Le Roy A., Arnoulet C., Vey N., Blaise D.,
Olive D., Chretien A.-S.* (Marseille, France)
83
Scientific
Programme
Physicians
PH-P002
Physicians Posters
PH-P008
ANALYSIS 52 CONSECUTIVE ALLOTRANSPLANTS OF
ACUTE LYMPHOBLASTIC LEUKAEMIA: EBMT RISK SCORE,
PRETRANSPLANT REMISSION STATUS AND GRAFT VERSUS HOST
DISEASE WERE THE STATISTICALLY SIGNIFICANT DETERMINING
FACTORS FOR SURVIVAL.
Reményi P., Torbágyi É., Lengyel L., Gopcsa L., Csukly Z., Barta A., Fábián J.,
Réti M., Masszi T., Árpád B.* (Budapest, Hungary)
PH-P009
BUSULFAN, FLUDARABINE, ANTI-THYMOCYTE GLOBULIN AND
LOW-DOSE TOTAL BODY IRRADIATION IN THE TREATMENT OF
JUVENILE MYELOMONOCYTIC LEUKEMIA WITH MYELOABLATIVE
Lewis V., Guilcher G. M., Truong T. H.*, Moorjani R. (Calgary, Canada)
PH-P010
TREATMENT OF RELAPSED Paediatric B-CELL PRECURSOR ALL
WITH TRANSLOCATION T(12;21)(P13;Q22) BY MEANS OF ALLOHSCT
Semyenova E. V., Stancheva N. V., Katerina V. A., Evdokimov A. V., Barkhatov
I. M., Boychenko E. G., Kravtsova V. M., Zubarovskaya L. S., Afanasyev B. V.,
Mamaev N. N., Gindina T. L.* (Saint-Petersburg, Russian Federation)
PH-P011
ANTI-THYMOCYTE GLOBULIN (ATG) COULD IMPROVE THE
OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION IN PATIENTS WITH AGGRESSIVE T CELL
TUMORS
shike Y., liping W., jieling J., yu C., jun Y., chun W.* (shanghai, China)
PH-P012
THIOTEPA-BASED VS TBI-BASED MYELOABLATIVE CONDITIONING
PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION (HSCT)
FOR ACUTE MYELOID LEUKEMIA (AML) IN FIRST COMPLETE
REMISSION (CR1): A RETROSPECTIVE ANALYSIS FROM THE ALWP
OF THE EBMT
Labopin M., Arcese W., Or R., Majolino I., Bacigalupo A., de Rosa G., Volin L.,
Beelen D., Veelken H., Schaap N. P., Kuball J., Cornelissen J., Nagler A., Mohty
M., Eder S.* and ALWP (Paris, France)
PH-P013
AZACYTIDINE IN THE TREATMENT OF ACUTE MYELOID
LEUKEMIAS RECURRING AFTER ALLOGENEIC TRANSPLANTATION:
A SINGLE CENTER EXPERIENCE.
Schieppati F., Filì C., Cancelli V., Cattina F., Ribolla R., Turra A., Bergonzi C.,
Skert C., Russo D., Malagola M.* (Brescia, Italy)
PH-P014
THE EXPERIENCE TO USE COMBINATION OF LOW DOSE
CYTARABINE WITH CLADRIBINE BEFORE ALLOGENEIC STEM CELL
TRANSPLANTATION
Kuzjaeva A. A., Zapreeva I. M., Kostroma I. I., Martinkevitch I. S., Chubukina
Z. V., Abdulkadyrov K. M., Gritsaev S. V.* (St.Petersburg, Russian Federation)
84
Physicians Posters
PH-P015
OUTCOME OF HAEMATOPOIETIC STEM CELL TRANSPLANTATION
IN PATIENTS WITH ACUTE MYELOID LEUKAEMIA (AML)
OR MYELODYSPLASTIC SYNDROME (MDS) WITH ADVERSE
CYTOGENETICS
Lobetti-Bodoni C., Dignan F., Woodward J., Waller M., Tholouli E., Gorcea C.
M.* (Manchester, United Kingdom)
MPACT OF NPM1 MUTATION ON THE OUTCOME OF PATIENTS
WITH NORMAL KARYOTYPE ACUTE MYELOID LEUKEMIA
AND ALLOCATED TO AUTOLOGOUS HEMATOPOIETIC CELL
TRANSPLANTATION IN FIRST COMPLETE REMISSION
Scientific
Programme
Physicians
PH-P016
Brunet S., Hoyos M., Esteve J., Ribera J. M., Escoda L., Tormo M., Guardia
R., Torres P., Arnan M., Queipo de Llano M. P., Garcia A., Martí J. M., Pedro
C., Sampol M. A., Bargay J., Salamero O., Font L., Heras I., Gonzalez J., Oriol
A., Pratcorona M., Sierra J., Garrido A.* and CETLAM cooperative group
(Barcelona, Spain)
PH-P017
5-AZACYTIDINE IN MYELOID MALIGNANCY AFTER ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION.
Bondarenko S. N., Morozova E. V., Kulagin A. D., Slesarchuk O. A., Stancheva
N. N., Ratc A. A., Zubarovkaya L. S., Afanasyev B. V., Ovechkina V.* (St
Petersburg, Russian Federation)
PH-P018
OUTCOMES OF AML PATIENTS WHO RELAPSE AFTER
ALLOGENEIC STEM CELLTRANSPLANTATION.
Cerretti R., Picardi A., De Angelis G., Di Piazza F., Ceresoli E., Cefalo M. G.,
Mariotti B., Biagi A., Dentamaro T., Mengarelli A., Chierichini A., Ferrari A.,
Tirindelli M. C., Arcese W., Cudillo L.* (Roma, Italy)
PH-P019
HIGH PRE-TRANSPLANT CD4 T LYMPHOCYTE COUNT AND DONOR
HLA MISMATCH MAY CONTRIBUTE TO RELAPSE OF ACUTE
LEUKAEMIA AFTER MYELOABLATIVE HAEMOPOIETIC STEM CELLS
TRANSPLANTATION (HSCT).
Heilmann C., Keiding N., Sengeløv H., Ryder L. P., Jacobsen N.* (Copenhagen,
Denmark)
PH-P020
LINES OF PRE-TREATMENT AND BLAST COUNT PRIOR TO HCT
IS PREDICTIVE FOR SURVIVAL IN REFRACTORY AML PATIENTS
TREATED WITH FLAMSA-RIC
Klink A., Behre G., Schenk T., Franke G.-N., Jentzsch M., Schwind S., Al-Ali H.
K., Hochhaus A., Niederwieser D., Sayer H., Pfrepper C.* (Leipzig, Germany)
PH-P021
THE PROGNOSTIC SIGNIFICANCE OF INTERMEDIATE AND
UNFAVORABLE CYTOGENETICS TO PREDICT OUTCOME IN
DENOVO ACUTE MYELOID LEUKEMIA (AML) AFTER STEM CELL
TRANSPLANTATION (SCT)
Alimoghaddam K., Jahani M., Moosavi S. A., Bahar B., Hamidieh A. A., Vaezi
M., Gheysari E., Torkamaniha E., Gerayeli N., Jalali A., Ghavamzadeh A.,
Yaghmaie M.* (tehran, Iran, Islamic Republic Of)
85
Physicians Posters
PH-P022
AN INTENT-TO-TRANSPLANT SINGLE CENTER ANALYSIS IN
ELDERLY PATIENTS WITH HIGH RISK ACUTE LEUKEMIA OR
MYELODYSPLASTIC SYNDROME: THE SAN RAFFAELE HOSPITAL
EXPERIENCE
Carrabba M. G., Messina C., Peccatori J., Lupo Stanghellini M. T., Sala E.,
Pavesi F., Claudiani S., Assanelli A., Corti C., Greco R., Giglio F., Ciceri F.,
Bernardi M.* (Milan, Italy)
PH-P023
BONE MARROW MESENCHYMAL STROMAL CELLS PROTECT
ACUTE LEUKEMIA CELLS FROM CYTOTOXIC AGENTS VIA
GALECTIN-3 MEDIATED WNT/Β-CATENIN SIGNALING.
Yanjun G., Lixia L., Lizhen L., Binsheng W., He H., Kaimin H.* (Hangzhou,
China)
PH-P024
CD44V6 AS A NEW TARGET FOR AML AND MM THERAPY
Casucci M., Falcone L., Camisa B., Gentner B., Oliverira G., Naldini L.,
Bordignon C., Ciceri F., Bonini C., Bondanza A., Nicolis Di Robilant B.* (Milan,
Italy)
PH-P025
FOR ADULTS WITH ACUTE MYELOID LEUKEMIA (AML): THE
TUNISIAN RESULTS
Abdejlil N., Lakhal A., Barhoumi W., Ben Hamed L., Kaabi H., Slama H.,
Laamouri A., Ladeb S., Ben Othman T., Torjemane L.* (Bab Saadoun, Tunisia)
PH-P026
THE OUTCOMES OF UNMANIPULATED HAPLOIDENTICAL
HEMATOPOIETIC STEM CELL TRANSPLANTATION PERFORMED
DURING THE FIRST COMPLETE REMISSION IN ADULT PATIENTS
WITH PH-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA
INDICATE NO DIFFERENCE BETWEEN THE HIGH- AND LOW-RISK
GROUPS
Xu L.-P., Liu D.-H., Zhang X.-H., Chen H., Chen Y.-H., Han W., Wang Y., Wang
F.-R., Wang J.-Z., Liu K.-Y., Huang X.-J., Mo X.-D.* (Beijing, China)
PH-P027
ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION
IN PATIENTS OLDER THAN 65 YEARS WITH HIGH RISK ACUTE
MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME: A
RETROSPECTIVE ANALYSIS ON 72 PATIENTS
Carrabba M. G., Lupo Stanghellini M. T., Messina C., Pavesi F., Claudiani S.,
Giglio F., Levati G. V., Assanelli A., Corti C., Peccatori J., Fabio C., Bernardi M.,
Sala E.* (Milan, Italy)
PH-P028
MYELODYSPLASTIC SYNDROME RELATED CYTOGENETIC ABNORMALITIES DO NOT HAVE NEGATIVE IMPACT ON SURVIVAL AFTER
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN
PATIENTS WITH ACUTE MYELOID LEUKEMIA WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC).
Uchida N., Kaji D., Ota H., Ishiwata K., Tsuji M., Yamamoto H., Yamamoto G.,
Asano-Mori Y., Maikino S., Yoneyama A., Masuoka K., Wake A., Izutsu K.,
Taniguchi S., Yuasa M.* (Minato-ku, Japan)
86
Physicians Posters
PH-P029
COMPARISON OF DIFFERENT PRETRANSPLANT PREDICTIVE
SCORES IN PATIENTS WITH REFRACTORY ACUTE MYELOID
LEUKEMIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
INCLUDING HIGHDOSE MELPHALAN: RESULTS OF A DOUBLECENTER OBSERVATIONAL STUDY
Ditschkowski M., Groth C., Silling G., Krug U., Trenschel R., Ottinger H.,
Müller-Tidow C., Berdel W. E., Koldehoff M., Elmaagacli A. H., Beelen D. W.,
Stelljes M., Steckel N. K.* (Essen, Germany)
INFLUENCE OF HIGH-DOSE ATG ON GVHD, POST-TRANSPLANT
IMMUNE RECONSTITUTION AND RELAPSE OF PATIENTS
RECEIVING ALLOGENEIC BLOOD STEM CELL TRANSPLANTATION
WITH SEQUENTIAL CONDITIONING FOR HIGH-RISK MYELOID
LEUKEMIA
Scientific
Programme
Physicians
PH-P030
Schroeder T., Dienst A., Nachtkamp K., Rachlis E., Germing U., Haas R.,
Kondakci M., Kobbe G., Groten A.* (Duesseldorf, Germany)
PH-P031
ALLOGENEIC TRANSPLANTATION IN SECONDARY AML: OUTCOME
ANALYSIS IN 71 CONSECUTIVE PATIENTS
Lupo Stanghellini M. T., Morelli M., Sala E., Marcatti M., Assanelli A.,
Carrabba M., Trinca S., Marktel S., Lunghi F., Guggiari E., Giglio F., Corti C.,
Peccatori J., Ciceri F., Bernardi M., Claudiani S.* (Milano, Italy)
PH-P032
REMOVAL OF AML-LEUKEMIC STEM CELLS FROM THE GRAFT BY
CD96 ANTIBODY TH-111
Kellner C., Peipp M., Schub N., Humpe A., Staudinger M., Gramatzki M.* (Kiel,
Germany)
PH-P033
OUTCOME OF CONDITIONING INTENSITY IN ACUTE MYELOID
LEUKEMIA WITH MONOSOMAL KARYOTYPE IN PATIENTS OVER
45 YEAR-OLD: A STUDY FROM THE ACUTE LEUKEMIA WORKING
PARTY (ALWP) OF THE EUROPEAN GROUP OF BLOOD AND
MARROW TRANSPLANTATION (EBMT).
Labopin M., Cornelissen J. J., Volin L., Richard Espiga C., Veelken J. H., Milpied
N., Cahn J. Y., Yakoub-Agha I., van Imhoff G. W., Michallet M., Michaux L.,
Nagler A., Mohty M., Poiré X.* and Acute Leukemia Working Party (Brussels,
Belgium)
PH-P034
PATIENTS WITH PRIMARY REFRACTORY OR RELAPSED ACUTE
MYELOID LEUKEMIA MAY ACHIEVE LONG-TERM REMISSION
FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION - A
SINGLE CENTER EXPERIENCE
Terwey T. T., Na I.-K., le Coutre P., Vuong L. G., Dörken B., Arnold R., Hemmati
P.* (Berlin, Germany)
PH-P035
OUTPATIENT-BASED SALVAGE REGIMEN WITH 10 DAYS OF
DECITABINE WITH OR WITHOUT DLI FOR RELAPSED MDS AND
AML AFTER ALLOGENEIC HSCT
Middeke J. M., Thiede C., Trautmann K., Röllig C., Schetelig J., Ehninger G.,
Bornhäuser M., Platzbecker U., Muetherig A.* (Dresden, Germany)
87
Physicians Posters
PH-P036
ALLOGENEIC RELATED DONOR STEM CELL TRANSPLANTATION IN
AML CR1: ANY RISK FACTOR FOR BETTER SURVIVAL?
Hindilerden F., Hasbal N., Serefhanoglu S., Kucukkaya R., Arat M., Güvenç
S.*, Ozcelik E. (Istanbul, Turkey)
PH-P037
IN PATIENTS WITH TREATMENT-RELATED ACUTE MYELOID
LEUKEMIA
Czyz A., Matuszak M., Gil L., Nowicki A., Dytfeld D., Komarnicki M., Łojko A.*
(Poznań, Poland)
PH-P038
CLINICAL IMPLICATION OF TET2 MUTATION WITH NORMAL
KARYOTYPE ACUTE MYELOID LEUKEMIA IN YOUNGER PATIENTS
Kim Y.-K., Jung S.-H., Yang D.-H., Lee J.-J., Lee I.-K., Kim D. D. H., Minden
M. D., Jung C. W., Jang J.-H., Kim H. J., Moon J. H., Sohn S. K., Won J.-H., Kim
S.-H., Kim N., Ogawa S., Yoshida K., Kook H., Kim N. Y., Ahn J.-S., Kim H.-J.*
(Jeollanam-do, Korea, Republic Of)
PH-P039
ADULT ACUTE LYMPHOBLASTIC LEUKEMIA - TBI BASED
PH-P037
IN PATIENTS WITH TREATMENT-RELATED ACUTE MYELOID
LEUKEMIA
Czyz A., Matuszak M., Gil L., Nowicki A., Dytfeld D., Komarnicki M., Łojko A.*
(Poznań, Poland)
PH-P038
CLINICAL IMPLICATION OF TET2 MUTATION WITH NORMAL
KARYOTYPE ACUTE MYELOID LEUKEMIA IN YOUNGER PATIENTS
Kim Y.-K., Jung S.-H., Yang D.-H., Lee J.-J., Lee I.-K., Kim D. D. H., Minden
M. D., Jung C. W., Jang J.-H., Kim H. J., Moon J. H., Sohn S. K., Won J.-H., Kim
S.-H., Kim N., Ogawa S., Yoshida K., Kook H., Kim N. Y., Ahn J.-S., Kim H.-J.*
(Jeollanam-do, Korea, Republic Of)
PH-P039
IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA - TBI BASED
MYELOABLATIVE CONDITIONING STILL SAFE AND EFFECTIVE
Urbaniak-Kujda D., Wróbel T., Kaczmar-Dybko A., Kuliczkowski K., Dybko J.*
(Wroclaw, Poland)
88
Physicians Posters
Aplastic anaemia - MONDAY, 31 MARCH 2014
PH-P040
UNMANUPLATED HAPLOIDENTICAL HSCT: A FEASIBLE WAY FOR
CHILDREN WITH SEVERE APLASTIC ANEMIA
Luan Z., Zhu Y., Li C. K., Luo C., lee V., Tang X., Chen J.* and China Paediatric
Bone Marrow Transplant Group (Shanghai, China)
PH-P041
SINGLE CENTRE EXPERIENCE OF ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANT (HSCT) IN HEAVILY PRE-TREATED
ADOLESCENT AND YOUNG ADULT (AYA) WITH FANCONI ANEMIA.
Aljurf M., Almohareb F., Alzahrani H., Chaudhri N., Alsharif F., Rasheed W.,
Mohamed S., Aldawsari G., Hanbali A., Ahmed S., Elhassan T., Alhuraiji A.*
PH-P042
Scientific
Programme
Physicians
(Riyadh, Saudi Arabia)
EFFECT OF STEM CELLS ON ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION IN ADULT PATIENTS WITH IDIOPATHIC
APLASTIC ANEMIA
Lee K.-H., Kim I., Sohn S. K., Kim S. J., Kim S. H., Park Y., Choi J. H., Kwak J. Y.,
Kim M. K., Bae S. H., Shin H. J., Won J. H., Lee W. S., Shin S. J., Park J.-H., Joo
Y. D., Kim H.* (Ulsan, Korea, Republic Of)
PH-P043
OUTCOME OF HAPLOIDENTICAL PBSC TRANSPLANTATION
FOR HIGH RISK APLASTIC ANEMIA WITH POST-TRANSPLANT
CYCLOPHOSPHAMIDE IS SIMILAR TO MATCHED SIBLING PBSCT
AND DEPENDS ON CHOICE OF DONORS: ADVERSE EFFECT OF
NATURAL KILLER CELL ALLOREACTIVITY
Apte S., Kannan S., Chakrabarti S., Jaiswal S. R.* (KOLKATA, India)
PH-P044
NON MYELOABLATIVE HAPLOIDENTICAL STEM CELL
TRANSPLANTATION WITH POST GRAFT HIGH DOSE
CYCLOPHOSPHAMIDE FOR REFRACTORY SAA OR AFTER FAILED
UNRELATED OR CORD BLOOD TRANSPLANT
Mufti G. J., Pagliuca A., Potter V., Clay J., Mclornan D., Raj K., De Lavallade H.,
Kenyon M., Marsh J., Kulasekararaj A.* (London, United Kingdom)
PH-P045
DEFINING PARTIAL REMISSION AFTER IMMUNOSUPPRESSION
THERAPY FOR SAA
Tichelli A., Schrezenmeier H., Socié G., Bacigalupo A., Höchsmann B., Peffault
de la Tour R., Passweg J., Dufour C., Marsh J., Rovó A.* and on behalf of the
Severe Aplastic Anemia Working Party (SAAWP) of the European Group for
Blood and Bone Marrow Transplantation (EBMT). (Basel, Switzerland)
PH-P046
DONOR TYPE APLASIA (DTA) OCCURRING 12-44 MONTHS AFTER
MATCHED SIBLING OR UNRELATED DONOR BONE MARROW
TRANSPLANTATION IN CHILDREN WITH SEVERE APLASTIC
ANAEMIA
Passweg J. R., Bajwa R., Stein J., Bradbury M., Morgan M., Cummins M.,
Cornish J. M., Moppett J. P., de la Fuente J., Steward C. G., Shaw A.* (Bristol,
United Kingdom)
89
Physicians Posters
Aplastic anaemia - MONDAY, 31 MARCH 2014
PH-P047
A COMPARISON BETWEEN PERIPHERAL BLOOD STEM CELL
TRANSPLANTATION AND BONE MARROW TRANSPLANTATION AS
PROGENITOR CELL SOURCE IN SEVERE APLASTIC ANEMIA
Alimoghaddm K., Jalili M., Jalali A., Sharifi Aliabadi L., Hamidieh A. A.,
Mousavi S. A., Bahar B., Vaezi M., Jahani M., Ghavamzadeh A.* (Tehran, Iran,
Islamic Republic Of)
PH-P048
FEASIBILITY AND OPTIMAL SCHEDULE OF USING ECULIZUMAB
IN PATIENTS WITH HEMOLYTIC PAROXYSMAL NOCTURNAL
HEMOGLOBINURIA (HPNH) WITH SEVERE APLASTIC ANEMIA
(SAA) PRIOR TO HAEMOPOIETIC STEM CELL TRANSPLANT (HSCT)
Potter V., Gandhi S., Mclornan D., delavallade H., Kavita R., Pagliuca A.,
Mufti G., Marsh J., Kenyon M., Benson-Quarm N., Large J., Kulasekararaj A.*
PH-P049
HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM AN
ALTERNATIVE DONOR FOR CHILDHOOD APLASTIC ANEMIA:
HLA HAPLOIDENTICAL FAMILY DONOR VS HLA MISMATCHED
UNRELATED DONOR
Sekiya Y., Kawashima N., Narita A., Irie M., Muramatsu H., Hama A., Kojima
S., Takahashi Y.* (Nagoya, Japan)
PH-P050
TRANSPLANTATION FROM MATCHED UNRELATED DONORS IN
Paediatric SEVERE APLASTIC ANEMIA: EXPERIENCE WITH TCR
ALPHA/BETA AND CD19 DEPLETION AS GRAFT PROCESSING
METHOD
Shelikhova L., Balashov D., Kurnikova E., Boyakova E., Skvortsova Y.,
Novichkova G., Maschan A., Gutovskaya E., Tsetlina V., Khismatullina R.,
Trakhtman P., Kalinina V., Maschan M.* (Moscow, Russian Federation)
90
Physicians Posters
Cell Therapy - MONDAY, 31 MARCH 2014
PH-P051
VIRUS SPECIFIC CYTOTOXIC T LYMPHOCYTE SUB-POPULATION
STUDY
DECOT V., BITTENCOURT M. D. C., CLEMENT L., STOLTZ J.-F., BENSOUSSAN
D.*, Yingying W. (Nancy, France)
IMMUNOAFFINITY SELECTION OF VIRUS ANTIGEN SPECIFIC
T-CELLS WITH A NEW FULLY AUTOMATED DEVICE: COMPARISON
BETWEEN CLINIMACS AND PRODIGY
Klöß S., Esser R., Marburger M., Tischer S., Priesner C., Aleksandrova K.,
Heuft H.-G., Goudeva L., Blasczyk R., Köhl U., Eiz-Vesper B., Maecker-Kolhoff
B., Arseniev L.* (Hannover, Germany)
PH-P053
DUAL SPECIFIC CYTOTOXIC POTENTIAL AND MEMORY
PHENOTYPE OF IL-15-ACTIVATED CYTOKINE-INDUCED KILLER
CELLS TARGETING VIRUS INFECTION AND LEUKEMIA IN
Paediatrics
Rettinger E., Quaiser A., Oelsner S., Cinatl J., Klingebiel T., Bader P.,
Pfirrmann V.* (Frankfurt/Main, Germany)
PH-P054
GENETICALLY MODIFIED CYTOKINE-INDUCED KILLER (CIK) CELLS
FOR TARGETED CANCER THERAPY
Rettinger E., Wels W. S., Pfirrmann V., Friede M. E., Bader P., Oelsner S.*
(Frankfurt am Main, Germany)
PH-P055
TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE WITH
DECIDUAL STROMAL CELLS AND TRACING WITH 111INDIUM
RADIOLABELLING
Kaipe H., Nava S., Gustafsson B., Jansson B., Axelsson R., Ringdén O., Erkers
T.* (Stockholm, Sweden)
PH-P056
STANDARDIZATION OF EX VIVO EXPANSION OF GAMMA/
DELTA T CELLS FOR IMMUNOTHERAPY OF HEMATOPOIETIC
MALIGNANCIES
Kim H., Bowersock J., Mineishi S., Lamb L.* (Birmingham, United States)
PH-P057
SELECTIVE DEPLETION OF RECIPIENT-ALLOREACTIVE T-CELLS
WHILE RETAINING VIRAL-SPECIFIC AND MEMORY T-CELLS
ENABLES SAFE AND EFFICACIOUS HAPLO-IDENTICAL HSCT
De Jong L., Roy D.-C., Ruediger M., Sidi Boumédine R., Giard M.-P., Velthuis
J.* (Amsterdam-Duivendrecht, Netherlands)
PH-P058
EX VIVO ACTIVATED AUTOLOGOUS NK CELLS EFFICIENTLY LYSE
TUMOR CELLS FROM METASTATIC COLORECTAL CARCINOMA
PATIENTS: A PERSPECTIVE FOR IMMUNOTHERAPEUTIC
APPROACHES.
Ferulli F., Turin I., Brugantelli S., Delfanti S., Tanzi M., Luinetti O., Maestri
M., Maccario R., Todisco E., Pedrazzoli P., Montini E., Paulli M., Pende D.,
Montagna D.* (Pavia, Italy)
91
Scientific
Programme
Physicians
PH-P052
Physicians Posters
PH-P059
EXPERIMENTAL AND CLINICAL STUDIES USING DECIDUAL
STROMAL CELLS FROM FETAL MEMBRANE LAYERS FOR IMMUNE
MODULATION AND GRAFT-VERSUS-HOST DISEASE
Erkers T., Heshmati Y., Magalhaes I., Nava S., Mollden P., Walfridsson J.,
Kaipe H., Ringdén O., Sadeghi B.* (Stockholm, Sweden)
PH-P060
FROM PERIPHERAL BLOOD OF COLORECTAL CANCER PATIENTS
FOR ADOPTIVE T-CELL TRANSFER
Delbue S., Signorini L., Dallari S., Elia F., Galli A., Della Valle A., Ferrante P.,
Bregni M., Carluccio S.* (Milano, Italy)
PH-P061
HAPLOIDENTICAL HEMATOPOIETIC STEM CELL
TRANSPLANTATION FOLLOWING MYELOABLATIVE CONDITIONING
REGIMENS IN HEMATOLOGIC DISEASES WITH G-CSF MOBILIZED
PERIPHERAL BLOOD STEM CELLS GRAFTS WITHOUT T CELL
DEPLETION: A SINGLE CENTER REPORT OF 38 CASES
Lu R., Li J., Qian S., Miao K.* (Nanjing, China)
PH-P062
FAST PRODUCTION OF HUMAN PLATELET LYSATE BY USE
OF ULTRASOUND FOR THE EX-VIVO EXPANSION OF BONE
MARROW-DERIVED MESENCHYMAL STROMAL CELLS
Albiero E., Alghisi A., Chieregato K., Lievore C., Madeo D., Rodeghiero F.,
Astori G., Bernardi M.* (Vicenza, Italy)
PH-P063
ABSENCE OF MICRONUCLEUS FORMATION IN CHO-K1 CELLS
CULTIVATED IN PLATELET LYSATE ENRICHED MEDIUM
PRODUCED BY PLATELET RICH PLASMA SONICATION
Adami V., Albiero E., Madeo D., Rodeghiero F., Astori G., Bernardi M.*
(Vicenza, Italy)
PH-P064
AUTOMATED WASHING OF AUTOLOGOUS HEMATOPOIETIC STEM
CELL GRAFTS AFTER THAWING DOES NOT IMPAIR ENGRAFTMENT
Drezet A., Huynh C., Autret A., Stoppa A.-M., Bouabdallah R., Coso D.,
Malenfant C., Lemarié C., Chabannon C., Calmels B.* (marseille, France)
PH-P065
HTERT/SURVIVIN MRNA-LOADED DENDRITIC CELL VACCINATION
COMBINED WITH EX-VIVO EXPANDED T CELL TRANSFER IN
STAGE IV MELANOMA PATIENTS SHOW A LONGER OVERALL
SURVIVAL IN PATIENTS WITH SUSTAINED IMMUNE RESPONSES
AGAINST HTERT
Torhaug S. B.-H., Lundby M., Mollatt C., Inderberg Suso E. M., Kolstad A.,
Gaudernack G., Rasmussen A. M., Aamdal S., Kvalheim G., Bigalke I.* (Oslo,
Norway)
PH-P066
DECIDUAL STROMAL CELL THERAPY MAY INDUCE MULTISPECIFIC
ANTI-HLA ANTIBODIES IN EPIDERMOLYSIS BULLOSA PATIENTS,
BUT NOT IN ALLOGENEIC SCT PATIENTS
Carlson L.-M., Erkers T., Nava S., Molldén P., Alheim M., Ringdén O., Kaipe
H.* (Stockholm, Sweden)
92
Physicians Posters
PH-P067
THE CYTOTOXICITY OF CYTOKINE INDUCED KILLER CELLS IS FULLY
RETAINED BY THE SORTED CD56+ CELL FRACTION AND SEEMS TO
BE INDEPENDENT BY LYTIC DEGRANULATION
Zanon C., Castegnaro S., Rodeghiero F., Astori G., Chieregato K.* (Vicenza,
Italy)
PH-P068
LYMPHODEPLETION FOLLOWED BY SUICIDE-GENE-TRANSDUCED
DONOR LYMPHOCYTE INFUSION: A STRATEGY TO SAFELY
ENHANCE THE GRAFT-VERSUS-TUMOR EFFECT
PH-P069
HUMAN MESENCHYMAL STROMAL CELLS, IN THE PRESENCE OF
GAMMA INTERFERON, INHIBIT JURKAT T CELL PROLIFERATION.
PH-P070
SAFE AND REPRODUCIBLE PRODUCTION OF FUNCTIONAL
DENDRITIC CELLS FOR IMMUNOTHERAPY IN GLIOBLASTOMA
PATIENTS
Scientific
Programme
Physicians
rosenzwajg M., redjoul R., marcais A., xhaard A., cabanne L., bernard C.,
debbache K., suarez F., peffaultdelatour R., gregoire L., beaumont J.-L., azar
N., bories D., Cordonnier C., cohen J., lemoine F., klatzmann D., cherai M.,
Maury S.* (Creteil, France)
Kindler V.* (Geneva 4, Switzerland)
Pogliani S., Dossena M., Pellegatta S., Finocchiaro G., Parati E. A., Frigerio S.,
Lisini D., Nava S.* (Milano, Italy)
PH-P071
IN VITRO EXPANSION AND FUNCTIONAL NORMALIZATION OF
T CELLS FROM CLL PATIENTS USING BLINATUMOMAB: A GMPCOMPLIANT PROTOCOL FOR ADOPTIVE TRANSFER
D’Amico A., Borleri G., Finazzi M. C., Nagorsen D., Introna M., Rambaldi A.,
Quaresmini G., Golay J.* (Bergamo, Italy)
PH-P072
PHENOTYPING AND FUNCTIONAL COMPARISON OF CMVCTLS IN-VITRO EXPANDED WITH CONVENTIONAL AND SMART
DENDRITIC CELLS
Borchers S., Daenthanasanmak A., Salguero Lopez G. A., Hambach L., EizVesper B., Stripecke R., Falk C., Köhl U., Ganser A., Messerle M., MischakWeissinger E., Varanasi P. R.* (Hannover, Germany)
PH-P073
INTERIM REPORT OF A CLINICAL STUDY WITH HAPLOIDENTICAL
NK-CELLS AGAINST HIGH RISK MDS AND AML
Carlsten M., Liu L., Shaffer M., Cooley S., Miller J. S., Watz E., Wahlin B.,
Palma M., Hansson L., Ljungman P., Hellström-Lindberg E., Ljunggren H.-G.,
Malmberg K.-J., Björklund A. T.* (Huddinge, Sweden)
PH-P074
IMPACT OF CD8-DEPLETED DONOR-LYMPHOCYTE INFUSIONS
AFTER T-CELL DEPLETED ALLOGENEIC HEMOPOIETIC STEM CELL
TRANSPLANTATION - LONG TERM FOLLOW UP DATA
Wehler D., Schmitt T., Kolbe K., Lay A. N., Theobald M., Meyer R. G., Herr W.,
Wagner E. M.* (Mainz, Germany)
PH-P075
DONOR LYMPHOCYTE INFUSION FOR AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION: A RETROSPECTIVE ANALYSIS OF 57 PATIENTS.
Damiani D., michelutti A., Patriarca F., Cavallin M., Battista M., Zanini F.,
Geromin A., Cerno M., Fanin R., Sperotto A.* (Udine, Italy)
93
Physicians Posters
PH-P076
INFLUENCE OF KIR GENOTYPE ON SURVIVAL IN THE SETTING OF
DUAL STEM CELL TRANSPLANTATION
Kwon M., Navarro A., Martinez Laperche C., Buces E., Perez Corral A.,
Pascual C., Balsalobre P., Muñoz C., Serrano D., Gayoso J., Buño I., Anguita J.,
Diez-Martín J. L., Bastos-Oreiro M.* (Madrid, Spain)
PH-P077
HYPOMETHYLATING AGENT AZACITIDINE INDUCES FOXP3
NEGATIVE HLA-G EXPRESSING I MMUNOREGULATORY T CELLS.
Vittoraki A., Kokkinou D., De Lastic A.-L., Marioli D., Zikos P., Spyridonidis A.,
Goudogianni V., Theofani E., Stamou P.* (Patras, Greece)
PH-P078
DIFFERENTIAL COSTIMULATORY REQUIREMENTS OF HUMAN
MEMORY T-CELL SUBSETS: IMPLICATIONS FOR ADOPTIVE
IMMUNOTHERAPY OF CANCER AND INFECTIONS
Cieri N., Bonini C., Volpin V.* (Milan, Italy)
PH-P079
LARGE-SCALE MYELOID DENDRITIC CELLS GENERATION FROM
UMBILICAL CD34+ CELLS USING G-REX BIOREACTORS
Papadopoulou A., Zogas N., Psatha N., Karponi G., Zervou F., Bougiouklis
D., Xagorari A., Yiangou M., Anagnostopoulos A., Yannaki E., Gounari E.,
Kaloyannidis P.* (Thessaloniki, Greece)
PH-P080
THIRD GENERATION AUTOLOGOUS MYELOID-DERIVED DENDRITIC
CELLS DEVELOPED FROM THE PATIENTS WITH CMML AND
NON-CML SUBTYPES OF MDS DEMONSTRATE PHENOTYPIC
PROPERTIES OF MATURE FUNCTIONAL DC
Bigalke I., Schendel D., Tjeldhorn L., Chowdhury O., Woll P., Jacobsen S. E.,
Kvalheim G. K., Anderson K.*, Dybedal I. (Oslo, Norway)
PH-P081
COMPARISON OF IMMUNOMODULATORY ACTIVITIES OF
EXOSOME-ENRICHED FRACTIONS
de Miroschedji K., Radtke S., Ludwig A.-K., Horn P. A., Beelen D. W., Giebel B.,
Kordelas L.* (Essen, Germany)
PH-P082
CHARACTERIZATION OF THE IN VITRO IMMUNOMODULATORY
PROPERTIES OF MICROVESICLES ISOLATED FROM
MESENCHYMAL STROMAL CELLS
Conforti A., Scarsella M., Giorda E., Simone B., Starc N., Li PIra G., Proia A.,
Carsetti R., Locatelli F., Bernardo M. E.* (Rome, Italy)
PH-P083
ESTABLISHMENT OF A GMP-COMPLIANT MESENCHYMAL
STROMAL CELL BANK FROM THE POOL OF BONE MARROW OF
EIGHT THIRD-PARTY HEALTHY DONORS
Boenig H., Bunos M., Kreyenberg H., Skific M., Michel K., Lucchini G.,
Klingebiel T., Bader P., Kuci S., Kuci Z.* (Frankfurt am Main, Germany)
PH-P084
DASATINIB FOR THE MODULATION OF M1/M2-MACROPHAGE
DIFFERENTIATION
Braun M., Fritzsch F., Reß M. L., Yoo Y.-E., Schlegel P. G., Wölfl M.*
(Würzburg, Germany)
94
Physicians Posters
Chronic leukaemia - MONDAY, 31 MARCH 2014
PH-P085
REDUCED-INTENSITY TRANSPLANTATION IN PATIENTS OLDER
THAN 60 YEARS WITH CHRONIC LYMPHOCYTIC LEUKEMIA:
SIMILAR RESULTS WITH RELATED OR UNRELATED DONOR,
EARLIER INDICATION FOR TRANSPLANTATION COULD IMPROVE
RESULTS - SINGLE CENTRE EXPERIENCE
Steinerova K., Vozobulova V., Lysak D., Vokurka S., Jindra P., Karas M.*
(Pilsen, Czech Republic)
THE OUTCOME OF REDUCED-INTENSITY TRANSPLANTATION IN
ELDERLY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
IN COMPARISON WITH ELDERLY PATIENTS TRANSPLANTED
FOR ACUTE MYELOID LEUKEMIA: IS THERE DIFFERENCE IN
TIMELINESS OF INDICATION FOR TRANSPLANTATION?
Scientific
Programme
Physicians
PH-P086
Steinerova K., Jungova A., Lysak D., Vokurka S., Vozobulova V., Jindra P.,
Karas M.* (Pilsen, Czech Republic)
PH-P087
OUTCOMES OF CORD BLOOD TRANSPLANTATION USING
REDUCED INTENSITY CONDITIONING REGIMEN FOR CHRONIC
LYMPHOCITYC LEUKEMIA: A RETROSPECTIVE STUDY ON BEHALF
OF EUROCORD, SFGM-TC AND CMWP-EBMT
Cornillon J., Kröger N., Schetelig J., Ruggeri A., Rocha V., Gluckman E.,
Chevallier P., Deconinck E., Cornelissen J. J., Andersen N. S., Maillard N.,
Blaise D., Nguyen-coq S., Ifrah N., Huynh A., Perez M. S. G., Cahn J.-Y.,
Milpied N., Mohty M., Michallet M., Bourhis J.-H., de Revel T., Berthou C.,
Fegueux N., Bordessoule D., Donnini I., Leone G., de Latour R. P., Xavier E.*
(Paris, France)
PH-P088
ALLOGENEIC STEM CELL TRANSPLANTATION FOR PRIMARY
MYELOFIBROSIS
Miriam L., Radocha J., Belohlavkova P., Zak P., Zavrelova A.* (Hradec Králové,
Czech Republic)
PH-P089
STEM CELL TRANSPLANTATION FOR CML IN CHILDREN AND
ADOLESCENTS FOLLOWING REDUCED INTENSITY CONDITIONING
- AN ALTERNATIVE TO LIFE-LONG TKIS?
Stein J., Faraci M., Sedlacek P., Meisel R., Kalwak K., Balduzzi A., MatthesMartin S.* (Vienna, Austria)
PH-P090
RUXOLITINIB TREATMENT DECELERATE CYTOKINE PRODUCTION
LEADING TO REDUCED T-CELL PROLIFERATION AND KILLING
FUNCTION.
Alchalby H., Wolschke C., Ayuk F. A., Heinzelmann M., Triviai I., Badbaran A.,
Hildebrandt Y., Kröger N., Stübig T.* (Hamburg, Germany)
PH-P091
EFFICACY OF RESCUE IMMUNOTHERAPY AND SURVIVAL IN
PATIENTS WITH HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA
(CLL) WHO HAD CLINICAL RELAPSE AFTER ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT).
Dietrich S., Herth I., Hegenbart U., Walter E., Rieger M., Stadtherr P.,
Bondong A., Ho A. D., Dreger P., Hahn M.* (Heidelberg, Germany)
95
Physicians Posters
Chronic leukaemia - MONDAY, 31 MARCH 2014
PH-P092
HIGH EVI1 EXPRESSION PREDICTS SHORT DISEASE-FREE
SURVIVAL AFTER HEMATOPOIETIC CELL TRANSPLANTATION FOR
CHRONIC MYELOID LEUKEMIA
Morozova E., Vlasova Y., Barabanshikova M., Barkhatov I., Zubarovskaya L.,
Mamaev N., Afanasyev B., Gorbunova A.* (St. Petersburg, Russian Federation)
PH-P093
(HSCT) FOR MYELOFIBROSIS: THE ROLE OF THE SPLEEN
Emaagacli A., Trenschel R., Gromke T., Beelen D. W., Ditschkowski M.,
Steckel N. K.* (Essen, Germany)
PH-P094
TO CONTRAST THE EFFECT OF IMATINIB AND ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE
TREATMENT OF CHRONIC MYELOID LEUKEMIA
Qiu H., Zhou M., Sha X., He G., Xu Y., Cen J., Pan J., Chen S., Sun A., Zhang R.,
Wu D.* (Suzhou, China)
PH-P095
(ALLO-HSCT) FOR CHRONIC MYELOID LEUKEMIA (CML): THE
TUNISIAN EXPERIENCE.
Abdejelil N., Lakhal A., Barhoumi W., Elfatmi R., Ladeb S., Menif S., Ben
Othman T., Torjemane L.* (Bab Saadoun, Tunisia)
PH-P096
ALLOGENEIC TRANSPLANTS FOR MYELOFIBROSIS : THE
TRANSPLANT SPECIFIC SCORE (TS) PREDICTS OUTCOME, ALSO
AFTER STRATIFYING FOR DISEASE SPECIFIC SCORE (DIPSS)
PH-P097
REDUCING SPLEEN SIZE BY JAK INHIBITION PRIOR
TO ALLOGENEIC STEM CELL TRANSPLANTATION FOR
MYELOFIBROSIS
Raiola A., Gualandi F., Ghiso A., Galaverna F.*, Bacigalupo A. (Genoa, Italy)
Alchalby H., Ditschkowski M., Wolf D., Wulf G., Zabelina T., Wolschke C.,
Stübig T., Ayuk F., Kröger N.* and CMWP (Hamburg, Germany)
PH-P098
BCR-ABL1 GENE TRANSLOCATION MONITORING IN LONG-TERM
SURVIVING CHRONIC MYELOID LEUKEMIA PATIENTS AFTER
MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION
Diverio D., Natalino F., Scalzulli E., Di Lascio A., Torelli G. F., Barberi W.,
Perrone S., Nanni M., Breccia M., Foà R., Ferretti A., Iori A. P.* (Rome, Italy)
PH-P099
SIGNIFICANCE OF ACHIEVING SECOND CHRONIC PHASE PRIOR
TO ALLOGENEIC STEM CELL TRANSPLANT FOLLOWING TYROSINE
KINASE INHIBITOR THERAPY: A RETROSPECTIVE STUDY FROM
THE CHRONIC MALIGNANCY WORKING PARTY OF THE EUROPEAN
GROUP FOR BLOOD AND MARROW TRANSPLANTATION
Szydlo R., Hoek J., Beelen D., Hamladji R., Kyrcz-Krzemien S., Bacigalupo A.,
Niederwieser D., Tischer J., Schwerdtfeger R., Volin L., Greinix H., Chalandon
Y., Kroeger N., Olavarria E., Gurman G., Milojkovic D.* (London, United
Kingdom)
PH-P100
96
RAPID RESOLUTION OF BONE MARROW FIBROSIS ON DAY +100
PREDICTS OUTCOME AFTER ALLOGENEIC SCT IN MYELOFIBROSIS
Alchalby H., Zabelina T., Kvasnicka H. M., Thiele J., Büsche G., Kreipe H.,
Kröger N.* and CMWP (Hamburg, Germany)
Physicians Posters
Experimental stem cell transplantation &
Tumour stem cells - MONDAY, 31 MARCH 2014
PH-P101
HAPLOIDENTIAL STEM CELL TRANSPLANTATION IS AN
ATTRACTIVE ALTERNATIVE TREATMENT IN PATIENTS WITH
BPDCN
L.P Xu, D.H. Liu, Y. Wang, Y.Q. Sun, X.J. Huangn, F.R. Wang* (Beijing,China)
IMPROVED RELAPSE-FREE SURVIVAL AFTER T-CELL REPLETE
HAPLOIDENTICAL BONE MARROW (BM) AND PERIPHERAL
BLOOD STEM CELLS (PBSC) TRANSPLANTATION FOLLOWING
MYELOABLATIVE CONDITIONING (MAC) AND POSTTRANSPLANTATION CY (PT-CY) IN HIGH-RISK HEMATOLOGIC
MALIGNANCIES
Scientific
Programme
Physicians
PH-P102
Severino A., Spirito F., Proia A., Natale N., Shardlow A., Montante B., Garzia
M., Locasciulli A., Majolino I., Simone M. D.* (Rome, Italy)
PH-P103
CLOFARABINE AND TREOSULFAN IN CONDITIONING FOR
ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT FROM
MATCHED DONORS: A MULTICENTRIC PHASE II STUDY
Giglio F., Forno B., Tassara M., Morelli M., Forcina A., Lorentino F., Assanelli
A., Marcatti M., Marktel S., Bernardi M., Corti C., Ciceri F., Peccatori J.,
Patriarca F., Deola S., Fagioli F., Zecca M., Cortelazzo S., Locatelli F., Fanin R.,
Mastaglio S.* (Milan, Italy)
PH-P104
CORD BLOOD T LYMPHOCYTES EXPANSION FOR THERAPEUTIC
USE
Pelé C., Duriez C.-L., Clerc A., Mazet S., Rigal D., Hequet O., Mialou V.* (LYON,
France)
PH-P105
MINOR-HISTOCOMPATIBILITY-ANTIGEN UTY AS TARGET
FOR GRAFT-VERSUS-LEUKEMIA AND GRAFT-VERSUSHAEMATOPOIESIS IN THE CANINE-MODEL
Goekmen F., Zorn J., Buhmann R., Kolb H.-J., Schmetzer H., Bund D.* (Munich,
Germany)
PH-P106
IMMUNMODULATION OF BLASTS IN AML-PATIENTS (PTS) WITH
CLINICALLY APPROVED RESPONSE MODIFIERS TO IMPROVE
ANTILEUKEMIC T-CELL REACTIVITY: AN EX VIVO SIMULATION OF
THE CLINICAL SITUATION
stankova Z., deen D., hirn A., vokac Y., kroell T., bund D., buhmann R.,
hausmann A., schmid C., tischer J., schmetzer H.* (Munich, Germany)
PH-P107
NEONATAL BONE MARROW TRANSPLANTATION STRATEGY FOR
THE CURE OF HURLER DISEASE SKELETAL PHENOTYPE
Azario I., Rambaldi B., Cersosimo S., Scagliotti V., Biondi A., Tomatsu S.,
Riminucci M., Serafini M., Pievani A.* (Monza, Italy)
97
Physicians Posters
Experimental stem cell transplantation &
Tumour stem cells - MONDAY, 31 MARCH 2014
PH-P108
EXPRESSION OF SURFACE-ASSOCIATED METALLO-PROTEINASE
82 KDA-PROMMP-9 VARIANT ON LEUKEMIC BLAST CELLS FROM
PATIENTS WITH AML, ALL, AND CLL
guenther T., sutanto W., schmohl J., schuster F., kraemer D., neuhaus K.,
koehne C.-H., hausmann A., pitsch T., salih H., ries C., Schmetzer H.* (Munich,
Germany)
PH-P109
MULTI-GENOTYPING OF MINOR HISTOCOMPATIBILITY ANTIGENS
(MHAGS) IN ALLOGENEIC STEM CELL TRANSPLANTATION AND
THEIR ROLE IN DETERMINING GRAFT VERSUS HOST DISEASE
(GVHD) AND GRAFT VERSUS LEUKEMIA (GVL) EFFECT
Skert C., Bernardi S., Malagola M., Ottaviani E., Bochicchio M. T., Iacobucci
I., Soverini S., Bonifazi F., Bandini G., Arpinati M., Motta M. R., Toffoletti E.,
Damiani D., Santoro A., Fabbiano F., Pastore D., Specchia G., Console G.,
Bruno M., Guadagnuolo V., De Benedittis C., Bergonzi C., Filì C., Turra A.,
Ribolla R., Cancelli V., Alghisi E., Perucca S., Di Palma A., Martinelli G., Russo
D., Carella G., Malagoli A., Cattina F.* (Brescia, Italy)
PH-P110
FEASIBILITY OF ALPHA BETA T- CELL DEPLETED ALLOGENEIC
STEM CELL TRANSPLANTATIONS FROM MATCHED RELATED AND
UNRELATED DONOR GRAFTS AND ENGRAFTMENT IN PATIENTS
WITH POOR RISK LEUKEMIA
te Boome L., Westinga K., Slaper-Cortenbach I., Kuball J., Van Der Wagen L.*
PH-P111
EXTRACELLULAR HMGB1 PROMOTES THE MIGRATION OF CORD
BLOOD CD34+ CELLS VIA SDF-1/CXCR4 AXIS
Yang L., Sun Z., Wang X., Liu X., Zhu X.* (Hefei, China)
PH-P112
EXPANDED CORD BLOOD T-CELLS USED AS DONOR LYMPHOCYTE
INFUSIONS AFTER UMBILICAL CORD BLOOD TRANSPLANTATION
Gertow J., Uhlin M., Mattsson J., Berglund S.* (Stockholm, Sweden)
PH-P113
NK CELL (FROM PRIMARY NK CELL CULTURES) MEDIATED
KILLING OF MULTIPLE MYELOMA CELLS IN VITRO
Hildebrandt Y., Giffey C., Jungk K., Eiermann T. H., Sierich H., Binder T. M. C.,
Kröger N.* (Hamburg, Germany)
98
Physicians Posters
Hematopoietic stem cells - MONDAY, 31 MARCH 2014
PH-P114
WHY ARE UNRELATED HAEMATOPOIETIC STEM CELLS
COLLECTIONS POSTPONED OR CANCELLED?
Bordalo F., Lopes S., Amado F., Ferreira S., Roncon S., Spínola A. I.* (Porto,
Portugal)
PH-P115
NEGATIVE SELECTION BY APOPTOSIS ENRICHES PROGENITORS IN
NAÏVE AND EXPANDED HUMAN UMBILICAL CORD BLOOD GRAFTS
PH-P116
TRYPAN BLUE ACCURATELY DEFINES THE VIABILITY OF CFU-GM
CELLS IN CORD BLOOD UNITS
Ögärd I., Anghem E., Palmqvist L., Frändberg S. U.* (Göteborg, Sweden)
PH-P117
VALIDATION OF THE REVISED DISEASE RISK INDEX FOR PATIENTS
UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION (HSCT) AFTER PARTIAL T-CELL DEPLETION
Roosnek E., Tirefort Y., Ansari M., Dantin C., Tsopra O., Masouridi-Levrat S.,
Chalandon Y., Beauverd Y.* (Geneva, Switzerland)
PH-P118
EXTRACORPOREAL PHOTOPHERESIS FOR PAEDIATRIC GRAFT
VS HOST DISEASE FOLLOWING HEMATOPOIETIC STEM CELL
TRANSPLANTATION FOR PRIMARY IMMUNODEFICIENCY - A
SINGLE CENTRE EXPERIENCE.
Slatter M., Robson H., Gennery A., Guest J.* (Newcastle upon Tyne, United
Kingdom)
PH-P119
A MEAN TO OPTIMIZE TRANSPLANT REGIMEN FOR
NEUROBLASTOMA: THE ROLE OF PRE-TRANSPLANT MIBG
SCINTIGRAPHY IN TARGETED ADMINISTRATION OF 131I-MIBG
ACCOMPANIED BY AUTOLOGOUS STEM CELL TRANSPLANTATION
Beiki D., Paragomi P., Fallahi B., Behfar M., Fard-Esfahani A., Hosseini A. S.,
Shamshiri A., Eftekhari M., Ghavamzadeh A., Hamidieh A. A.* (Tehran, Iran,
Islamic Republic Of)
PH-P120
IMAGING FEATURES OF POSTERIOR REVERSIBLE
ENCEPHALOPATHY SYNDROME (PRES) AFTER ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION IN Paediatric
PATIENTS: A PROSPECTIVE STUDY.
Radmard A. R., Kooraki S., Behfar M., Hashemi Taheri A. P., Ghavamzadeh
A., Hamidieh A. A.* (Tehran, Iran, Islamic Republic Of)
PH-P121
RESULTS OF HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS
HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE
TREATMENT OF Paediatric BRAIN TUMORS
Morozova E., Kazantsev I., Iukhta T., Safonova S., Punanov Y., Goloschapov
O., Estrina M., Babenko E., Shiriaev S., Zubarovskaya L., Zheludkova O.,
Afanasyev B., Gevorgian A.* (Saint-Petersburg, Russian Federation)
99
Scientific
Programme
Physicians
Stein J., Mizrahi K., Askenasy N., Yaniv I.* (Tel Aviv, Israel)
Physicians Posters
PH-P122
PRIOR MD-ARAC CHEMOTHERAPY AFFECTING PERIPHERAL
BLOOD HEMATOPOIETIC STEM CELL MOBILIZATION IN AML
Xie M., Wei X., Jing H., Dai M., Zhang Y., Wei Q., Li X., Wei Y., Huang F., Feng
R.* (Guangzhou, China)
PH-P123
EXPLORING THE HETEROGENEITY OF THE HEMATOPOIETIC STEM
AND PROGENITOR CELL POOL:
Boreström C., Li S., Palmqvist L., Frändberg S. U.* (Göteborg, Sweden)
PH-P124
THE EFFECT OF MOBILISATION REGIMEN AND DAY
OF COLLECTION ON REGULATORY T CELL LEVELS IN
HAEMATOPOIETIC PROGENITOR CELL APHERESIS PRODUCTS
Johnston J. V., Ingleton S. A.-M., Patel B. J., Smith M. A., Wells J. C.* (Sutton,
United Kingdom)
PH-P125
ADOPTIVE THERAPY WITH DONOR LYMPHOCYTE
INFUSION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION - EXPERIENCE OF THE POLISH Paediatric
GROUP FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION
(PPGHSCT)
Rewucka-siewiera K., Krasowska-Kwiecien A., Pieczonka A., Debski R.,
Zaucha-Prazmo A., Drabko K., Kowalczyk J., Wysocki M., Gorczynska E.,
Kalwak K., Chybicka A., Wachowiak J., Gozdzik J.* and PPGHSCT (Krakow,
Poland)
PH-P126
CHANGES IN THE GUT MICROBIOME IN SEVERE COMBINED
IMMUNODEFICIENCY THROUGH HAEMATOPOIETIC STEM CELL
TRANSPLANTATION
Stewart C., Cummings S., Gennery A., Lane J.* (Newcastle upon Tyne, United
Kingdom)
PH-P127
IMPLEMENTATION OF NONCRYOPRESERVED GRAFTS IN
FOR PATIENTS WITH MULTIPLE MYELOMA; SINGLE CENTER
EXPERIENCE
Genadieva Stavric S., Stojanoski Z., Pivkova Veljanovska A., Georgievski B.,
Cadievski L.* (Skopje, Macedonia, The Former Yugoslav Republic Of)
PH-P128
FEAM COMPARED WITH BEAM AS CONDITIONING REGIMEN IN
AUTOLOGOUS TRANSPLANT:SINGLE CENTRE EXPERIENCE
Anna M., Rosa D. F., Mariapaola F., Giuseppina G., Silvia S., Daniela C.,
Bernardo R., Clara D. R., Mariarosaria M., Stefania C., Giulia R., Angelo O.,
Vincenzo P.* (Tricase, Italy)
PH-P129
LONG-TERM FOLLOW UP OF BONE DENSITY AND REPRODUCTIVE
HEALTH IN FEMALE SURVIVORS AFTER HEMATOPOIETIC STEM
Bergström I., Ljungman P., Landgren B.-M., Leblanc K., Naessén S.*
(Stockholm, Sweden)
100
Physicians Posters
PH-P130
SINGLE CENTRE EXPERIENCE OF SECOND ALLOGENEIC
HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR
HAEMATOLOGICAL DISORDERS.
Gudger A., Hussein H., Dyer P., Patel J., Holder K., Baker L., Bratby L., Lovell
R., Kishore B., Milligan D., Paneesha S., Khwaja J., Nikolousis E., Seymoor F.*
PH-P131
DISEASE RISK INDEX (DRI) AND HEMATOPOIETIC CELL
TRANSPLANTATION COMORBIDITY INDEX (HCT-CI)
PREDICT SURIVIVAL AFTER HAPLOIDENTICAL STEM CELL
TRANSPLANTATION: A COMPARATIVE STUDY WITH EBMT RISK
SCORE IN 183 CONSECUTIVE PATIENTS
Sala E., Morelli M., Marcatti M., Assanelli A., Carrabba M., Marktel S., Lunghi
F., Guggiari E., Giglio F., Corti C., Bernardi M., Ciceri F., Peccatori J., LupoStanghellini M. T.* (Milan, Italy)
PH-P132
CD 34+ CELL NUMBER AND CELL VIABILITY IMPACT ON
ENGRAFTMENT
Lukić M., Zatezalo V., Radić-Krišto D., Jakšić B., Jurenec S.* (Zagreb, Croatia)
PH-P133
PHARMACOKINETICS OF TREOSULFAN AND ITS MONOEPOXIDE
IN CHILDREN UNDERGOING HSCT
Wróbel T., Kasprzyk A., Romański M., Wiela-Hojeńska A., Kałwak K.,
Wachowiak J., Szpecht D., Główka F.* (Poznan, Poland)
PH-P134
VALIDATION OF THE SPECTRA OPTIA® SEPARATOR FOR
HEMATOPOIETIC STEM CELL COLLECTION: IMPACT OF
PLERIXAFOR
Thomsen A.-M. E., Moller B. K., Segel E. K., Sorensen B.* (Aarhus N, Denmark)
PH-P135
SUCCESSFUL ANTI-A/B IMMUNOADSORPTION IN A PATIENT
WITH MAJOR ABO-INCOMPATIBLE ALLOGENEIC BONE MARROW
TRANSPLANTATION
Kühne T., von der Weid N., Halter J., Buser A., Passweg J., Schindera C.*
(Basel, Switzerland)
PH-P136
OUTCOME AND PROGNOSTIC INDICATORS OF ADULT PATIENTS
WITHEMATOPOIETIC STEM CELL TRANSPLANTS (HSCT) ADMITTED
TO THE INTENSIVE CARE UNIT (ICU)H
Abdel-Rahman F., Al-Rawi O., Najar R., Hawari F., Addasi A., Abujazar H.*
(Amman, Jordan)
101
Scientific
Programme
Physicians
(Birmingham, United Kingdom)
Physicians Posters
Lymphoma - MONDAY, 31 MARCH 2014
PH-P137
PHASE 2 TRIAL OF HIGH-DOSE GEMCITABINE, BUSULFAN AND
MELPHALAN WITH AUTOLOGOUS STEM CELL TRANSPLANT (ASCT)
FOR PATIENTS WITH REFRACTORY HODGKIN’S LYMPHOMA (HL)
Popat U., Anderlini P., Andersson B., Valdez B., Bassett R., Hosing C., Ahmed
S., Qazilbash M., Shpall E. J., Alousi A., Champlin R., Jones R. B., Kebriaei P.,
Oki Y., Fanale M., Hagemeister F., Dabaja B., Reed V., Pinnix C., Tewari P.,
Worth L., Nieto Y.* (Houston, United States)
PH-P138
HAPLOIDENTICAL STEM CELL TRANSPLANTATION (HAPLO-SCT)
WITH REDUCED INTENSITY CONDITIONING (RIC) REGIMENS AND
HIGH DOSE CYLOPHOSPHAMIDE POST-TRANSPLANT (PT-CY)
AS GVHD PROPHYLAXIS IN PATIENTS WITH RELAPSED OR
REFRACTORY HODGKIN´S DISEASE.
Balsalobre P., Castilla C., Pascual M. J., Kwon M., Serrano D., López-Corral
L., Pérez-Simón J. A., Bermúdez A., Martínez C., Pascual C., Heras I., Solano
C., Figuera A., Sampol M. A., Ferrá C., Herrera P., Buño I., Díez-Martín J. L.,
Gayoso J.* and GETH (Grupo Español de Trasplante Hematopoyético) (Madrid,
Spain)
PH-P139
SECOND ALLOGENEIC STEM CELL TRANSPLANTATION (ALLOSCT) IN PATIENTS WITH RELAPSED LYMPHOMA AFTER FIRST
ALLO-SCT. A RETROSPECTIVE STUDY OF THE EBMT LYMPHOMA
WORKING PARTY.
Boumendil A., Finel H., Apperley J. F., Ciceri F., Finke J., Van Hoof A., Ifrah
N., Kyrcz-Krzemien S., Milone G., Mufti G. J., Or R., Russell N. H., Dreger P.,
Horstmann K.* and Lymphoma Working Group (Heidelberg, Germany)
PH-P140
AUTOLOGOUS STEM CELL TRANSPLANTATION WITH BEEAM
(BENDAMUSTINE, ETOPOSIDE, CYTARABINE, MELPHALAN) IN
AGGRESSIVE NHL AND HODGKIN´S LYMPHOMA
Moestl M., Koller E., Sallaberger E., Hundsamer A., Linkesch W., Tinchon C.,
Mulabecirovic A., Keil F., Noesslinger T.* (Vienna, Austria)
PH-P141
PROGNOSTIC SIGNIFICANCE OF EBMT SCORE AND SERUM
SOLUBLE IL-2R LEVEL ON OUTCOMES AFTER ALLOGENEIC
HEMATOPOIETIC CELL TRANSPLANTATION FOR ADULT T-CELL
LEUKEMIA/LYMPHOMA
Nakano N., Kubota A., Tokunaga M., Itoyama T., Makino T., Takeuchi S.,
Takatsuka Y., Utsunomiya A., Tokunaga M.* (Kagoshima, Japan)
PH-P142
TANDEM TRANSPLANT AUTO/AUTO OR AUTO/ALLO IN
REFRACTORY AND VERY UNFAVORABLE RELAPSE OF HODGKIN
LYMPHOMA (HL) PATIENTS: ANALYSIS OF EARLY DEATHS IN A
PROSPECTIVE MULTICENTRIC NON INTERVENTIONAL STUDY OF
THE LYSA SFGM-TC.
deau B., bologna S., delmer A., lissandre S., quittet P., CHAOUI D., oberic L.,
CORNILLON J., clavert A., clementine S., ROBIN M., Brice P.* and LYSA and
SFGM-TC (paris, France)
102
Physicians Posters
PH-P143
THE CLINICAL ROLE OF INTERIM PET/CT FOR PREDICTING
THE OUTCOME OF FRONTLINE AUTOLOGOUS STEM CELL
TRANSPLANTATION IN PATIENTS WITH HIGH RISK DIFFUSE
LARGE B-CELL LYMPHOMA
PH-P144
DIFFERENCE IN THE OUTCOMES OF HODGKIN LYMPHOMA
PATIENTS WHO HAD PERSISTENT VS PROGRESSIVE VS
RELAPSED DISEASE FOLLOWING HIGH DOSE CHEMOTHERAPY
AND AUTOLOGOUS-SCT
Rauf M. S., Elhassan T. A. M., Maghfoor I., Akhtar S.* (Riyadh, Saudi Arabia)
PH-P145
EFFICACY OF HIGH-DOSE THERAPY AND AUTOLOGOUS
HEMATOPOIETIC CELL TRANSPLANTATION INTENSIFICATION
AFTER RITUXIMAB-BASED FRONT-LINE TREATMENT OF
AGGRESSIVE LYMPHOMAS: RESULTS OF A SYSTEMATIC REVIEW
AND META-ANALYSIS
Kumar A., Reljic T., Castrovinci P., Nishihori T., Ayala E., Savani B. N.,
Djulbegovic B., Hamadani M., Kharfan-Dabaja M. A.* (Tampa, United States)
PH-P146
BASE-LINE QUALITY OF LIFE IMPAIRMENT AND ITS POTENTIAL
PROGNOSTIC VALUE IN LYMPHOMA PATIENTS UNDERGOING
(AHSCT)
Melnichenko V. Y., Mochkin N. E., Kurbatova K. A., Gorodokin G., Novik A. A.,
Ionova T. I., Fedorenko D. A.* (Moscow, Russian Federation)
PH-P147
BENDABEAM PLUS AUTOLOGOUS STEM CELL TRANSPLANT
PRODUCE A 3-YEAR PROGRESSION-FREE SURVIVAL RATE OF
75% IN HEAVILY PRE-TREATED HODGKIN AND NON-HODGKIN
LYMPHOMA
Stefani P. M., Capria S., Malerba L., Galieni P., Gaudio F., Specchia G., Meloni
G., Gherlinzoni F., Giardini C., Gobbi M., Santoro A., Ferrara F., Rocchi M., Ocio
E. M., Caballero M. D., Loscocco F., Isidori A., Visani G.* (Pesaro, Italy)
PH-P148
SPLENECTOMY PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION INCREASES THE RISK FOR POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE
Uhlin M., Mattsson J., Remberger M., Norström M.* (Stockholm, Sweden)
PH-P149
REDUCED INTENSITY CONDITIONING ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ADULTS
WITH RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA
IN THE RITUXIMAB ERA
Devlin S. M., Castro-Malaspina H. R., Barker J. N., Giralt S., Sauter C., Perales
M.-A., Mussetti A.* (Milan, Italy)
103
Scientific
Programme
Physicians
Yang D.-H., Yhim H.-Y., Ahn J.-S., Kim Y.-K., Lee J.-J., Kim H.-J., Jung S.-H.,
Kwak J.-Y.* (Jeonju, Korea, Republic Of)
Physicians Posters
PH-P150
THIOTEPA-BASED HIGH-DOSE PREPARATION VS BEAM FOR
(AUTOHSCT) IN LYMPHOMA OTHER THAN PCNSL: A
RETROSPECTIVE UPDATE FROM THE EBMT
Boumendil A., Finel H., de Rosa G., Martelli M., Liso V., Scime R., Janvier M.,
Mazza P., Kobbe G., Bunjes D., Majolino I., Ferrara F., Rambaldi A., Delmer A.,
Sureda A., Dreger P.* and EBMT Lymphoma Working Party (Paris, France)
PH-P151
ALLOGENEIC STEM CELL TRANSPLANTATION WITH REDUCED
INTENSITY CONDITIONING REGIMEN IN PATIENTS WITH
RELAPSED HODGKIN´S LYMPHOMA
Berro M., Prates M. V., Yantorno S., Milone J., Basquiera A. L., Adriana
B., García J. J., Remaggi G., Martinez Rolon J., Burgos R., Foncuberta C.,
Feldman L., Jaimovich G., Real J., Milovic V., Arberbide J., Makiya M., Dibar E.,
Kusminsky G., Rivas M. M.* and GATMO (Pilar, Argentina)
PH-P152
DA-EPOCH +/- R FOLLOWED BY CONSOLIDATION WITH
AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN THE
FIRST-LINE TREATMENT OF POOR-RISK, AGGRESSIVE NONHODGKIN LYMPHOMA (NHL) - A SINGLE CENTER EXPERIENCE
Pejsa V., Lucijanic M., Mitrovic Z., Ajdukovic R., Pirsic M., Kusec R., Purgaric
M., Jaksic O., Maricic I., Prka Z.* (Zagreb, Croatia)
PH-P153
SECOND LINE SALVAGE REGIMENS PRIOR TO HIGH DOSE
CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANT
ARE A VALID OPTION IN PROGRESSIVE HODGKIN’S LYMPHOMA
PATIENTS REFRACTORY TO FIRST LINE SALVAGE REGIMENS
Maghfoor I., Elhassan T. A. M., Akhtar S., Rauf M. S.* (Riyadh, Saudi Arabia)
PH-P154
HEMATOPOIETIC STEM CELL TRANSPLANTATION IN REFRACTORY
OR RECURRENT LYMPHOMAS OF CHILDREN AND ADOLESCENTS:
A MULTICENTER SURVEY OF TURKISH Paediatric BMT STUDY
GROUP
Kesik V., Aksoylar S., Küpesiz A., Öztürk G., Ataş E., Karakükcü M., Karasu G.,
Kansoy S., Yeşilipek A., Erbey F., Anak S., Uygun V., Ünal E., Yılmaz S., Tanyeli
A., Elli M., Atay D., Taçyıldız N., Kaya Z., Kurucu N., Ünal E., Koçak Ü., Hazar
V.* (İstanbul, Turkey)
PH-P155
ROLE OF FRONTLINE CONSOLIDATION WITH STEM CELL
TRANSPLANTATION IN SYSTEMIC PERIPHERAL T-CELL
LYMPHOMAS
Boschini C., Rossi A., Delaini F., Grassi A., Algarotti A., Micò C., Trezzi R.,
Gianatti A., Barbui A. M., Rambaldi A., Gritti G.* (Bergamo, Italy)
PH-P156
104
FAVORABLE OUTCOME FOR PATIENTS WITH LYMPHOID
MALIGNANCIES FOLLOWING ALLOGENEIC STEM CELL
TRANSPLANTATION USING FLUDARABINE TREOSULFAN,
COMPARED WITH OTHER REDUCED INTENSITY CONDITIONING
REGIMENS
Shem-Tov N., Volchek Y., Danylesko I., Avigdor A., Nagler A., Shimoni A.,
Yerushalmi R.* (Tel-Hashomer, Israel)
Physicians Posters
PH-P157
ALLOGENEIC STEM CELL TRANSPLANTATION AFTER
AUTOLOGOUS SCT FOR PRIMARY MEDIASTINAL B CELL
LYMPHOMA IN THE RITUXIMAB ERA: A RETROSPECTIVE STUDY
BY THE EBMT LYMPHOMA WORKING PARTY
Boumendil A., Socié G., Gutiérrez García G., Or R., Beelen D., Castagna L.,
Kröger N., Berthou C., Finel H., Dreger P., Wulf G., Kroschinsky F., Portratz J.,
Avivi I.* and EBMT Lymphoma Working Party (Haifa, Israel)
PH-P158
TREATMENT RESPONSE OF EATL PATIENTS IN AMSTERDAM
Visser O., de Baaij L., Mulder C. J., Cillessen S. A., Bouma G., Nijeboer P.*
PH-P159
Scientific
Programme
Physicians
(Amsterdam, Netherlands)
OUTCOME ANALYSIS OF 152 PRIMARY REFRACTORY
DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) PATIENTS
YOUNGER THAN 60 YEARS MANAGED WITH AND WITHOUT
HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL
TRANSPLANTATION
Soudy H., Rauf M. S., Rehman A., Elhassan T. A. M., Maghfoor I., Akhtar S.*
(Riyadh, Saudi Arabia)
PH-P160
EARLY DOSE INTENSIFICATION WITH AUTOLOGOUS STEM CELL
TRANSPLANTATION RESULTS IN IMPROVED DISEASE CONTROL IN
PATIENTS WITH PTCL NOS, AILD AND ALCL
Baumgarten A., Bertz H., Finke J., Marks R., Fritsch K.* (Freiburg, Germany)
PH-P161
TEAM (THIOTEPA,ETOPOSIDE,CYTARABINE,MELPHALAN) AS
CONDITIONING REGIMEN FOR LYMPHOMA TREATMENT WITH
AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION
(AHSCT)
Palumbo G., Merla E., Greco M., Fontana A., Specchia G., Pisapia G., Mazza
P., Guarini A., Rana A., Ditonno P., Ferrara F., Musto P., Pastore D., Scimè R.,
Pellegrini F., Capalbo S., Cavallaro A. M., Cascavilla N., Carella A. M.* (San
Giovanni Rotondo , Italy)
PH-P162
LOWER RELAPSE AND BETTER PROGRESSION FREE SURVIVAL
FOR CHEMOSENSITIVE HODGKIN LYMPHOMA PATIENTS
UNDERGOING HAPLOIDENTICAL AS COMPARED TO HLAIDENTICAL DONOR TRANSPLANTATION
Crocchiolo R., Bramanti S., Furst S., Giordano L., Sarina B., El Cheikh J.,
Garciaz S., Granata A., Broussais F., Devillier R., Coso D., Boubdallah R.,
Chabannon C., Santoro A., Carlo-Stella C., Blaise D., Castagna L.* (Rozzano,
Italy)
PH-P163
MOBILIZATION OF HEMATOPOIETIC STEM CELLS BY A
BENDAMUSTINE-CONTAINING REGIMEN IN HODGKIN’S
LYMPHOMA: RESULTS UPDATE
Carlo-Stella C., Castagna L., Gandolfi S., Brusamolino E., Santoro A., Re A.,
Pulsoni A., Merli F., Gabutti C., Liberati A. M., Annechini G., Anastasia A.*
(Brescia, Italy)
105
Physicians Posters
PH-P164
THE LYMPHOCYTES TO MONOCYTES RATIO IDENTIFIES A PATIENT
SUBGROUP AMONG HIGH RISK DLBCL THAT MAY BENEFIT FROM
UPFRONT INTENSIVE TREATMENT WITH AUTOGRAFT
Masciulli A., Scarano M., Delaini F., Rossi A., Ladetto M., Corradini P., Di
Nicola M., Patty C., Mulè A., Zanni M., Zoli V., Billio A., Gallamini A., Di
Raimondo F., Ferreri A. J. M., Benedetti F., Leoni P., Semenzato G., Frezzato
M., Flenghi L., Marchioli R., Barbui T., Gianni A. M., Tarella C., Cortelazzo S.,
Rambaldi A., Barbui A. M.* (Bergamo, Italy)
PH-P165
MANAGEMENT OF POSTRANSPLANT RELAPSING OR PERSISTENT
DISEASE IN LYMPHOID MALIGNANCIES: EXPLORING GRAFT
VERSUS LYMPHOMA EFFECT.
Lopez-Godino O., Lopez-Corral L., Martin A., Garcia-Sanz R., Mateos M.
V., Sanchez-Guijo F., Vazquez L., del Cañizo C., Caballero D., Cabrero M.*
(Salamanca, Spain)
PH-P166
TREATMENT OF PATIENTS WITH HODGKIN LYMPHOMA
RELAPSING AFTER AUTOLOGOUS HAEMATOPOIETIC STEM
CELL TRANSPLANTATION- A POLISH LYMPHOMA RESEARCH
GROUP (PLRG) MULTICENTER RETROSPECTIVE ANALYSIS OF
PROGNOSTIC FACTORS AND LONG-TERM OUTCOME
Romejko-Jarosinska J., Manko J., Drab E., Nasilowska-Adamska B., Czerw
T., Giza A., Knopinska-Posluszny W., Drozd-Sokolowska J., Stelmach P.,
Dybko J., Lojko-Dankowska A., Hus M., Walewski J., Komarnicki M., Czyz A.*
(Poznan, Poland)
PH-P167
SERUM TARC LEVEL MONITORING MAY PREDICT DISEASE
RELAPSE DETECTED BY PET SCAN AFTER REDUCED INTENSITY
ALLOGENEIC STEM CELL TRANSPLANTATION IN HODGKIN’S
LYMPHOMA PATIENTS
Rezzonico F., Spina F., Dodero A., Mazzocchi A., Crippa F., Alessi A., Dalto S.,
Viviani S., Corradini P., Farina L.* (Milan, Italy)
PH-P168
RITUXIMAB MAINTENANCE THERAPY AFTER AUTOLOGOUS
STEM CELL TRANSPLANTATION PROLONGS PROGRESSION FREE
SURVIVAL IN PATIENTS WITH MANTLE CELL LYMPHOMA
Weidle J., Meissner J., Radujkovic A., Ho A., Dreger P., Witzens-Harig M.,
Dietrich S.* (Heidelberg, Germany)
PH-P169
EBMT SCORE ONLY PREDICTS DAY 100 OVERALL SURVIVAL
AND OVERALL SURVIVAL AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION IN ADULT T-CELL LEUKEMIA/LYMPHOMA
PATIENTS
Nakano N., Kubota A., Tokunaga M., Takatsuka Y., Utsunomiya A., Takeuchi
S.* (Kagoshima, Japan)
106
Physicians Posters
Minimal residual disease, Tolerance, Chimerism &
Immune reconstitution - MONDAY, 31 MARCH 2014
PH-P170
A SIGNIFICANT EARLY DETECTION OF POOR OUTCOME IN ACUTE
LEUKEMIA PATIENTS HAVING A MINIMAL RESIDUAL DISEASE
USING MULTIPARAMETER FLOW CYTOMERTY COMBINED TO
MIXED CHIMERISM AT THREE MONTHS AFTER ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION
Sobh M., Plesa A., Dubois V., Mollet I., Labussière H., Gilis L., Ducastelle S.,
Barraco F., Thomas X., Nicolini F. E., Michallet M., Beckerich F.* (PIERRE
PH-P171
EFFICACY OF AZACITIDINE TO RESTORE FULL DONOR CHIMERISM
IN MDS OR AML PATIENTS AFTER ALLOGENEIC HSCT: A
THERAPEUTIC OPTION FOR TREATMENT OF EARLY RELAPSE
Guidi S., Nozzoli C., Saccardi R., Angarano R., Boncompagni R., Sanna A.,
Santini V., Bosi A., Donnini I., Gozzini A.* (Firenze , Italy)
PH-P172
IMMUNOPHENOTYPIC REMISSION AFTER ALLOGRAFTING IN
MULTIPLE MYELOMA
Brunello L., Festuccia M., Gilestro M., Maffini E., Ferrando F., Talamo E.,
Passera R., Boccadoro M., Omedè P., Bruno B., Giaccone L.* (Torino, Italy)
PH-P173
PREDICTIVE ROLE OF MINIMAL RESIDUAL DISEASE BEFORE
AND AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A
COMPARISON BETWEEN MULTIPARAMETER FLOW CYTOMETRY
AND WILM’S TUMOR 1 EXPRESSION
Carella A. M., Minervini M. M., Savino L., di Nardo F., de Waure C., Greco M.
M., Merla E., Melpignano A., Spirito A., Capalbo S., Palumbo G., Perla G., De
Cillis G. P., Cascavilla N., Rossi G.* (San Giovanni Rotondo (FG), Italy)
PH-P174
MRD MONITORING EARLY AFTER ALLOGENEIC
TRANSPLANTATION WAS MORE PREDICTIVE THAN KIT
MUTATION IN ADULT T (8; 21) AML AND ALLOW FURTHER RISK
STRATIFICATION: RESULTS FROM A MULTI-CENTER STUDY
qin Y.-Z., wu D.-P., liu Q.-F., wang J.-B., liu D.-H., xu L.-P., liu Y.-R., chen J.,
dai M., cheng H.-Y., huang X.-J., wang Y.* (beijing, China)
PH-P175
MONITORING MLL EXPRESSION MAY HELP IDENTIFY MLLREARRANGED AL PATIENTS AT HIGH RISK OF RELAPSE AFTER
Wang Y., Qin Y., Xu L., Liu D., Liu K., Huang X., Liu J.* (Beijing, China)
107
Scientific
Programme
Physicians
BENITE CEDEX, France)
Physicians Posters
Myelodysplasia - MONDAY, 31 MARCH 2014
PH-P176
A SINGLE-CENTRE EXPERIENCE OF ALLOGENEIC
HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN
MYELOFIBROSIS
Dignan F., Tholouli E., Routledge D. J. M.* (Manchester, United Kingdom)
PH-P177
DISEASE-FREE SURVIVAL OF MYELODYSPLASTIC
SYNDROME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION IS NOT ASSOCIATED WITH DISEASE STATUS
AND DONOR SOURCES
Wu T., Cao Y. X., Zhao L. Y., Liu Y. D., Zhou R. J., Zhang P. J., Xiong M., Lu D.,
Sun J. R., Wei J. Z., Ji Q. S., Lu Y.* (lang fang, China)
PH-P178
COMPARISON OF DIFFERENT PRETRANSPLANT STRATEGIES
PRIOR ALLOGENEIC TRANSPLANTATION IN PATIENTS WITH MDS:
UPFRONT TRANSPLANTATION VS. INDUCTION CHEMOTHERAPY
Groten A., Saure C., Dienst A., Rachlis E., Kondakci M., Germing U., Haas R.,
Schroeder T., Kobbe G., Wegener N.* (Duesseldorf, Germany)
PH-P179
ALLOGENEIC STEM CELL TRANSPLANTATION FOR HYPOPLASTIC
MDS IS COMPLICATED BY INCREASED REJECTION, WHEREAS
DISEASE RELAPSE IS THE PREDOMINANT CAUSE OF TREATMENT
FAILURE IN ACQUIRED HYPOPLASIA IN MDS.
Raj K., McLornan D., De Lavallade H., Potter V., Kulasekararaj A., Kenyon M.,
Marsh J., Pagliuca A., Mufti G., Clay J.* (London, United Kingdom)
PH-P180
IMPROVED SURVIVAL WITH ALLOGENEIC STEM CELL
TRANSPLANTATION IN PATIENTS WITH MYELODYSPLASTIC
SYNDROME OF HIGH AND VERY-HIGH RISK BY IPSS-R
Ahn J. S., Kim H. J., Song I. C., Jo D. Y., Lee H. S., Kim Y. S., Bae S. H., Moon J.
H., Sohn S. K.* (Deagu, Korea, Republic Of)
PH-P181
MYELOABLATIVE CONDITIONING WITH FLUDARABINE
AND (IV) BUSULFAN (F-BU4) FOR ALLOGENEIC STEM CELL
TRANSPLANTATION IN PATIENTS WITH MYELODYSPLASIC
SYNDROMES
Ahmed Nacer R., Mehdid F., Belhadj R., Rahmoune N., Baazizi M., Ait Ouali
D., Bouarab H., Hamladji R. M., Benakli M., Harieche F., Talbi A.* (Algiers,
Algeria)
PH-P182
ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION IN
MDS-PATIENTS: A RETROSPECTIVE, SINGLE INSTITUTION STUDY
COMPARING NMA VS. MA CONDITIONING.
Vindeloev L., Hovgaard D., Schjoedt I. M., Andersen N. S., Petersen S. L.,
Sengeloev H., Friis L. S.* (Copenhagen, Denmark)
PH-P183
FLUDARABINE AND TREOSULPHAN IS AN EFFECTIVE
CONDITIONING REGIMEN FOR ADULT PATIENTS WITH MDS
UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION.
LeBlanc K., Engström M., Jädersten M., Reykdal S., Mattsson J., Remberger
M., Hellström-Lindberg E., Ljungman P.* (Stockholm, Sweden)
108
Physicians Posters
Myelodysplasia - MONDAY, 31 MARCH 2014
PH-P184
IMPACT OF R-IPSS CYTOGENETICS ON OUTCOME AFTER
ALLO-SCT FROM HLA-IDENTICAL SIBLINGS OR HLA-MATCHED
UNRELATED DONORS FOR MYELODYSPLASTIC SYNDROMES: A
STUDY OF THE SOCIÉTÉ FRANÇAISE DE GREFFE DE MOELLE ET
THÉRAPIE CELLULAIRE (SFGM-TC)
Damaj G., Duhamel A., Robin M., Michallet M., Chevallier P., Beguin Y., Blaise
D., Cornillon J., Clavert A., Mohty M., Huynh A., Vigouroux S., Yakoub-Agha
I., N’Guyen S., Bories P., Thiébault-Bertrand A., Gauthier J.* and Société
Française de Greffe de Moelle et de Thérapie Cellulaire - SFGM-TC (Lille,
PH-P185
Scientific
Programme
Physicians
France)
THIOTEPA-BASED CONDITIONING FOLLOWED BY ALLOGENEIC
SCT IN PATIENTS WITH MDS A SURVEY OF THE CHRONIC
MALIGNANCIES WORKING PARTY OF EBMT
de Wreede L., van Biezen A., de Witte T., Kröger N.* and Chronic
Malignancies Working Party (Hamburg, Germany)
PH-P186
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
FOR JAPANESE FANCONI ANEMIA PATIENTS WITH MYELOID
MALIGNANCIES
Morimoto T., Shimizu T., Koike T., Takakura H., Ohtsubo K., Fukumura A.,
Itosu M., Muroi K., Koh K., Kato S., Yabe H., Yabe M.* (Isehara, Japan)
PH-P187
IMPACT OF ACUTE GVHD ON OUTCOME OF ALLOGENEIC
HEMATOPOIETIC STEM CELL IN CHILDREN AND ADOLESCENTS
SUFFERING FROM MYELODYSPLASTIC SYNDROME
Borovkova A. S., Stancheva N. V., Kozhokar P. V., Razumova S. V., Bykova
T. A., Semenova E. V., Paina O. V., Marcova I. V., Smirennikova M. M.,
Ekushov K. A., Fedukova Y. G., Morozova E. V., Bondarenko S. N., Kozlov A.
V., Zubarovskay L. S., Afanasyev B. V., Ratc A. A.* (Saint-Petersburg, Russian
Federation)
PH-P188
ESSENTIAL THROMBOCYTOSIS PATIENTS HAVE ACCUMULATION
OF CD8+ CELLS IN THE MARROW AND THE PROPORTION OF
MARROW CELLS PRODUCED IL-17
Sedzimirska M., Klimczak A., Dlubek D., Jaskula E., Lange A.* (Wroclaw,
Poland)
109
Physicians Posters
Non-hematopoietic stem cells - MON, 31 MAR 14
PH-P189
CHARACTERIZATION OF SPLEEN-DERIVED MESENCHYMAL STEM
CELLS IN PH-NEG MPN PATIENTS
Mantelli M., Ingo D. M., Lenta E., Aronica A., Bonetti E., Cobianchi L., Zonta
S., Baleri S., Acquafredda G., Catenacci L., Moretta A., Maccario R., Rosti V.,
Zecca M., Barosi G., Bernardo M. E., Avanzini M. A.* (Pavia, Italy)
PH-P190
ADIPOCYTE HYPERPLASIA INDUCED BY ARA-C IS INHIBITED BY
NAC-INDUCED DECREASE OF INTRACELLULAR REACTIVE OXYGEN
SPECIES (ROS) LEVEL
Zhu R., Zhang Y., Lu W., Liu K., Wang W.* (Beijing, China)
PH-P191
GENETIC SIGNATURE OF MESENCHYMAL STROMAL
CELLS DERIVED FROM HUMAN BONE MARROW CD271+
MONONUCLEAR CELLS
Kuci Z., Kollet J., Kreyenberg H., Boenig H., Klingebiel T., Bader P., Kuci S.*
(Frankfurt am Main, Germany)
PH-P192
MESENCHYMAL STROMAL CELLS INHIBIT PROLIFERATION OF
CMV-SPECIFIC CD8+ T CELLS
Schmitt A., Malcherek G., Dreger P., Wuchter P., Diehlmann A., Ho A. D.,
Michael S.*, Jin N. (Heidelberg, Germany)
PH-P193
PHENOTYPICAL AND FUNCTIONAL CHARACTERIZATION OF
IN VITRO EXPANDED BONE MARROW MESENCHYMAL STEM
CELLS FROM PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST
DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Tie R., He Y., Fu S., Sheng L., Yu X., Huang H., Wang B.*, Hu Y. (Hangzhou,
China)
PH-P194
HUMAN PLACENTAL MESENCHYMAL STEM CELLS (PMSCS)CONDITIONED MEDIA SHOWED THE LONG-TERM EFFICACY FOR
SUPPORTING STEMNESS OF HUMAN INDUCED PLURIPOTENT
STEM CELLS EX VIVO
Jung J.-H., Kim J. H., Sung H. J., Kim B. S., Hong S. C., Park Y.* (Seoul, Korea,
Republic Of)
110
Physicians Posters
Reduced-intensity conditioning - MON, 31 MAR 14
PH-P195
COMBINATION OF FLUDARABINE, AMSACRINE AND CYTARABINE
FOLLOWED BY REDUCED-INTENSITY CONDITIONING AND
15 PATIENTS WITH MYELOFIBROSIS
PH-P196
PHASE II PROSPECTIVE MULTICENTRE STUDY TESTING THE
EFFICACY AND SAFETY OF A CLOFARABINE (CLO), I.V. BUSULFAN
(BU) AND ANTITHYMOCYTE GLOBULINS (ATG)-BASED RIC
REGIMEN BEFORE ALLO-SCT FOR HIGH-RISK MDS OR ACUTE
LEUKEMIA: THE CLORIC TRIAL.
Labopin M., Socie G., Vigouroux S., Furst S., Detrait M., Lioure B., Guillaume
T., Delaunay J., Peffault de La Tour R., Milpied N., El-Cheikh J., Blaise D.,
Michallet M., Bilger K., Moreau P., Mohty M., Chevallier P.* and on behalf of
the SFGM-TC (NANTES, France)
PH-P197
SECOND RIC ALLOGENEIC TRANSPLANT AS A RESCUE STRATEGY
FOR ACUTE LEUKAEMIA PATIENTS WHO RELAPSE AFTER AN
INITIAL RIC ALLOGENEIC TRANSPLANTATION: ANALYSIS OF RISK
FACTORS AND TREATMENT OUTCOMES
Mohty M., Labopin M., Ciceri F., Finke J., Holler E., Tischer J., Lioure B.,
Gribben J., Kanz L., Blaise D., Dreger P., Nagler A., Held G., Arnold R., Vrhovac
R.* and Acute Leukemia Working Party of the EBMT (Zagreb, Croatia)
PH-P198
A SINGLE CENTER EXPERIENCE OF MATCHED SIBLING DONORS
PBSCS BONE MARROW TRANSPLANTATION FOR 31 CASES OF
FANCONI ANEMIA USING LOW DOSE CYCLOPHOSPHAMIDE
Abdelfattah R., Sobhy A., Abdel-Mooti M., El-Haddad A., Fahmy O.,
Mahmoud H. K., Elsayed M., Fathy G. M.* (cairo, Egypt)
PH-P199
SEQUENTIAL CHEMOTHERAPY FOLLOWED BY REDUCED INTENSITY CONDITIONING AND ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION FOR HIGH RISK ACUTE MYELOID LEUKEMIA PATIENTS
IN FIRST COMPLETE REMISSION: A PROSPECTIVE PILOT STUDY
Sobh M., Labussière H., Hayette S., Tigaud I., El Hamri M., Gilis L., Barraco F.,
Ducastelle S., Nicolini F. E., Thomas X., Michallet M.* (PIERRE BENITE CEDEX,
France)
PH-P200
ALLOGENEIC STEM CELL TRANSPLANTATION FOR HEMATOLOGIC
MALIGNANCIES: 4GY TBI TO INTENSIFY TREOSULFAN AND
FLUDARABINE-BASED CONDITIONING
Zuanelli Brambilla C., Lorentino F., Piemontese S., Crucitti L., Greco R.,
Morelli M., Messina C., Forcina A., Lupo Stanghellini M. T., Vago L., Marktel
S., Marcatti M., Assanelli A., Corti C., Bernardi M., Bonini C., Ciceri F.,
Peccatori J., Giglio F.* (Milan, Italy)
PH-P201
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR
PRIMARY AND SECONDARY MYELOFIBROSIS: RESULTS OF A
SINGLE-CENTER RETROSPECTIVE ANALYSIS
Haen S. P., Faul C., Vogel W., Kanz L., Bethge W., Dorn C.* (Tuebingen,
Germany)
111
Scientific
Programme
Physicians
Doubek M., Brychtova Y., Tomiska M., Horky O., Sandecka V., Mayer J., Krejci
M.* (Brno, Czech Republic)
Physicians Posters
Reduced-intensity conditioning - MON, 31 MAR 14
PH-P202
ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH
SYSTEMIC AL AMYLOIDOSIS; A NON-INTERVENTIONAL STUDY
(NIS) BY THE PLASMA CELL DISORDER SUBCOMMITTEE OF THE
CHRONIC MALIGNANCY WORKING PARTY OF THE EBMT
Hegenbart U., Iacobelli S., Hoek J., Passweg J., Bordessoule D., de Witte T.,
Garderet L., Kröger N., Schönland S. O.* (Heidelberg, Germany)
PH-P203
IN PATIENTS ≥ 60 YEARS WITH ADVANCED MYELOID DISEASE ALLOHCT IS A FEASIBLE CURATIVE THERAPY: - RESULTS IN 250
CONSECUTIVE PATIENTS WITH AML/MDS
Luebbert M., Ohneberg K., Zeiser R., Wäsch R., Marks R., Finke J., Bertz H.*
(Freiburg, Germany)
PH-P204
FLUDARABINE COMBINED WITH REDUCED OR MYELOABLATIVE
DOSES OF INTRAVENOUS BUSULFAN RESULTS IN SIMILAR
OUTCOME AFTER ALLOGENEIC STEM-CELL TRANSPLANTATION
(SCT) IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA IN
REMISSION.
Volchek Y., Danylesko I., Nagler A., Shem-Tov N., Shimoni A.*, Yerushalmi R.
PH-P205
COMPARISON OF INTENSIVE CHEMOTHERAPY AND
HYPOMETHYLATING AGENTS PRIOR TO ALLOGENEIC STEM CELL
TRANSPLANTATION FOR ADVANCED MDS (RAEB, RAEB-T). A
STUDY OF THE MDS SUBCOMMITTEE OF THE CMWP OF EBMT
Iacobelli S., van Biezen A., Maertens J., Bourhis J.-H., Passweg J., YakhoubAgha I., Tabrizi R., Jacques-Olivier B., Kroeger N., Robin M., Chevallier P.,
Challandon Y., Hyunh A., de Witte T., Potter V.* and CLWP EBMT (London,
United Kingdom)
PH-P206
RECONSTITUTION OF GPI-ANCHOR-NEGATIVE NK CELL POPULATIONS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOLLOWING ALEMTUZUMAB-BASED CONDITIONING
Wolff D., Theobald M., Meyer R. G., Ullrich E., Wagner E. M., Lay A. N.* (Mainz,
Germany)
PH-P207
ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS 60 YEARS
AND OLDER: POTENTIALLY CURATIVE THERAPY FOR HAEMATOLOGICAL MALIGNANCY WITH LOW TREATMENT RELATED MORTALITY.
Publicover A., Hill K., Hurlock C., Jarvis L., Newman J., Main S., McKeag N.,
Orchard K. H., Richardson D. S.* (Southampton, United Kingdom)
PH-P208
ALPHA/BETA T CELL DEPLETION OF HLA-IDENTICAL SIBLING
STEM CELL TRANSPLANTATION: TWO-CENTER EXPERIENCE
Uzay A., Akyol G., Ratip S., Pala Ç., Şıvgın S., Eser B., Ünal A., Ovalı E., Çetin
M., Kaynar L.* (Kayseri, Turkey)
PH-P209
ASSESSMENT OF THE HEMATOPOIETIC CELL TRANSPLANTATION COMORBIDITY INDEX IN OLDER PATIENTS RECEIVING REDUCED-INTENSITY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Mehta J., Monreal J., Galvin J. P.* (Chicago, United States)
112
Physicians Posters
Regenerative medicine - Monday, 31 March 2014
PH-P210
INFLAMMATION CONVERTS HUMAN MESOANGIOBLASTS INTO
TARGETS OF ALLOREACTIVE IMMUNE RESPONSES: IMPLICATIONS
FOR ALLOGENEIC CELL THERAPY OF DMD
Tedesco F. S., Bondanza A., Tonlorenzi R., Carbone M. R., Gerli M., Marktel S.,
Napolitano S., Cicalese M. P., Ciceri F., Peretti G., Cossu G., Bonini C., Noviello
M.* (Milan, Italy)
BONE MARROW MONONUCLEAR CELLS LOCAL IMPLANTATION
IN PATIENTS WITH AVASCULAR NECROSIS OF THE HEAD OF THE
FEMUR
Zdziarski R., Lange J., Mordak-Domagala M., Dlubek D., Wodzislawski W.,
Jaskula E., Lange A.* (Wroclaw, Poland)
PH-P212
BONE MARROW DERIVED MONONUCLEAR CELLS IMPLANTATION
DECREASES SYMPTOMS OF LOWER LIMB ISCHEMIA: LONG TERM
POST TREATMENT OBSERVATION
Lange J., Dlubek D., Maslowski L., Mizia S., Witkiewicz W., Lange A.*
(Wroclaw, Poland)
PH-P213
GMP MESENCHYMAL STEM CELL PRODUCTION FROM PATIENTS
AFFECTED BY PROGRESSIVE SUPRANUCLEAR PALSY: A PHASE I
STUDY.
Montemurro T., Viganò M., Parazzi V., Baluce B., Lavazza C., Budelli S.,
Marino L., Lazzari L., Pezzoli G., Giordano R.* (Milano, Italy)
Solid tumours - Monday, 31 March 2014
PH-P214
NATURAL KILLER CELL BASED THERAPIES FOR OSTEOSARCOMA
PH-P215
ALLOGENEIC HEMOPOIETIC STEM CELL TRANSPLANTATION WITH
REDUCED-INTENSITY CONDITIONING REGIMEN IN CHILDREN AND
YOUNG ADULTS WITH NEUROBLASTOMA AND EWING SARCOMA
Valentín J., Patiño A., López-Collazo E., Martínez-Romera I., Pérez-Martínez
A., Fernandez L.* (Madrid, Spain)
Gevorgyan A., Kozlov A., Shiryaev S., Andreeva T., Jukhta T., Morozova E.,
Klimov A., Shvetsov A., Punanov Y., Safonova S., Zubarovskaya L., Afanasyev
B., Kazantsev I.* (Saint-Petersburg, Russian Federation)
PH-P216
EVALUATION OF LIGANDS FOR NATURAL KILLER CELL ACTIVATING
RECEPTORS IN METASTATIC COLORECTAL CARCINOMA CELLS AND
THEIR ROLE IN NK CELL-MEDIATED LYSIS
Turin I., Brugnatelli S., Matteo T., Lisini D., Maestri M., Rovati B., Luinetti O.,
Pedrazzoli P., Paulli M., Maccario R., Montagna D.* (Pavia, Italy)
PH-P217
HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN Paediatric
SOLID TUMORS: THE EXPERIENCE OF CHILDREN HOSPITAL OF
BRESCIA, ITALY
Federica B., Marta C., Carmelita D., Lucia Dora N., Fabian S. R., Fulvio P.,
Arnalda L., Alessandra B.* (Brescia, Italy)
PH-P218
DESMOPLASTIC SMALL ROUND CELL TUMOR (DSRCT): A
RETROSPECTIVE ANALYSIS OF 26 ADULTS PATIENTS (PTS) FROM A
SINGLE INSTITUTION
De Sanctis R., Bertuzzi A., Quagliuolo V., Santoro A., Marrari A., Marchetti S.,
Castagna L.* (Rozzano, Italy)
113
Scientific
Programme
Physicians
PH-P211
Physicians Posters
Solid tumours - Monday, 31 March 2014
PH-P219
BUSULPHAN-MELPHALAN VERSUS CARBOPLATIN-ETOPOSIDEMELPHALAN CONDITIONING REGIMEN IN CHILDREN WITH
NEUROBLASTOMA UNDERWENT AUTOLOGOUS STEM CELL
TRANSPLANTATION
PH-P220
ROLE OF NK CELLS DURING ANTITUMORAL IMMUNE ACTIVATION
INDUCED BY X-RAY AND HYPERTHERMIA
Babacan O., Korkmazer N., Kesik V., Atas E.* (Ankara, Turkey)
Finkel P., Mayer F., Boesl K., Werthmoeller N., Mackensen A., Frey B., Gaipl
U., Ullrich E.* (Erlangen, Germany)
PH-P221
SUCCESSFUL GENERATION OF HPV-SPECIFIC T CELL LINES FOR T
CELL THERAPY OF PATIENTS WITH HPV-POSITIVE HEAD AND NECK
CANCER
Guido I., Secondino S., Quartuccio G., Gurrado A., Paglino C., Pellerano A.,
Acquafredda G., Rubert L., Maccario R., Zecca M., Comoli P., Pedrazzoli P.,
Basso S.* (Pavia, Italy)
PH-P222
STEM CELL RESCUE FROM IRRADIATION OF MULTIPLE TUMOR
SITES COMBINED WITH HIGH-DOSE CHEMOTHERAPY, FOLLOWED
BY REDUCED INTENSITY CONDITIONING AND HAPLODISPARATE
STEM CELL TRANSPLANTATION IN PATIENTS WITH ADVANCED
Paediatric SARCOMAS: PRELIMINARY RESULTS
Wawer A., Teichert von Luettichau I., Bender H.-U., Grunewald T. G.,
Blaeschke F., Bauer F., Steinborn M., Röper B., Andratschke N., Molls M.,
Salat C., Issels R. D., Klingebiel T., Bader P., Dirksen U., Jürgens H., Kolb H.-J.,
Koscielniak E., Thiel U., Burdach S.* (Munich, Germany)
Stem cell donor - Monday, 31 March 2014
PH-P223
USE OF UNRELATED DONORS IN ELDERLY PATIENTS (AGE >60
YEARS) UNDERGOING REDUCED-INTENSITY CONDITIONING
HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR
HEMATOLOGIC MALIGNANCIES.
devilier R., furst S., crocchiolo R., granata A., faucher C., mohty B., harbi S.,
bouabdallah R., vey N., castagna L., chababnnon C., blaise D., devilier R.,
furst S., crocchiolo R., granata A., faucher C., mohty B., harbi S., bouabdallah
R., vey N., castagna L., chababnnon C., blaise D., Elcheikh J.* (marseille,
France)
PH-P224
COMPARISON BETWEEN HLA ALLELE AND ANTIGEN MISMATCHED
UNRELATED BONE MARROW TRANSPLANTATION IN 6183 JMDP
RECIPIENTS.
Atsuta Y., Morishima Y., Kawase T., Ohashi K., Fukuda T., Miyamura K., Eto
T., Kato C., Iwato K., Sawada A., Kanda Y., Kato S.* (Isehara, Japan)
PH-P225
WHO IS THE BEST HAEMATOPOIETIC STEM CELL DONOR FOR A
MALE PATIENT WITH ACUTE LEUKAEMIA?
Labopin M., Solders M., Beelen D., Arnold R., Ehninger G., Milpied N.,
Niederwieser D., Hamladji R.-M., Krzemien S. K., Ganser A., Socié G.,
Stelljes M., Volin L., Craddock C., Mohty M., Ringdén O.* and Acute
Leukemia Working Party of the European Group for Blood and Marrow
Transplantation (Stockholm, Sweden)
114
Physicians Posters
Stem cell donor - Monday, 31 March 2014
PH-P226
COMPARABLE OUTCOME OF HAPLOIDENTICAL AND
MATCHED SIBLING DONOR PERIPHERAL BLOOD STEM CELL
TRANSPLANTATION FOLLOWING MYELOABLATIVE CONDITIONING
FOR POOR RISK ACUTE MYELOID LEUKEMIA
Khattry N., Chakrabarti S., Punatar S., Gupta A., Bagal B., Jaiswal S. R.* (NEW
DELHI, India)
PH-P227
HLA-DPB1 DISPARITY AS A RICK FACTOR FOR 10/10 HLA
MATCHED-UNRELATED DONOR HSCT
PH-P228
Scientific
Programme
Physicians
Makarenko O., Alyanskiy A., Alekseikova I., Fediukova I., Bondarenko S.,
Ivanova N., Kuzmich E.* (St-Petersburg, Russian Federation)
IS THE BONE MARROW ASSESSMENT AN EVALUATION
THAT OFFERS MORE SAFETY IN ALLOGENEIC STEM CELLS
TRANSPLANTATION? RESULTS IN 725 HEALTHY RELATED
DONORS
MALATO S., RONCHI P., GUGGIARI E., COPPOLA M., SALA E., LORENTINO F.,
CORTI C., PECCATORI J., BERNARDI M., MARCATTI M., PONZONI M., MILANI
R., BELLIO L., LUPO STANGHELLINI M., CICERI F., GATTILLO S.* (MILAN, Italy)
PH-P229
THE PYROSEQUENCING: A NEW PROMISING APPROACH TO
PERFORM HLA TYPING AND SELECT THE STEM CELL DONOR IN A
QUICKLY, SIMPLE AND ACCURATE WAY
Cattina F., Soverini S., Ottaviani E., Carella G., Malagoli A., Malagola M., Skert
C., Filì C., Alghisi E., Perucca S., Di Palma A., De Benedittis C., Bochicchio M.
T., Bergonzi C., Martinelli G., Russo D., Bernardi S.* (Brescia, Italy)
PH-P230
STRATEGY, POLICY AND ALGORITHM OF ADULT PATIENTS WITH
HIGH RISK HAEMATOLOGICAL MALIGNANCIES CANDIDATED TO
AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT: AN
ANALYSIS FROM THE ROME TRANSPLANT NETWORK.
Cudillo L., Cerretti R., De Angelis G., De Fabritiis P., Dentamaro T., Avvisati
G., Tirindelli M. C., Mengarelli A., Marchesi F., Montefusco E., Ferrari A.,
Chierichini A., Anaclerico B., Andreani M., Testi M., Mangione I., Di Piazza F.,
Arcese W., Picardi A.* (Rome, Italy)
PH-P231
MARROW HARVESTING FROM INFANT DONORS IN COMPARISON
OF YOUNG DONORS IN TERM OF THE GRAFT PRODUCT
Alfieri C., DeAngelis G., Gallucci C., Ribersani M., Marziali M., Isgrò A.,
Armiento D., Cardarelli L., gaziev J., Sodani P., Lucarelli G., Paciaroni K.*
(rome, Italy)
PH-P232
SAFETY OF HEMATOPOIETIC STEM CELL DONATION FOR
VOLUNTEER DONORS: THE EXPERIENCE OF THE SECOND
OPINION SIMTI COMMITEE OF ITALIAN BONE MARROW DONOR
REGISTRY (IBMDR)
Sacchi N., Vassanelli A.* (Verona, Italy)
115
Physicians Posters
Stem cell mobilisation and Graft engineering Monday, 31 March 2014
PH-P233
BIOSIMILAR G-CSF (FILGRASTIM) IS (COST)EFFECTIVE FOR
PERIPHERAL BLOOD STEM-CELL MOBILIZATION BEFORE
AUTOLOGOUS TRANSPLANTATION-A SINGLE CENTRE
EXPERIENCE
Stylianou C., Konstantelos I., Elena L., Antoniades M., Melanthiou F., Braimi
M., Tsitskari T., Michael M. D.* (Nicosia, Cyprus)
PH-P234
SPECTRA OPTIA VERSUS COBE SPECTRA APHERESIS DEVICES:
HOW DOES THE NEW TECHNOLOGY SUIT BETTER PBSC
COLLECTION?
Pinchasov A., Shpringer M., Senyor G., Tartakovsky B., Naparstek E., Eshel
R.* (Tel-Aviv, Israel)
PH-P235
CHEMOMOBILIZATION WITH HIGH-DOSE ETOPOSIDE AND G-CSF
RESULTS IN EFFECTIVE AND SAFE STEM CELL COLLECTION IN
HEAVILY PRETREATED LYMPHOMA PATIENTS
Gulbas Z., Ozkan H. A.* (Istanbul, Turkey)
PH-P236
CRYOPRESERVATIVE VERSUS NON CRYOPRESERVATIVE IN
(EGYPTIAN EXPERIENCE)
Elzimaity M. T., Attia M. H., Elsayed H. M., Shalaby N. M., Mohamed A. A.,
Moussa M.* (Cairo, Egypt)
PH-P237
NON INTERVENTIONAL PROSPECTIVE CLINICAL STUDY ON
PERIPHERAL BLOOD STEM CELL MOBILIZATION IN PATIENTS
WITH RELAPSED LYMPHOMAS
Finel H., Dreger P., Sureda A., Luan J., Giebel S., Pohlreich D., Shimoni A.,
Ringhoffer M., Sucak G., Schaap M., Schouten H., van Gorkom G.* and on
behalf of the Lymphoma Working Party of the European Group for Blood
and Marrow Transplantation (EBMT) (Maastricht, Netherlands)
PH-P238
LENOGRASTIM (MYELOSTIM®) VS BIOSIMILAR FILGRASTIM
(ZARZIO®) FOR AUTOLOGOUS PERIPHERAL BLOOD STEM
CELLS MOBILIZATION IN ADULT PATIENTS WITH HEMATOLOGIC
MALIGNANCIES: A SINGLE INSTITUTION EXPERIENCE
Gumenyuk S., Vacca M., Pandolfi A., Dessanti M. L., Palombi F., Pisani F.,
Romano A., Spadea A., Mengarelli A., Marchesi F.* (Rome, Italy)
PH-P239
EFFECTS OF A NEW DOSING SCHEME OF ATG-F OF DONOR NK
CELLS AND IMMUNE RECOVERY IN HAPLOIDENTICAL T AND B
CELL DEPLETED STEM CELL TRANSPLANTATION.
Feuchtinger T., Meisel R., Schuster F., Kyzirakos C., Schlegel P., Klose C.,
Teltschik H.-M., Gruhn B., Schwinger W., Urban C., Martinius H., Pflueckhahn
U., Teltschik R., Schumm M., Handgretinger R., Lang P.* (Tuebingen, Germany)
PH-P240
116
BIOSIMILAR COMPARED WITH ORIGINATOR FILGRASTIM FOR
RELATED-DONOR ALLOGENEIC STEM CELL MOBILISATION: A
PROSPECTIVE-HISTORICAL CONTROL STUDY
Ribeil J.-A., Turner M., Hermine O., Blanche S., Cavazzana-Calvo M., Lefrère
F.* (Paris, France)
Physicians Posters
PH-P241
BLOOD GRAFT STEM CELL SUBCLASSES AND LYMPHOCYTE
SUBSETS IN NHL PATIENTS MOBILIZED WITH CHEMOTHERAPYG-CSF PLUS PLERIXAFOR INJECTION DUE TO POOR
MOBILIZATION - A PROSPECTIVE GOA STUDY
PH-P242
SUCCESSFUL TRANSITION FROM COBE SPECTRA TO SPECTRA
OPTIA APHERESIS DEVICE FOR ALLOGENEIC AND AUTOLOGOUS
PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
Berg B., Reufi B., Wieczorek A., Lorusso A., Movassaghi K., Uharek L., TietzeBürger C.* (Berlin, Germany)
PH-P243
QUANTIFICATION OF THE TIME AND EFFORT REQUIRED FOR
AUTOLOGOUS PERIPHERAL BLOOD STEM CELL COLLECTION: A
EUROPEAN PERSPECTIVE
Azar N., Reitan J. F., Kadota R. P., Iqbal S. U., Naoshy S., Hübel K., Mohty M.*
(Paris , France)
PH-P244
STEM CELL GRAFT VIABILITY AFFECT CLINICAL OUTCOME AFTER
ALLOGENEIC HSCT
Remberger M., Watz E., Mattsson J., ringden O., Uhlin M.* (Stockholm,
Sweden)
PH-P245
AUTOLOGOUS HEMATOPOIETIC STEM CELL MOBILIZATION
WITH PLERIXAFOR (P) PLUS G-CSF (G) IN PATIENTS <65 AND
≥65 YEARS OF AGE IN FRONTLINE AND MOBILIZATION FAILURE
SETTINGS FOR MULTIPLE MYELOMA (MM) AND NON-HODGKIN’S
LYMPHOMA (NHL)
Micallef I., Kadota R. P., Llanos S. R., Schriber J.* (Scottsdale, United States)
PH-P246
EFFECTIVE DEPLETION OF CD45RA+ NAÏVE T CELLS USING
THE CLINIMACS® SYSTEM TO PRODUCE DONOR LYMPHOCYTE
INFUSIONS FOR ANTIVIRAL BOOST FOLLOWING HAPLOIDENTICAL
TRANSPLANTATION
Hult A., Persson Å., Lenhoff S., Toporski J., Scheding S., Turkiewicz D., Dykes
J.* (Lund, Sweden)
PH-P247
OSMOZ: AN OBSERVATIONAL STUDY OF THE USE OF PLERIXAFOR
FOR STEM CELL MOBILIZATION AND COLLECTION IN 262
PATIENTS TREATED AT 33 FRENCH TRANSPLANT PROGRAMMES
OVER A 1-YEAR PERIOD
BIJOU F., Jean-Michel M., Milpied N., Grouin J.-M., Mohty M., Chabannon C.*
(Marseille, France)
PH-P248
SEPARATION OF CD8+ LYMPHOCYTES FROM PERIPHERAL
BLOOD PROGENITOR CELL PRODUCTS USING AFFINITY BEAD
ACOUSTOPHORESIS
Urbansky A., Lenshof A., Dykes J., Laurell T., Scheding S.* (Lund, Sweden)
117
Scientific
Programme
Physicians
Valtola J., Ropponen A., Siitonen T., Kuitunen H., Savolainen E.-R., Kuittinen
T., Pyörälä M., Mäntymaa P., Pelkonen J., Nousiainen T., Jantunen E.,
Varmavuo V.* (Kuopio, Finland)
Physicians Posters
PH-P249
INVOLVEMENT OF SOLUBLE FORMS OF RECEPTOR OF THE
UROKINASE-TYPE PLASMINOGEN ACTIVATOR (UPAR) IN
HEMATOPOIETIC STEM CELL HOMING
Rocco M., Sessa M., Giudice V., Selleri C., Ricci P., Ragno P., Li Santi A.,
Gorrasi A., Serio B., Montuori N.* (Naples, Italy)
PH-P250
FILGRASTIM (BIOSIMILAR) IN ALTERNATE DAYS FOR THE
MANAGEMENT OF NEUTROPENIA AFTER AUTOLOGOUS
HEMATOPOIETIC STEM CELL TRANSPLANTATION - EXPERIENCE
OF A SINGLE CENTER
Vaz C., Branca R., Roncon S., Campos A., Constanço C., Campilho F.* (Porto,
Portugal)
PH-P251
USE OF BIOSIMILAR FILGRASTIM FOR PERIPHERAL BLOOD STEM
CELL MOBILIZATION IN AUTOLOGOUS TRANSPLANTATION: AN
ANALYSIS OF EFFICACY AND SAFETY
Gerivaz R., Schuh J., Costa F., Ferreira G., Botelho de Sousa A.* (Lisboa,
Portugal)
PH-P252
SELECTIVE PHOTODEPLETION OF RECIPIENT-ALLOREACTIVE
T-CELLS ENABLES SAFE AND EFFICACIOUS HAPLOIDENTICAL
HSCT: INTERIM RESULTS FROM A PHASE II TRIAL IN PATIENTS
WITH AML, ALL, AND MDS
Maertens J., Walker I., Foley R., Lewalle P., Selleslag D., Velthuis J., Gerez L.,
Reitsma K., Wagena E., Roy J., Lachance S., Mielke S., Roy D.-C.* (Montreal,
Canada)
PH-P253
PERIPHERAL BLOOD PROGENITOR CELL COLLECTION - A
COMPARISON OF 2 APHAERESIS EQUIPMENTS
Bordalo F., Ferreira S., Amado F., Bernardo A. P., França M., Rosales M.,
Roncon S., Lopes S. M.* (Porto, Portugal)
PH-P254
PLERIXAFOR ON-DEMAND COMBINED WITH CHEMOTHERAPY
AND GRANULOCYTE COLONY-STIMULATING FACTOR TO MOBILIZE
PERIPHERAL STEM CELLS FOR AUTOLOGOUS TRANPLANTATION.
ANALYSIS OF COLLECTION AND ENGRAFTMENT
CHARACTERISTICS OF 29 PATIENTS WITH LYMPHOMA AND
MYELOMA
Morciano M., Ostuni A., Mele A., De Francesco R., Fina M., Greco G., Sibilla S.,
Carlino D., Rossini B., De Risi C., Citiso S., Rizzo G., Abbruzzese L., Vincenzo
P.* (Tricase, Italy)
PH-P255
AUTOLOGOUS STEM CELL COLLECTION IN LYMPHOMA AND
MYELOMA PATIENTS: SINGLE CENTER ANALYSIS WITH INTENT TO
SUCCESSFULLY MOBILIZE AND TRANSPLANT
Bilgen H., Hindilerden F., Serefhanoglu S., Kucukkaya R., Ozcelık E., Arat M.,
Güvenç S., Hasbal N.* (Istanbul, Turkey)
118
Physicians Posters
Stem cell source - Monday, 31 March 2014
PH-P256
THE INFLUENCE OF AUTOLOGOUS GRAFT COMPOSITION ON
ENGRAFTMENT
Vacca M., Pandolfi A., Iudicone P., Scocchera R., Fioravanti D., Ipsevich F.,
Pezzotti P., Severino A., Majolino I., Pierelli L.* (Rome, Italy)
PH-P257
HLA-A, -B, -C AND -DRB1 HIGH RESOLUTION MATCHING CAN
IMPROVE PATIENT’ OUTCOME AFTER DOUBLE UMBILICAL
ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT)
PH-P258
EFFICACY AND FEASIBILITY OF UMBILICAL CORD BLOOD
TRANSPLANTATION WITH MYELOABLATIVE NON-TBI
CONDITIONING REGIMEN USING FLU180/IVBU12.8/MEL80 FOR
ADULT PATIENTS WITH ADVANCED HEMATOLOGICAL DISEASES
Kubota A., Tokunaga M., Takeuchi S., Takatsuka Y., Utsunimiya A., Nakano
N.* (Kagoshima, Japan)
PH-P259
COMPARISON OF UMBILICAL CORD BLOOD AND HAPLOIDENTICAL
DONOR GRAFTS IN ADULTS WITH HIGH RISK HEMATOLOGIC
DISEASES AFTER FLUDARABINE CYCLOPHOSPHAMIDE AND TBI 2
GY BASED REDUCED-INTENSITY CONDITIONING REGIMEN STEM
CELL TRANSPLANTATION.
crocchiolo R., furst S., bramanti S., sarina B., granata A., faucher C., mohty B.,
harbi S., bouabdallah R., vey N., santoro A., chabannon C., castagna L., blaise
D., Elcheikh J.* (marseille, France)
PH-P260
OUTCOMES OF OLDER PATIENTS UNDERGOING 2 STEP
APPROACH TO HAPLOIDENTICAL AND MATCHED RELATED
PERIPHERAL BLOOD HEMATOPOIETIC STEM CELL
TRANSPLANTATION (HSCT): A SINGLE INSTITUTIONAL
EXPERIENCE
Carabasi M., Filicko J., Alpdogan S., Wagner J., Rosado S., Rudolph S.,
Kasner M., Martinez U., Weiss M., Flomenberg N., Grosso D., Gaballa S.*
(Philadelphia, United States)
PH-P261
IS HLA-G -725 G/C/A POLYMORPHISM ABLE TO PREDICT THE
LEVEL OF SOLUBLE HLA-G? PERSPECTIVES IN CORD BLOOD
TRANSPLANTATION.
Bergamaschi P., Badulli C., Genovese V., Marchesi A., Pasi A., Romano B.,
Zorzetto M., Martinetti M., Salvaneschi L., Tinelli C., Sbarsi I.* (PAVIA, Italy)
PH-P262
FIRST APPLICATION OF THE EBMT RISK SCORE IN DOUBLE
UMBILICAL CORD BLOOD TRANSPLANTATION FOR
HEMATOLOGICAL MALIGNANCIES: SIGNIFICANT IMPACT ON
DIFFERENT OUTCOMES
Sobh M., Robin M., Fegueux N., Furst S., Mohty M., Yakoub-Agha I., Marry
E., Rocha V., Blaise D., Milpied N., Nicolini F. E., Michallet M., Labussière H.*
(Pierre Bénite, France)
119
Scientific
Programme
Physicians
Chevallier P., Guillaume T., Delaunay J., Moreau P., Mohty M., Gagne K.,
Devys A., Herry P., Castagnet S., Cesbron A., Malard F.* (Nantes, France)
Physicians Posters
PH-P263
DETERMINANTS OF ENGRAFTMENT AND SINGLE-UNIT
PREDOMINANCE AFTER DOUBLE UMBILICAL CORD BLOOD (DUCB)
ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT) IN
ADULTS: HHV-6 REACTIVATION DURING APLASIA, LOWER UNITUNIT HLA MATCHING AND YOUNGER UCB UNIT AGE MAY REPRE
Guillaume T., Jacques D., Foucher Y., Tessoulin B., Malard F., Precupanu
C., Peterlin P., Derenne S., Herry P., Cesbron A., Gagne K., Lode L., Illiaquer
M., Imbert-Marcille B.-M., Le Gouill S., Moreau P., Labopin M., Mohty M.,
Chevallier P., Le Bourgeois A.* (Nantes, France)
PH-P264
THE NUMBER OF TOTAL NUCLEATED CELLS AND CD34 CELLS
IN BONE MARROW HARVESTS ARE BETTER PREDICTORS FOR
ENGRAFTMENT THAN NUCLEATED CELL COUNTS IN BONE
MARROW GRAFTS AFTER CELL CONCENTRATION AND/OR
VOLUME REDUCTION.
von dem Borne P., Zwaginga J. J., Rozier Y., Bakker-Steenveld H., Lankester
A., Netelenbos T.*, Overdevest J. (Leiden, Netherlands)
PH-P265
ENGRAFTMENT AND OUTCOME AFTER ASCT WITH PLERIXAFORMOBILZED STEM CELLS IN POOR MOBILIZERS.
Angelova O., Ditlbacher A., Schmidt S., Nachbaur D.* (Innsbruck, Austria)
PH-P266
UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION (UCBT)
IN ADULTS: SINGLE CENTRE EXPERIENCE USING CORD BLOOD
UNITS SOURCED FROM UK CORD BANKS
Russell N., Byrne J., Das-Gupta E., Kaur H., Watson L., Pearce L., Gomez S.,
Tulpule S.* (Nottingham, United Kingdom)
PH-P267
NO SIGNIFICANT ADVANTAGE OF PERIPHERAL BLOOD
STEM CELLS OVER BONE MARROW FOR MYELOABLATIVE
CONDITIONING UNRELATED DONOR TRANSPLANTATION IN
ADULTS WITH HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA
Eom K.-S., Kim Y.-J., Chung N.-G., Kim H.-J., Min C.-K., Kim D.-W., Lee J.-W.,
Min W.-S., Park C.-W., Park S.-K., Kwak J.-Y., Kim J.-A., Lee S.* (Seoul, Korea,
Republic Of)
PH-P268
TOTAL BODY IRRADIATION-FLUDARABINE-CYTARABINE
CONDITIONING REGIMEN FOR UNRELATED DOUBLE CORD
BLOOD TRANSPLANTATION IN ADULTS WITH HIGH-RISK ACUTE
LYMPHOBLASTIC LEUKEMIA IN KOREA
Eom K.-S., Kim Y.-J., Kim J.-A., Park S.-K., Kwak J.-Y., Kim H.-J., Chung N.-G.,
Min C.-K., Kim D.-W., Lee J.-W., Min W.-S., Park C.-W., Lee S.* (Seoul, Korea,
Republic Of)
PH-P269
120
LOW CD34 CELL DOSE IS ASSOCIATED WITH HIGHER NONRELAPSE AND OVERALL MORTALITY AFTER REDUCED INTENSITY
CONDITIONING HEMATOPOIETIC STEM CELL TRANSPLANTATION
FOR ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC
SYNDROME
Physicians Posters
PH-P270
HAPLOIDENTICAL T-REPLETE TRANSPLANT WITH POSTTRANSPLANT HIGH DOSE CYCLOPHOSPHAMIDE (PT-HDCY) IN
PATIENTS OLDER THAN 60 YEARS: EARLY OUCOMES COMPARED
TO HLA MATCHED RELATED (MRD) OR UNRELATED (MUD)
TRANSPLANTS
CASTAGNA L., FÜRST S., CROCCHIOLO R., DEVILLIER R., BRAMANTI S.,
EL CHEIKH J., GRANATA A., SARINA B., HARBI S., MOHTY B., LEMARIE C.,
CHABANNON C., SANTORRO A., Blaise D.* (Marseille, France)
PH-P271
PERIPHERAL STEM CELL TRANSPLANT WITH CD34+ SELECTION
AND CD3 ADD-BACK FOR HIGH RISK HEMATOLOGICAL PATIENTS
michelutti A., geromin A., cerno M., battista M., patriarca F., fanin R.,
Sperotto A., damiani D.* (Udine, Italy)
PH-P272
CLINICAL GRADE PROCESSING OF BONE MARROW HARVESTS IN
A FULLY AUTOMATED SYSTEM
Dal Pozzo S., Urbani S., Lombardini L., Bosi A., Saccardi R., Santosuosso M.,
Mazzanti B.* (Florence, Italy)
PH-P273
STERILITY TESTING OF CORD BLOOD: VALIDATION OF MINIMAL
VOLUME OF INOCULUM TO DETECT THE GROWTH OF BOTH
AEROBIC AND ANAEROBIC MICRORGANISMS
Cambieri P., Genovese V., Marchesi A., Romano B., Sbarsi I., De Vitis S.,
Salvaneschi L., Marone P., Bergamaschi P.* (PAVIA, Italy)
PH-P274
UMBILICAL CORD BLOOD FOR HAEMATOPOIETIC STEM CELL
TRANSPLANTATION IN 23 PATIENTS: ACCEPTABLE TOXICITY
PROFILE AND EXCELLENT TREATMENT OPTION FOR PATIENTS
WITH GRAFT FAILURE
Troch M., Worel N., Schellongowski P., Sperr W. R., Schwarzinger I.,
Mitterbauer-Hohendanner G., Fischer G., Dieckmann K., Schulenburg A.,
Greinix H. T., Kalhs P., Rabisch W., Bojic M.* (Vienna, Austria)
PH-P275
CELL COMPOSITION OF DONOR LYMPHOCYTE INFUSION
DISPLAYS DISTINCT ROLES IN DIFFERENT TYPES OF ALLOGENEIC
Wang Y., Yan C., Huang X., Zhao X.* (Beijing, China)
PH-P276
EVALUATION OF DIFFERENT ALTERNATIVE GRAFT SOURCES IN
THE TREATMENT OF HEMATOLOGICAL DISORDERS: COMPARISON
OF OUTCOMES OF HLA-MISMATCH UNRELATED DONOR,
UNRELATED UMBILICAL CORD BLOOD, OR HLA-HAPLOIDENTICAL
RELATED DONOR TRANSPLANTATION.
Engel N., Fritsch S., Prevalsek D., Reibke R., Hill W., Ledderose G., Schmid C.,
Kolb H. J., Tischer J., Laubender R. P., Zoellner A. K., Abdu-Hamdeh T., Schulz
C., Hausmann A.* (Munich, Germany)
121
Scientific
Programme
Physicians
Ringdén O., Le-Rademacher J., Battiwalla M., Chen J., Ho V. T., Kebriaei P.,
Keever-Taylor C. A., Kindwall-Keller T. L., Lazarus H. M., Laughlin M., Lill M.
C., O´Brien T., Perales M.-A., Rocha V., Savani B. N., Szwajcer D., Valcarcel
D., Eapen M., Törlén J.* and Center for International Blood and Marrow
Transplant Research (CIBMTR) (Stockholm, Sweden)
Physicians Posters
PH-P277
INTRABONE INFUSION OF POSITIVELY SELECTED CD34+ CELLS
FROM HAPLOIDENTICAL DONORS TO REDUCE THE RISK OF
GRAFT REJECTION
Perotti C., Tolva A., Comoli P., Del Fante C., Bergami E., Mina T., Raschetti
R., Introzzi F., Strocchio L., Viarengo G., Locatelli F., Bernardo M. E., Merli P.,
Zecca M.* (Pavia, Italy)
PH-P278
UK EXPERIENCE OF UNRELATED CORD BLOOD
TRANSPLANTATION (UCBT) IN ADULTS: A RETROSPECTIVE
ANALYSIS ON BEHALF OF EUROCORD AND THE BRITISH SOCIETY
OF BLOOD AND MARROW TRANSPLANTATION (BSBMT)
Danby R., Ruggeri A., Marks D., Hough R., Pagliuca A., Potter M., Russell
N., Craddock C., Clark A., Miller P., Gluckman E., Cook G., Shaw B., Rocha
V., Snowden J.* and British Sociey of Blood and Marrow Transplantation
(BSBMT) and Eurocord (Sheffield, United Kingdom)
PH-P279
SALVAGE HAPLOIDENTICAL TRANSPLANTATION USING NON
MYELOABLATIVE CONDITIONING FOR PRIMARY GRAFT FAILURE
IN CORD BLOOD TRANSPLANTATION
Zhu X., Liu H., Zheng C., Geng L., Yao W., Tong J., Song K., Sun Z., Tang B.*
(Hefei, China)
PH-P280
RAPID AND SUSTAINED ENGRAFTMENT OF A SINGLE ALLOGENEIC
EX-VIVO EXPANDED CORD BLOOD UNIT (CBU) AFTER REDUCED
INTENSITY CONDITIONING (RIC) IN ADULTS. PROOF OF REALITY
dazey B., ivanovic Z., vigouroux S., tabrizi R., pigneux A., dilhuydy M.-S.,
bouabdallah K., leguay T., sauvezie M., duchez P., lafarge X., marit G., boiron
J.-M., Milpied N.* (Bordeaux, France)
PH-P281
THE SAFETY AND EFFICACY OF THE USE OF INFANTS AS
HAEMATOPOIETIC STEM CELL DONORS FOR THEIR MATCHED
SIBLINGS
munirathinam D., kumar V., doss H., Raj R.* (CHENNAI, India)
PH-P282
EVALUATION OF CELL DOSE TO ACHIEVE ENGRAFTMENT IN
UNRELATED CORD BLOOD TRANSPLANTATION
Tabuchi K., Takahashi Y., Kudo K., Kato K., Sakamaki H., Kawa K., Suzuki R.,
Kanamori H., Mori S., Murata M., Kanda Y., Yabe H.* (Isehara, Japan)
PH-P283
CLINICAL EVALUATION OF AN AUTOMATIC DILUTION/WASHING
METHOD OF CORD BLOOD UNIT ADMINISTRATION AND
OUTCOMES IN PATIENTS WITH MALIGNANT AND NO MALIGNANT
HEMATOLOGICAL DISEASES
Garcia-Cadenas I., Canals C., Diaz Heredia C., Barba P., Elorza I., Olive T.,
Martino R., Azqueta C., Ferra C., Badell I., Duarte R., Valcarcel D., Querol S.,
Castillo N.* (Barcelona, Spain)
122
Physicians Posters
PH-P284
STEM CELL MOBILIZATION FOR AUTOLOGOUS TRANSPLANT IN
HEMATOLOGIC MALIGNANCIES. THREE-YEAR EXPERIENCE AT A
SINGLE INSTITUTION
PH-P285
IMPACT OF THE HEMATOPOIETIC STEM CELL SOURCE IN
ALLOGENEIC HSCT IN PAEDIATRIC ALL: A RETROSPECTIVE STUDY
ON BEHALF OF THE EBMT PAEDIATRIC DISEASES WORKING
PARTY
Zecca M., Mouhab A., Baruchel A., Chybicka A., Biondi A., Volin L., Labopin M.,
Dalle J.-H., Peters C., Simonin M.* and EBMT working party (Paris , France)
PH-P286
HIGHER COUNTS OF PLASMACYTOID DENDRITIC CELLS IN THE
ALLOGRAFT ARE ASSOCIATED INCREASED RISK OF ACUTE GVHD
AFTER STEM CELL TRANSPLANTATION
Yamamoto M., Kimura E., Colturato V. A. R., Souza M., Mauad M., Ikoma M.
V., Oliveira P. G. A., Kerbauy F. R., Hamerschlack N., Novis Y., Ginani V. C.,
Seber A., Rocha V., Orfao A., Rodrigues C. A., Carvalho A. P. V., Goncalves M.
V.* (Sao Paulo, Brazil)
PH-P287
PERIPHERAL BLOOD STEM CELLS COLLECTION IN Paediatrics
PATIENTS USING THE CELLULAR SEPARATOR SPECTRA OPTIA
Coutinho M., Bordalo F., Lopes S., Bernardo A., Amado F., Ferreira S.,
Baptista T., Roncon S.* (Oporto, Portugal)
PH-P288
COMPOSITION OF PBPC ALLOGRAFTS: CONTENT OF
ALLOREACTIVE CELLS AND HEMATOPOIETIC PROGENITOR CELLS
IS DEPENDENT ON THE APHERESIS DEVICE
Robitzsch T., Rox J. M., Fischer J. C.* (Düsseldorf, Germany)
PH-P289
PREDICTORS DETERMINING THE EFFICACY OF CORD BLOOD
HARVESTING AS A BIOLOGICAL MATERIAL FOR THE STEM CELL
TRANSPLANTATION AND THERAPY
Gladysz D., Marszalek I., Poteralska K., Oldak T., Pawelec K., Baran J.,
Boruczkowski D.* (Warszawa, Poland)
PH-P290
SIGNIFICANT INCREASE OF CELL QUANTITY IN UMBILICAL CORD
BLOOD UNIT DERIVED FROM SINGLE DONOR
Murzyn M., Czaplicka I., Olkowicz A., Oldak T., Baran J., Orczykowska A.,
Placzkowska J., Zagorska K., Piskula J., Poteralska K., Marszalek I., Balogh I.,
Pujal J.-M., Brasov R., Boruczkowski D.* (Warszawa, Poland)
PH-P291
ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER
DOUBLE UMBILICAL CORD BLOOD TRANSPLANTATION
Economopoulou D., Panitsas F., Xenou E., Kesari A., Komitopoulou A.,
Tzannou I., Garofalaki M., Poulopoulou Z., Karatza M. E., Tziotziou I.,
Vasileiou S., Bika I., Papageorgiou M., Gigantes S., Apostolidis I., Harhalakis
N., Karakasis D., Baltadakis I.* (Athens, Greece)
123
Scientific
Programme
Physicians
Mallano S., Shafii Bafti M., Trisolini S. M., Annechini G., Canichella M.,
Gentilini F., Paisano P., Polino A., La Rocca U., Mohamed S., Quattrocchi L.,
Vitale A., Foà R., Meloni G., Capria S.* (Rome, Italy)
Physicians Posters
Tolerance, Chimerism & Immune reconstitution Monday, 31 March 2014
PH-P292
ACUTE GRAFT-VS-HOST-DISEASE IMPAIRS A CXCR4RELATED INCREASE OF CIRCULATING HUMAN LYMPHOID
PROGENITORS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Glauzy S., andre-Schmutz I., Ezine S., Larghero J., Peffault de Latour R.,
Moins-Teisserenc H., Servais S., Robin M., Socié G., Toubert A., Clave E.*
(PARIS, France)
PH-P293
FAVORABLE IMPACT OF NATURAL KILLER CELL RECONSTITUTION
ON CHRONIC GRAFT-VERSUS-HOST DISEASE AND CMV
REACTIVATION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Kheav V. D., Peffault de Latour R., Busson M., Scieux C., Haas P., Maki G.,
Carmagnat M., Xhaard A., Robin M., Ribaud P., Charron D., Dulphy N., Socié
G., Moins-Teisserenc H., Mazeron M.-C., Toubert A.* (Paris, France)
PH-P294
QUANTITATIVE CHIMERISM:AN INDEPENDENT ACUTE LEUKEMIA
PROGNOSIS INDICATOR FOLLOWING ALLOGENEIC HEMATOPOIETIC
Guoxuan L., Yazhen Q., Xiaojun H., Xiaoying Q.* (Beijing, China)
PH-P295
FUNCTIONAL ANALYSIS OF IMMUNE RECONSTITUTION FOLLOWING
PH-P296
KINETICS AND QUALITY OF GAMMA/DELTA T-CELL
RECONSTITUTION AFTER TCR-ALPHA/BETA/CD19-DEPLETED
HAPLOIDENTICAL HSCT
Konukiewitz L., Bertz H., Finke J., Waterhouse M.* (Freiburg, Germany)
Rutella S., Bertaina A., Pagliara D., Pinto R. M., Merli P., Lucarelli B., Brescia
L., Airoldi I., Zorzoli A., Barbarito G., Pistoia V., Moretta L., Prigione I.,
Locatelli F.* (Rome, Italy)
PH-P297
GRAFT-VS-HOST-DISEASE AFFECTS NEW B CELL PRODUCTION
AND PROLIFERATION AFTER ALLOGENEIC HEMATOPOIETIC STEM
Soret J., Maki G., Moins-Teisserenc H., Toubert A., Peffault de Latour R.,
Robin M., Glauzy S., Socié G., Clave E.* (PARIS, France)
PH-P298
ULTRA LOW-DOSE IL-2 MEDIATED EXPANSION OF REGULATORY T
CELLS AS GVHD PROPHYLAXIS FOR RECIPIENTS OF ALLOGENEIC
HEMATOPOIETIC STEM CELLS
Kennedy-Nasser A., Barrett A. J., Ito S., Yvon E., Krance R., Leung K., Heslop
H. E., Brenner M. K., Bollard C.* (Washington , United States)
PH-P299
NOVEL IMAGING REVEALS EARLY ENGRAFTMENT AND STEM CELL
HOMING AFTER HSCT
Holter Chakrabarty J. L., Lindenberg L., Gea-Banacloche J., Blacklock Schuver
B., Hickstein D., Kochenderfer J., Wilder J., Kurdziel K., Steinberg S., Khuu
H., Fowler D. H., Halverson D., Avila D. N., Selby G., Taylor T. N., Mann J.,
Hsu J., Pavletic S. Z., Bollard C. M., Choyke P., Gress R. E., Williams K. M.*
(Washington , United States)
PH-P300
IMMUNE RECONSTITUTION OF DENDRITIC CELLS
SUBPOPULATIONS IN THE PERIPHERAL BLOOD AFTER PAEDIATRIC
Elze M. C., Heinze A., Kloess S., Klingebiel T., Serban M., Hutton J., Koehl U.,
Ciocarlie O.*, Arseniev L. (Hannover, Germany)
124
Physicians Posters
Tolerance, Chimerism & Immune reconstitution Monday, 31 March 2014
PH-P301
REDUCED INTENSITY ALLOGENEIC TRANSPLANTS OUTCOMES
FOR HIGH RISK AML ARE FAVOURED BY ACQUISITION OF EARLY
FULL DONOR T CELL CHIMERISM:SINGLE CENTER EXPERIENCE
PH-P302
IMPACT OF HLA-DISPARITY DEGREE ON B-CELL RECONSTITUTION
AFTER UNRELATED STEM CELL TRANSPLANTATION FOR ACUTE
LEUKEMIA.
Sperotto A., Damiani D., Michelutti A., Cavallin M., Tiribelli M., Cerno M.,
Battista M. L., Fanin R., Patriarca F., Medeot M.* (Udine, Italy)
PH-P303
LOW COUNTS OF NATURAL KILLER CELLS CD56 BRIGHT CD16
NEGATIVE AFTER ENGRAFTMENT ARE ASSOCIATED WITH WORSE
SURVIVAL IN PATIENTS RECEIVING ALLOGENEIC HEMATOPOIETIC
Yamamoto M., Kimura E., Colturato V. A. R., Souza M., Mauad M., Ikoma M.
V., Oliveira P. G. A., Carneiro T. X., Kerbauy F. R., Hamerschlack N., Novis Y.,
Ginani V. C., Seber A., Rocha V., Orfao A., Rodrigues C. A., Goncalves M. V.*
(Sao Paulo, Brazil)
Autoimmune diseases
Tuesday, 1 April 2014
PH-P304
FOR TAKAYASU’S ARTERITIS: REPORT OF THREE CASES
Stracieri A. B. L., Pieroni F., Cunha R. G., Malta R., Zombrilli A. F., Simões B.
P., Oliveira M. C., Nilsen L., Leopoldo V., Dias J. B. E., Moraes D. A.* (Ribeirão
Preto, Brazil)
PH-P305
AUTOLOGUS HEMATOPOIETIC STEM CELLS TRANSPLANTATION IN
PATIENTS WITH SYSTEMIC SCLEROSIS- LONG TERM FOLLOW-UP.
Kyrcz-Krzemień S., Grygoruk-Wiśniowska I., Kopińska A., Widuchowska M.,
Kucharz E., Koclęga A., Krawczyk-Kuliś M.* (KATOWICE, Poland)
PH-P306
QUALITY OF LIFE EVALUATIONS IN MULTIPLE SCLEROSIS
PATIENTS TWO YEARS AFTER AUTOLOGOUS HEMATOPOIETIC
Simões B. P., Garcia J. T., Santos M. A., Guimarães F. B., Moraes D. A., Dias J.
B. E., Oliveira-Cardoso E. A., Oliveira M. C.* (Ribeirão Preto, Brazil)
PH-P307
ANALYSIS OF LONG TERM HEMATOPOIETIC AND IMMUNE
RECONSTITUTION AFTER AUTOLOGOUS HEMATOPOIETIC STEM
CELL TRANSPLANTATION (AHSCT) FOR SEVERE SYSTEMIC
SCLEROSIS
Douay C., Marjanovic Z., Hij A., Toubert A., BRIGANT F., Clave E., Kheav D.,
Homyrda L., Wu C., Moins-Teisserenc H., Farge D.* (Paris, France)
125
Scientific
Programme
Physicians
Hussein H., Seymoor F., Dyer P., Patel J., Holder K., Baker L., Bratby L.,
Kishore B., Lovell R., Paneesha S., Milligan D., Khwaja J., Nikolousis E.,
Gudger A.* (Birmingham, United Kingdom)
Physicians Posters
Autoimmune diseases - Tuesday, 1 April 2014
PH-P308
AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN
NEUROMYELITIS OPTICA: A RETROSPECTIVE STUDY OF THE EBMT
AUTOIMMUNE DISEASES WORKING PARTY IN COLLABORATION
WITH THE UNIVERSITY OF SAO PAOLO RIBEIRÃO PRETO BRAZIL
Bondanza A., Oliveira M. C., Badoglio M., Burman J., Piehl F., Hagglund H.,
Krasulova E., Pinto Simoes B., Carlson K., Pohlreich D., Labopin M., Saccardi
R., Comi G., Mancardi G. L., Bacigalupo A., Ciceri F., Farge D., Greco R.*
(Milano, Italy)
PH-P309
LONG-TERM DISEASE CONTROL OF REFRACTORY
NEUROMYELITIS OPTICA AFTER ALLOGENEIC HEMATOPOIETIC
Bondanza A., Vago L., Moiola L., Rossi P., Furlan R., Martino G., Radaelli M.,
Martinelli V., Carbone M. R., Lupo Stanghellini M. T., Assanelli A., Bernardi
M., Corti C., Peccatori J., Bonini C., Vezzulli P., Falini A., Ciceri F., Comi G.,
Greco R.* (Milano, Italy)
PH-P310
EXCELLENT LONG-TERM SURVIVAL AFTER AUTOLOGOUS STEMCELL TRANSPLANTATION FOR RCDII
Visser O., van Wanrooij R. L., van Gils T., Wierdsma N. J., Bontkes H. J.,
Mulder C. J., Bouma G., Nijeboer P.* (Amsterdam, Netherlands)
PH-P311
CMV AND EBV REACTIVATION AFTER AUTOLOGOUS
HAEMOPOIETIC STEM CELL TRANSPLANTATION WITH BEAM
CONDITIONING REGIMEN FOR MULTIPLE SCLEROSIS AND
LYMPHOMA: A RETROSPECTIVE SINGLE CENTER CASE-CONTROL
STUDY
Innocenti C., Donnini I., Nozzoli C., Bosi A., Repice A., Massacesi L., Portaccio
E., Amato M. P., Rigacci L., Guidi S., Saccardi R., Di Gioia M.* (Florence, Italy)
PH-P312
LONG-TERM FOLLOW-UP RESULTS AFTER AUTOLOGOUS
HEMATOPOIETIC STEM CELL TRANSPLANTATION IN SYSTEMIC
SCLEROSIS
Annaloro C., Saporiti G., Cavalieri S., Zaccara E., Tagliaferri E., Grifoni F.,
Giordano R., Mometto G., Maglione W., Motta B., Cortelezzi A., Onida F., Del
Papa N.* (Milan, Italy)
PH-P313
AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION
IN SEVERE AUTOIMMUNE DISEASES : ANALYSIS OF 97 PATIENTS
FROM THE FRENCH REGISTRY.SFGM-TC AND EBMT.
MARJANOVIC Z., HADJ-KHELIFA S., MARTIN T., LIOURE B., SACCARDI R.,
BADOGLIO M., CRAS A., LAUNAY D., YAKOUB-AGHA I., FARGE D., TERRIOU
L.* and ADWP (LILLE, France)
PH-P314
LONG TERM EFFICACY AND SAFETY OF UNSELECTED
HAEMATOPOIETIC STEM CELLS AUTOTRANSPLANTATION FOR
REFRACTORY CROHN’S DISEASE
Cassinotti A., Cavalieri S., Saporiti G., Tagliaferri E., Grifoni F., Motta B.,
Mometto G., Cortelezzi A., Annaloro C., Ardizzone S., Fichera M., De Franchis
R., Fociani P., Nebuloni M., Usardi P., Onida F.* (Milan, Italy)
126
Physicians Posters
Early complications/Late effects
& quality of life - Tuesday, 1 April 2014
PH-P315
IMPACT OF ABO INCOMPATIBILITY ON OUTCOME AFTER
UNRELATED ALLOGENEIC STEM CELL TRANSPLANTATION
Ziakova B., Sopko L., Rimajova V., Pavlikova D., Batorova A., Mistrik M.,
Bojtarova E.* (Bratislava, Slovakia)
PH-P316
LONG-TERM SURVIVORS AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION IN EARLY LIFE. A DANISH NATIONAL COHORT
STUDY
Gøtzsche F., Larsen H. B., Heilmann C., Sengeløv H., Jensen J. N.*
PH-P317
PREDICTING FACTORS FOR INPATIENT MORTALITY AND LONG
TERM SURVIVAL IN ALLOGENEIC STEM CELL TRANSPLANTATION
RECIPIENTS ADMITTED TO INTENSIVE CARE UNIT
de Lavallade H., Szydlo R., Potter V., Clay J., McLornan D., Raj K., Pagliuca
A., Kenyon M., Kulasekararaj A., Marsh J., Mufti G., Floro L.* (London, United
Kingdom)
PH-P318
MECHANISMS AND PREVENTION OF FATAL CARDIOTOXICITY
FOLLOWING HIGH-DOSE CYCLOPHOSPHAMIDE THERAPY
Kurauchi K., Miyahara E., Okamoto Y., Kawano Y., Nishikawa T.* (Kagoshima,
Japan)
PH-P319
SLEEP DISORDERS AND PSYCHOLOGICAL DISTURBANCES DURING
HOSPITALIZATION FOR HEMATOPOIETIC CELL TRANSPLANT.
Martino R., Barba P., Artaza G., Ballarin G., Castillo N., Cortés S., Esquirol A.,
Garcia-Cadenas I., Romans J., Mensa I., Giraldez P., Valcárcel D., Brunet S.,
Laborda R., Gich I., Sierra J., Barata A.* (Barcelona, Spain)
PH-P320
UODENAL TUBE FEEDING: A SAFE METHOD OF NUTRITIONAL
SUPPORT IN STEM CELL TRANSPLANTATION PATIENTS
Koene H., Hoes L.* (Nieuwegein, Netherlands)
PH-P321
AUTOIMMUNE HEMOLYTIC ANEMIA AFTER DUAL CORD BLOOD
TRANSPLANTATION
FORES R., REGIDOR C., DE LAIGLESIA A., BAUTISTA G., ROJAS M., DORADO
N., FERNANDEZ C., CABRERA J. R., MORALES A., BUENO J. L., MORILLO D.*
(MADRID, Spain)
PH-P322
IN ACUTE LEUKEMIA A PROPHYLAXIS USING DEFIBROTIDE
DURING ALLOGENEIC HSC TRANSPLANTATION REDUCES TRM
INDEPENDENTLY FROM ANY IMPROVEMENT OF LIVER TOXICITY
Leotta S., La Fauci A., Berritta D., Cupri A., Di Marco A., Spina P., Parisi M.,
Milone G.* (Catania, Italy)
PH-P323
CARDIAC TROPONIN LEVEL MONITORING IN PATIENTS WITH
MALIGNANT LYMPHOMA DURING HIGH-DOSE CHEMOTHERAPY
IN COMBINATION WITH AUTOLOGOUS STEM CELL
TRANSPLANTATION.
Sarzhevskiy V., Melnichenko V., Vakhromeeva M., Kolesnikova D.* (Moscow,
Russian Federation)
127
Scientific
Programme
Physicians
(Copenhagen, Denmark)
Physicians Posters
PH-P324
INTRAPULMONARY RECOMBINANT FACTOR VII FOR DIFFUSE
ALVEOLAR HEMORRHAGE AFTER HEMATOPOIETIC STEM CELL
TRANSPLANTATION IN CHILDREN
Kim B. J., Park J. A.* (Busan, Korea, Republic Of)
PH-P325
PROGNOSIS OF ALLOGENEIC HEMATOPOIETIC STEM
CELL RECIPIENTS ADMITTED TO INTENSIVE CARE UNIT. A
RETROSPECTIVE SINGLE-CENTER STUDY.
Nielsen J., Lindmark A., Sengeløv H., Lindgaard S. C.* (Copenhagen, Denmark)
PH-P326
SIGNIFICANT IMPACT OF IRON CHELATION AFTER ALLOGENEIC
HEMATOPOETIC STEM CELL TRANSPLANTATION ON DISEASE
RECURRENCE: POTENTIAL ANTI-LEUKEMIC ACTIVITY
Sobh M., Labussière H., Ducastelle S., Barraco F., Gilis L., Thomas X., Franck
E Nicolini F. E. N., Chapuis-Cellier C., Michallet M.* (PIERRE BENITE CEDEX,
France)
PH-P327
RISK FACTORS AND OUTCOME OF PULMONARY COMPLICATION
OF Paediatric PATIENTS AFTER HEMATOPOIETIC STEM CELL
TRANSPLANTATION.
Sugiyama M., Terashita Y., Sato T., Cho Y., Iguchi A., Ariga T., Ohshima J.*
(Sapporo-Shi, Japan)
PH-P328
PREDICTORS OF ADVERSE REACTIONS DURING STEM CELL
INFUSION IN CHILDREN RECEIVING AUTOLOGOUS AND
Lewis V., Guilcher G. M., Dewey D., Prokopishyn N. L., Truong T. H.*, Moorjani
R. (Calgary, Canada)
PH-P329
RISK FACTORS FOR POSTERIOR REVERSIBLE ENCEPHALOPATHY
SYNDROME IN Paediatric ALLOGENEIC STEM CELLS
TRANSPLANTATION: A TWO-CENTERS EXPERIENCE.
Vendemini F., Masetti R., Cordelli D. M., Giordano L., Rondelli R., Massaccesi
E., Morello W., Porta F., Franzoni E., Prete A., Pession A., Zama D.* (Bologna,
Italy)
PH-P330
POST-TRANSPLANT ALTERATIONS OF BODY-MASS-INDEX
(BMI) AND THEIR POTENTIAL IMPACT ON THE OUTCOME AFTER
ALLOGENEIC STEM CELL TRANSPLANTATION (SCT)
Diederichs T., Weber T., Müller L. P.* (Halle, Germany)
PH-P331
PREVALENCE, RISK FACTORS AND OUTCOMES OF BRONCHIOLITIS
OBLITERANS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Martoni A., Bardasi G., Massaccesi E., Zama D., Morello W., Cazzato S.,
Masetti R., Rondelli R., Prete A., Pession A., Bertelli L.* (Bologna, Italy)
128
Physicians Posters
PH-P332
DATA FROM AN INDEPENDENT REGISTRY CORROBORATES RESULTS
OF A PREVIOUS STUDY CONFIRMING THE EFFECTIVENESS OF DEFIBROTIDE IN THE TREATMENT OF SEVERE VENO-OCCLUSIVE DISEASE
PH-P333
PLATELET CONSUMPTION AND PLATELET TRANSFUSION
REFRACTORINESS IS A RELIABLE EARLY MARKER OF VENOOCCLUSIVE LIVER DISEASE IN A SUBGROUP OF PAEDIATRIC
HAEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
Sufliarska S., Bodova I., Chocholova A., Fabri O., Cingel V., Horakova J., Svec
P.* (Bratislava, Slovakia)
PH-P334
BRONCHOALVEOLAR LAVAGE FLUID PROTEIN PROFILE IN
HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
Viken K., Dey, S., Steinbach M. S., Wu B., Jagtap P. D., Higgins L., Kumar
V., Bitterman P. B., Arora M., Ingbar D. H., Wendt C. H., Bhargava M.*
(Minneapolis, United States)
PH-P335
OCCURRENCE, CLINICAL PRESENTATIONS AND MANAGEMENT
OF ISOLATED EXTRAMEDULLARY RELAPSES AFTER ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE
LEUKEMIAS: AN UPDATED SINGLE INSTITUTIONAL ANALYSIS OF
571 PATIENTS
Kyrcz-Krzemien S., Markiewicz M., Kopera M., Waclawik A., Bialas K.,
Dobrzynska E., Kata D.* (Katowice, Poland)
PH-P336
OCCUPATIONAL STATUS AMONG ADULT SURVIVORS FOLLOWING
ALLOGENEIC STEM CELL TRANSPLANTATION IN CHILDHOOD
Johansson E., Wettergren L., Ljungman P., Alexanderson K., Winterling J.*
(Stockholm, Sweden)
PH-P337
DISCONTINUING IMMUNOSUPPRESSIVE THERAPY FOLLOWING
AN ALLOGENEIC HEMOPOIETIC STEM CELL TRANSPLANT (HSCT)
: A CROSS SECTIONAL ANALYSIS OF 799 PATIENTS , 1 YEAR POST
TRANSPLANT.
Galaverna F., Di Grazia C., Lamparelli T., Gualandi F., Bregante S., van Lint
M. T., Varaldo R., Ghiso A., Signori A., Stasia A., Raiola A. M., Bacigalupo A.,
Dominietto A.* (Genoa, Italy)
PH-P339
DEFERASIROX IMPROVES HEMATOPOIESIS AFTER ALLOGENEIC
Guiducci B., Giardini C., Loscocco F., Ricciardi T., Isidori A., Visani G.* (Pesaro, Italy)
PH-P340
TREATMENT OF POST-HEMATOPOIETIC STEM CELL
TRANSPLANTATION (HSCT) HAEMORRHAGIC CYSTITIS WITH
INTRAVESCICAL HYALURONIC ACID
Bertapelle P., Busca A., D’Ardia S., Allione B., Giaccone L., Aydin S., Frairia
C., Pecoraro C., Festuccia M., Brunello L., Maffini E., Ferrando F., Bruno B.,
Cavallo R., Dellacasa C. M.* (TORINO, Italy)
129
Scientific
Programme
Physicians
Prentice G., Ehrhardt M., Korman S., Horowitz M. M., Richardson P., Eapen
M.* (Milwaukee, United States)
Physicians Posters
PH-P341
THE INFLUENCE OF ANTI-HLA ANTIBODIES ON OUTCOMES OF
FROM HLA-MISMATCHED UNRELATED DONORS
Koclega A., Mizia S., Siekiera U., Dobrowolska A., Dzierzak-Mietla M.,
Zielinska P., Bialas K., Kyrcz-Krzemien S., Markiewicz M.* (Katowice, Poland)
PH-P342
SOCIAL SUPPORT AND PSYCHOLOGICAL ISSUES IN HIGH DOSE
CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANT
PATIENTS IN THE KINGDOM OF SAUDI ARABIA
Soudy H., Rauf M. S., Elhassan T. A. M., Maghfoor I., Akhtar S.* (Riyadh, Saudi
Arabia)
PH-P343
FLUDARABINE-BASED SECOND TRANSPLANTATION FOR
SECONDARY GRAFT FAILURE AFTER FIRST ALLOGENEIC STEM
XU L., LIU D., LIU K., HUANG X., Sun Y.* (Beijing, China)
PH-P344
THE APPLICATION OF SECOND TIME ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION: REASONS AND
OUTCOME
Gunduz M., Ozen M., Atilla E., Arslan O., Ozcan M., Akan H., Beksac M.,
Gurman G., Topcuoglu P.* (Ankara, Turkey)
PH-P345
TACROLIMUS EXTENDED RELEASE FORMULATION GIVEN AS
AN ALTERNATIVE TO CICLOSPORINE A IN CASE OF RENAL
IMPAIRMENT AFTER ALLOGENEIC HSCT: RESULTS FROM A
PROSPECTIVE PILOT STUDY
Morisset S., Cohen S., Manchon M., Schwiertz V., Ranchon F., Vantard N.,
Serrier C., Quintela A., Cazac C., Hospital C., Chapel V., Sar S., Rioufol C.,
Michallet M., Barraco F., Detrait M. Y.* (Pierre Benite, France)
PH-P346
SIGNIFICANTLY REDUCED RISK OF SINUSOIDAL OBSTRUCTION
SYNDROME OF THE LIVER IN RECENT YEARS IN PATIENTS
RECEIVING BUCY PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM
Ringden O., Engstrom M., Berglund S., Ljungman P., Winiarski J., Uhlin M.,
Svahn B.-M., Remberger M., Hassan M., Mattsson J.* (Stockholm, Sweden)
PH-P347
ASSESSING QUALITY OF LIFE BEFORE HSCT: TAKING CARE OF
CAREGIVERS TO TAKE CARE OF PATIENTS
Morelli M., Greco R., Lupo Stanghellini M. T., Marcatti M., Corti C., Bernardi
M., Ciceri F., Carrabba M., Peccatori J., Sarno L., Alacqua D., Levati G., Giuliani
S.*, Giglio F. (Milan, Italy)
PH-P348
VENO-OCCLUSIVE DISEASE IN CHILDREN FOLLOWING
HAEMATOPOIETIC STEM CELL TRANSPLANTATION. A SEVENTEEN
YEARS EXPERIENCE IN ONE Paediatric BONE MARROW
TRANSPLANTATION CENTRE
Ben Arush M., Elhasid R., Arad Cohen N., Postovsky S., Ben Barak A.,
Zaidman I., Mandel-Shorer N.* (Haifa, Israel)
130
Physicians Posters
PH-P349
REHABILITATION NEEDS IN HEMATOLOGY AND BONE MARROW
TRANSPLANTATION UNIT: ONE YEAR EXPERIENCE AT SAN
RAFFAELE INSTITUTE
Bernardi M., Ciceri F., Carrabba M., Peccatori J., Levati G., Gatti R., Soliman C.,
Greco R., Morelli M., Messina C., Giglio F., Cervi P.* (Milan, Italy)
THE QUALITY OF LIFE FOLLOWING ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTATION - THE RETROSPECTIVE STUDY OF
CZECH TRANSPLANT CENTRES
Trnkova M., Jircikova J., Lanska M., Steinerova K., Keslova P., Koristek Z.,
Raida L., Dolezal T., Benesova K., Cetkovsky P., Trneny M., Valkova V.*
(Prague , Czech Republic)
PH-P351
IS FEASIBLE AFTER SOLID ORGAN TRANSPLANTATION: FINAL
ANALYSIS BY THE EARLY COMPLICATIONS SUBCOMMITTEE OF THE
COMPLICATIONS AND QUALITY OF LIFE WORKING PARTY, EBMT
Wiktor-Jedrzejczak W., Schoemans H., Ljungman P., Kobbe G., Beguin Y.,
Lang P., Sykora K. W., te Boome L., van Biezen A., van der Werf S., Mohty M.,
de Witte T., Marsh J., Dreger P., Kroeger N., Duarte R., Ruutu T., Basak G. W.*
(Warsaw, Poland)
PH-P352
EBMT SCORE OR SORROR’S COMORBIDITY INDEX : WHICH ONE IS
THE BEST FOR PREDICTING TRANSPLANT OUTCOME?
Akı Z., Sucak G., Yegin Z. A.* (ankara, Turkey)
PH-P353
LATE MORTALITY AND CAUSE OF DEATH AMONG LONG
SURVIVORS AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION
Nakasone H., Inamoto Y., Inoue M., Ishida Y., Kaneko H., Iwato K., Miyamoto
T., Hashimoto H., Mori T., Sawa M., Hirokawa M., Yamashita T., Atsuta Y., Iida
M.* and Late Effect and Quality of Life Working Group of the Japan Society
for Hematopoietic Cell Transplantation (Nagakute, Japan)
PH-P354
PALIFERMIN DECREASES ORAL MUCOSITIS AND IMPROVES
SURVIVAL IN CHILDREN UNDERGOING AUTOLOGOUS
Czyzewski K., Debski R., Krenska A., Wysocki M., Styczynski J.* (Bydgoszcz,
Poland)
PH-P355
INCREASED RISK FOR NON-RELAPSE MORTALITY IN
PATIENTS WITH IRON OVERLOAD UNDERGOING STEM CELL
TRANSPLANTATION
Kozlowska-Skrzypczak M., Mackowiak K., Czyz A., Dytfeld D., LojkoDankowska A., Matuszak M., Nowicki A., Komarnicki M., Gil L. A.* (Poznan,
Poland)
PH-P356
INCIDENCE AND RISK FACTORS OF HEPATIC VENO-OCCLUSIVE
DISEASE AFTER HEMATOPOETIC STEM CELL TRANSPLANTATION
IN CHILDREN
Uygun V., Kılıç S. C., Berber Z., Daloglu H., Pekun F., Dincer Z., Hazar V.,
Yesilipek A., Karasu G.* (Istanbul, Turkey)
131
Scientific
Programme
Physicians
PH-P350
Physicians Posters
PH-P357
ENDOCRINE DISORDERS AFTER AUTOLOGOUS AND ALLOGENEIC
Pezzullo L., Ferrara I., Rocco M., Fontana R., Annunziata S., Giudice V., Sessa
M., Selleri C., Serio B.* (Salerno, Italy)
PH-P358
ROLE OF PARENTERAL NUTRITION IN PATIENTS UNDERGOING
AUTOLOGOUS STEM CELL TRANSPLANTATION
Martínez Quesada M. J., de León Marcano E., López López J. A., Durán Nieto
S., González Sierra P., Almagro Torres F.* (Jaen, Spain)
PH-P359
THE EFFECT OF ANTI-THYMOCYTE GLOBULIN ON CLINICAL
OUTCOMES IN PATIENTS RECEIVED MYELOABLATIVE
CONDITIONING WITH BUSULFAN AND FLUDARABINE FOR
ALLOGENEIC TRANSPLANTATION
Park S. K., Won J. H., Kim S. H., Yun J., Kim H. J., Kim K. H., Bae S. B., Park H.
S., Hong D. S.* (Bucheon, Korea, Republic Of)
PH-P360
VENTILATION HETEROGENEITY OF PERIPHERAL AIRWAYS
(SACIN*VT) ASSESSED BY NITROGEN MULTIPLE BREATH
WASHOUT (N2-MBW) IS AN ACCURATE AND SENSITIVE
MARKER OF BRONCHIOLITIS OBLITERANS - THE SAN RAFFAELE
EXPERIENCE IN HSCT SETTING
De Giacomi F., Orsini A., Guggiari E., Corti C., Forcina A., Perini T., Piemontese
S., Pavesi F., Milani R., Peccatori J., Bernardi M., Assanelli A., Bonini C., Ciceri
F., Cremona G., Calcaterra B., Levati G., Lupo-Stanghellini M.* (Milan, Italy)
PH-P361
PROGNOSTIC FACTORS AND OUTCOMES OF HAEMATOLOGICAL
PATIENTS WITH ICU ADMISSION DURING THE 100 FIRST DAYS OF
AUTOHSCT.
Del Campo R., Borras J., Romero P., Cladera A., Gomez D., Gonzalez E., Guerra
J. M., Mascaro M., Serra F., Bargay J. J., Vazquez Fernandez I.* (Palma de
Mallorca, Spain)
PH-P362
COMPARISON OF FOUR-TIMES-DAILY VERSUS ONCE-DAILY
INTRAVENOUS BUSULPHAN AS PART OF THE CONDITIONING
THERAPY FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION
GONZALEZ A. J., DUEÑAS V., SOLANO J., PALOMO P., GUTIERREZ L.,
GONZALEZ A. P., GONZALEZ S., RAYÓN C., MARTINEZ-MUGICA C., VALLEJO
C.* (OVIEDO, Spain)
PH-P363
IMPACT OF SMOKING ON OVERALL SURVIVAL, NON RELAPSE
MORTALITY AND SECOND CANCERS AFTER REDUCED INTENSITY
ALLOGENEIC STEM CELL TRANSPLANTATION FOR HEMATOLOGIC
MALIGNANCIES
De Philippis C., Farina L., Dodero A., Montefusco V., Corradini P., Spina F.*
(Milan, Italy)
132
Physicians Posters
PH-P364
EXTRAMEDULLARY RELAPSE OF ACUTE LEUKEMIA AFTER
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION:
DIFFERENT CHARACTERISTICS BETWEEN ACUTE MYELOID
LEUKEMIA AND ACUTE LYMPHOBLASTIC LEUKEMIA
PH-P365
BUDGET IMPACT ANALYSIS OF INTRAVENOUS VERSUS ORAL
BUSULFAN FOR CONDITIONING PRIOR TO HEMATOPOIETIC STEM
CELL TRANSPLANTATION IN ADULT PATIENTS - A GERMAN
HEALTH CARE PROVIDERS’ PERSPECTIVE
Schopohl D., Ostermann H., Berger K. C.* (Munich, Germany)
PH-P366
TREATMENT OF RELAPSED ACUTE LEUKEMIA AFTER
BY SALVAGE CHEMOTHERAPY WITH LOW-DOSE CYTARABINE
AND ACLARUBICIN COMBINED WITH GRANULOCYTE COLONYSTIMULATING FACTOR PRIMING: MORE EFFECTIVE AND LESS
TOXIC?
Sun A., Zhu X., Wu D., Zhou H., Tang X.* (Suzhou , China)
PH-P367
INCIDENCE AND EVOLUTION OF PTLD IN 1370 TRANSPLANTS
BETWEEN 1998 AND 2013. SINGLE CENTER EXPERIENCE
Buenasmañanas D., Serrano J., Quintana L., Rodriguez Villa A., Rojas R.,
Martin C., Molina J. R., Gomez P., Sanchez García J., Garcia Torres E.*,
Rodriguez G. (Córdoba, Spain)
PH-P368
AVASCULAR NECROSIS AFTER ALLOGENEIC TRANSPLANTATION
HEMATOPOIETIC PROGENITORS: SINGLE-CENTER EXPERIENCE
Blanquer M., Sánchez-Salinas A., Moraleda J. M., Monserrat J., Majado M. J.,
Cabañas-Perianes V., Melero A.* (Murcia, Spain)
PH-P369
RISK SCORE FOR OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTATION IN CHILDHOOD
Wolff I., Beck J. F., Arndt C., Gruhn B.* (Jena, Germany)
PH-P370
IMPACT OF GLUTATHİONE S-TRANSFERASE AND CYTOCHROME
P450 POLYMORPHİSMS ON CLINICAL OUTCOME AFTER
ALLOGENEIC HEMATOPOIETIC STEM CELL TANSPLANTATION
Bozbey H. U., Akgul S. U., Oguz F., Sargın D., Kalayoglu-Besisik S.* (Istanbul,
Turkey)
PH-P371
CARDIOVASCULAR RISK FACTORS AND BODY HABITUS IN LONG
TERM SURVIVORS OF STEM CELL TRANSPLANTATION
Apperley J., Todd J., Salooja N., Erblich T.* (London, United Kingdom)
PH-P372
AGE RELATED INCREASE IN THE INCIDENCE OF SECOND SOLID
MALIGNANCY (SSM) AFTER HAEMATOPOETIC STEM CELL
TRANSPLANTATION
Tomlins J., Leather A., Dennis M., Cavet J., Somervaille T., Bloor A., Kulkarni
S., Murray J.* (Manchester, United Kingdom)
133
Scientific
Programme
Physicians
Ge L., Sun A., Zhu X., Wu D., Tang X.* (Suzhou , China)
Physicians Posters
Graft-versus-host disease - clinical - Tuesday, 1
April 2014
PH-P373
PROMISING OUTCOMES FROM INTRA-ARTERIAL STEROID
INFUSIONS IN PATIENTS WITH TREATMENT-RESISTANT ACUTE
GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE
Koh H., Nakamae H., Hirose A., Nakamae M., Hayashi Y., Okamura H.,
Yoshimura T., Miki Y., Yamamoto A., Sakai Y., Matsuoka T., Nishida N.,
Nakane T., Hino M., Koh S., Nanno S., Nakashima Y., Takeshita T., Nishimoto
M.* (Osaka, Japan)
PH-P374
GALECTIN-1 AS A NOVEL PROGNOSTIC BIOMARKER IN
HAEMATOLOGIC MALIGNANCIES TREATED WITH NONMYELOABLATIVE HAEMOPOIETIC STEM CELL TRANSPLANTATION
Ludvigsen M., Kamper P. M. H., Hjortebjerg R. M., Sørensen B. S., Nielsen B.,
Honoré B., d´Amore F. A., Petruskevicius I.* (Aarhus, Denmark)
PH-P375
COMPARISON OF ALARM RATES, TREATMENT TIMES, AND BUFFY
COAT COLLECTIONS OBTAINED WITH SOFTWARE VERSION 4.1
VERSUS 3.0 OF THE THERAKOS® CELLEX® PHOTOPHERESIS
SYSTEM, WHEN USED TO TREAT ADULT AND PAEDIATRIC
PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE.
Whittle R., Foster M., Maher T., Goodgrove R., Robertson L., Swift C., Mayo J.,
Hammerton F., Alfred A., Taylor P., Denney H.* (Rotherham, United Kingdom)
PH-P376
ADOPTIVE TRANSFER OF ALLOGENEIC REGULATORY T CELLS
INTO PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE
Theil A., Oelschlägel U., Maiwald A., Döhler D., Ossmann D., Middeke J. M.,
Shayegi N., Trautmann-Grill K., von Bonin M., Platzbecker U., Schetelig J.,
Ehninger G., Bonifacio E., Bornhäuser M., Tuve S.* (Dresden, Germany)
PH-P377
HAPLOIDENTICAL STEM CELL TRANSPLANTATION (HAPLO-HSCT)
WITH HIGH DOSE CYLOPHOSPHAMIDE POST-TRANSPLANT
(PT-CY) AS GVHD PROPHYLAXIS IN HIGH RISK HEMATOLOGIC
MALIGNANCIES: MULTICENTRIC SPANISH EXPERIENCE
Balsalobre P., Castilla C., Pascual M. J., Kwon M., Serrano D., López-Corral L.,
Pérez-Simón J. A., Bermúdez A., Rovira M., Pérez-Corral A., Heras I., Solano
C., Figuera A., Sampol M. A., Ferrá C., Herrera P., Buño I., Díez-Martín J. L.,
González M. S., Anguita J., Montesinos P., Gayoso J.* and on behalf of GETH
(Grupo Español de Trasplante Hematopoyético) (Madrid, Spain)
PH-P378
RISK FACTORS FOR STEROID-REFRACTORY ACUTE GRAFTVERSUS-HOST DISEASE AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION FROM MATCHED RELATED OR UNRELATED
DONORS
Vigouroux S., Tabrizi R., Pigneux A., Leguay T., Bouabdallah K., Dilhuydy M.S., Duclos C., Lascaux A., Dumas P.-Y., Dimicoli-Salazar S., Marit G., Milpied
N., Calmettes C.* (BORDEAUX, France)
PH-P379
134
EXTRACORPOREAL PHOTOPHERESIS FOR GRAFT-VERSUS-HOST
DISEASE: THE ROLE OF PATIENT-, TRANSPLANT-, DIAGNOSTIC
CRITERIA AND HEMATOLOGICAL VALUES ON RESPONSE.
RESULTS FROM A LARGE SINGLE CENTER STUDY
Albiani R., Sini B., Fagioli F., Berger M.* (Turin, Italy)
Physicians Posters
April 2014
PH-P380
IMPACT OF FEMALE DONOR ON ALLOGENEIC STEM CELL
TRANSPLANTATION OUTCOME OF MALE RECIPIENT AFTER
T-CELL DEPLETION BY RABBIT ANTITHYMOCYTE GLOBULIN
PH-P381
A PROSPECTIVE COMPARATIVE STUDY OF EXTRACORPOREAL
PHOTOPHERESIS PERFORMED USING THE OPEN-LOOP COBE®
SPECTRA OR SPECTRA OPTIA® SYSTEM VERSUS THE CLOSEDLOOP THERAKOS™ CELLEX™ SYSTEM
Sabbag E., Mashiach T., Stravets T., Badian A., Finkelbaum S., Smarkatin K.,
Hayun M., Ofran Y., Dann E. J.* (Haifa, Israel)
PH-P382
HUMAN CHORIONIC GONADOTROPIN HORMONE INDUCES
INDOLEAMINE 2,3-DIOXYGENASE AND INTERLEUKIN-10
EXPRESSION IN PATIENTS WITH GRAFT-VERSUS-HOST-DISEASE
Ditschkowski M., Steckel N., Gromke T., Ottinger H., Hillen U., Trenschel R.,
Beelen D., Koldehoff M., Elmaagacli A.* (Hamburg, Germany)
PH-P383
PHARMACODYNAMIC PREDICTION OF GVHD RISK IN REDUCED-INTENSITY CONDITIONING REGIMEN ALLOGENEIC STEM CELL TRANSPLANTATION (RIC ALLOSCT) USING MYCOPHENOLATE MOFETIL
(MMF) PLUS CYCLOSPORINE A (CSA) AS GVHD PROPHYLAXIS
Millán O., Rovira M., Fernández-Avilés F., Suárez-Lledó M., Urbano-Ispízua
Á., Brunet M., Martinez C.* (Barcelona, Spain)
PH-P384
UNDER-EXPOSURE TO MYCOPHENOLATE ACID (MPA) AFTER
REDUCED-INTENSITY CONDITIONING REGIMEN ALLOGENEIC
STEM CELL TRANSPLANTATION (RIC ALLOSCT) USING
MYCOPHENOLATE MOFETIL (MMF) PLUS CYCLOSPORINE A (CSA)
AS GVHD PROPHYLAXIS IS ASSOCIATED TO HIGH RISK OF GRADE
Millán O., Rovira M., Fernández-Avilés F., Suárez-Lledó M., Urbano-Ispízua
Á., Brunet M., Martinez C.* (Barcelona, Spain)
PH-P385
TREATMENT OF STEROID-REFRACTORY GRAFT VERSUS HOST
DISEASE (SR-GVHD) AFTER BONE MARROW TRANSPLANT
(BMT) FOR PRIMARY IMMUNE DEFICIENCY - SINGLE CENTRE
EXPERIENCE.
Slatter M., Nademi Z., Abinun M., Gennery A., Altmann T.* (Newcastle upon
Tyne, United Kingdom)
PH-P386
THE ANALYSIS OF HEMATOGONES (HGS) AFTER ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)
Haraguchi K., Kakihana K., Ishida S., Oshikawa G., Kobayashi T., Okuyama Y.,
Ohashi K., Sakamaki H., Doki N.* (Tokyo, Japan)
PH-P387
CYCLOSPORINE A IN COMBINATION WITH MYCOPHENOLATE
MOFETIL OR METHOTREXATE FOR PROPHYLAXIS OF GVHD
Dübbers M., Borchert K., Glaeser D., Schmitt M., Junghanss C., Hilgendorf I.*
(Rostock, Germany)
135
Scientific
Programme
Physicians
Vigouroux S., Tabrizi R., Pigneux A., Leguay T., Bouabdallah K., Dilhuydy M.S., Duclos C., Lascaux A., Dumas P.-Y., Dimicoli-Salazar S., Marit G., Milpied
N., Calmettes C.* (BORDEAUX, France)
Physicians Posters
April 2014
PH-P388
T CELLS EXPRESSING THE HOMING RECEPTORS CCR7 AND CD62L
MEDIATE THE PATHOGENESIS OF GRAFT-VERSUS-HOST DISEASE
PORTERO I., ROYG M., KREUTZMAN A., FERNANDEZ ARANDOJO C., RAMIREZ
A., MUÑOZ CALLEJA C., Gomez Garcia De Soria V.* (MADRID, Spain)
PH-P389
EXTRACORPOREAL PHOTOPHERESIS IN ACUTE GRAFT-VERSUSHOST DISEASE: CLINICAL OUTCOME, SURVIVAL AND STEROID
SPARING EFFECT IN 20 PATIENTS TREATED OVER A 6-YEAR
PERIOD.
Rinaldi C., Isola M., Patriarca F., Zannier M. E., Fanin R., De Angelis V.,
Savignano C.* (Udine, Italy)
PH-P390
CIRCULATING ENDOTHELIAL CELLS COUNT CHANGES ARE
A DYNAMIC BIOMARKER OF ACUTE GVHD IN PATIENTS
UNDERGOING ALLOGENEIC HSCT
Skert C., Verardi R., Di Palma A., Bianchetti A., Neva A., Braga S., Malagola
M., Russo D., Marini M., Almici C.* (Brescia, Italy)
PH-P391
SINGLE NUCLEOTIDE POLYMORPHISMS WITHIN THE
THROMBOMODULIN GENE (THBD) PREDICT RISK OF NONRELAPSE MORTALITY IN PATIENTS WITH GRAFT-VERSUS-HOST
DISEASE
Rachakonda S. P., Penack O., Blau O., Dietrich S., Dreger P., Kumar R.,
Isermann B., Luft T.* (Heidelberg, Germany)
PH-P392
COMBINED HLA AND SEX-MISMATCHED HSCT IS ASSOCIATED
WITH INCREASED CD4+ AND CD8+ T CELL NUMBERS IN ACUTE
GVHD CUTANEOUS INFILTRATES
van Halteren A. G., de Hond T., van Dijk M., Kloos R. Q., Lankester A. C.,
Bierings M. B., Spierings E., Thus K.* (Utrecht, Netherlands)
PH-P393
HIGH-DOSE RITUXIMAB IN THE CONDITIONING REGIMEN BEFORE
ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED
B-CELL LYMPHOMAS IS ASSOCIATED WITH REDUCED GVHDRELATED DEATHS, BUT DID NOT IMPROVE DISEASE CONTROL.
Spina F., Sarina B., Patriarca F., Carella A. M., Levis A., Bosi A., Falda M.,
Di Raimondo F., Di Bartolomeo P., Dalto S., Bacigalupo A., Rambaldi A.,
Corradini P., Carniti C., Dodero A.* and GITMO (milano, Italy)
PH-P394
THE USE OF AUTOLOGOUS SERUM EYEDROPS IN SEVERE OCULAR
GRAFT VERSUS HOST DISEASE
Yasmin A., Wong K., McQuaker G., Parker A., Copland M., Anijeet D., Kanna
R., Clark A., Laing A.* (Glasgow, United Kingdom)
PH-P395
EXTRACORPOREAL PHOTOAPHERESIS FOR THE TREATMENT OF
ACUTE GRAFT VERSUS HOST DISEASE (AGVHD). A SINGLE CENTER
EXPERIENCE.
Ferremi Leali P., Ferrari E., Sala M. L., Tiburzi A., Skert C., Bergonzi C., Filì C.,
Cancelli V., Cattina F., Ribolla R., Turra A., Marini M., Russo D., Malagola M.*
(Brescia, Italy)
136
Physicians Posters
April 2014
PH-P396
ASSOCIATION BETWEEN URIC ACID LEVELS AND ACUTE GRAFT
VERSUS HOST DISEASE
Blau O., Uharek L., Blau I., Penack O., Ostendorf B. N.* (Berlin, Germany)
PH-P397
THE IMPACT OF ENTEROCOCCAL FLORA ON INTESTINAL GVHD
AND OVERALL SURVIVAL
Koestler J., Gessner A., Oefner P., Hahn J., Holler E., Sporrer D.* (Regensburg,
PH-P398
INCREASED REG3A SERUM LEVELS CORRELATE WITH SEVERE
GASTROINTESTINAL DAMAGE FROM EARLY ACUTE GI GVHD, LATE
ACUTE GI GVHD AND NEUTROPENIC ENTEROCOLITIS
Kreutz M., Ferrara J., Schmid K., Peter K., Sporrer D., Haffner S., Wolff D., Herr
W., Levine J., Holler E.* (Regensburg, Germany)
PH-P399
MULTI-STATE MODELS ENHANCE INSIGHT IN OUTCOMES AFTER
ALLOGENEIC STEM CELL TRANSPLANTATION FOR AML/MDS
FOLLOWED BY DONOR LYMPHOCYTE INFUSIONS
Eefting M., Halkes C., von dem Borne P., Kersting S., Marijt E., Veelken H.,
Putter H., Schetelig J., Falkenburg J., de Wreede L.* (Leiden, Netherlands)
PH-P400
OUTCOME OF CHILDREN DEVELOPING GRADE III-IV ACUTE
GRAFT-VERSUS-HOST-DISEASE AFTER ALLOGENEIC
HAEMATOPOIETIC STEM CELL TRANSPLANTATION.
Locatelli F., Lawitschka A., Cornish J., Bader P., Dalle J. H., Sedlacek P., Yaniv
I., Peters C., Bertaina A.* (Rome, Italy)
PH-P401
PROSPECTIVE STUDY OF EXTRACORPOREAL PHOTOCHEMOTHERAPY
USING A REDUCED INTENSITY REGIMEN IN GRAFT VERSUS HOST DISEASE
Lopez V., Fernandez M., Heras I., Castilla-Llorente C., Vicente V., Lozano M.
L.* (Murcia, Spain)
PH-P402
EXTRACORPOREAL PHOTOPHERESIS AND RITUXIMAB FOR THE
TREATMENT OF STEROID REFRACTORY GRAFT VERSUS HOST
DISEASE
Kryzauskaite L., Bertasiute A., Trociukas I., Griskevicius A., Matuzeviciene
R., Sinkevic K., Zvirblis T., Ivanauskaite V., Griskevicius L., Cekauskiene R.*
(Vilnius, Lithuania)
PH-P403
MONOCLONAL GAMMOPATHY AFTER ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANT AS A POSSIBLE
MARKER FOR GVHD ONSET
Zallio F., Catania G., Corsetti M. T., Mele L., Dallavalle F., Tamiazzo S., Baraldi
A., Salvi F., Pini M., Monaco F.* (Alessandria, Italy)
PH-P404
EXTRACORPOREAL PHOTOPHERESIS IN TREATMENT OF
PATIENTS WITH STEROID REFRACTORY OR RELAPSED CHRONIC
GVHD: A SINGLE CENTER RETROSPECTIVE ANALYSIS OF A ONCE
WEEKLY INITIAL SCHEDULE
Guellstorf M., Wolbers T., Zabelina T., Wolschke C., Alchalby H., Stuebig T.,
Lellek H., Zander A., Kroeger N., Ayuk F.* (Hamburg, Germany)
137
Scientific
Programme
Physicians
Germany)
Physicians Posters
April 2014
PH-P405
ANTI-CD20 THERAPY IN COMBINATION WITH NILOTINIB FOR THE
TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE
te Boome L., Meijer E., Kuball J., Van Der Wagen L.* (Utrecht, Netherlands)
PH-P406
GRAFT-VERSUS-HOST DISEASE AFTER DONOR LYMPHOCYTES
INFUSIONS IN PATIENTS WITH RELAPSED HEMATOLOGICAL
MALIGNANCIES AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION
Mendeleeva L., Galtseva I., Kuzmina L., Pokrovskaya O., Parovichnikova E.,
Savchenko V., Bogdanov R.* (Moscow, Russian Federation)
PH-P407
A LIMITED SAMPLING STRATEGY FOR THERAPEUTIC DRUG
MONITORING OF MYCOPHENOLATE MOFETIL FOR PROPHYLAXIS
OF ACUTE GRAFT VERSUS HOST DISEASE IN ALLOGENEIC STEM
Pathak K., Mittal S., Gurjar M., Patil A., Bagal B., Khattry N., Gota V.* (Navi
Mumbai, India)
PH-P408
GENETIC BACKGROUND OF IMMUNE REACTIONS AFTER
Paediatric STEM CELL TRANSPLANTATION - WHOLE GENOME
EXPRESSION STUDY.
Gozdzik J., Bik-Multanowski M., Krasowska-Kwiecien A., Dluzniewska A.,
Wiecha O., Czogala W., Grabowska A., Pietrzyk J. J., Siedlar M., Fijorek K.,
Skoczen S.* (Krakow, Poland)
PH-P409
PRE-TRANSPLANT CONDITIONING RESULTS IN OVERT DERMAL
RECRUITMENT OF HLA CLASS II POSITIVE MACROPHAGE-LIKE
CELLS AFTER TRANSPLANTATION
van der Zouwen B., Kruisselbrink A. B., van Balen P., Eefting M., Jordanova
K., Falkenburg J., Jedema I.* (Leiden, Netherlands)
PH-P410
EARLY OCCURRENCE OF SEVERE HYPOALBUMINEMIA IS
ASSOCIATED WITH ACUTE GVHD ONSET AND GRADING AFTER
ALLOGENEIC HCT
Miladinovic B., Nishihori T., Ayala E., Tsalatsanis A., Mathews J., Mina A.,
Pidala J., Field T., Fernandez H. F., Betts B., Hillgruber R., Coyle D., Tomblyn
M., Kumar A., Anasetti C., Kharfan-Dabaja M. A.* (Tampa, United States)
PH-P411
SINGLE NUCLEOTIDE POLYMORPHISMS (SNPS) IN INTERLEUKIN
1A AND 1B GENES ASSOCIATE WITH PATIENT SUSCEPTIBILITY TO
COMPLICATIONS AFTER HLA-IDENTICAL SIBLING ALLO-SCT.
Martínez-Laperche C., González-Rivera M., Bosch-Vizcaya A., MartínAntonio B., Guillem V., Nieto J., González M., de la Cámara R., Brunet S.,
Jiménez-Velasco A., Espigado I., Vallejo C., Sampol A., Serrano D., Kwon M.,
Gayoso J., Balsalobre P., Urbano-Izpizua A., Solano C., Gallardo D., DíezMartín J., Buno I., Buces E.* and on behalf of the GvHD/Immunotherapy
committee of the Spanish Group for Hematopoietic Transplantation (GETH)
(Madrid, Spain)
138
Physicians Posters
April 2014
PH-P412
VITAMIN D DEFICIENCY AND COMPLICATIONS AFTER ALLOGENEIC
Alm J., Malmberg K.-J., Björklund A., Labopin M., Ljungman P., Le Blanc K.,
Von Bahr L.* (Stockholm, Sweden)
PH-P413
ORAL METRONIDAZOLE IN COMBINATION WITH QUINOLONES VS
ORAL QUINOLONES ALONE FOR THE PREVENTION OF AGVHD
PH-P414
DONOR B CELLS POPULATIONS, IFNG-PRODUCING T CELLS,
AND CD56BRIGHT NK CELLS CORRELATE WITH DEVELOPMENT
OF CHRONIC GVHD IN G-CSF STIMULATED SIBLING DONOR
PERIPHERAL BLOOD AND BONE MARROW: RESULTS FROM THE
CANADIAN BMT GROUP 0601 RANDOMIZED, PHASE III TRIAL
Kariminia A., Panzarella T., Ivison S., Levings M., Broady R., Aljurf M., Foley
R., Devins G., Kerr H., Lee S. J., Szwajcer D., Toze C., Couban S., Subrt P.,
Rozmus J., Schultz K.* (Vancouver, Canada)
PH-P415
SCLERO-CORNEAL LENSES SAFE AND EFFICIENT FOR THE
TREATMENT OF KERATOCONJUNCTIVITIS SICCA IN PATIENTS
WITH REFRACTORY OCULAR GVHD.
RICHET M., COITEUX V., ERNOULD F., DULERY R., RANDON T., LABALETTE P.,
YAKOUB-AGHA I., MAGRO L.* (LILLE, France)
PH-P416
IMPACT OF NIH GLOBAL SCORING SYSTEM OF CHRONIC GRAFTVERUS-HOST DISEASE ON THE OUTCOMES FOLLOWING STEM
Elez M., Balint B., Tarabar O., Marjanovic S., Zivanovic Ivic A., Todoric
Zivanovic B., Strnad M., Tatomirovic Z., Tasic O., Ostojic G., Malesevic M.,
Tukic L., Stamatovic D.* (Belgrade, Serbia)
PH-P417
MIRSNPS ARE ASSOCIATED WITH AGVHD AFTER UNRELATED
ALLO-HSCT IN CHINESE HAN POPULATION
Hu Y., Luo Y., Tan Y., Huang H., Zhang C.* (Hangzhou, China)
PH-P418
IMPAIRED NK CELLS CYTOTOXICITY AGAINST ACTIVATED,
ALLOREACTIVE DONOR T CELLS IN GVHD CAN BE PARTLY
RESTORED BY IL-15 EX VIVO
Fu H., Hu Y., Luo Y., Shi J., Tan Y., He Y., Lai X., Sheng L.*, Huang H.
(Hangzhou, China)
PH-P419
IMPLEMENTATION AND DISSEMINATION OF CHRONIC GRAFTVERSUS-HOST DISEASE NIH CRITERIA AND RECOMMENDATIONS
- FORMATION OF A MULTIDISCIPLINARY TEAM AND PROGRAM AT
THE UNIVERSITY HOSPITAL CENTER ZAGREB, CROATIA
Grce M., Pulanic D., Nemet D., Pavletic S. Z., Serventi-Seiwerth R., Matic N.,
Ceovic R., Bilic E., Ljubas D., Rajic L., Bilic E., Durakovic N., Peric Z., Klepac
Pulanic T., Dusek D., Bojanic I., Batinic D., Vrhovac R., Kovac K., Grkovic L.*,
Mravak-Stipetic M. (Zagreb, Croatia)
139
Scientific
Programme
Physicians
Buenasmañanas D., Martin C., Rodriguez G., Serrano J., Joaquin S.-G., Chic
Acevedo C., Casaño J., Rojas R., Garcia Torres E.* (Córdoba, Spain)
Physicians Posters
April 2014
PH-P420
SERUM IL-2 LEVELS REGULATE CHRONIC GRAFT VERSUS HOST
DISEASE SEVERITY VIA CD4+ FOXP3+ REGULATORY T CELL
HOMEOSTASIS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Luo Y., Tan Y., Gu Y., Huang H., Hu Y.* (Hangzhou, China)
PH-P421
LARGE SCALE CLINICAL CHARACTERIZATION OF AUTOANTIBODIES
IN PATIENTS WITH CHRONIC GVHD
Hakim F., Gounden V., Rose J., Cowen E. W., Naik H. B., Hasni S. A., Mays
J., Curtis L., Cole K., Avila D., Taylor T., Mitchell S., Baruffaldi J., Baird K.,
Steinberg S., Pavletic S. Z., Kuzmina Z.* (Bethesda, United States)
PH-P422
TOTAL GAMMA-GLUTAMYLTRANSFERASE ACTIVITY AND
ITS FRACTIONS IN ALLOGENIC AND AUTOLOGUS STEM CELL
TRANSPLNTATION: CORRELATION WITH ACUTE GRAFT VERSUS
HOST DISEASE AND TRANSPLANT RELATED MORTALITY
Bertaggia I., Franzini M., Paolocchi A., Bramanti E., Passera R., Bruno B.,
Bruno B., Bacigalupo A., Petrini I., Petrini M., Benedetti E.* (Pisa, Italy)
PH-P423
IMPACT OF CD3/TREGS RATIO IN DONOR GRAFT ON SURVIVAL
RATES IN ALLOGENEIC PERIPHERAL BLOOD STEM CELL
TRANSPLANTATION
Pastore D., Mestice A., Carluccio P., Perrone T., Gaudio F., Curci P., Ricco A.,
Russo Rossi A., Giordano A. M., Specchia G., Delia M.* (Bari, Italy)
PH-P424
MEASUREMENT OF SERUM IP-10 LEVELS AND PB DENDRITIC
CELL (DC) NUMBERS AT 3 MONTHS AFTER ALLOGENEIC HSC
TRANSPLANTATION AS POTENTIAL BIOMARKERS OF CHRONIC
GVHD.
Chirumbolo G., Ulbar F., Stanzani M., Arpinati M., Tolomelli G.* (Bologna, Italy)
PH-P425
RAPAMYCIN-INDUCED COMPARTMENTALIZATION OF TREGS
AFTER UNMANIPULATED HLA-HAPLOIDENTICAL HSCT PROTECTS
FROM GVHD AND LIKELY DOES NOT INTERFERE WITH GVL
EFFECTS
Peccatori J., Forcina A., Noviello M., Valtolina V., Cieri N., Lupo Stanghellini
M. T., Olek S., Battaglia M., Ciceri F., Bonini C., Bondanza A., Gullotta F.*
(Lecce, Italy)
PH-P426
URINARY PROTEOMIC PATTERN ANALYSIS OUTPERFORMS
PLASMA BIOMARKERS FOR THE PREDICTION OF ACUTE
GRAFT-VERSUS-HOST DISEASE IN HEMATOPOIETIC STEM CELL
TRANSPLANTED PATIENTS
Borchers S., Hambach L., Metzger J., Schweier P., Diedrich H., Krauter J.,
Ganser A., Stadler M., Eder M., Mischak-Weissinger E., Human C.* (Hannover,
Germany)
PH-P427
SAFETY AND EFFICACY OF TACROLIMUS AND MINI DOSE
METHOTREXATE IN CHILDREN
Munirathinam D., Kumar V., Doss H., Sri K., Raj R.* (CHENNAI, India)
140
Physicians Posters
April 2014
PH-P428
ECP FOR ACUTE GVHD WITH DIFFERENT METHODS IN Paediatric
PATIENTS
Pichler H., Peters C., Matthes S., Lawitschka A., Holter W., Witt V.* (Vienna,
Austria)
PH-P429
THERAPY WITH ACITRETIN IS EFFECTIVE IN REFRACTORY
SCLERODERMATOUS CHRONIC GRAFT VERSUS HOST DISEASE
Bermudez A., Ibarrondo P., Yañez L., Insunza A., Conde E., De Miguel C.*
PH-P430
HIGH LEVELS OF SOLUBLE HUMAN LEUKOCYTE ANTIGEN G
FAVOR TOLERANCE AFTER
Wagner B., Horn P. A., Beelen D. W., Rebmann V., Kordelas L.* (Essen, Germany)
PH-P431
CD4+CD25++ LYMPHOCYTE LEVELS ARE CLOSELY ASSOCIATED
WITH AN OVERT MANIFESTATION OF AGVHD BUT IF LOW AT HEMATOLOGICAL RECONSTITUTION MAY BE PREDICTIVE OF HERPES
VIRUSES REACTIVATION AND POORER SURVIVAL POST ALLOHSCT
Lange J., Mordak-Domagala M., Dlubek D., Sedzimirska M., Tarnowska A.,
Borowik A., Jaskula E., Lange A.* (Wroclaw, Poland)
PH-P432
SUPERIOR OVERALL SURVIVAL AFTER SIMULTANEOUS SALVAGE
THERAPY BY PENTOSTATIN AND MYCOPHENOLATE MOFETIL
FOR SEVERE INTESTINAL STEROID REFRACTORY ACUTE GRAFT
VERSUS HOST DISEASE
Schmitt T., Bug G., Schetelig J., Schwerdtfeger R., Schaefer-Eckart K., Schmid
C., Kobbe G., Heidenreich D., Rühe E., Bornhaeuser M., Martin H., Dreger
P., Klein S.* and german cooperative transplant study group (Mannheim,
Germany)
PH-P433
HYPERACUTE GRAFT-VERSUS-HOST DISEASE (GVHD): SINGLE
CENTER EXPERIENCE
López-Godino O., Cabral R., Dávila J., Caballero J. C., Sánchez-Nieto D.,
Pérez-López R., Bastida J. M., López-Parra M., Cabrero M., Sánchez-Guijo F.,
Vázquez L., del Cañizo C., López-Corral L., Caballero D., Redondo A., Alonso
S.* (Salamanca, Spain)
PH-P434
SWITCH OF CYCLOSPORINE TO TACROLIMUS IN CHILDREN AFTER
Dalle J.-H., Alby-Laurent F.* (Paris, France)
PH-P435
IMPACT OF SMALL BOWEL EXPLORATION USING VIDEO-CAPSULE
ENDOSCOPY IN THE MANAGEMENT OF DIARRHEA AFTER
Jourdain F., Maunoury V., Magro L., Coiteux V., Colombel J.-F., Yakoub-Agha
I., Dulery R.* (Lille, France)
PH-P436
LOW INCIDENCE OF LATE NRM AND SEVERE CGVHD IN A PHASE
II TRIAL OF THYMOGLOBULIN®, TACROLIMUS AND SIROLIMUS
FOR GVHD PREVENTION
Gul Z., Chen W., Smith D., Mitchell A., Abidi M., Ayash L., Lum L., Deol A.,
Ratanatharathorn V., Uberti J., Al-Kadhimi Z.* (Atlanta, United States)
141
Scientific
Programme
Physicians
(Santander, Spain)
Physicians Posters
Graft-versus-host disease - preclinical & animal
models - Tuesday, 1 April 2014
PH-P437
INCREASED TH17/TREG RATIO IN LIVER CHRONIC GRAFT-VERSUSHOST-DISEASE
Bossard C., Brissot E., Chevallier P., Guillaume T., Delaunay J., Mosnier J.-F.,
Moreau P., Grégoire M., Gaugler B., Mohty M., Malard F.* (Nantes, France)
PH-P438
THE ROLES OF DONOR T CELLS FROM DISTINCT ORIGIN IN
CLINICALLY RELEVANT MURINE CHRONIC GVHD MODEL
PH-P439
LENALIDOMIDE POTENTIATES HUMAN T CELL ALLORESPONSES
BY SELECTIVELY INCREASING PROLIFERATION OF ALLOREACTIVE
CD8+ CELLS WHICH EXHIBIT A NOVEL GENE EXPRESSION
PROFILE - IMPLICATIONS FOR IMID THERAPY AFTER ALLOGENEIC
HAEMATOPOIETIC CELL TRANSPLANT.
Ueha S., Teshima T., Kosugi M.*, Matsushima K. (Bunkyo-ku, Japan)
Davies J., LeDieu R., Kotsiou E., Petty R., Sangaralingam A., Gribben J., Besley
C.* (London, United Kingdom)
PH-P440
MICRORNA-181A ALTERS GRAFT-VERSUS-HOST-DISEASE BY
MODULATING T CELL ALLOREACTIVITY
Dallmann I., Krueger A., Ganser A., Scherr M., Eder M., Koenecke C., Lee C.W.* (Hannover, Germany)
PH-P441
PENTRAXIN 3 AS GRAFT-VERSUS-HOST DISEASE (GVHD)
BIOMARKER IN A COHORT OF Paediatric PATIENTS WITH
HEMATO-ONCOLOGIC DISEASES
De Lorenzo P., Masciocchi F., Vinci P., Pasqualin F., Bonanomi S., Di Gregorio
A., Migliavacca M., Pavan F., Di Maio L., Garlanda C., Mantovani A., Biondi A.,
Valsecchi M. G., Balduzzi A., Bottazzi B., Rovelli A., D’Amico G., Dander E.*
(Monza, Italy)
PH-P442
EFFECT OF PERI-TRANSPLANT PRO-INFLAMMATORY MILIEU ON
HEPARANASE EXPRESSION IN DONOR CELLS BY STIMULATION
OF PB AND CB MNC WITH LPS: STRONG ASSOCIATION WITH
RS4693608 SNP
Shimoni A., Baryakh P., Morgulis Y., Mayorov M., Beider K., Shteingauz A.,
Ilan N., Vlodavsky I., Nagler A., Ostrovsky O.* (Ramat Gan, Israel)
PH-P443
PROTEOMIC PEPTIDE PROFILING IN THE LIVER DURING ACUTE
GRAFT-VERSUS-HOST DISEASE
Pérez-Hernandez D., Cordes S., Mengwasser J., Dittmar G., Penack O., Shi
Y.* (Berlin, Germany)
PH-P444
TARGET ORGAN TROPISM OF EFFECTOR T CELL POPULATIONS IN
CHRONIC GRAFT-VERSUS-HOST DISEASE
Denney H., Maher T., Foster M., Alfred A., Chantry A., Taylor P., Whittle R.*
(Rotherham, United Kingdom)
PH-P445
BONE MARROW DERIVED MESENCHYMAL STROMAL CELLS (BMSC)
ARE EFFICIENT MODULATORS OF XENOGENEIC GRAFT VERSUS
HOST DISEASE
Amarnath S., Salem B., Laurence A., Eckhaus M., Melenhorst J. J., Rose J. J.,
Sabatino M., Stroncek D., Fowler D. H., Barrett A.* (Bethesda, United States)
PH-P446
142
DEFINING THE BIODISTRIBUTION AND IMMUNOMODULATORY
MECHANISMS OF HUMAN MESENCHYMAL STROMAL CELLS
FOLLOWING ALLOGENEIC BMT
Auletta J. J., Eid S. K., Keller M. D., Wuttisarnwattana P., Wilson D. L., Silva I.,
Cooke K. R.* (Baltimore, United States)
Physicians Posters
Haemoglobinopathy & Inborn errors of metabolism
- Tuesday, 1 April 2014
PH-P447
HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH
CD3+/19+ DEPLETED PBSC FOR ADVANCED STAGE SICKLE CELL
DISEASE
Kleis M., Föll J., Corbacioglu S., Heinzelmann B. C.* (Regensburg, Germany)
PH-P448
HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR
MUCOPOLYSACCHARIDOSIS VII
PH-P449
ALLOGENEIC STEM TRANSPLANTATION IN PATIENTS WITH
CLASS 2 AND CLASS 3 THALASSEMIA MAJOR: A SINGLE-CENTER
EXPERIENCE FROM SOUTH INDIA
Badiger S., K.S N., Damodar S., Bhat S.* (Bangalore, India)
PH-P450
A COMPARISON BETWEEN PERIPHERAL BLOOD STEM CELL
TRANSPLANTATION AND BONE MARROW TRANSPLANTATION IN
THALASSEMIA MAJOR
Hamidieh A. A., Alimoghaddam K., Jahani M., Mousavi S. A., Bahar B.,
Vaezi M., Jalali A., Sharifi Aliabadi L., Ghavamzadeh A.* (Tehran, Iran, Islamic
Republic Of)
PH-P451
THIRTY YEARS’ EXPERIENCE OF ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTATION FOR GAUCHER DISEASE IN
SWEDEN
Kämpe Björkvall C., Myhr-Eriksson K., Markuszewska-Kuczyńska A.,
Hägglund H., Lauri B., Remberger M., Ljungman P., Groth C.-G., Ringdén O.,
Machaczka M.* (Stockholm, Sweden)
PH-P452
IMPROVED ENGRAFTMENT AND TRANSFUSION INDEPENDENCY
AFTER CYCLOSPORINE WITHDRAWAL IN PATIENT WITH MIXED
CHIMERISM AFTER MATCHED SIBLING TRANSPLANT FOR
THALASSEMIA MAJOR
Yaqub N., Marwah P., Soni R., Itrat F., Khan A., Khan Gilani S., El Missiry M.,
Hussain M. H., Uderzo C., Faulkner L., Khalid S.* (Firenze, Italy)
PH-P453
HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR BETATHALASSEMIA MAJOR: A SINGLE CENTER EXPERIENCE
Unal Ince E., Uysal Z., Ileri T.*, Ertem M. (Ankara, Turkey)
PH-P454
ALLOGENEIC UNRELATED HEMATOPOIETIC STEM CELL
TRANSPLANTATION WITH REDUCED INTENSITY CONDITIONING
(RIC) IN CHILDREN WITH HURLER SYNDROME (SINGLE CENTRE
EXPERIENCE)
Stancheva N. V., Ratc A. A., Kozhokar P. V., Bykova T. A., Semenova E. V.,
Paina O. V., Marcova I. V., Razumova S. V., Ekushov K. A., Zubarovskaya L. S.,
Afanasyev B. V., Smirennikova M. M., Fedukova Y. G., Borovkova A. S.* (St.
Petersburg, Russian Federation)
143
Scientific
Programme
Physicians
Torrent M., Pardo N., Pineda M., Coll M., Gort L., Fernandez E., Badell I.,
Sisinni L.* (Barcelona, Spain)
Physicians Posters
Haemoglobinopathy & Inborn errors of metabolism
- Tuesday, 1 April 2014
PH-P455
CONDITIONING WITH TREOSULFAN, FLUDARABINE, THIOTEPA
AND ATG FOR MATCHED FAMILY DONOR TRANSPLANTATION IN
CHILDREN WITH SICKLE CELL ANEMIA
Bleeke M., Grosse R., Kordes U., Schrum J., Müller I., Hartz B.* (Hamburg,
Germany)
PH-P456
DEPLETION OF TCRΑ/Β +/CD19+ CELLS AS A NOVEL APPROACH IN
SCT FOR OSTEOPETROSIS
S C., S G., F B., R B., A B., A L., F P.* (Brescia, Italy)
PH-P457
30 YEARS OF EXPERIENCE OF ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTATION FOR INBORN ERRORS OF
METABOLISM
Remberger M., Svahn B.-M., Gustafsson B., Solders G., Naess K., Machaczka
M., Mattsson J., Ringdén O., Solders M.* (Stockholm, Sweden)
PH-P458
T-CELL DEPLETED HAEMATOPOIETIC STEM CELLS
TRANSPLANTATION WITH ADD BACK OF CD45RA NEGATIVE
DONOR LYMPHOCYTES INFUSION: ABOUT 5 CASES
touzot F., dal coritvo L., cros G., chomton M., creidy R., brignier A., moshous
D., blanche S., fischer A., cavazzana M., Neven B.* (paris, France)
PH-P459
HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR
HEMOGLOBINOPATHY(SICKLE CELL DISEASE) IN NIGERIA- 2013
UPDATE BY NIGERIAN GROUP FOR BLOOD AND MARROW
TRANSPLANT (NGBMT)
enomamien B., Bazuaye N. G.* (benin, Nigeria)
PH-P460
INDICATION FOR STEM CELL TRANSPLANTATION IN SICKLE CELL
DISEASE: IS OLDER AGE A CONTRAINDICATION? SINGLE CENTER
EXPERIENCE IN BRAZIL
Cunha R., Moraes D., Dias J. E., Darrigo Jr. L. G., Grecco C. E., Stracieri A. B. P.,
Oliveira M. C., Pieroni F., Barros G. M., Simões B. P.* (Ribeirão Preto, Brazil)
PH-P461
PRE-CONDITIONING IMMUNOMODULATION AND REDUCED
TOXICITY CONDITIONING (RTC) IN ALLO-SIBLING HSCT OF
ADOLESCENTS AND YOUNG ADULTS WITH SICKLE CELL ANEMIA
(SCA) AND THALASSEMIA MAJOR (TM)
Al-Mohareb F., Alzahrani H., Osman S. A., AL Dawsari G., Aljurf M., Ibrahim
K., Almahayni M. H., Al-Haj Ali B., AbuJaafar S., Youniss R.,
PH-P461
PRE-CONDITIONING IMMUNOMODULATION AND REDUCED
TOXICITY CONDITIONING (RTC) IN ALLO-SIBLING HSCT OF
ADOLESCENTS AND YOUNG ADULTS WITH SICKLE CELL ANEMIA
(SCA) AND THALASSEMIA MAJOR (TM)
Al-Mohareb F., Alzahrani H., Osman S. A., AL Dawsari G., Aljurf M., Ibrahim
K., Almahayni M. H., Al-Haj Ali B., AbuJaafar S., Youniss R., ElHassan T.,
Mohamed S. Y.* (riyadh , Saudi Arabia)
144
Physicians Posters
Infectious complications - Tuesday, 1 April 2014
PH-P462
DOSE CYTOMEGALOVIRUS INFECTION PREDICT A LOWER RISK
OF DISEASE RELAPSE AFTER HEMATOPOIETIC STEM CELL
TRANSPLANTATION? A META-ANALYSIS OF OBSERVATIONAL
STUDIES
Zhang Y.-L., Liu L., Luo X.-H.* (Chongqing, China)
CLINICAL DESCRIPTION OF CRYPTOCOCCAL INVASIVE FUNGAL
INFECTION (IFI) IN HEMATOPOIETIC CELL TRANSPLANTATION
(HCT); A SINGLE CENTER EXPERIENCE
Tegtmeier B. R., Kriengkauykiat J., Ito J. I., Dadwal S. S.* (Duarte, United
States)
PH-P464
EFFICACY AND TOXICITY IN CLINICAL PRACTICE OF ANTIFUNGAL
COMBINATION THERAPY FOR PROVEN OR PROBABLE
INVASIVE MOLD DISEASES IN HEMATOPOIETIC STEM CELL
TRANSPLANTATION.
Cesaro S., Busca A., Lazzarotto D., Caira M., Russo D., Fanin R., Pagano L.,
Candoni A.* (Udine, Italy)
PH-P465
COMPARISON OF LEVOFLOXACIN PROPHYLAXIS VERSUS
NO PROPHYLAXIS IN PATIENTS RECEIVING AUTOLOGOUS OR
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.
RETROSPECTIVE COHORT STUDY FROM A SINGLE CENTER.
Fernandez J., Morgades M., Vives S., Sancho J.-M., Xicoy B., Moreno M.,
Ferrrà C., Vila J., Ribera J.-M., Batlle M.* (Badalona, Spain)
PH-P466
FRENCH REAL LIFE COHORT ON THE USE OF MICAFUNGIN FOR
INVASIVE FUNGAL INFECTIONS: RESULTS IN HAEMATOLOGY
PATIENTS FROM THE MYRIADE STUDY
Leverger G., Gachot B., Milpied N., Timsit J.* (Paris, France)
PH-P467
INCIDENCE OF ADENOVIRAL DNA IN POLISH ADULTS
UNDERGOING ALLOGENEIC HAEMATOPOIETIC STEM CELL
TRANSPLANTATION
Rynans S., Przybylski M., Basak G. W., Tomaszewska A., Halaburda K.,
Jedrzejczak W. W., Mlynarczyk G., Dzieciatkowski T.* (Warsaw, Poland)
PH-P468
PREVENTION PNEUMOCYSTIS JIROVECII PNEUMONIA BY
PROPHYLACTIC INTRAVENOUS PENTAMIDINE IN HEMATOLOGIC
PATIENTS: EFFICACY AND SAFETY
Iglesias Domínguez L., Albo López C., Vázquez Álvarez J., Fernández Mellid
E., Alvarez Pequeño L.* (VIGO, Spain)
PH-P469
RISK FACTORS FOR THE DEVELOPMENT OF INVASIVE
FUNGAL INFECTION IN PATIENTS UNDERGOING ALLOGENEIC
Koksoy E. B., Ozen M., Arslan O., Ozcan M., Konuk N., Akan H., Beksac M.,
Gurman G., Topcuoglu P.* (Ankara, Turkey)
145
Scientific
Programme
Physicians
PH-P463
Physicians Posters
PH-P470
A PROPHYLACTIC STRATEGY INCLUDING IGM-ENRICHED
IMMUNOGLOBULIN AFTER ALLOGENEIC HEMATOPOIETIC
TRANSPLANTATION RESULTS IN LOW TRM, LOW RATE OF EARLY
INFECTIONS AND NO SEVERE LIVER TOXICITY
Leotta S., La Fauci A., Berritta D., Cupri A., Di Marco A., Spina P., Parisi M.,
Spadaro A., Milone G.* (Catania, Italy)
PH-P471
TOXOPLASMA GONDII DNA POSITIVITY IN HSCT PATIENTS IS AGEAND TIME-DEPENDENT FOR DIFFERENT BIOLOGICAL SAMPLES
Zubarovskaya L., Bondarenko S., Eismont Y., Vladovskaya M., Afanasyev B.
V., Chukhlovin A. B.* (St.Petersburg, Russian Federation)
PH-P472
HEPATITIS B REACTIVATION FOLLOWING ALLOGENEIC HSCT
PH-P473
SUPPORTIVE CARE AND INFECTIOUS COMPLICATIONS IN CORD
BLOOD AND HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN
ADULTS WITH HIGH RISK HEMATOLOGIC DISEASES.
Olioso P., Santarone S., Papalinetti G., Pennese E., Di Bartolomeo P., Bavaro
P.* (Pescara, Italy)
crocchiolo R., vai A., furst S., bramanti S., sarina B., granata A., faucher
C., mohty B., harbi S., bouabdallah R., vey N., santoro A., chabannon C.,
castagna L., blaise D., Elcheikh J.* (marseille, France)
PH-P474
PRE-ENGRAFTMENT INITIATION OF BRINCIDOFOVIR (CMX001) IN
HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS IS SUPPORTED
BY LACK OF MYELOID TOXICITY
Grimley M., Brundage T., Mommeja-Marin H., Morrison M., Papanicolaou G.*
(New York, NY, United States)
PH-P475
PROLONGED FLUCONAZOLE PROPHYLAXIS IS NOT REQUIRED
IN PATIENTS WITH ACUTE LEUKEMIAS OR MYELODYSPLASTIC/
MYELOPROLIFERATIVE DISORDERS AFTER REDUCED-INTENSITY
CONDITIONING (RIC) ALLOGENEIC STEM CELL TRANSPLANTATION
(ALLO-SCT): A PAIR-MATCHED ANALYSIS
Cahu X., Guillaume T., Delaunay J., Ayari S., Precupanu C., Peterlin P.,
Harousseau J. L., Milpied N., Moreau P., Mohty M., Chevallier P., Brissot E.*
(NANTES, France)
PH-P476
ANTIBODY RESPONSE TO IMMUNIZATION WITH LIVEATTENUATED VACCINES IN ADULT SURVIVORS AFTER
Asano-Mori Y., Ota H., Nishida A., Ishiwata K., Takagi S., Yamamoto H.,
Yamamoto G., Uchida N., Izutsu K., Wake A., Yoneyama A., Taniguchi S.,
Narita M., Tsuchihashi R., Tsuji M.* (Tokyo, Japan)
PH-P477
ANALYSIS OF CD19+/CD38+/CD27HIGH PLASMA BLASTS
IN ALLOGENEIC STEM CELL TRANSPLANT PATIENTS AFTER
ROUTINELY PERFORMED RE-VACCINATION
Mach M., Mackensen A., Winkler T., Winkler J.* (Erlangen, Germany)
146
Physicians Posters
PH-P478
PROSPECTIVE STUDY OF THE PERFORMANCE OF THE SERUM
GALACTOMANNAN ASSAY AS PART OF A DIAGNOSTIC-DRIVEN
STRATEGY FOR HIGH-RISK HEMATOLOGY PATIENTS ON
POSACONAZOLE PRIMARY PROPHYLAXIS
Arnan M., Fernández de Sevilla A., Gudiol C., Ayats J., Cuenca-Estrella M.,
Duarte R. F., Cuesta I., Patiño B., Sánchez-Ortega I.* (Barcelona, Spain)
EBV- ASSOCIATED DISEASES POST ALLOGENEIC SCT AFTER
REDUCTION OF ATG DOSAGE, SINGLE CENTER EXPERIENCE
Kinch A., Arvidson J., Sällström K., Pauksens K., Hallböök H.* (Uppsala,
Sweden)
PH-P480
PRE-TRANSPLANT DONOR AND RECIPIENT INFLUENZA
VACCINATION ENHANCES SERO-RESPONSE RATES IN THE FIRST
SIX MONTHS AFTER HSCT
Ljungman P., Maeurer M., Aoun M., Machado C., Testa L., Vilas Boas L. S.,
Ambati A.* (Stockholm, Huddinge, Sweden)
PH-P481
EARLY AND AGGRESSIVE MANAGEMENT OF IFI IN
ALLOTRANSPLANTED PATIENTS PRODUCES LOW MORBIDITY
AND MORTALITY.
Malagola M., Turra A., Skert C., Filì C., Bergonzi C., Ribolla R., Cattina F.,
Russo D., Cancelli V.* (Brescia, Italy)
PH-P482
BLOOD STREAM INFECTIONS: A MAJOR CAUSE OF EARLY
MORTALITY IN HEMATOPOIETIC STEM CELL TRANSPLANT
Mateos M., Martínez D., González A. J., Dueñas V., Solano J., González A. P.,
González S., Rayón C., Vallejo C., Palomo P.* (Oviedo, Spain)
PH-P483
THE CLINICAL AND FINANCIAL BURDEN OF PREEMPTIVE
MANAGEMENT OF CMV DISEASE AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION
Jain N., Ito S., Muranski P., Hourigan C., Childs R., Battiwalla M., Haggerty J.,
Ramos C., Cook L., Lu K., Barrett A.* (Bethesda, United States)
PH-P484
GENERATION OF CLINICAL-GRADE CMV-SPECIFIC T-CELLS:
T-CELL DONOR SELECTION AND MANUFACTURING OF T CELLS
Priesner C., Arseniev L., Aleksandrova K., Maecker-Kolhoff B., Tischer S.,
Goudeva L., Heuft H.-G., Blasczyk R., Köhl U., Eiz-Vesper B.* (Hannover,
Germany)
PH-P485
EPIDEMIOLOGY AND MANAGEMENT OF CARBAPENEMASEPRODUCING KLEBSIELLA PNEUMONIA INFECTIONS IN ALLOGENIC
HSCT RECIPIENTS: A SINGLE CENTER EXPERIENCE
Giammarco S., Chiusolo P., Laurenti L., Sorà F., Spanu T., Tumbarello M.,
Pagano L., Sica S., Caira M.* (Rome, Italy)
147
Scientific
Programme
Physicians
PH-P479
Physicians Posters
PH-P486
ACTIVE SURVEILLANCE AND PROMPT ANTIMICROBIAL
THERAPY ALLOW REDUCING INFECTIOUS MORTALITY DUE
TO CARBAPENEMASE-PRODUCING KLEBSIELLA SSP IN
Cichero P., Xue E., Greco R., Lorentino F., Crucitti L., Orsini A., Perini T., Lupo
Stanghellini M. T., Marktel S., Assanelli A., Giglio F., Morelli M., Marcatti M.,
Bernardi M., Peccatori J., Ciceri F., Corti C., Forcina A.* (Milan, Italy)
PH-P487
HUMAN HERPES VIRUS 6 AFTER ALLOGENEIC HEMATOPOIETIC
Lorentino F., Crucitti L., Vago L., Lupo Stanghellini M. T., Forcina A., Giglio
F., Morelli M., Levati G., Orsini A., Carbone M. R., Valtolina V., Noviello M.,
Marktel S., Assanelli A., Carrabba M., Marcatti M., Peccatori J., Bernardi M.,
Bonini C., Corti C., Ciceri F., Greco R.* (Milano, Italy)
PH-P488
FIDAXOMICIN TREATMENT FOR CLOSTRIDIUM DIFFICILE IN
ALLOGENEIC TRANSPLANT RECIPIENTS
Oksi J., Salmenniemi U., Putkonen M., Kauppila M., Oksman M., Remes K.,
Itälä-Remes M., Salmi T.* (Turku, Finland)
PH-P489
RAPID MOLECULAR DETECTION OF PATHOGENS IN 1941 BLOOD SAMPLES FROM 516 CONSECUTIVE PATIENTS WITH FEBRILE NEUTROPENIA
Mancini N., Lorentino F., Crucitti L., Barbanti M. C., Forcina A., Orsini A., Vago
L., Giglio F., Morelli M., Levati G., Sala E., Clerici D., Lupo Stanghellini M. T.,
Carrabba M., Marktel S., Assanelli A., Marcatti M., Bernardi M., Peccatori J.,
Corti C., Clementi M., Ciceri F., Greco R.* (Milano, Italy)
PH-P490
EBV-REACTIVATION AFTER ALLOGENEIC HSCT - A SINGLE
CENTER SCREENING-EXPERIENCE
Lay A. N., Theobald M., Meyer R. G., Wagner E. M., Wachsmuth-Melm M.*
(Mainz, Germany)
PH-P491
ADENOVIRUS TYPE A31 AS A CAUSE OF AN UNEXPECTED
PERSISTENT INCREASED INCIDENCE OF ADENOVIRAEMIA ON A
STEM CELL TRANSPLANTATION UNIT
Torres B., Alonso L., Moppett J., Cummins M., Cornish J., Muir P., Steward C.,
Sivaprakasam P.* (Bristol, United Kingdom)
PH-P492
ASSESSMENT OF BACTERIAL GUT COLONIZATION PRIOR TO
ALLOGENEIC STEM CELL TRANSPLANTATION AS A TOOL FOR
PREDICTION OF SYSTEMIC INFECTIONS DURING EARLY POSTHSCT
PERIOD
Bilinski J., Rusicka P., Halaburda K., Tormanowska M., Boguradzki
P., Marchel H., Bieńko D., Swoboda-Kopeć E., Wiktor-Jedrzejczak W.,
Paluszewska M., Basak G. W.* (Warsaw, Poland)
PH-P493
PROSPECTIVE STUDY OF ANTI-CMV SPECIFIC IMMUNE RECONSTITUTION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
WITH THE CMV QUANTIFERON METHOD. PRELIMINARY RESULTS.
Gigantes S., Baltadakis I., Xenou E., Xirokosta A., Vlachos P., Apostolidis I.,
Karakasis D., Foundoulis K., Harhalakis N., Grispou I.* (Athens, Greece)
148
Physicians Posters
PH-P494
EFFICACY AND SAFETY OF CMV-SPECIFIC T CELL LINE (CMV-TCL)
FOR CMV REACTIVATIONS IN HIGH RISK ADULT PATIENTS (PTS)
AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
Comoli P., Vai A., Crocchiolo R., Sarina B., Basso S., Mineri R., Santoro A.,
Castagna L., Bramanti S.* (Rozzano, Italy)
HUMAN HERPESVIRUS 6 REACTIVATION ASSOCIATED WITH
DELAYED ENGRAFTMENT AFTER AUTOLOGOUS STEM CELL
TRANSPLANTATION (ASCT) IN HEMATOLOGICAL PATIENTS
Bramanti S., Vai A., Crocchiolo R., Sarina B., Tordato F., Mineri R., Santoro A.,
PH-P496
GAMMA-HERPESVIRUS LOAD AS SURROGATE MARKER OF
PRECOCIOUS DEATH IN HIV-POSITIVE LYMPHOMA PATIENTS
SUBMITTED TO HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS
PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
Zanussi S., Tedeschi R., Bortolin M. T., Talamini R., Rupolo M., Scaini C.,
Basaglia G., Mazzucato M., Abruzzese L., Tirelli U., Zanet E., Michieli M., De
Paoli P., Pratesi C.* (Aviano (Pordenone), Italy)
PH-P497
DAY 30 MORTALITY OF ASYMPTOMATIC HSCT RECIPIENTS WITH
RESPIRATORY VIRUS INFECTION DETECTED BY MULTIPLEX
PCR IN RESPIRATORY SAMPLES TAKEN IMMEDIATELY BEFORE
TRANSPLANTATION.
Souza M. O., Zanetti L. P., Silva P. M., dos Santos A. C. F., Colturato V. R.,
Souza A. C. M., Machado C.* (Jahu, Brazil)
PH-P498
POOR PROGNOSIS OF INVASIVE ASPERGILLOSIS IN PATIENTS
UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION
COMPARED TO THOSE TREATED FOR LEUKEMIA
Dulery R., Regany K., Bouketouche M., Alfandari S., Berthon C., Gauthier J.,
Carpentier B., Van de Wyngaert Z., Magro L., Yakoub-Agha I., Bonnet S.*
(Lille, France)
PH-P499
PROFILE OF TOLL-LIKE RECEPTORS ON MONOCYTES AND
LYMPHOCYTES IN RELATION TO INFECTIOUS COMPLICATIONS
AND OUTCOME IN ALLOGENEIC STEM CELL TRANSPLANTATION
Fogli M., Garrafa E., Perucca S., Fiorentini S., Turra A., Ribolla R., Filì C.,
Bergonzi C., Bernardi S., Malagola M., Cancelli V., Cattina F., Alghisi E.,
Caruso A., Russo D., Skert C.* (Brescia, Italy)
PH-P500
CONSISTENT HHV-6 DNAEMIA POST-ALLO TRANSPLANTATION
IS CHARACTERIZED BY HIGHER LEVELS OF HHV-6 IN THE BLOOD
AND SIGNIFICANTLY HIGHER INCIDENCE OF GVHD AS COMPARED
WITH PATIENTS WITH OCCASIONAL HHV-6 DNAEMIA.
Van Leer Buter C., Riezebos-Brilman A., Niesters H. G., Span L. F.*
(Groningen, Netherlands)
149
Scientific
Programme
Physicians
PH-P495
Physicians Posters
PH-P501
LOW INCIDENCE OF LATE INFECTIONS AFTER STEM CELL
TRANSPLANTATION USING T-CELL REPLETE GRAFT FROM
HAPLOIDENTICAL DONOR AND POST-TRANSPLANT HIGH-DOSE
CYCLOPHOSPHAMIDE SUGGESTS A SATISFACTORY IMMUNE
RECONSTITUTION AFTER TRANSPLANTATION
Bramanti S., Vai A., Sarina B., Mauro E., Carlo-Stella C., Santoro A., Castagna
L., Crocchiolo R.* (Rozzano, Italy)
PH-P502
UTILITY OF POSACONAZOLE MONITORING AND FACTORS
AFFECTING ITS LEVELS IN PATIENTS UNDERGOING
HEMATOPOIETIC STEM CELL TRANSPLANTATION:SINGLE CENTER
EXPERIENCE FROM INDIA
Gurjar M., Pathak K., Bagal B., Gota V., Khattry N., Shetty N., Doshi K. H.*
(Navi Mumbai, India)
PH-P503
SERIAL MONITORING OF BLOOD CONCENTRATION OF
VORICONAZOLE IN ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANT RECIPIENTS
Kato J., Koda Y., Kohashi S., Okamoto S., Mori T.* (Tokyo, Japan)
PH-P504
FUNCTIONAL PATTERNS OF CYTOMEGALOVIRUS (CMV)-SPECIFIC
CD8+ T CELLS THAT ASSOCIATE WITH PROTECTION FROM AND
CONTROL OF CMV DNAEMIA AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION (ALLOSCT)
Giménez E., Amat P., Muñoz-Cobo B., de la Cámara R., Nieto J., López
J., Bravo D., Remigia M. J., Arbona C., Piñana J. L., Navarro D., Solano C.,
Montoro J.* (Valencia, Spain)
PH-P505
HIGHER RISK OF HHV6 REACTIVATION AMONG PATIENTS
UNDERGOING UMBILICAL CORD BLOOD TRANSPLANTATION
Carneiro T. X., Kerbauy F. R., Hamerschlack N., Novis Y., Seber A., Rodrigues
C. A., Ueda M., Real J. M., Moreira E. S., Oliveira J. S., Granato C., Goncalves M.
V., Oliveira P. G. A.* (Sao Paulo, Brazil)
PH-P506
EBV DETECTED VIRAL LOAD IN PERIPHERAL BLOOD OF DONORS
AT THE TIME OF TRANSPLANT HAS NO IMPACT ON EBVLYMPHOPROLIFERATIVE DISEASE DEVELOPMENT IN RECIPIENTS
Papalexandri A., Batsis I., Mallouri D., Marvaki A., Touloumenidou A., Xocheli
A., Afisidis A., Zerva P., Tsorlini E., Yannaki E., Anagnostopoulos A., Sakellari
I.* (Thessaloniki, Greece)
PH-P507
CIPROFLOXACIN PROPHYLAXIS REDUCES THE INCIDENCE OF
SEVERE BK HEMORRHAGIC CYSTITIS IN CORD BLOOD PLUS
THIRD-PARTY DONOR DUAL TRANSPLANT RECIPIENTS. A
SINGLE-CENTRE EXPERIENCE.
Arnan M., Fernández de Sevilla A., Gudiol C., Duarte R. F., Patiño B.,
Sánchez-Ortega I.* (Barcelona, Spain)
150
Physicians Posters
PH-P508
NON-ASPERGILLUS (NA), NON-MUCORALES (NM) INVASIVE
MOLD INFECTIONS IMI IN RECIPIENTS OF HEMATOPOIETIC CELL
TRANSPLANTATION (HCT)
Tegtmeier B. R., Kriengkauykiat J., Ito J. I., Dadwal S. S.* (Duarte, United
States)
ADENOVIRUS INFECTION IN Paediatric ALLOGENEIC HSCT:
IMPACT OF A VIRO-IMMUNOLOGICAL MONITORING AND
PREEMPTIVE TREATMENT STRATEGY ON OUTCOME
Introzzi F., Tolva A., Basso S., Guido I., Quartuccio G., Mina T., Pellerano
A., Grignano M. A., Calafiore L., Cugno C., Baldanti F., Zecca M., Comoli P.,
Rubert L.* (Pavia, Italy)
PH-P510
SURVEY OF CURRENT PRACTICES USED FOR PREVENTION OF
CENTRAL VENOUS CATHETER ASSOCIATED INFECTION (CLABSI) IN
HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS.
Mank A., Iacobelli S., Hoek J., Styczyński J., Cesaro S., Johansson E., Snarski
E.* and Infectious Diseases Working Party of EBMT (Warszawa, Poland)
PH-P511
BLOOD STREAM INFECTIONS CAUSED BY MULTI-DRUGRESISTANT BACTERIA IN HEMATOLOGIC AND HSCT PATIENTS
Simeone E., Lazzarotto D., Zanini F., Scarparo C., Fanin R., Candoni A.,
Zannier M. E.* (Udine, Italy)
PH-P512
RELIABLE ASSAY FOR MONITORING CMV-SPECIFIC T CELL
IMMUNITY FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANTATION
Pan D., Halgreen C., Hahn T., Pedersen H., Wallace P., Brix L.* and Philip
Mcarthy, Dalin Pan, Kivin Jacobsen, Yali Zhang, Joseph Tario (Copenhagen,
Denmark)
151
Scientific
Programme
Physicians
PH-P509
Physicians Posters
Multiple myeloma - Tuesday, 1 April 2014
PH-P513
NON-MYELOABLATIVE ALLOGRAFTS IN MULTIPLE MYELOMA:
TIME FOR A RE-LOOK?
Shipton M. J., Bodagh N., Tholouli E., Dignan F., Woodward J., Rodriguez O.
R., Waller M., Gibbs S. D.* (Manchester, United Kingdom)
PH-P514
HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL
TRANSPLANTATION IN MULTIPLE MYELOMA WITH RENAL
FAILURE
Mendeleeva L., Urnova E., Firsova M., Nareyko M., Kuzmina L., Rekhtina I.,
Tauson I., Varlamova E., Parovichnikova E., Savchenko V., Pokrovskaya O.*
(Moscow, Russian Federation)
PH-P515
PERSISTENCE OF EXTRAMEDULLARY DISEASE BY PET/CT IS
AN INDEPENDENT PREDICTOR OF ADVERSE OUTCOME AFTER
ALLOGENEIC TRANSPLANT IN MULTIPLE MYELOMA
Carobolante F., Zamagni E., Montefusco V., Bruno B., Englaro E., Isola M.,
Buttignol S., Stocchi R., Corradini P., Cavo M., Fanin R., Patriarca F.* (Udine,
Italy)
PH-P516
OUTCOME AFTER ALLOGENEIC STEM-CELL TRANSPLANTATION
WITH REDUCED-INTENSITY CONDITIONING IN PATIENTS WITH
MULTIPLE MYELOMA.
Moreau P., Chevallier P., Guillaume T., Delaunay J., Peterlin P., Mohty M.,
Bourcier J.*, Malard F. (Nantes, France)
PH-P517
BEAM VS MELPHALAN BASED CONDITIONING THERAPY FOR
SECOND AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) FOR
MULTIPLE MYELOMA (MM)
Jain T., Deol A., Kim S., Dyson G., Uberti J., Abidi M., Veeraputhiran M.*
(Detroit, United States)
PH-P518
VERY LOW RATE OF RE-ADMISSION AFTER AN EARLY
DISCHARGE OUTPATIENT MODEL FOR AUTOGRAFTING IN
MULTIPLE MYELOMA PATIENTS: AN ITALIAN MULTI-CENTER
RETROSPECTIVE STUDY
Montanari M., Ferrara F., Ciceri F., Scortechini I., Console G., Messina G.,
Irrera G., Palmieri S., Marktel S., Cimminiello M., Castagna L., Milone G.,
Offidani M., Tripepi G., Bruno B., Lemoli R. M., Rambaldi A., Olivieri A.,
Martino M.* and on behalf of “Gruppo Italiano per il Trapianto di Midollo
Osseo, Cellule staminali emopoietiche e terapia cellulare” (GITMO) - Sezione
Trapianto Autologo (Reggio Calabria, Italy)
PH-P519
PHASE I/II TRIAL OF LENALIDOMIDE AND HIGH-DOSE
MELPHALAN AS PREPARATIVE REGIMEN FOR RELAPSED
MYELOMA
Thall P., Fox P., Shah N., Bashir Q., Shah J., Parmar S., Kebriaei P., Nieto
Y., Dinh Y., Popat U., Hosing C., Lin P., Shpall E., Orlowski R., Champlin R.,
Afrough A., Qazilbash M.* (Houston, United States)
152
Physicians Posters
PH-P520
AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN
LIGHT CHAIN AMYLOIDOSIS (AL) WITH RENAL INVOLVEMENT
Saliba R. M., Dinh Y., Ahmed S., Nieto Y., Bashir Q., Shah N., Howell J., Parmar
S., Hosing C., Popat U., Shpall E., Champlin R., Qazilbash M., Cornelison A.
M.* (Houston, United States)
(AUTO-HCT) FOR MULTIPLE MYELOMA (MM) IN THE INPATIENT
(INPT) VS. OUTPATIENT (OUTPT) SETTINGS
Saliba R. M., Dinh Y., Ahmed S., Nieto Y., Bashir Q., Shah N., Parmar S.,
Hosing C., Popat U., Shpall E., Champlin R., Qazilbash M., Cornelison A. M.*
(Houston, United States)
PH-P522
REDUCED INTENSITY ALLOGENEIC TRANSPLANTATION IN
MULTIPLE MYELOMA
Matthews J., Guy A., Farrell M., Taussig D., Smith M., Oakervee H., Cavenagh
J., Gribben J., Hassan S.* (London, United Kingdom)
PH-P523
THE ASSOCIATION BETWEEN COX-2 EXPRESSION AND SURVIVAL
IN MYELOMA PATIENTS
Hekimgil M., Cagirgan S., Donmez A., Tombuloglu M., Soyer N., Vural F.*
(Izmir, Turkey)
PH-P524
ALLOGENEIC TRANSPLANTATION AFTER 8 GY TBI/
CYCLOPHOSPHAMIDE CONDITIONING IN PATIENTS WITH
ADVANCED MULTIPLE MYELOMA - A RETROSPECTIVE SINGLE
CENTER ANALYSIS.
Bondong A., Goldschmidt H., Neben K., Ho A. D., Dreger P., Hegenbart U.,
Herfarth K., Schmitt T., Schoenland S.* (Heidelberg, Germany)
PH-P525
INDUCTION OF PROLIFERATION AND SURVIVAL OF MULTIPLE
MYELOMA CELLS BY CD137 LIGAND REVERSE SIGNALING
Fu C., Liu H., Wang J., Ma L., Ju S., Wu D.* (Suzhou, China)
PH-P526
T CELL REPLETE HAPLOIDENTICAL TRANSPLANTATION FOR
REFRACTORY MULTIPLE MYELOMA USING NONMYELOABLATIVE
CONDITIONING AND HIGH-DOSE POST TRANSPLANT
CYCLOPHOSPHAMIDE
Bramanti S., Vai A., El Cheikh J., Furst S., Crocchiolo R., Sarina B., Harbi S.,
Granata A., Mauro E., Stoppa A. M., Carlo-Stella C., Santoro A., Blaise D.,
PH-P527
INFLUENCE OF ASCT ON DURATION OF RESPONSE (DOR) AND
OVERALL SURVIVAL (OS) OF PATIENTS WITH REFRACTORY OR
RELAPSED MULTIPLE MYELOMA TREATED BY CASE-ADJUSTED
BORTEZOMIB-BASED SALVAGE REGIMENS - A REPORT BY THE
POLISH MYELOMA STUDY GROUP
Walter-Croneck A.* and Polish Myeloma Study Group (Lublin, Poland)
153
Scientific
Programme
Physicians
PH-P521
Physicians Posters
PH-P528
CONTINUOUS MAINTENANCE THERAPY WITH ALTERNATE-DAY
LOW DOSE LENALIDOMIDE IN MULTIPLE MYELOMA PATIENTS
AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION INCREASES
THE NUMBER OF CIRCULATING NATURAL KILLER CELLS
Ferrara I., Rocco M., Fontana R., Annunziata S., Sessa M., Giudice V., Villani
G., Esposito B., Selleri C., Serio B., Pezzullo L.* (Salerno, Italy)
PH-P529
AUTOLOGOUS STEM CELL TRANSPLANTATION IN THE
TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA- OUR
EXPERIENCE
Stamatovic D., Elez M., Balint B., Tarabar O., Madjaru L., Zivanovic Ivic A.,
Tatomirovic Z., Tukic L., Marjanovic S.* (Belgrade, Serbia)
PH-P530
SURVIVAL ANALYSIS IN PATIENTS WITH MULTIPLE
MYELOMA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION, A SINGLE CENTER STUDY
Bunjes D., von Harsdorf S., Müller L., Langer C., Greiner J., Liebisch P., Döhner
H., Hofmann S.* (Ulm, Germany)
PH-P531
THIOTEPA-BASED CONDITIONING FOLLOWED BY ALLOGENEIC
SCT IN PATIENTS WITH MULTIPLE MYELOMA A SURVEY OF THE
CHRONIC MALIGNANCIES WORKING PARTY OF EBMT
Iacobelli S., van Biezen A., Garderet L., Kröger N.* and CMWP (Hamburg,
Germany)
PH-P532
“REAL WORLD DATA” ON CLINICAL FEATURES, PROGNOSIS AND
POST AUTOLOGOUS HAEMOPOETIC STEM CELL TRASPLANTATION
(AHCT) SURVIVAL IN MULTIPLE MYELOMA IN THE ERA OF
NOVEL AGENTS: A REPORT OF THE HELLENIC SOCIETY OF
HAEMATOLOGY IN 489 PATIENTS
Pouli A., Terpos E., Mallouri D., Eleutherakis-Papaiakovou E., Giannopoulou
E., Apostolou C., Kotsopoulou M., Delimpasi S., Symeonidis A., Batsis I.,
Kaloyiannidis P., Vardaka M., Christoulas D., Papadopoulou A., Verrou E.,
Konstantinidou P., Anagnostopoulos A., Dimopoulos M.-A., Sakellari I.,
Katodritou E.* (Thessaloniki, Greece)
PH-P533
SINGLE CENTRE EXPERIENCE OF AUTOLOGOUS STEM CELL
TRANSPLANT FOR MULTIPLE MYELOMA AND AL AMYLOIDOSIS IN
DIALYSIS DEPENDENT PATIENTS
Gibbs S., Waller M., Woodward J., Dignan F., Tholouli E., Alimam S.*
(Manchester, United Kingdom)
PH-P534
LONG-TERM FOLLOW-UP OF ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION FOR MULTIPLE MYELOMA PATIENTS
Lopez-Corral L., Bastida J. M., Garcia-Sanz R., Mateos M. V., SanchezGuijo F., Vazquez L., del Cañizo C., Caballero D., Lopez-Parra M., Labrador
J., Perez-Lopez E., Caballero T., Ocio E. M., Gutierrez N., Perez-Simon J. A.,
Cabrero M., Lopez-Godino O.* (Salamanca, Spain)
154
Physicians Posters
PH-P535
A SECOND VACCINATION AGAINST INFLUENZA VIRUS IMPROVES
IMMUNE RESPONSES IN PATIENTS WITH MULTIPLE MYELOMA
Hahn M., Goldschmidt H., Ho A. D., Schnitzler P., Schweiger B., Michael S.*
(Heidelberg, Germany)
PH-P536
MRD NEGATIVITY PROLONGS PFS BUT NOT OS AFTER UPFRONT AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
PH-P537
ALLOREACTIVE NK CELL THERAPY IN THE RAG2-/--/- MULTIPLE
MYELOMA MODEL
Sarkar S., Wieten L., Martens A., Noort W., Groen R., Bos G.* (Maastricht,
Netherlands)
Paediatric issues - Tuesday, 1 April 2014
PH-P538
TCR-ALPHA/BETA-DEPLETED HSCT IN PATIENTS WITH PRIMARY
IMMUNODEFICIENCY DISEASES
Maschan M., Skvortsova Y., Shelikhova L., Gutovskaya E., Shasheleva
D., Shipitsina I., Ilushina M., Shekhovtsova Z., Tzetlina V., Khismatullina
R., Tatarinova O., Novichkova G., Maschan A., Kurnikova E., Boyakova E.,
Levadniy A., Muzalevsky J., Balashov D.* (Moscow, Russian Federation)
PH-P539
SUBSTANTIAL RATE OF MIXED CHIMERISM AFTER TREOSULFANBASED CONDITIONING IN CHILDREN WITH NON-MALIGNANT
DISEASES
Schuster F., Meisel R., Siepermann M., Borkhardt A., Babor F., Friemann V.,
Schmidt E., Fouz H.* (Duesseldorf, Germany)
PH-P540
UK EXPERIENCE OF UNRELATED CORD BLOOD
TRANSPLANTATION IN PAEDIATRIC PATIENTS
Danby R., Vora A., Slatter M., Wynn R., Lawson S., Steward C., Gibson B.,
Potter M., de la Fuente J., Shenton G., Cornish J., Gennery A., Snowden J.,
Bonney D., Velangi M., Ruggeri A., Gluckman E., Hough R., Rocha V., Veys P.*
and on behalf of Eurocord and BSBMT (London, United Kingdom)
PH-P541
CIDOFOVIR FOR HUMAN ADENOVIRUS INFECTIONS AFTER Paediatric HEMATOPOIETIC STEM CELL TRANSPLANTATION: LIMITED
EFFECT ON VIRAL LOAD DESPITE CONSIDERABLE NEPHROTOXICITY
Oomen M. A., Jol-van der Zijde C. M., Ball L. M., Bresters D., Kollen W. J.,
Smiers F. J., Vermont C. L., Bredius R. G., Sukhai R. N., Schilham M. W., Van
Tol M. J., Lankester A. C., Lugthart G.* (Leiden, Netherlands)
PH-P542
OUTCOMES AFTER A SEQUENTIAL CLOFARABINE AND
CYTARABINE-BASED CHEMOTHERAPY FOLLOWED BY REDUCEDINTENSITY CONDITIONING AND ALLOGENEIC STEM CELL
TRANSPLANTATION IN CHILDREN WITH PRIMARY REFRACTORY
OR RELAPSED ACUTE MYELOID LEUKEMIA: A PILOT STUDY.
Sirvent A., Marion S., Méchinaud F., Mohty M., Guillaume T., Chevallier P.,
Rialland F., Grain A.* (NANTES, France)
155
Scientific
Programme
Physicians
Hirviniemi M., Kairisto V., Juvonen V., Kauppila M., Salmenniemi U., Salmi T.,
Itälä-Remes M., Remes K., Putkonen M.* (Turku, Finland)
Physicians Posters
PH-P543
A PRELIMINARY POPULATION PHARMACOKINETIC MODEL FOR
DOSE SELECTION OF TREOSULFAN USED IN CONDITIONING
TREATMENT PRIOR TO HAEMATOPOIETIC STEM CELL
TRANSPLANTATION (HSCT) IN CHILDREN.
Ruppert M., Scheulen M. E., Wachowiak J., Nemecek E. R., Lioznov M.,
Spaans E., Pichlmeier U., Wullf B., Baumgart J., Beelen D. W., Hilger R. A.,
Sykora K.-W., Beier R., Van Den Berg P. J.* (Breda, Netherlands)
PH-P544
IMPACT OF A CHANGE IN PROTECTED ENVIRONMENT ON THE
OCCURRENCE OF SEVERE BACTERIAL AND FUNGAL INFECTIONS
IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Domenech C., Bacchetta J., Bertrand Y., Ploton C., Bienvenu A. L., Mialou V.,
Galumbrun C., Libbrecht C.* (Lyon, France)
PH-P545
BLINATUMOMAB IN Paediatric PATIENTS WITH RELAPSED/
REFRACTORY (R/R) B-CELL PRECURSOR ACUTE LYMPHOBLASTIC
LEUKAEMIA (BCP-ALL): A PHASE I/II STUDY
Gore L., Zugmaier G., Handgretinger R., Rizzari C., Trippett T. M., Borkhardt
A., Rheingold S. R., Bader P., Bhojwani D., Cooper T. M., DuBois S. G., O’Brien
M. M., Zwaan C. M., Holland C., Mergen N., Fischer A., Zhu M., Hijazi Y.,
Whitlock J., von Stackelberg A., Locatelli F.* (Rome, Italy)
PH-P546
MESENCHYMAL STEM CELL TREATMENT FOR STEROID
RESISTANT GRAFT-VERSUS-HOST DISEASE IN CHILDREN
Atay D., Akcay A., Ovali E., Ozturk G., Erbey F.* (Istanbul, Turkey)
PH-P547
PREVALENCE AND SEVERITY OF LATE EFFECTS AFTER
ALLOGENEIC HSCT FOR HAEMATOLOGICAL MALIGNANCIES IN
CHILDREN TRANSPLANTED UNDER THE AGE OF THREE YEARS.
Lawitschka A., Duarte R., Rovo A., Peters C., Bresters D.* and Complications
& Quality of life and Paediatric Diseases Working Parties (Leiden,
Netherlands)
PH-P548
VIRAL INFECTIONS IN CHILDREN AND ADOLESCENTS AFTER
HEMATOPOIETIC STEM CELL TRANSPLANTATION: SINGLE CENTER
10 YEAR EXPERIENCE.
Fernández Navarro J. M., Fuentes Socorro C., Andrés Moreno M. D. M.,
Verdeguer A., Escobar Pirela H. D.* (Valencia, Spain)
PH-P549
REDUCED INTENSITY CONDITIONING REGIMEN AND ALLOGENEIC
STEM CELL TRANSPLANTATION FROM RELATED OR UNRELATED
HLA IDENTICAL DONOR IN ADVANCED EWING SARCOMA.
Rondelli R., Luksch R., Pession A., Locatelli F., Fagioli F., Prete A.* (Bologna,
Italy)
PH-P550
156
INFUSION-RELATED FEBRILE REACTION:RISK FACTOR
FOR ENGRAFTMENT SYNDROME FOLLOWING PAEDIATRIC
HAPLO-IDENTICAL ALLOGENEIC HEMATOPOIETIC STME CELL
TRANSPLANTATION
Huang X. J., Xu L. P., Wang F. R., Wang Y., Chen Y.* (Beijing, China)
Physicians Posters
PH-P551
HOME-CARE DURING NEUTROPENIA AFTER ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN
AND ADOLESCENTS IS SAFE AND MAY BE ADVANTAGEOUS TO
ISOLATION IN THE HOSPITAL
PH-P552
THE PHARMACOKINETIC PROFILE OF TREOSULFAN
IN Paediatric PATIENTS UNDERGOING ALLOGENEIC
Bredius R., Zwaveling J., Smiers F., den Hartigh J., Guchelaar H.-J., Lankester
A., Ten Brink M.* and Paediatric diseases and Inborn Errors (Leiden,
Netherlands)
PH-P553
MONONUCLEAR CELL COLLECTION USING THE OPTIA FOR
CHILDREN WEIGHING LESS THAN 12.5 KG
Comey N., Smith O., O’Marcaigh A.* (Dublin, Ireland)
PH-P554
FAISABILITY OF OVARIAN TISSUE CRYOPRESERVATION IN
PAEDIATRICS BEFORE TRANSPLANTATION: A GAMBLE ON THE
FUTURE
Chambon F., Gremeau A. S., Brugnon F., Pouly J. L., Janny L., Merlin E.,
Rochette E., Doré E., Isfan F., Deméocq F., David A., Kanold J.* (Clermont
Ferrand, France)
PH-P555
RESULTS OF HEMATOPOIETIC STEM CELL TRANSPLANTATION
FOR PRIMARY IMMUNODEFICIENCIES IN CHILDREN IN MEXICO: A
MULTICENTRIC REPORT
Perez-Garcia M., González-Ramella O., Olaya-Vargas A., Aguilar-Escobedo
D., Flores-Cacho T. D. L., Orozco-Alvarado A. L., Gonzalez-Llano O., ManciasGuerra C., del Campo-Martinez M. D. L. A., Montero-Ponce I., Gaytan
-Morales F., Pompa-Garza M. T., Muñoz-Ronquillo T., Amador-Sanchez R.,
Ortiz-Sandoval M., Navarro-Martin del Campo R.* and Asociación Mexicana
de trasplante de células hematopoyéticas y terapia celular pediátrica
(Guadalajara, Mexico)
PH-P556
THE RECENT SINGLE CENTRE EXPERIENCE WITH Paediatric
SOLID TUMORS OF A NEW STEM CELL TRANSPLANTATION AND
CELL THERAPY UNIT
Cabañas V., Blanquer M., Sánchez-Salinas A., Monserrat-Coll J., PascualGázquez J. F., Galera A., Llinares E., Bermúdez-Cortés M., Moraleda J. M.,
Fuster J. L.* (Murcia, Spain)
PH-P557
MAJOR ABO INCOMPATIBLE BONE MARROW TRANSPLANTATION
IN CHILDREN: DETERMINING WHAT RESIDUAL VOLUME OF
DONOR RED CELLS CAN SAFELY BE INFUSED FOLLOWING RED
CELL DEPLETION.
Lau W., Gassas A., McDougall E., Ali M., Egeler M., Schechter Finkelstein T.,
Doyle J., Courtney S., Patrick K.* (Toronto, Canada)
157
Scientific
Programme
Physicians
Remberger M., Törlen J. K., Engström M., Fjaertoft G., Mattsson J., Svahn
B.-M., Ringdén O.* (Stockholm, Sweden)
Physicians Posters
PH-P558
COMMON GAMMA CHAIN- AND JAK3-DEFICIENT SCID,
CONDITIONED VERSUS UNCONDITIONED TRANSPLANT: A SINGLE
CENTRE EXPERIENCE
Nademi Z., Leahy T., Brigham K., Barge D., Hambleton S., Abinun M., Flood
T., Cant A., Slatter M., Gennery A., Kharya G.* (Newcastle upon Tyne, United
Kingdom)
PH-P559
HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR
RAG1/2 SEVERE COMBINED IMMUNODEFICIENCY OR OMENN
SYNDROME: A SINGLE CENTRE EXPERIENCE
Nademi Z., Hambleton S., Abinun M., Flood T., Cant A., Slatter M., Brigham
K., Barge D., Gennery A., Elfeky R.* (Newcastle upon Tyne, United Kingdom)
PH-P560
ANTI-THYMOCYTE GLOBULIN (ATG) EXPOSURE IS RELATED TO
OVERALL SURVIVAL IN CHILDREN RECEIVING ALLOGENEICHEMATOPOIETIC CELL TRANSPLANTATION (HCT): TOWARDS
INDIVIDUALIZED DOSING TO IMPROVE SURVIVAL
Jol-van der Zijde C., van Kesteren C., van Tol M., Knibbe C., Bredius R.,
Boelens J. J., Admiraal R.* (Utrecht, Netherlands)
PH-P561
INTERIM ANALYSIS OF THE RANDOMIZED PROSPECTIVE
EXERCISE THERAPY STUDY IN THE Paediatric STEM CELL
TRANSPLANTATION (BISON)
Arndt S., Bader P., Siegler K., Klingebiel T., Rosenhagen A., Banzer W., SennMalashonak A.* (Frankfurt am Main, Germany)
PH-P562
NON-TBI CONDITIONING FOR CHILDREN WITH ALL BEFORE FIRST
ALLOGENEIC HSCT
Zubarovskaya N., Diaz de Heredia C., Locatelli F., Dalle J.-H., Bader P.,
Wachowiak J., Yesilipek A., Peters C.* (Vienna, Austria)
PH-P563
CONGENITAL DISORDERS. A SINGLE CENTRE EXPERIENCE.
Morreale G., Giardino S., Bagnasco F., Terranova P., Di Martino D., Di Rocco
M., Lanino E., Faraci M.* (Genova, Italy)
PH-P564
CLOFARABIN/FLUDARABIN + EXPOSURE-TARGETED BUSULFAN
IN MYELOID AND LYMPHOBLASTIC LEUKEMIAS IN CHILDREN:
FIRST RESULTS OF A DUTCH NATIONAL COHORT
Boelens J., Versluys B., Kollen W., Bredius R., Lankester A., Bierings M.*
PH-P565
IN CONGENITAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS:
17-YEARS SINGLE Paediatric CENTRE EXPERIENCE
Faraci M., Morreale G., Bagnasco F., Micalizzi C., Marcenaro S., Lanino E.,
Giardino S.* (Genoa, Italy)
158
Physicians Posters
PH-P566
SINGLE CENTRE RETROSPECTIVE ANALYSIS OF 34 PATIENTS
WITH X-SCID TRANSPLANTED WITH PARENTAL HLAHAPLOIDENTICAL GRAFTS
PH-P567
IMMUNE RECONSTITUTION AFTER HAEMATOPOIETIC STEM CELL
TRANSPLANTATION WITH TCR ΑLFA/BETA AND CD19 DEPLETION
IN CHILDREN WITH NON MALIGNANT DISEASES. A SINGLE
CENTRE EXPERIENCE.
mainardi C., pillon M., calore E., gazzola M. V., strano A., destro R., varotto S.,
putti M. C., sainati L., basso G., messina C., Tumino M., boaro M. P.* (padova,
Italy)
PH-P568
BUSULFAN-BASED MYELOABLATIVE PREPARATIVE REGIMENS
FOR Paediatric AML RESULT IN EXCELLENT OUTCOMES AT DAY
100
Logan B., Fei M., Pulsipher M. A., Navarro W., Jacobsohn D. A.* and on
behalf of the 09-MRD study team (Washington, United States)
PH-P569
IS HEPCIDIN A BETTER MARKER OF IRON OVERLOAD IN
CHILDREN TREATED WITH HEMATOPOIETIC STEM CELL
TRANSPLANTATION?
Gożdzik J., Drabko K., Woźniak M., Kowalczyk J. R., Zaucha-Prażmo A.*
(Lublin, Poland)
PH-P570
ANTIFUNGAL PROPHYLAXIS WITH POSACONAZOLE VS.
FLUCONAZOLE OR ITRACONAZOLE IN PAEDIATRIC PATIENTS
WITH NEUTROPENIA
Eikemeier M., Schulz A., Hartmann U., Schwarze C. P., Ebinger M.,
Handgretinger R., Müller I., Döring M.* (Tübingen, Germany)
PH-P571
VALIDATION OF A TEST DOSE STRATEGY FOR ADMINISTERING
INTRAVENOUS BUSULFAN IN THE SETTING OF PAEDIATRIC
MYELOABLATIVE STEM CELL TRANSPLANTATION: CLINICAL AND
PHARMACOKINETIC RESULTS
Okamoto Y., Tanabe T., Kurauchi K., Kawano Y., Kodama Y., Shinkoda Y.,
Nakagawa S., Abematsu T., Nishikawa T.* (Kagoshima, Japan)
PH-P572
TANDEM HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM
CELL RESCUE IN HIGH RISK NEUROBLASTOMA PATIENTS: A
SINGLE CENTER EXPERIENCE
Kim H., Lee J. W., Park K. D., Shin H. Y., Ahn H. S., Kim S. J.* (Seoul, Korea,
Republic Of)
PH-P573
THYMOGLOBULINE IN EFFICIENT EXPANSION OF CYTOKINEINDUCED KILLER (CIK) CELLS AND POSSIBILITY OF CIK CELL
CLINICAL APPLICATION IN POSTTRANSPLANT SETTING.
Rybka B., Ryczan R., Noworolska-Sauren D., Ussowicz M., Kalwak K.,
Mielcarek M.* (Wroclaw, Poland)
159
Scientific
Programme
Physicians
Schulz A., Schuetz C., Furlan I., Wiesneth M., Debatin K.-M., Friedrich W.,
Hoenig M., Kleila D.* (Ulm, Germany)
Physicians Posters
PH-P574
REDUCED INTENSITY CONDITIONING HAPLOIDENTICAL BONE
MARROW TRANSPLANTATION WITH A POST-INFUSION
CYCLOPHOSPHAMIDE APPROACH IS FEASIBLE AND ENABLES
FULL DONOR ENGRAFTMENT FOR CHILDREN SUFFERING FROM
SICKLE CELL DISEASE.
Harrington Y., O’Boyle F., Killeen N., O’Brien N., Warner E., Chakravorty S.,
Karnik L., de la Fuente J., Katsarou A.* (London, United Kingdom)
PH-P575
INTERNATIONAL STUDY ON OUTCOMES OF HAEMATOPOIETIC
STEM CELL TRANSPLANT FOR DNA-DSB REPAIR DEFECTS.
Slatter M. A., Gaspar B., Albert M., Ghosh S., Meisel R., Guengoer T., Drabko
K., Karasu G., Lange A., Kalwak K., Pasic S., Heilmann C., Imai K., Shaw P.,
Schultz K., Eapen M., Horwitz E., Gennery A. R., Slack J.* and IEWP EBMT,
CIBMTR (Newcastle upon Tyne, United Kingdom)
PH-P576
VORICONAZOLE AS ANTIFUNGAL PROPHYLAXIS DURING
NEUTROPENIC PHASE IN CHILDREN UNDERGOING ALLOGENEIC
Buenasmañanas D., García-Torres E., Rodríguez-Villa A., Rojas R., Martín C.,
Serrano J., Gómez P., Molina J. R.* (Córdoba, Spain)
PH-P577
SUCCESSFUL TREATMENT FOR SECONDARY AML AND MDS
FOLLOWING MYELOABLATIVE HEMATOPOETIC STEM CELL
TRANSPLANTATION FOR CHILDREN, ADOLESCENTS AND YOUNG
ADULTS
Cooper L., Tarek N., Worth L. L., Petropoulis D., Lee D. A., Champlin R. E.,
Rondon G., Tewari P., Maher O.* (Houston, United States)
PH-P578
ANESTHESIA FOR BRONHOSCOPY IN PAEDIATRIC PATIENTS
AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION AND
HIGH DOSE CHEMOTHERAPY
Lazarev A., Goncharova E., Zinnatullin I., Volkova A., Kozlov A., Bogomolniy
M., Zubarovskaya L., Afanasyev B., Bochishcheva M.* (St Petersburg, Russian
Federation)
PH-P579
CURRENT RESULTS WITH TRANSPLANTATION OF TCRΑΒ/CD19
DEPLETED STEM CELLS FROM HAPLOIDENTICAL DONORS IN
CHILDREN
Feuchtinger T., Teltschik H.-M., Schumm M., Schlegel P., Pfeiffer M., Ebinger
M., Schwarze C.-P., Handgretinger R., Lang P.* (Tuebingen, Germany)
PH-P580
LOW DOSE CYCLOPHOSPHAMIDE AND FLUDARABINE-BASED
CONDITIONING REGIMEN FOR PAEDIATRIC MATCHED RELATED
DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION IN
SEVERE APLASTIC ANEMIA
Balashov D., Trakhtman P., Maschan M., Novichkova G., Roumyantsev A.,
Maschan A., Kirgizov K., Skorobogatova E.* (Moscow, Russian Federation)
160
Physicians Posters
PH-P581
COMPARISON OF TWO DOSES OF ANTITHYMOCYTE GLOBULIN IN
PAEDIATRIC PATIENTS WITH APLASTIC ANEMIA WHO RECEIVED
ALLOGENEIC BONE MARROW TRANSPLANTATION
Uchida N., Takahashi S., Ohno Y., Kouzai Y., Kanamori H., Mori S., Nagamura
T., Kato K., Murata M., Suzuki R., Atsuta Y., Kojima S., Yabe H.* (Isehara,
Japan)
LEFLUNOMIDE TREATMENT FOR THE BK VIRUS-ASSOCIATED
HEMORRHAGIC CYSTITIS IN ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTATION RECIPIENTS: REPORT OF TWO
PAEDIATRIC CASES FROM A SINGLE-CENTRE
Scientific
Programme
Physicians
PH-P582
EKER I., BABACAN O., IRKILATA H. C., KARAMAN B., KOC O., KUREKCI A. E.,
GURSEL O.* (Ankara, Turkey)
PH-P583
A TOTAL LYMPHOID IRRADIATION (TLI) BASED REDUCED
INTENSITY CONDITIONING REGIMEN FOR CHILDREN AND
ADOLESCENTS UNDERGOING HEMATOPOIETIC STEM CELL
TRANSPLANT FOR HIGH-RISK NON-MALIGNANT DISORDERS
Al-Mousa A., Al-Zaben A., Frangoul H., Hussein A. A.* (Amman, Jordan)
PH-P584
PHARMACOKINETICS OF HIGH DOSE INTRAVENOUS TREOSULFAN
IN CHILDREN PRIOR TO ALLOGENEIC HCT
Winter R., Nademi Z., Standing J., Amrolia P., Veys P., Silva J., Nikolajeva
O., Prunty H., Heales S., Gennery A., Slatter M., Chiesa R.* (London, United
Kingdom)
PH-P585
TCR-ALPHA/BETA+/CD19+-DEPLETION IN HEMATOPOIETIC STEM
CELLS TRANSPLANTATION FROM MATCHED UNRELATED AND
HAPLOIDENTICAL DONORS IN PAEDIATRIC ACUTE LEUKEMIA
PATIENTS
Shelikhova L., Tatarinova O., Balashov D., Kurnikova E., Boyakova E.,
Bobrynina V., Skvortsova Y., Ilushina M., Shipitsina I., Shasheleva D.,
Shekhovtsova Z., Novichkova G., Maschan A., Maschan M.* (Moscow, Russian
Federation)
PH-P586
HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN
CHILDREN WITH ACUTE LEUKEMIA - REMISSION STATUS AT
TRANSPLANTATION PREDICTS OUTCOME
Dykes J., Lenhoff S., Bekassy A. N., Toporski J., Turkiewicz D.* (Lund, Sweden)
PH-P587
RETRANSPLANTATION WITH HAPLOIDENTICAL T CELL DEPLETED
GRAFTS AFTER 7 GRAY (GY) TOTAL NODAL IRRADIATION (TNI)BASED RECONDITIONING AFTER GRAFT FAILURE IN PAEDIATRIC
PATIENTS
Heinzelmann F., Feuchtinger T., Handgretinger R., Lang P., Teltschik H.-M.*
(Tübingen, Germany)
161
Physicians Posters
PH-P588
AUTOIMMUNE HEMOLYTIC ANEMIA AFTER HEMATOPOIETIC
STEM CELL TRANSPLANTATION: REVIEW OF NINE CASES.
RUBIO P. M., CORRAL D., ALONSO T., BUENO D., GONZALEZ B., PLAZA D.,
RIESCO S., SASTRE A.* (Madrid, Spain)
PH-P589
HEMATOPOIETIC STEM CELL TRANSPLANTATION FOLLOWING
CONDITIONING WITH BUSULFAN, CYCLOPHOSPHAMIDE
AND MELPHALAN IN CHILDREN WITH THERAPY RELATED
MYELODYSPLASTIC SYNDROME
Ammann R., Truckenmüller W., De Moerloose B., Dworzak M., Hasle H.,
Schmugge M., Starý J., van den Heuvel-Eibrink M., Zecca M., Masetti R.,
Noellke P., Locatelli F., Niemeyer C., Strahm B., Yoshimi A.* and of the
European Working Group of MDS in Childhood (EWOG-MDS) (Freiburg,
Germany)
PH-P590
A PILOT STUDY OF POST-TRANSPLANT DECITABINE IN CHILDREN
WITH HEMATOLOGIC MALIGNANCIES
Shelikhova L., Balashov D., Skvortsova Y., Novichkova G., Maschan A.,
Gutovskaya E., Tsetlina V., Khismatullina R., Ilushina M., Shasheleva D.,
Maschan M.* (Moscow, Russian Federation)
PH-P591
A SINGLE CENTER EXPERIENCE WITH ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACQUIRED
SEVERE APLASTIC ANAEMIA IN CHILDHOOD
Eker N., Tayfun F., Hazar V., Yesilipek M., Hos P., Yasar A., Dogru Ö., Kupesiz
O., Guler E.* (Antalya, Turkey)
PH-P592
HAPLOIDENTICAL HSCT MAY PROVIDE THE POTENTIAL OF
ALLOREACTIVE NK CELLS IN NEUROBLASTOMA. RESULTS OF
IN VITRO STUDIES ON NK SINGLE CELL CLONE LEVEL USING
LAN-1 AND LS NEUROBLASTOMA CELL LINES WO/W GD2MAB
REVEALING SIGNIFICANT IMPACT OF KIR R/L-MISMATCH
Matela M., Horrer A., Kyzirakos C., Pfeiffer M., Handgretinger R., Lang P.,
Schlegel P.* (Tübingen, Germany)
PH-P593
HLA MISMATCHED ALTERNATIVE DONOR SCT IN APLASTIC
ANEMIAS AND REFRACTORY CYTOPENIAS IS SAVE AND FEASIBLE
USING A REDUCED INTENSITY CONDITIONING AND A T- AND
B-CELL DEPLETED GRAFT BUT REQUIRES INTENSIVE IMMUNE
ABLATION
Teltschik H.-M., Pfeiffer M., Müller I., Schrauder A., Heinzelmann F.,
Handgretinger R., Lang P., Feuchtinger T.* (Tübingen, Germany)
PH-P594
COMPARISON OF STATIC AND DYNAMIC NK CELL EXPANSION
PROCEDURE USING UNTOUCHED AND CD3-DEPLETED PBMCS
OF HEALTHY DONORS FOR POSTTRANSPLANT NK TRANSFER TO
AUGMENT ANTITUMOR ACTIVITY WITH AND WITHOUT ADCCMEDIATING ANTIBODY APPLICATION
Klaffschenkel R., Klose C., Teltschik R., Horrer A., Matela M., Siegel G.,
Kyzirakos C., Pfeiffer M., Handgretinger R., Lang P., Schlegel P.* (Tübingen,
162
Germany)
NURSES EDUCATION DAY
NURSES EDUCATION DAY - SUNDAY, 30 MARCH 2014
09:30 - 17:00 Management of early and late effects after haematopoietic Stem
Brown 1-2
cell transplantation and their impact of the patient’s quality of life
09:00 - 09:15 Coffee and registration
10:00 - 10:15 Welcome and introduction
Chair: Erik Aerts (Switzerland)
Anna Mantecon (Spain)
10:15 - 11:00 Chemotherapy and extravasation
Catherine O’Brien (Ireland)
11:00 - 11:45 Indications and the right choice of CVAD for SCT patients: impact
and cost effectiveness
Ton van Boxtel (Netherlands)
11:45 - 12:30 Medication adherence
Sabine Degen Kellerhalls (Switzerland)
Scientific
Programme
Nurses
13:30 - 14:15 GvHD - prevention
14:15 - 15:00 Fatigue
Laura Orlando (Italy)
15:30 - 16:15 Body image and self-esteem
Sarah Liptrott (Italy)
16:15 - 17:00 Complimentary Therapies
Jacqui Stringer (United Kingdom)
17:00
Closing
163
NURSES PROGRAMME
SCIENTIFIC PROGRAMME NURSES GROUP - MON, 31 MAR 14
08:00 - 09:30Opening session
Space 1 & 2
Chair: Elisabeth Wallhult (Sweden)
09:45 - 11:00 Quality of life
Space 3
Chair: Inger Andersson (Sweden)
10:00 - 10:30 Patients
Diana Greenfield (United Kingdom)
10:30 - 11:00 Family
Jeannette Winterling (Sweden)
09:45 - 11:00 Paediatric issues
Brown 2
Chair: Merja Stenvall (Finland)
09:45 - 10:10 Socially disadvantaged parents for children treated with
allogeneic haematopoietic stem cell transplantation (HSCT)
Hanne Baekgaard (Denmark)
10:10 - 10:35 Parents´experiences one year on from their child´s
haematopoietic stem cell transplant for primary
immunodeficiency
Penny Titman (United Kingdom)
10:35 - 11:00 The minot stem cell donor: Ethical and practical aspects
Daphna Hutt (Israel)
09:45 - 11:00 Disease update
Amber 1+2
Chair: Joachim Ahrens (Germany)
09:45 - 10:10 MDS
Theo de Witte (Netherlands)
10:10 - 10:35 AML
Martin Höglund (Sweden)
10:35 - 11:00 ALL
Adele Fielding (United Kingdom)
164
NURSES PROGRAMME
09:45 - 11:00Oral session 1
Amber 8
Chair: Letizia Galgano (Italy)
Patric Crombez (Belgium)
09:45 - 10:03 NO001 IN HOUSE EDUCATION PROGRAMME: A NECESSITY OR A NICETY?
Woodward J., Hill L., Tholouli E., Waller M.* (Manchester, United Kingdom)
10:03 - 10:21 NO002 SHARING KNOWLEDGE. EDUCATIONAL PROJECTS
ALMODOVAR A. R., Trigoso E. P.* (RIBARROJA DEL TURIA, Spain)
10:31 - 10:39 NO003 DEVELOPMENT OF A CURRICULUM FOR HEMATOLOGY NURSING
Schilstra J., Schoordijk M.* and on behalf of the Special Interest Group Hematology (part of V&VN Oncology; the Dutch Nurses’ Association (Amsterdam, Netherlands)
10:39 - 10:57 NO004 THE DEVELOPMENT OF THE LYMPHOMA LEARNING
PROGRAMME
Goode V., Gresch B., Pfau R., Samaras P., Aerts E.*, Liptrott S. and EBMT
Swiss Nurses Working Group (Zürich, Switzerland)
Brown 3
Scientific
Programme
Nurses
11:30 - 13:00GvHD
Chair: John Murray (United Kingdom)
11:30 - 12:15 Treatment and their impact
12:15 - 13:00 Nursing management
Daniela Previtalia (Italy)
11:30 - 13:00 Make easy
Brown 2
Chair: Simone van der Linden (Netherlands)
11:30 - 12:00 Molecular testing
G. E. de Greef (Netherlands)
12:00 - 12:30 HLA typing and donor’s choice
12:30 - 13:00 Cytogenetics
Linda Fogelstrand (Sweden)
11:30 - 13:00 Research Committee
Amber 3+4
Chair: Sarah Liptrott (Italy)
11:30 - 12:00 Questionnaire
Corien Eeltink (Netherlands)
12:00 - 12:30 Qualitative Research
Sabine Degen Kellerhalls (Switzerland)
12:30 - 13:00 Quantitative Research/clinical trials
165
PROGRAMME NURSES
Amber 8
Chair: Reggie Belkhedim (Saudi Arabia)
Marta Vicedomini (Italy)
11:30 - 11:50 NO005 IMPLEMENTATION OF A PRE-HAEMATOPOIETIC
STEM CELL TRANSPLANT PRE-HABILITATION PROGRAM TO
PREPARE PATIENTS PHYSICALLY AND PSYCHOLOGICALLY FOR
TRANSPLANT AND TO ENHANCE RECOVERY AFTER DISCHARGE
Kenyon M., Doorga M., Cave D., Lim C.* (London, United Kingdom)
11:50 - 12:10 NO006 THE SWEDISH REGISTER OF PALLIATIVE CARE(SRPC) IS A
GOOD TOOL FOR IMPROVING PALLIATIVE CARE
Garelius H. G., Andersson I., Krantz K. K.* (goteborg, Sweden)
12:10 - 12:30 NO007 CHILDREN AS SIBLING DONORS - NEW SETTING FOR
CHILDREN DONATING BONE MARROW
Berthelsen A.-M., Pedersen L.* (Copenhagen, Denmark)
12:30 - 12:50 NO008 THE SEVEN STEPS: THE NEXT STEPS - A HANDBOOK FOR
LONG TERM RECOVERY AND SURVIVORSHIP
Shaw B., Kenyon M.* (London, United Kingdom)
14:00 - 15:30 Palliative care/End of life issues
Space 3
Chair: Sabine Degen Kellerhalls (Switzerland)
Monika Fliedner (Switzerland)
Maria Taranger (Sweden)
14:00 - 15:30 Management challenges
Brown 2
Chair: Caroline Bompoint (France)
14:00 - 14:30 Eldery patients
Corien Eeltink (Netherlands)
14:30 - 15:00 Shared care
Mairead NiChonghaile (Ireland)
15:00 - 15:30 Intercultural relationship in nursing
Emanuele Galli (Italy)
14:00 - 15:30 Alternative care environment
Amber 7
Chair: Daphna Hutt (Israel)
14:00 - 14:30 Challenges of delivering care in an alternative environment
Christina Gallego (Spain)
14:30 - 15:00 Information and eductaion needs of patients and carers
15:00 - 15:30 Delivering home based therapy
166
Susanne Heijmenberg (Netherlands)
PROGRAMME NURSES
Amber 8
Chair: Frederica Buzzi (Italy)
Eugenia Trigoso (Spain)
14:00 - 14:20 NO009 CAREGIVING EXPERIENCE DURING HEMATOPOIETIC STEM
CELLS T RANSPLANTATION: FAMILY AND TEAM ALLIANCE IN
PATIENT CARE
pagani E., assanelli A., giglio F., bernardi M., corti C., jacopo P., sarno L., ciceri
F., Giuliani S.* (milan, Italy)
14:20 - 14:40 NO010 TRANSITIONING FROM PAEDIATRIC TO ADULT CARE POSTHSCT: A CANADIAN PERSPECTIVE
Mcgillis L.* (Toronto, Canada)
14:40 - 15:00 NO011 DILEMMAS IN PAEDIATRIC STEM CELL TRANSPLANTATION: AN
OVERVIEW OF MORAL DELIBERATION AS A MODEL TO IMPROVE CARE
van Iperen C., Bredius R., Ball L., Engberts D., van Harmelen M., de Jong C.*
(Leiden, Netherlands)
Scientific
Programme
Nurses
15:00 - 15:20 NO012 THE PROCESS OF NEGOTIATION IN A PAEDIATRIC STEM
CELL TRANSPLANT (SCT) UNIT: A QUALITATIVE STUDY.
Bagnasco A., Petralia P., Todeschini A., Sasso L., Calza S.* (Genoa, Italy)
16:00 - 17:30CVAD
Brown 2
16:00 - 17:30 The effect of education, skills and care on CVAD outcomes
Ton van Boxtel (Netherlands)
16:00 - 17:30 Symptom Management
Amber 1+2
Chair: Hanne Baekgaard (Denmark)
16:00 - 16:30 Oral mucositis: Update and New Trends
Barry Quinn (United Kindom)
16:30 - 17:00 Nutritional Support Process in HSCT patients: Why, When and How
Stefano Botti (Italy)
17:00 - 17:30 Symptom Management of Multiple Myeloma patients
Simone van der Linden (Netherlands)
16:00 - 17:30Infection
Amber 5
Chair: John Murray (United Kingdom)
16:00 - 16:45 Prevention and management of resistant organisms
16:45 - 17:00 Prevention and management of fungal infections
167
PROGRAMME NURSES
Amber 8
Chair: Simona Calza (Italy)
Joachim Ahrens (Germany)
16:00 - 16:20 NO013 BONE MARROW TRANSPLANT COORDINATORS’
PERCEPTIONS ON RELATED DONORS CARE: A PROSPECTIVE
NATIONAL EXPLORATORY SURVEY
bompoint C., belhocine R., gomez A., rubio M. T., mohty M., recchia E., fradet
A., Polomeni A.* (Paris, France)
16:20 - 16:40 NO014 EFFECTIVE PATIENT MANAGEMENT WITHIN HAEMATOONCOLOGY: APPLICATION OF CLINICAL CARE PATHWAYS.
Suardi T., Liptrott S., Magon G., Martinelli G., Orlando L., Clerici M.* (Milan,
Italy)
16:40 - 17:00 NO015 PATIENTS` EXPERIENCE OF SEXUALITY 1-YEAR AFTER
Schmidt M., Jarden M., Thygesen K.* (Copenhagen Ø, Denmark)
17:00 - 17:20 NO016 EARLY DISCHARGE AFTER ALLOGRAFT WITH REDUCEDINTENSITY CONDITIONING : FEASIBILITY AND COST
Chevallier N., Schmitt S.* and K. Bilger, J-C Moulin, N. Frantz, A. Laplace, R.
Herbrecht and B. Lioure (STRASBOURG Cedex, France)
168
PROGRAMME NURSES
SCIENTIFIC PROGRAMME NURSES GROUP - TUES, 1 APR 14
09:30 - 11:00 Joint Session Physicians / Nurses: CLABSI project
Space 4
Emilian Snarski (Poland)
09:30 - 11:00 Disease update
Amber 5
Chair: Mairead NiChonghaile (Ireland)
09:30 - 10:00 MPN - Biology and pathophysiology
10:00 - 10:30 Treatment - HSCT
Eduardo Olavarria (Spain)
10:30 - 11:00 New therapies
Alessandro Rambaldi (Italy)
09:30 - 11:00Apheresis
Chair: Aleksandra Babic (Italy)
Scientific
Programme
Nurses
Amber 7
09:30 - 10:15 Patient management
10:15 - 11:00 New challenges - mobilisation, biosimilars
Daniele Laszlo (Italy)
11:30 - 13:00 Patient information and education needs
Space 4
Chair: Arno Mank (Netherlands)
11:30 - 12:15 Patient education post HSCT
John Murray (United Kingdom)
12:15 - 13:00 Patient advocacy
Jana Pelouchova (Czech Republic)
11:30 - 13:00 Joint session with nurses: Chronic GVHD
Brown 3
Chair: Olle Ringden (Sweden)
11:30 - 12:00 Pathophysiology
12:00 - 12:30 Results of the international survey of EBMT-NCI task force
12:30 - 13:00 TKI based treatment
Attilio Olivieri (Italy)
169
PROGRAMME NURSES
11:30 - 13:00 Care of the carer
Amber 3+4
Chair: Sara Zulu (United Kingdom)
11:30 - 12:15 Family / carer
12:15 - 13:00 Carer - nurse perspective
Eugene Beirne (Ireland)
Amber 5
Chairs: Marieke Schoordijk (Netherlands) & Massimiliano Vicini (Italy)
11:30 - 11:50 NO017 NURSING RESEARCH PRIORITIES: A SURVEY FROM THE
EBMT NURSES GROUP (EBMT-NG) RESEARCH SUB COMMITTEE.
Eeltink C., Calza S., Johansson E., Stringer J., Liptrott S.* (Milan, Italy)
11:50 - 12:10 NO018 DIFFERENCES IN HEALTH BEHAVIOURS BETWEEN
SURVIVORS AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL
TRANSPLANTATION AND THE GENERAL POPULATION: THE
PROVIVO STUDY
Götz A., Halter J., Schanz U., Stussi G., Dobbels F., De Geest S., Kirsch M.*
(Basel, Switzerland)
12:10 - 12:30 NO019 MEDICATION NONADHERENCE TO TAKING
IMMUNOSUPPRESSANTS AFTER ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTATION IS ASSOCIATED WITH CGVHD:
PROVIVOMED - A MULTICENTER CROSS-SECTIONAL STUDY
Kirsch M., Fierz K., Halter J., Nair G., De Geest S., Gresch B.* (Basel ,
Switzerland)
12:30 - 12:50 NO020 SET-UP OF A LONG-TERM FOLLOW-UP CLINIC FOR
YOUNG ADULTS WHO HAD AN ALLOGENEIC STEM CELL
TRANSPLANTATION DURING CHILDHOOD: IMPACT OF A
GOOD COLLABORATION BETWEEN PAEDIATRIC AND ADULT
HEMATOLOGICAL TEAMS.
Van Lancker S., Bordon V., Kerre T., Dhooge C., De Munter J.* (Ghent, Belgium)
11:30 - 13:00Adolescent
Amber 7
Chair: Clara Soliman (Italy)
11:30 - 12:15 Medical care of adolescents with blood disorders
Maria Pia Cicalese (Italy)
12:15 - 13:00 Nursing care of adolescents with blood disorders
Sabrina Agazzi (Italy)
170
PROGRAMME NURSES
13:00 - 14:00 Gentium Nurses’ Symposium: Active management of veno-occlusive
Space 4
disease: what should you do now?
13:00 - 13:05 Welcome and introduction
13:05 - 13:20 Understanding the nurse’s role in VOD: treating a life-threatening
complication of HSCT
Sarah Marktel (Italy)
13:20 - 13:40 The patient journey in severe VOD: a nurse’s perspective
Mairead Ni Chonghaile (Ireland)
13:40 - 13:55 Severe VOD in practice: what would you do now?
Erik Aerts (Switzerland)
13:55 - 14:00 Enhancing nurse education in VOD: a new nurse training
14:00 - 15:30 Plenary 4: Joint session with nurses: Holistic care in transplant
Gold Plenary
14:00 - 14:20 Outcomes in the transplant recipient-caregiver team during
allogeneic transplantation
Moira Stephens (Australia)
14:20 - 14:40 Care of the older patient undergoing transplantation
Margot Gosney (United Kingdom)
14:40 - 15:00 Physical therapy Spiritual care and the role of hope
Tullio Proserpio (Italy)
15:00 - 15:20 Palliative care and end-of-life in the transplant patient
Augusto Caraceni (Italy)
14:15 - 15:45 Making sense of…
Brown 1
Chair: Reggie Belkhedim (Saudi Arabia)
14:15 - 14:45 Transfusion in HSCT
M. R. van Bohemen-Onnes (Netherlands)
14:45 - 15:15 GvHD grading/scoring
15:15 - 15:45 The European Transplant Activity Survey: trends and
developments during 20 years of transplantation.
Helen Baldomero (Switzerland)
171
Scientific
Programme
Nurses
programme from EBMT
PROGRAMME NURSES
Amber 5
Chairs: Marta Gavezzotti (Italy) & Irena Skoda (Slovenia)
14:15 - 15:35 NO021 ORAL AND GASTRO-INTESTINAL MUCOSITIS IN
MYELOABLATIVE ALLOGENEIC HSCT PATIENTS FOLLOWING 12 GY
TOTAL BODY IRRADIATION IN 3 VERSUS 6 FRACTIONS
Boll S., Hovgaard D., Specht L., Fog L., Sengelov H., Schmidt M.* (Copenhagen,
Denmark)
14:35 - 14:55 NO022 CHANGES IN ELECTROLYTE LEVELS AFTER
LEUKAPHERESIS
Eliasson L., Wahlin A., Åström F., Skagerlind L.* (Umeå, Sweden)
14:55 - 15:15 NO023 SURVIVING SEPSIS: DOOR TO NEEDLE TIME:
MANAGEMENT OF THE ACUTELY UNWELL PATIENT.
Murray J., Lowiss S.*, Morgan H. (Manchester, United Kingdom)
15:15 - 15:35 NO024 DEVELOPING AN OUTREACH SERVICE FOR PATIENTS WITH
ACUTE GRAFT VERSUS HOST DISEASE
Foster M., Denney H., Goodgrove R., Robertson L., Hammerton F., Mayo J.,
Whittle R., Alfred A., Taylor P., Maher T.* (Rotherham, United Kingdom)
14:15 - 15:45New Therapies
Amber 7
Chairs: Marco van Valkenburg (Netherlands)
14:15 - 14:45 HSCT for auto immune disorders
14:45 - 15:15 HSCT in Multiple Sclerosis
Riccardo Saccardi (Italy)
15:15 - 15:45 HSCT in solid organ malignancies
SCientific Programme Nurses Group - Wed, 2 Apr 14
09:00 - 10:30 Pre-transplant issues
Brown 3
Chair: Mairead NiChonghaile (Ireland)
09:00 - 09:30 Donor
Bronwen Shaw (United Kingdom)
09:30 - 10:00 Cell sources
10:00 - 10:30 Co-morbidity
172
PROGRAMME NURSES
SCIENTIFIC PROGRAMME NURSES GROUP - WED, 2 APR 14
09:00 - 10:30Late effects
Amber 3+4
09:00 - 09:30 Cardiac late effects
Hans Kolb (Germany)
09:30 - 10:00 Nursing aspects about late effects
F. Witkamp (Netherlands)
10:00 - 10:30 The patient’s experience
Derk de Groot (Netherlands)
09:00 - 10:30Complications
Amber 6
Chair: Simone van der Linden (Netherlands)
09:30 - 09:50 Engraftment syndrome
Sara Zulu (United Kingdom)
Scientific
Programme
Nurses
09:50 - 10:10 TTP
Speaker: John Murray (United Kingdom)
10:10 - 10:30 Platelet transfusion in HSCT
M. R. van Bohemen-Onnes (Netherlands)
11:00 - 12:45 Closing Session
Brown 3
Chair: Elisabeth Wallhult (Sweden)
11:00 - 11:20 NO025 A BONE MARROW TRANSPLANTATION UNIT IN
SWITZERLAND (WEST) AND ISRAEL (EAST): DIFFERENCES AND
SIMILARITIES - EXCHANGE PROGRAM GRANTED BY EBMT
NURSES GROUP
Poetzsch K., atzir L.* (Haifa, Israel)
11:20 - 11:30
11:30 - 11:40
11:40 - 11:50
11:50 - 12:00
12:00 - 12:10
12:10 - 12:25
EBMT activities
Exchange visit
Paediatric Committee
Scientific Committee
Prize for best poster and oral presentation
How to make an abstract
Mairead NiChonghaile (Ireland)
12:25 - 12:35 Presentation Istanbul 2015
12:35 - 12:45 Summary and closing remarks
13:00 - 13:15 Congress Closing Session
Gold Plenary
173
NURSES GROUp POSTERS
MONDAY, 31 MARCH & TUESDAY, 1 APRIL 2014
Research outcomes for patient / family
NP001
EARLY ENTERAL NUTRITION AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION IS ASSOCIATED WITH A REDUCED RISK OF
ACUTE GRAFT-VERSUS-HOST DISEASE
Vigouroux S., Tabrizi R., Duclos C., Milpied N., Sarrazin-Robert C., Renck M.*
(Pessac, France)
NP002
A NUTRITIONAL SCREENING AND TREATMENT-SPECIFIC CARE
PATHWAY FOR ADULT TRANSPLANT PATIENTS
Roberts L., Fackrell S., Allman S., Duckett K., Henderson L., Marks D., Radia
R., Hull Z.* (bristol, United Kingdom)
NP003
DOES THE DISCHARGE FOLLOW UP SERVICE IMPROVE PATIENT
SATISFACTION AND EXPERIENCE?
Blagburn N., Rys-Halska S.* (Manchester, United Kingdom)
NP004
HERPES ZOSTER INFECTION IN THE POST HAEMAPOETIC STEM
CELL TRANSPLANT PAEDIATRIC POPULATION: A SINGLE CENTRE
EXPERIENCE
O’Brien M., Smyth E.* (Dublin, Ireland)
NP005
A COMPARATIVE STUDY OF THE EFFECT OF MOUTHWASHES
WITH AN IONIC SOLUTION (CAPHOSOL™) VS . LIDOCAINE
1‰ VISCOUS SOLUTION, ON THE MUCOSITIS ASSOCIATED
TO DIFFERENT CONDITIONING REGIMENS IN AUTOLOGOUS
Hernandez Blanco M. C., Prieto Casarrubios C.* and M.Tirado Ojeda,E.
Méndez Gutierrez del Valle,I.S Casado Coloma,M.B. Pablos Cuesta,N.
Herrero de la Iglesia,G. Burgos (Madrid, Spain)
NP006
CRYOTHERAPY REDUCES THE SEVERITY AND DURATION OF ORAL
MUCOSITIS FOLLOWING HIGH DOSE MEPHALAN IN MULTIPLE
MYELOMA PATIENTS
van der Lans M., Ottevanger L.* (Rotterdam, Netherlands)
NP007
LASER THERAPY - A NEW TREATMENT OPTION ON ORAL MUCOSITIS
Dittus D., Döring M., Handgretinger R., Schulze Selting K., Barth M.*
(Tübingen, Germany)
NP008
A RETROSPECTIVE STUDY OF NUTRITIONAL ASPECT IN THE
PATIENT UNDERGOING HSCT FOR B- THALASSAEMIA AND SICKLE
CELL ANAEMIA IN A MULTIETHNIC GROUP. TOTAL PARENTERAL
NUTRITION (TPN) VS ORAL NUTRITION
Dubali M.* and D.Martino; D.Ferreli; J.Varghese; E.Leva; D.Francesconi
(Roma, Italy)
NP009
174
NURSING CHALLENGES IN DIET CONTROL FOR HEMATOPOLETIC
STEM CELL TRANSPLANT (HSCT)PATIENTS IN A DEVELOPING
COUNTRY, NIGERIA
nappier J., izekor E., odia O., ogie-omoruyi A., imafidon E.* and nursing
group (benin, Nigeria)
NP010
NUTRITIONAL INTERVENTION TO PATIENTS UNDERGOING
HEMATOPOIETIC CELL TRANSPLANTATION: SINGLE CENTER
EXPERIENCE
Arribas L., Peiro I., Sanchez M., Arnan M., Sanchez-Ortega I., Duarte R.,
Patiño B.* (Hospitalet de Llobregat, Spain)
NP011
PAIN BELIEFS AND AFFECTING FACTORS OF THE
HAEMATOLOGICAL CANCER PATIENTS RECEIVED STEM CELL
TRANSPLANTATION.
Özdemir L., Derya Ister E.* (ADIYAMAN, Turkey)
NP012
MECHANICALLY VENTILATED PATIENTS: IS IT POSSIBLE TO
PREDICT WHO WILL SURVIVE?
Radin J., Katzir L.* (Haifa, Israel)
NP013
EPIDEMIOLOGY AND OUTCOME IN PATIENTS ADMITTED TO
THE INTENSIVE CARE UNIT AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION
Scientific
Programme
Nurses
Kristiansen J., Fløisand Y., Gedde-Dahl T., Wahlø K.* (Oslo, Norway)
Quality projects patient
NP014
IMPLEMENTATION OF A PHYSICAL ACTIVITY AND PSYCHOEDUCATION INTERVENTION IN PATIENTS UNDERGOING
Aarup T. L., Sommerset J. D., Jarden M., Bardram F.* (Copenhagen, Denmark)
NP015
DELIRIUM MANAGEMENT IN STEM CELL TRANSPLANT PATIENTS
- A PRACTICE DEVELOPMENT PROJECT
Berger C., Erhardt C., Stern M., Medinger M., Hasemann W., Kirsch M.,
Gerwig N.* (Basel, Switzerland)
NP016
HOPE-HOPELESSNESS LEVELS OF BONE MARROW TRANSPLANT
PATIENTS AND THE AFFECTING FACTORS
Olgun N., Gulbas Z., Ozdas T.* (Kocaeli, Turkey)
NP017
DISTRESS- THERMOMETER FOR PATIENTS WITH A STEM CELL
TRANSPLANTATION
Eng B., Schmid M.* (Zürich, Switzerland)
NP018
A COMPARATIVE STUDY OF THE QUALITY OF LIFE IN LONG-TERM
VS SHORT-TERM HAEMOPOIETIC TRANSPLANT (HT) SURVIVORS
García M., Ortín M., Vazquez L., López L., Delgado M., Caballero D., Salinero
M.* (SALAMANCA, Spain)
NP019
CAREGIVER BURDEN AMONG PRIMARY CAREGIVERS OF
PATIENTS UNDERGOING PERIPHERAL BLOOD STEM CELL
TRANSPLANTATION: A CROSS SECTIONAL STUDY
Ozdemir L., Akgul N.* (Ankara, Turkey)
175
NP020
PROTECTION DURING HEMOPOIETIC STEM CELL
TRANSPLANTATION: A SURVEY FROM THE QUALITY OF LIFE
WORKING PARTY OF THE ROME TRANSPLANT NETWORK
Pignatelli A., Tendas A., D’apolito A., Mauroni M. R., Molinari V., Di veroli A.,
Papa C., Carli I., Chierichini A., Cacciaraichi S., Tomarchio V., Mazzaroni M.,
Sollazzo F., Conte E., Viggiani C., Dipiazza F., Avvisati G., Arcese W., Annibali
O.* (Roma, Italy)
NP021
A SUCCESSFUL MATCHED DONOR SEARCH - DOES IT ALWAYS
END WITH HCT?
Cohen O., Naparstek E., Rom E.* (Tel Aviv, Israel)
NP022
TITLE: FOLLOW-UP WITHIN SCT; A NEED OR IS IT SECONDARY:
NP023
FERTILITY AND SEXUAL FUNCTION IN FEMALE HODGKIN
LYMPHOMA SURVIVORS OF REPRODUCTIVE AGE
Rademaker M., Suijk L.* (Amsterdam, Netherlands)
Visser O., Eeltink C.* (Amsterdam, Netherlands)
NP024
BONE MARROW TRANSPLANTATION FOR PATIENTS WITH
MENTAL ILLNESS - IS IT POSSIBLE?
Sabah I., Tal S., Torati S., Atar N.* (Ramat Gan, Israel)
Ambulatory
NP025
AUTOLOGOUS PERIPHERAL BLOOD STEM CELL
TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA IN A
COMBINED OUT-PATIENT AND IN-PATIENT SETTING
Zmijakova A., Kourilova P., Svabova H.* (Brno, Czech Republic)
NP026
AMBULATORY CARE: FUTURE-PROOFING CLINICAL
HAEMATOLOGY SERVICES TO DELIVER ON QUALITY, SAFETY AND
PATIENT EXPERIENCE
Brokka O., Bradley K.* (London, United Kingdom)
NP027
PATIENT EXPERIENCE OF BONE MARROW TRANSPLANTATION IN
AMBULATORY CARE
evans C., encinas M.* (London, United Kingdom)
Aphresis
NP028
A SINGLE CENTRE AUDIT LOOKING AT THE PREDICTABILITY OF
PERIPHERAL BLOOD STEM CELL HARVESTING USING DIFFERENT
MOBILISATION REGIMES
Kenyon M., Tatam E., Hess D., Lim C.* (London, United Kingdom)
NP029
PLATELET DEPLETION: THE IMPERIAL COLLEGE HEALTHCARE
NHS TRUST EXPERIENCE
Brokka O., Haynes R.* (London, United Kingdom)
176
NP030
VALIDATION OF PBSC COLLECTION WITHIN JACIE PROGRAM: A
MULTICENTER EVALUATION
Baglioni M., Martinelli G., Negri M., Laszlo D., Babic A.* (milan, Italy)
NP031
SINGLE CENTRE EXPERIENCE OF TRANSITION FROM COBE
SPECTRA AUTO PBSC TO SPECTRA OPTIA MNC VERSION 7
SOFTWARE, ANALYSIS OF 34 AUTOLOGOUS PBSC COLLECTIONS
TO DETERMINE HARVEST AND COST EFFICIENCY.
Wiggens C., Christian A., Mangles M., Hammond L.* (Bournemouth, United
Kingdom)
NP032
TRANSFER OF KNOWLEDGE ON APHERESIS IN A
DEMONSTRATION CENTRE
de Greef G., Engelman-Rijper C.*, van Gent-van der Sanden M. (Rotterdam,
NP033
A SINGLE CENTRE EXPERIENCE OF UP TO 3 DAY STEM CELL
COLLECTION USING CYCLOPHOSPHAMIDE AND G-CSF (CYCLO-G)
MOBILISATION FOR 2 TRANSPLANTS IN MULTIPLE MYELOMA.
Lim C., kenyon M., cave D., Doorga-Scammell M.* (london, United Kingdom)
NP034
MONOCYTAPHERESIS FOR PRODUCTION OF DENDRITIC CELL
VACCINES; A COMPARISON BETWEEN SPECTRA OPTIA® AND
COBE SPECTRA® APHERESIS SYSTEMS
Smith R., Dierickx D., Berckmans D.* (Leuven, Belgium)
NP035
A SINGLE CENTRE EXPERIENCE OF RELATED DONOR SELECTION;
A REVIEW OF CLINICAL PRACTICE.
Shireen K., Michelle K., Pagliuca T., lim C., Victoria P., Mijovic A., Cave D.*
NP036
GRANULOCYTE TRANSFUSIONS IN A PATIENT WITH ACUTE
MYELOID LEUKEMIA SUFFERING FROM LIFE-THREATENING
MUCORMYCOSIS AFTER HAPLOIDENTICAL HEMATOPOIETIC CELL
TRANSPLANTATION
Haj D., Abu-Yaman M., Broitman M., Levin D., Dvir R., Manistersky M.,
Rosenfeld-Kedar H., Achituv S., Hareuveni M., Elhasid R., Bitan M.* ( Tel-Aviv,
Israel)
Education for patients
NP037
SURVEY OF EDUCATIONAL NEEDS INVOLVES PATIENTS AFTER
BONE MARROW TRANSPLANTATION
Brambilla M., Osorio M., Cuccaro S., Marktel S., Corti C., Ciceri F., Soliman C.*
(Milan, Italy)
NP038
EVALUATION OF A DISCHARGE INSTRUCTION BOOKLET FOR
ALLOGRAFT PATIENT
VAUZELLE K., OTMANE CHERIF M., CHICAUD O., GIRAULT S., TURLURE P.,
BORDESSOULE D., ABRAHAM J., TARDIEU L.* (Limoges, France)
177
Scientific
Programme
Nurses
Netherlands)
NP039
ASSESSMENT OF PRE HEMATOPOIETIC STEM CELLS TRANSPLANTATION PATIENT AND FAMILY EDUCATION USING A MULTIMEDIA DVD
Ciglio A. C. C. C., Sá G. R., Waisbeck T. M. B., Nogueira R. M. G., Kerbauy F. R.,
Costa L. S. S., Vogel C.* (São Paulo, Brazil)
NP040
THE AYA BOX: A PATIENT CENTERED INSTRUMENT IN
COMMUNICATION WITH ADOLESCENTS AND YOUNG ADULTS
(AYA) WITH CANCER AND THEIR CARE GIVING PARENTS
Decoene E., Belpaeme N., Vandevelde V., Verhaeghe S., Dillen L., Raes A.,
Quaghebeur M.* (Gent, Belgium)
NP041
NATIONAL POST-TRANSPLANT FOLLOW-UP CARE LOGBOOK FOR
PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION: AN INITIATIVE BY THE SFGM-TC.
TARDIEU L.*, BOMPOINT C., CONTENTIN N., CORNILLON J., DECONINCK
E., GODIN S., GUIRAUD M., HUYNH A., MAGRO L., MAILLARD N., MILPIED
N., PORCHERON S., RECCHIA E., RUBIO M.-T., SAMY J.-P., WALLART A.,
YAKOUB-AGHA I., DENDONCKER C., TIPTON R. and Société Française de
Greffe de Moelle et de Thérapies Cellulaires (SFGM-TC) (Limoges, France)
NP042
PRE-TRANSPLANT INFORMATION GUIDE FOR PATIENT AND
FAMILY. HEMATOPOIETIC CELL TRANSPLANT PROGRAM
Peralta T., Azor R., Palleja M., Arnan M., Sanchez-Ortega I., Duarte R., Patiño
B.* (Hospitalet de Llobregat, Spain)
NP043
START TO FINISH NURSE CONSULTATION: A PATIENT EDUCATION
STRATEGY TRANSCENDING FROM PRE-ADMISSION TO POSTDISCHARGE CONTACT
Schneider M., Bensch H. L.* (Munich, Germany)
PICC / CVC
NP044
AN ALGORITHM-BASED APPROACH TO IDENTIFY THE MOST
APPROPRIATE VENOUS ACCESS FOR SYSTEMIC CANCER THERAPY
Trentin D., Bevacqua S., Paternoster C., Saracino L.* (Milano, Italy)
NP045
PREVENTING CENTRAL LINE-ASSOCIATED BLOODSTREAM
INFECTION IN A HEMATOPOIETIC STEM CELL TRANSPLANTATION
UNIT: RESULTS OF “GETTING TO ZERO” ACTION
Ko B.-S., Tang J.-L., Chen J.-Y., Chang Y.-C., Chang C.-F.* (Taipei, Taiwan,
Province of China)
NP046
CENTRAL VENOUS CATHETER-RELATED COMPLICATIONS
AFTER BONE MARROW TRANSPLANTATION IN PATIENT WITH
HEMATOLOGICAL MALIGNANCIES
Russo L., Cusumano G.*, Meliambro N., Gangemi T., Trimarco T., Gallo S.,
Repaci I., Avenoso R., Campolo G., Rossetti A. (Reggio Calabria, Italy)
NP047
178
INDICATORS RELATED TO CENTRAL VENOUS CATHETER
MANAGEMENT
Orlando L., Liptrott S., Vicedomini M., Magarò A.* (Milan, Italy)
NP048
NURSING CHALLENGES IN THE CARE OF CENTRAL VENOUS
CATHETER (CVC) FOR HEMATOPOIETIC STEM CELL TRANSPLANT
PATIENTS IN A DEVELOPING COUNTRY NIGERIA
onunu D., otitigbe P., igbinovia J., idehen P., ogunlere B.* and nursing group
(benin, Nigeria)
NP049
CONSULTANT NURSE IN VESSEL HEALTH: CLINICAL AND MENTAL
COMPETENCY
Trenta F., Colandrea G., Sili A., Conti F., Mauroni M., Molinari V.* (Rome, Italy)
NP050
THE USE OF PERIPHERALLY INSERTED CENTRAL CATHETER (PICC)
IN PATIENTS UNDERGOING HEMATOPOIETIC PROGENITOR CELLS
(HPC) TRANSPLANTATION
NP051
THE DEVELOPMENT OF EDUCATIONAL INTERVENTIONS FOR
PROTECTIVE ISOLATION: RESULTS OF A GITMO SURVEY
Gori E., De Cecco V., Botti S., Gargiulo G., Orlando L.* and NG BOARD GITMO
(Gruppo Italiano Trapianto di Midollo Osseo) (Milan, Italy)
NP052
ADVERSE EVENTS AND DANGEROUS SITUATIONS IN THE
CLINICAL STEM COLLECTION AND TRANSPLANTATION UNIT AT A
SINGLE TRANSPLANT CENTRE
Lauraeus-Käkelä E., Salovaara H., Kauppila M., Järviö H.* (Turku, Finland)
NP053
HOW DO WE IMPROVE SUPPORT FOR THE POST ALLOGENEIC
TRANSPLANT PATIENT?
Leonard H.* (Sutton, United Kingdom)
NP054
CONTINUOUS VENO-VENOUS HEMOFILTRATION IN BMT UNIT:
THE NURSING CARE
Agazzi S., Preziosi L., Nunez L., Peccatori J., Giglio F., Greco R., Ciceri F.,
Soliman C.* (Milan, Italy)
NP055
NURSES’S FORMATION : HAEMATOLOGY’ PASSPORT
NP056
PROJECT OF SUPERVISION FOR HEMATOLOGY-ONCOLOGY
NURSES - FIRST EXPERIENCES
CONTENTIN N., BERTRAND E., TILLY H., COLLARD S.* (ROUEN, France)
Zitkova M.*, Spackova J. (Brno, Czech Republic)
NP057
JACIE ACCREDITATION:- 2 YEARS IN THE MAKING
NP058
THERAPEUTIC PATIENT EDUCATION: EXPERIMENTAL PROJECT ON
EDUCATIONAL PROGRAM
Monroe D., Vieira S.* (LONDON, United Kingdom)
cannavale F., Olcese E., Trucchi C., Barresi M., Castagnoli P., Ciccarelli V.,
Pastorino T., Pau R., Cambiaso M., Nappi A., Pastore S., Francesia Berta
M., Dell’avversana C., Floriddia A., Garbarino R., Toscano A., Raucci M.,
Sobiczewska K., Ghibaudo E., Deiana G. M.* (genoa, Italy)
179
Scientific
Programme
Nurses
Trenta F., Colandrea G., Soave S., Brunetti M., Conti F., Di Piazza F., Cesarini
V., Gulli A., Orteca N., Zisa G., Cirri C., Valentini E., Volpe P., Undetti D., Salis
F., Macagnino F., Adamo M., Amorese M., De vita A., Federici D., Colella S.,
Beccia R., Mauroni M. R., Molinari V.* (Rome, Italy)
NP059
BACK TO BASICS’, A TRANSPLANT TRAINING PROGRAM FOR
NURSES
Mills L., Simpson D.* (London, United Kingdom)
NP060
OBSERVATIONS OF CLINICAL PRACTICE: A PROSPECTIVE AUDIT
OF HPC INFUSIONS
Cabinum C., Rintala T.* (London, United Kingdom)
NP061
NURSING STAFF AS A PARTNER IN THE IMPLEMENTATION
OF CLINICAL STUDY PROTOCOLS IN THE HEMATOLOGY
DEPARTMENT: PROFESSIONAL, CLINICAL AND ADMINISTRATIVE
CHALLENGES
cohen I., katzir L., Kazman N.* (Haifa, Israel)
NP062
FOR AUTOIMMUNE DISEASES: NURSING CARE PERSPECTIVE
Nilsen L., Rodrigues M. C. O., Galvão C. M., Silveira R. C. C. P.* (Ribeirao Preto,
Brazil)
NP063
HOW WE SET UP THE RECORDING AND INVESTIGATION OF THE
ADVERSE EVENTS IN OUR UNIT?
Chantepie S., Moreno V., Desvoye S., Nonnenmacher M., Marin E., Reman O.,
Kientz N.* (Caen, France)
NP064
A CENTRAL ROLE FOR THE NURSE PRACTITIONER IN
AUTOLOGOUS STEM CELL TRANSPLANTATION OUTPATIENT CARE
Veelken H., von dem Borne P., Oudshoorn M.* (Leiden, Netherlands)
NP065
THE CHANGING FACE OF TRANSPLANTATION AND NURSING
PRACTICE AT HARLEY STREET AT UCH
dowling E., Mills L., Jackson C., Tania B., Simpson D.* (London, United
Kingdom)
NP066
ADVANTAGES OF HAVING A UNIT BASED CHARITY
NP067
NURSING WORKLOAD REQUIRED BY PATIENTS UNDERGOING
Stringer J., Murray J., Leather A.* (Manchester, United Kingdom)
Padilha K. G., Lima M. H. M., Trevisan D. D., Oliveira H. C., Póvoa V. C. O.,
Hosokawa M. M. T., Vieira A. P. G., Simmelink V. L. M. S., Secoli S. R., Silva J.
B.* (Campinas, Brazil)
NP068
ERROR - ONE YEAR AFTER, LESSONS LEARNED
NP069
NURSES’ INTENT TO LEAVE AND JOB SATISFACTION IN
HEMATOLOGY/ ONCOLOGY AREAS: IMPLICATIONS FOR POLICY
AND PRACTICE
Stenvall M.* (Helsinki, Finland)
Dagamseh M. S.* (Riyadh, Saudi Arabia)
NP070
180
KEEPING OUR HEMATOLOGY NURSES “HAPPY”
Mank A. P., Veldhoen-Tijben R. C.* (Amsterdam, Netherlands)
Paediatric
NP071
A SINGLE CENTRE REVIEW OF ADMISSION TO PICU - IS OUR CARE
IMPROVING?
Webster H.* (Manchester, United Kingdom)
NP072
NURSING IN TEENAGERS WITH GRAFT VERSUS HOST
DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION.
Badanova I., Osipchuk L., Averyanova M., Gortinskaya-Oleschko S., Zubarovskaya L., Afanasyev B., Badanova A.* (St. Petesburg, Russian Federation)
NP073
TO EVALUATE THE NUMBER OF BACTERIAL AND FUNGAL
INFECTIONS DURING TWO TIMES PERIOD IN CHILDREN WITH
(HSCT) WITH DIFFERENT METHODS OF ISOLATION PROCEDURE.
Goutagny M.-P., Perroux J., Libbrecht C., Bertrand Y., Bohat C., Flamand H.*
NP074
EARLY DETECTION AND MANAGEMENT OF ORAL MUCOSITIS
IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL
TRANSPLANTATION USING DAILY ASSESSMENT FORM
Sasinin S., Yoshuaeng R., Prasertsang N., Wuthijaroonpan S., Kamchom M.,
Kruecharn A., Kaewmanee J.* (Bangkok, Thailand)
NP075
THE PARENTS’ EXPERIENCE OF UNCERTAINTY DURING THEIR
CHILD’S BONE MARROW TRANSPLANTATION: A QUALITATIVE
AND COGNITIVE ANALYSIS
Trevisan N., Ceron M., Bernardi M.* (Padova, Italy)
NP076
TOUCHING SCREEN. THE SCHOOL AT THE HOSPITAL
NP077
SPECIAL EDUCATION FOR PAEDIATRIC STEM CELL TRANSPLANT
NURSES. AN ADVANCED COURSE FOR A NARROW
SPECIALIZATION IN HELSINKI, FINLAND
HERNANDEZ D., Trigoso E. P.* (RIBARROJA DEL TURIA, Spain)
Sällström P.* (Helsinki, Finland)
NP078
TRANSPLANT FOR LIFE: A TRAINING MOVIE FOR CHILDREN IN
PREPARATION FOR A BONE MARROW TRANSPLANT
zaidman I., Ben-Arush M., Porat I.*, Ofir R. (Haifa, Israel)
NP079
SAFETY-MANAGEMENT FOR CRITICALLY ILL PAEDIATRIC
TRANSPLANT PATIENTS: IMPLEMENTATION OF A COMMON
STANDARD FOR THE INFUSION OF CATECHOLAMINES
Langer K.* (Vienna, Austria)
NP080
FERTILITY RECOVERY AND PREVALENCE OF PREGNANCY AFTER
HEMATOPOIETIC STEM CELL TRANSPLANTATION: A 15-YEAR
SINGLE INSTITUTION EXPERIENCE
Nehme R., Dabaja M., Otrock Z., Bazarbachi A., Baydoun M.* (BEIRUT, Lebanon)
181
Scientific
Programme
Nurses
(Lyon, France)
Quality Management
QUALITY MANAGEMENT PROGRAMME - TUE, 1 APR 14
08:00 - 09:00 JACIE Education Session
Amber 8
An introduction to JACIE for beginners - overview of JACIE and the
accreditation process
Chair: Eoin McGrath (Spain)
08:00 - 08:15 Accreditation Process
I. Bargalló (Spain)
08:15 - 08:30 Centre Experience
Carole Charley (United Kingdom)
08:30 - 08:45 Inspector Experience
Ivana Ferrero (Italy)
09:00 - 11:00 Accredited: What happens next?
Brown 2
Round-table with international experience
Chair: Yvonne Schellekens (Netherlands)
Bernadette Odijk (Netherlands)
Mara Magri (Italy)
Dominique Latinne (Belgium)
Sarah Holtby (United Kingdom)
Lillemor Eliasson (Sweden)
Yvonne Westerman (Netherlands)
Phuong HUYNH (Belgium)
Deborah Anderson (United Kingdom)
Julie Dolva (Norway)
11:30 - 13:00 JACIE Session - Mixed Themes
Amber 8
Chair: Alessandro Rambaldi (Italy)
Christian Chabannon (France)
11:30 - 11:43 Patient viewpoint
Marco Braico (Italy)
11:43 - 12:06 Paradigm of Care: Ego or Eco system
Erik Heineman (Netherlands)
12:06 - 12:24 6th edition FACT-JACIE Standards
12:24 - 12:52 Towards the implementation of the Single European Code in the
field haematopoietic stem cells for transplantation
Ioana Siska (Germany)
12:52 - 13:00 Results from the AHCTA Surveys - Developing recommendations
for cell collections and cell processing laboratory staff
qualifications, training and competency
Kathy Loper (United States)
Ineke Slaper-Cortenbach (Netherlands)
182
Quality Management
QUALITY MANAGEMENT PROGRAMME - TUE, 1 APR 14
13:10 - 14:00Lunchtime Controversy
Amber 8
Increasing minimum transplant volumes in the FACT-JACIE standards will
improve quality and survival outcomes
Anna Sureda (Spain)
14:00 - 15:00 Solutions session 1:
Amber 8
Challenges in implementing QM: views from 3 centres
Chair: Maurizio Aricò (Italy)
14:00 - 14:20 Large Allo-graft programme
Ulrike Buttkereit (Germany)
14:20 - 14:40 Transplant programme in a developing country
Erna West (South Africa)
14:40 - 15:00 Autologous-only programme
Christine Protheroe (United Kingdom)
15:20 - 16:20 Solutions session 2:
Amber 8
Indicators, Internal Audits and Follow-up
Chair: Maria Vittoria Gazzola (Italy) & Elena Vassalo (Italy)
15:20 - 15:40 How we established indicators
Olivia Caunday (France)
Data/Quality
Management
15:40 - 16:00 How we audit / what we audit
Alessandro Lanti (Italy)
16:00 - 16:20 Closing the loop - follow-up methodologies
John Drain (United Kingdom)
16:30 - 17:30Oral Sessions
Amber 8
Chair: Desirée Caselli (Italy)
Archangelo Prete (Italy)
16:30 - 16:42 RFID FOR STEM CELL TRACKING: CAN TECHNOLOGY IMPROVE
THE QUALITY OF CARE?
Vittorio Montefusco (Italy)
16:42 - 16:54 PLEASE SIR, NO MORE HARDCOPY TRAINING RECORDS: A NOVEL
EXAMPLE OF HOW TO IMPLEMENT ELECTRONIC TRAINING AND
COMPETENCY RECORDS
Simon M. Hack (United Kingdom)
16:54 - 17:06 HEMATOPOIETIC STEM CELL TRANSPLANTATION QUALITY
MANAGEMENT SUPPORT THROUGH A DEDICATED WEB-BASED
APPLICATION
Rajat K. Agarwal (India)
183
Quality Management
QUALITY MANAGEMENT GROUP POSTERS - TUE, 1 APR 14
QM-P001
COMPARISON OF ISHAGE-BASED CD34 (+) CELL ENUMERATION
PROTOCOLS ON BD FACS CANTO II AND ATTUNE FLOW
CYTOMETERS
Unver G., Sariturk C., Baran Y., Yeral M., Boga C., Ozdogu H., Kozanoglu I.*
(Adana, Turkey)
QM-P002
THE QUALITY MANAGEMENT SYSTEM: THE MACEDONIAN
EXPERIENCE - ONE STEP CLOSER TO JACIE ACCREDITATION
Grubovic R. M.* (Skopje, Macedonia, The Former Yugoslav Republic Of)
QM-P003
IMPLEMENTATION OF ISBT 128- AND EUROCET 128 CODING AND
LABELING OF CELLULAR THERAPY PRODUCTS; EXPERIENCE OF
THE LEIDEN UNIVERSITY MEDICAL CENTER.
Zwaginga J. J., Korfage N., Kouprie-Bakker L., van den Muijsenberg J.,
Overdevest J., Noort A., Beer-Wekking I., Netelenbos T., Pronk-Ziermaier I.*
(Leiden, Netherlands)
QM-P004
DEVELOPMENT OF AN INTEGRATED CLINICAL SUPPORT
SYSTEM FOR TRANSPLANT PATIENTS AT UNIVERSITY HOSPITAL
SOUTHAMPTON NHS FOUNDATION TRUST
Stoffel J., Jarvis L., Hill K., McKeag N., Lamb J., Main S., Hutchins D., Newman
J., Lyons A., Cable D., Richardson D., Orchard K., Hurlock C.* (Southampton,
United Kingdom)
QM-P005
VALIDATION OF A NEW, EASIER,QUICKER SYSTEM FOR ROOM
STERILIZATION THROUGH MICRONEBULISATION OF HYDROGEN
PEROXIDE AND POSITIVE SILVER IONS
Zucchetti E., Lanzo G., Turrini M., Lotesoriere I., Deodato M., Forno B.,
Mazzola E., Morra E., Grillo G., Marenco P.* (Milano, Italy)
184
Data Management
STATISTICAL COURSE - Saturday, 29 March 2014
15:00 - 18:00 Statistical Course: Basic Statistics
Suite 5
Richard Szydlo (United Kingdom)
Antonella Santucci (Italy)
STATISTICAL COURSE - Sunday, 30 March 2014
09:00 - 12:00 Statistical Course: Survival Analysis
Suite 5
Richard Szydlo (United Kingdom)
Antonella Santucci (Italy)
Data Management Programme - Mon, 31 Mar 14
09:00 - 12:00 Data management training course: Data Entry: Tidy up your data
Suite 5
(Booking required via EBMT website)
09:00 - 09:40NIH-defined GvHD
Amber 6
09:45 - 10:25 Multiple myeloma
Amber 6
Curly Morris (Ireland)
10:30 - 11:10 Viral serology
Amber 6
Jan Styczynski (Poland)
Amber 6
Data/Quality
Management
11:40 - 12:20 Graft manipulation
Alvaro Urbano-Ispizua (Spain)
12:25 - 13:00 Collecting long term follow up data
Amber 6
Marja Pekkanen (Finland)
14:00 - 17:00 Data management training course: Data Retrieval
Suite 5
(Booking required via EBMT website)
14:00 - 14:40 Aplastic Anaemia
Amber 6
14:45 - 15:25 Cell Therapy
Amber 6
Willem Fibbe (Netherlands)
16:00 - 17:00 Common data reporting problems
Amber 6
Shelley HEWERDINE (United Kingdom)
17:00 - 18:15 Data Managers’ Reception
185
Data Management
Data Management Programme – TUE 1 APR 14
09:00 - 17:00 Preview sessions of the new EBMT Registry System
Suite 5
09:00 - 10:25Introduction to HSCT & the Med-A form*
Amber 6
*SESSIONS FOR NEW (OR NEARLY NEW) DATA MANAGERS
Tuula Rintala (United Kingdom)
10:30 - 11:00 The Role of Data Management in EBMT*
Amber 6
Carmen Ruiz de Elvira (United Kingdom)
11:30 - 12:10 Data confidentiality*
Amber 6
Henk Jan van der Wijk (Netherlands)
12:15 - 12:55 Graft loss and immune reconstitution
Amber 6
Attilio Bondanza (Italy)
13:10 - 15:30 Statistical Symposium
BROWN 2
Gloria Tridello (Italy)
Grazia Valsecchi (Italy)
Laura Antolini (Italy)
Liesbeth de Wreede (Netherlands)
Lucie Biard (France)
Ronald Brand (Netherlands)
13:10 - 15:30 DM-O001 - ESTIMATING THE SURVIVAL PROBABILITY WITH
INTERVAL-CENSORED DATA
Bogaerts J., Tridello G.* (Verona, Italy)
13:10 - 15:30 DM-O002 - CENTRE EFFECT IN CLINICAL EPIDEMIOLOGY
ILLUSTRATED IN A MULTICENTRE HSCT STUDY.
Resche-Rigon M., Labopin M., Biard L.* (Paris, France)
13:10 - 15:30
DM-O003 - A MULTI-STATE MODEL FOR TREATMENT SUCCESS AFTER SCT
Schetelig J., Putter H., De Wreede L.* (Leiden, Netherlands)
14:00 - 14:40 Haplo transplants (Nurses presentation)
Amber 6
Daphna Hutt (Israel)
14:45 - 15:25 Cytogenetics & markers
Amber 6
186
Richard Schlenk (Germany)
Data Management
Data Management POSTERS – TUE 1 APR 14
DM-P001
ACCURATE DATA ENTERING A DIFFICULT TASK
DM-P002
GVHD - FROM A DATA MANAGER’S PERSPECTIVE
DM-P003
COMPARING OUTCOME RESULTS BETWEEN HSCT CENTERS:
TOWARDS A NEXT LEVEL OF QUALITY DATA MANAGEMENT
Petersen H., Larsen H., Roepstorff C.* (Copenhagen, Denmark)
Greinix H., Lindner B.* and on behalf of the Austrian Stem Cell
Transplantation Registry (ASCTR) (Innsbruck, Austria)
Bierings M., Versluys B., van Valkenburg M., De Wildt A.*, Boelens J. J.,
Gerhardt C. (Utrecht, Netherlands)
DM-P004
RISING RATES OF TRANSPLANT ACTIVITY IN EASTERN
MEDITERRANEAN REGION 2000-2010- REPORT OF THE EMBMT
Aljurf M., Hamidieh A. A., ElHaddad A., Ben Othman T., Abdel-Rahman F.,
Mahmoud H. K., Bazarbachi A., Torjemane L., Kelta M., Adil S., Alkindi S.,
Hussain F., Al-Seraihy A., Ghavamzadeh A., Hamladji R.-M., Hussein A.,
Ibrahim A., Alabdulaaly A., Jarrar M., Ahmed P., Ramzi M., Bekadja M.-A.,
Benchekroun S., Ahmed S. O.* and on behalf of the EMBMT (Riyadh , Saudi
Arabia)
MODEL COMPARISONS OF COMPETING RISKS IN
AUTOLOGOUS AND ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION: 364 LYMPHOMA AND LEUKEMIA PATIENTS
Akhtar S., Mohamed S. Y., Chaudhri N., Hussain F., Aljurf M., Shoukri M.,
Elhassan T. A.* (Riyadh, Saudi Arabia)
Data/Quality
Management
DM-P005
187
GENERAL INFORMATION
General information IN ALPHABETICAL ORDER
ABSTRACTS
All accepted abstracts are published in a Supplement of the Bone Marrow Transplantation
Journal available during the congress. This supplement will be available online only.
BADGES
Access to all scientific events will only be possible with your personal badge which you
will receive at the registration desk. All participants are requested to wear their name badge
throughout the congress. For replacement of a lost badge EUR 70.- will be charged.
CURRENCY
All official congress prices are indicated in Euro (€). The official currency in the Italy is the Euro
(€). All major credit cards are accepted in most hotels, restaurants and shops.
CLOAKROOM
A cloakroom is available in the registration area.
EBMT BOOTH
Throughout the meeting EBMT staff will be available at the EBMT stand (No. 309) to answer
any questions you may have or to deal with any matters concerning the EBMT.
EXHIBITION
The EBMT 2014 exhibition presenting the latest technical equipment and pharmaceutical
products will take place in the MiCo South Wing, Level 0.
Sunday 30 March 2014............. 10:00 - 18:30
Tuesday 1 April 2014................. 09:00 - 19:30
Monday 31 March 2014............ 09:00 - 19:30
Wednesday 2 April 2014.......... 08:30 - 13:00
HOTEL ACCOMMODATION
MCI Suisse SA, the EBMT Congress Organiser is present with a desk in the registration area
during the meeting. For assistance on-site, please go to the hotel desk in the main registration area.
INSTRUCTIONS FOR SPEAKERS & AUTHORS
Please locate your session room in due time and be there at least 15 minutes prior to the
start of the session. Lecturers should deliver and view / check the presentation at the Preview
Room at least 2 hours prior to the start of the respective Session. For Sessions starting at
08:00, the PowerPoint presentation should be delivered on the previous day, before 17:00 in
order to avoid any delay.
Please make sure you copy your presentation to the proper place. If you have a movie in the
presentation or have difficulties with uploading, please ask help from the onsite technicians.
Exceptions: Please note that the main session rooms are connected to the Presentation
Management System however, the following rooms are not connected. If you have
an oral presentation scheduled in one of the following rooms, you must take your
presentation on a USB key directly to the room:
Suite 1 - Suite 2 - Suite 3 - Suite 4 - Suite 5 - Suite 6 - Suite 7 - Suite 8 - Suite 9 - Office 19
SPEAKER PREVIEW OPENING HOURS:
Saturday 29 March.............. 15:00 - 19:00
Sunday 30 March................. 08:00 - 20:00
Monday 31 March................ 07:30 - 18:30
INSURANCE
Tuesday 1 April..................... 07:30 - 18:30
Wednesday 2 April............... 07:30 - 13:15
It is recommended that participants obtain adequate cover for travel, health and accident
insurance before they depart from their countries. EBMT and MCI as organisers cannot accept
responsibility for personal injuries, or loss of, or damage to, private property belonging to the
congress articipants and accompanying persons.
188
GENERAL INFORMATION
General information IN ALPHABETICAL ORDER
INTERNET CORNER
An internet corner is located in the exhibition area and is available to all congress participants
during the opening hours of the exhibition. In this area WiFi is also available.
LANGUAGE
The official language of the congress is English. No simultaneous translation will be provided.
LUNCHES
Delegates lunches will be served from Monday to Wednesday:
Monday (exhibition area).....................................................................................................13:00 - 14:00
Tuesday (exhibition area).....................................................................................................13:00 - 14:00
Wednesday (Gold Plenary Foyer)......................................................................................13:15 - 14:15
MILAN
Home to Leonardo da Vinci’s “The Last Supper,” Milan is the largest city in northern Italy and
the second largest city in the country. Strategically placed at the gateway to the Italian peninsula, Milan and the surrounding region of Lombardy have been ruled by the Celts, Romans,
Goths, Lombards, Spaniards, and Austrians at some stage of its history. Today, Milan is the
cosmopolitan capital of the region of Lombardy and of the province of Milan. It is the engine
room of the Italy’s economy and home of its stock exchange, yet what really sets Milan apart,
is its thoroughly modern creative streak
Networking Events
OPENING SESSION & RECEPTION: SUNDAY 30TH MARCH
The Opening Session will be held in MiCo from 18.30-20:00 with a Reception immediately
following outside the session room. Open to all registered attendees.
NETWORKING EVENING: TUESDAY 1ST APRIL
To be held in the beautiful city of Milan from 19.30 onwards, dinner and entertainment included. Ticket required to attend, can be purchased via the congress registration system.
Physician Rate: 90 EUR per ticket (inc vat)
All other categories: 65 EUR per ticket (inc vat)
Please note, no bus transfer is provided by the congress. Please use public transportation.
More Information available at registration area
SPEAKER PREVIEW ROOM
VENUE
The EBMT 2014 will take place at the Fiera Milano Congressi (MiCo). Designed in 2002 and
enlarged in 2005 and 2011, MiCo is the newest, largest and most flexible conference centre in
Italy. MiCo is conveniently located right in the heart of the city, surrounded by several nearby
hotels and efficiently served by Milan’s public transportation.
MiCo Piazzale Carlo Magno, 1 20149 Milano - ITALY www.micmilano.it
Wifi
Congress participants can access the complimentary Wifi service
Network: ebmt2014
Password: TAKEDA
189
General
Information
There will be a centrally located Speakers’ Service Centre connected to all lecture rooms. All
speakers are kindly asked to hand in their PowerPoint presentations at least one two hours
prior to their lecture. The Seaker Preview Room is located in the Tower Lounge on level 2 of the
congress centre.
GENERAL INFORMATION
REGISTRATION INFORMATION
REGISTRATION AREA OPENING HOURS
The registration area will be open at the following times:
Saturday 29 March 2014................................................................................................................. 17:00 - 19:00
Sunday 30 March 2014.................................................................................................................... 08:00 - 20:00
Monday 31 March 2014................................................................................................................... 07:30 - 18:00
Tuesday 1 April 2014........................................................................................................................ 07:30 - 18:30
Wednesday 2 April 2014................................................................................................................. 07:30 - 13:30
REGISTRATION FEES
Physicians
Nurses Group
Data Mgmt Group
Quality Mgmt Group
Cell Processing
Technician
Doctors in training
Postgraduate
students*
Until
15 Jan 2014
As from
16 Jan - 26 Feb14
As from
27 Feb 2014
Member
€ 300.-
€ 300.-
€ 480.-
Non-Member
€ 450.-
€ 560.-
€ 650.-
Member
€ 200.-
€ 320.-
€ 380.-
Non-Member
€ 300.-
€ 420.-
€ 480.-
Cell Processing
Day Card
€ 250.-
Quality Management
Day Card
€ 250.-
Nurses & AHP
Education Day
€ 75.-
*proof of your status as a Doctor in Training or Postgraduate student will be requested and is required during the registration process
**due to recent changes in EU VAT regulations, registration fees are subject to Italian VAT, currently at a level of 22%.
CANCELLATION / REFUND POLICY
All cancellations are to be sent to MCI Suisse SA in writing (fax, letter, or email). For cancellations received before Wednesday 12 February 2014 deposits will be refunded less EUR
50.00 for administrative costs. After this date, no refunds will be possible. A handling fee of
EUR 25.00 per registration will be charged for every registration modification received after
Wednesday 12 February 2014. For a badge name change, written permission from the original
participant will be required, along with full contact details of the substitution.
190
GENERAL INFORMATION
General
Information
CONGRESS CENTRE PLANS – LEVEL 0
191
GENERAL INFORMATION
192
GENERAL INFORMATION
General
Information
193
GENERAL INFORMATION
CONGRESS CENTRE PLANS – LEVEL m
194
GENERAL INFORMATION
REGISTRATION INFORMATION
Multi-platform technologies
Sepax 2 cell processing
and Smart-Max cell
preparation systems
•
Automated & safe solutions for cell processing
•
Closed and mobile system with full traceability
•
Highly efficient and consistent cell recoveries
•
Custom-made applications and process control
cell preparation
General
Information
cell expansion
cryo-preservation
adipose
cultured
cells
whole
blood
cell thawing
dilution
Smart-Max
Sepax®2
Discover our multifunctional technologies at booth n°215
www.biosafe.ch
195
EXHIBITORS & SPONSORS
Exhibition Floor Plan
AABB Center for Cellular Therapies............ 213
Abbott Molecular.......................................... 008
Adienne Pharma & Biotech......................... 306
AIRINSPACE.................................................. 218
American Society for Blood and Marrow
Transplantation (ASBMT)............................ 106
Best Theratronics......................................... 001
Bioquell.......................................................... 320
BioRep Srl...................................................... 110
Biosafe SA..................................................... 215
Biotype Diagnostic GmbH........................... 006
Celgene International.................................. 312
CellGenix GmbH............................................ 004
EUROCET128................................................. 105
Cesca Therapeutics, Inc............................... 313
Consarctic® GmbH........................................ 321
CTI Life Sciences........................................... 305
EBMT............................................................. 309
European School of Haematology.............. 103
EXEM CONSULTING SA................................ 307
Exprit srl........................................................ 107
Fresenius Kabi Deutschland GmbH........... 318
GE Healthcare............................................... 102
Gentium......................................................... 205
Gilead Sciences............................................. 204
HEMASOFT.................................................... 217
Histogenics................................................... 216
ICCBBA........................................................... 212
Immudex....................................................... 003
International Myeloma Workshop............. 101
Kaneka Corporation..................................... 223
Lophius Biosciences GmbH......................... 002
MACOPHARMA............................................. 210
MAK-SYSTEM............................................... 007
MARCELL....................................................... 221
Medac GmbH................................................ 314
Miltenyi Biotec GmbH.................................. 308
MSD............................................................... 113
MVE Chart..................................................... 108
Neovii-Biotech GmbH ................................. 209
Ontime Onboard Courier............................. 214
OriGen Biomedical........................................ 005
PIERRE FABRE MÉDICAMENT.................... 211
Remedy Informatics.................................... 203
SIAD Healthcare Spa.................................... 104
Takeda Pharmaceutical Intern. GmbH....... 315
Terumo BCT................................................... 208
Therakos........................................................ 317
Wisepress Medical Bookshop..................... 322
196
PROFILES
AABB Center for Cellular Therapies
BOOTH N°213
Email: mregis@aabb.com
Phone: +1 301-215-6513
Website: www.aabbcct.org
As the field of HSCT and cellular therapies expands, so does AABB’s commitment to supporting
the community of professionals. The AABB Center for Cellular Therapies (AABB CCT) is devoted to
developing programs, services and resources critical to donor and patient care, product safety
and successful outcomes. Visit the AABB CCT booth and learn more about AABB’s international
accreditation.
Abbott Molecular
BOOTH N°008
Email: John.Norton@abbott.com
Phone: +49 6122 58 0
Website: www.abbottmolecular.com
In the complex and diverse HLA environment, high resolution is increasingly essential. Sequencebased typing is the gold standard high resolution technique. With AlleleSEQR reagents, achieving high
resolution has never been clearer. Abbott Molecular offers your laboratory the most advanced options
to meet the diverse challenges of your HLA typing needs.
ADIENNE Pharma & Biotech
BOOTH N°306
Email: emanuele.vitari@adienne.com
adienne@adienne.co
Phone: +39.335.8738731
+39.02.40700445
Website: www.adienne.com
ADIENNE is a biotech company dedicated to the treatment of rare and severe diseases. Founded in
October 2004, it is located in Caponago (Italy) and is active at world-wide level.
ADIENNE is involved in biotechnology research and production, holding its laboratories and
manufacturing site, with fully integrated research & development, regulatory and medical structures.
AIRINSPACE
BOOTH N°218
Airinspace SE is a French high technology manufacturing company specializing in the
decontamination of air in critical care applications. The unique combination of modules which ‘trap
and burn’ biological and particulate material were originally developed for the MIR space station and
now in the Plasmair range, play a leading role improving air quality in critical care environments.
197
Sponsors &
Exhibitors
Email: contact@airinspace.com
Phone: +33 1 30 07 01 01
Website: www.airinspace.com
PROFILES
Alexion Pharma InternationalSPONSOR
Email: banderete@alxn.com
Phone: +41 21 318 40 00
Website: www.alexionpharma.com
Alexion is a biopharmaceutical company focused on serving patients with severe and rare disorders
through the innovation, development and commercialisation of life-transforming therapies. Alexion
has developed a treatment for paroxysmal nocturnal hemoglobinuria (PNH) and atypical heamolytic
uremic syndrome (aHUS), two severe and life-threatening ultra-rare diseases. Alexion is developing
other highly innovative product candidates which are being investigated across multiple severe and
ultra-rare disorders.
AMGEN (EUROPE) GmbHSPONSOR
Email: jhippenm@amgen.com
Phone: + 41 41 3690 300
Website:
www.amgenoncology-international.com
Amgen, a biotechnology pioneer, discovers, develops, and delivers innovative human therapeutics.
Our therapeutics have changed the practice of medicine, helping people around the world in the fight
against serious illnesses. With a deep and broad pipeline of potential new medicines, we continue to
advance science to serve patients.
American Society for Blood & Marrow
Transplantation(ASBMT)
BOOTH N°106
Email: mail@asbmt.org
Phone: +1 (847) 427-0224
Website: www.asbmt.org
The American Society for Blood and Marrow Transplantation is an international professional
membership association of more than 2,000 physicians, investigators and other healthcare
professionals promoting blood and marrow transplantation and cellular therapy research, education,
scholarly publication and clinical standards.
ASTELLAS PHARMA EUROPE LTDSPONSOR
Email:
Astellas.European.Comms@astellas.com
Phone: +44 (0) 203 379 8000
Website: www.astellas.eu
As a young and forward thinking company with a rich heritage, Astellas is dedicated to improving
people’s lives through the introduction of innovative and reliable pharmaceutical products. In Europe,
Astellas’ strategic focus and core expertise lie in Transplantation, Urology, Dermatology, AntiInfectives and Pain Management and it is committed to developing a strong presence in Oncology.
198
PROFILES
Best Theratronics
BOOTH N°001
Email: info@theratronics.ca
Phone: +1-613-591-2100
Website: www.theratronics.ca
Best Theratronics Ltd. is a Canadian component of TeamBest™. We manufacture blood and
research irradiators (Gammacell® 1000 & 3000, Raycell® Mk2, Gammacell® 40E and GammaBeam®
X200), external beam therapy units (Equinox® and GammaBeam® 100-80), and are developing the
GammaBeam® 500 for Total Body Irradiation which is performed in preparation for bone marrow
transplantation.
Bioquell
BOOTH N°320
Email: info@bioquell.com
Phone: +441264835835
Website: www.bioquell.com
Bioquell are the world leaders in the use of hydrogen peroxide vapour (HPV) technology for the
decontamination of rooms, laboratory cabinets, isolators and equipment. With a comprehensive
range of instruments, consumables, services and validation, Bioquell can assure the highest levels of
performance whilst maximising uptime for all facilities.
BioRep Srl
BOOTH N°110
Email: customerservice@biorep.it
Phone: +39 02 58014369
Website: www.biorep.it
BioRep, founded in Milan in 2003, belongs to Sapio Group and is a leading
Biological Resource Centre specialized in laboratory and biorepository
services. Thanks to an exclusive agreement with Coriell Institute, BioRep has become a cutting edge
company specialized in collection, transportation, processing, cryopreservation, distribution of high
quality biological material.
Biosafe SA
BOOTH N° 215
Biosafe develops and manufactures solutions for cell processing in both adult stem cell banking
and regenerative medicine. The Sepax cell processing technology has been adopted for leading
clinical research studies in cellular therapy, transplantation and bedside applications. The system of
devices and accessories provides the user with flexibility and customization through a combination of
application-specific software protocols and single-use kits.
199
Sponsors &
Exhibitors
Email: helene.hausmann@biosafe.ch
Phone: +4122 365 27 27
Website: www.biosafe.ch
PROFILES
Biotype Diagnostic GmbH
BOOTH N°006
Email: info@biotype.de
Phone: +49(0)351/8838-400
Website: www.biotype.de
Biotype designs molecular CE/IVDs products reliably supporting healthcare professionals
elucidating complex medical questions. For leukemia and chimerism analysis after allo-transplant
routine-fit multiplex assays are provided mediating highest sensitivity and accuracy. Expert support
to our products is mandatory and sustains our excellent client relationships.
Celgene International
BOOTH N°312
Phone: +41 32 729 8500
Website: www.celgene.com
Celgene is a global biopharmaceutical company committed to improving
the lives of patients worldwide. We seek to deliver truly innovative and lifechanging drugs for our patients through the discovery, development, and commercialization of products for cancer and other severe, immune, inflammatory conditions. Celgene employs more than 4,500 employees worldwide.
Cell MedicaSPONSOR
Email: info@cellmedica.co.uk
Phone: +44 (0)20 7554 4070
Website: www.cellmedica.co.uk
Cell Medica, London, is a leading cellular therapeutics company in the field of personalized T-cell
immunotherapies for the treatment of cancer and infections post allogeneic hematopoietic stem cell
transplantation.
The company recently expanded its European operations with a commercial manufacturing facility
in Berlin, Germany and has initiated US operations in Houston, Texas.
CellGenix GmbH
BOOTH N°004
Email: info@cellgenix.com
Phone: +49 761 888890
Website: www.cellgenix.com
CellGenix is an international leading manufacturer and supplier of GMP cytokines and serum-free
media for the ex vivo cell culture of DC, T-Cells, NK-Cells, Hematopoietic Stem Cells, MSCs, Chondrocytes,
ESCs and iPSCs in pre-clinical and clinical settings. CellGenix products are manufactured in accordance
with GMP guidelines and USP <1043> & <92>.
200
PROFILES
Cesca Therapeutics, Inc.
BOOTH N°313
Email: Marketing@cescatherapeutics.com
Phone: +1.916.858.5100
Website: www.cescatherapeutics.com
Cesca Therapeutics Inc. is engaged in research, development, and commercialization of autologous
cell-based therapeutics for use in regenerative medicine. We are also a leader in developing and
manufacturing automated blood, cord blood and bone marrow processing systems and companion
disposable products that enable separation, processing and cryopreservation of cell and tissue
therapy products.
CONSARCTIC® GmbH
BOOTH N°321
Email: info@consarctic.de
Phone: +49 (6024) 80274
Website: www.consarctic.de
CONSARCTIC® GmbH is a specialist in designing of biobanks for cryopreservation/-conservation
of blood cells, tissues, transplants etc. Our products are known e.g. under BIOFREEZE®, BIOTRACE®,
BIOLOG®, BioCryoCon®, CryoBioSparce® and receive certification (DIN-EN ISO9001, DIN-EN ISO13485,
MDD 93/42/EEC).
Standing for high quality medical equipment, consulting, planning, design, installation, IQ/OQ,
delivery, service (24 hours) and maintenance.
CTI Life Sciences
Booth N°305
Email: ContactUs@CTI-LifeSciences.com
Phone: + 0800 088 5356
+1 206-282-7100
Website: www.CellTherapeutics.com
Cell Therapeutics, Inc. (CTI) is a public biopharmaceutical company focused on the acquisition,
development and commercialization of less toxic and more effective ways to treat cancer. CTI is
focused on treatments that target blood-related cancers. Headquartered in Seattle; its wholly-owned
subsidiary, CTI Life Sciences Limited (CTILS), is based in London.
Email: nicolas.jaillard@univ-paris-diderot.fr
Phone: +33 1 57 27 68 33
Website: www.esh.org
BOOTH N°103
ESH
EUROPEAN
SCHOOL OF
HAEMATOLOGY
The European School of Haematology (ESH) is a non-profit institution for continuing education
founded in 1986, to promote and facilitate access to state of the art and cutting-edge knowledge in
haematology and related disciplines, at the European level.
ESH also develops tools for continuing education produced in collaboration with international
experts in the field.
201
Sponsors &
Exhibitors
European School of Haematology
PROFILES
EUROCET128
BOOTH N°105
Email: cnt@iss.it
Phone: 0039.064990.4040
Website: www.eurocet128.eu
Eurocet 128 is a Service Contract that has been awarded by EC to a consortium of 3 organisations.
The consortium includes:
• The Italian National Transplant Centre (CNT), which maintains the Eurocet Registry;
• ICCBBA, which maintains the ISBT 128 coding standard for human substances, and
• Artman Technologies, a software company.
Exem Consulting
BOOTH N°307
Email: iaconianni@exemconsulting.ch
Phone: +41797788746
Website: WWW.EXEMCONSULTING.COM
Exem Consulting is a Swiss company specialized in
Healthcare consulting activities: we have a huge experience in the JACIE/FACT/NETCORD/EFI
consulting.
Education and training addressed to physicians, burses and hospital staff.
Clinical trials and observational studies management: we have developed an informatic platform,
called BREIN (Biomedical Research Environment) finalized to assist physicians in the management of
scientific studies (www.exembr.org)
Exprit Srl
BOOTH N°107
Email: info@expr.it
Phone: +39 055600157
Website: www.exprit.eu
Exprit in business since 1994 with public and private hospitals is a firm specializing in management
consulting and professional formation. EDP Progetti is a company leader in the design and
implementation of software solutions for enterprises and public administration. Medical Ware focuses
its action in healthcare software development by mixing the multi-faceted skills of its founders.
French Society of Bone MarrowSPONSOR
Transplantation & Cell Therapies(SFGM-TC)
Email: sfgm-tc@orange.fr
Phone: +33 (0)3 28 55 40 18
Website: www.sfgm-tc.com
The SFGM-TC is a France based association that seeks to improve the results of hematopoietic
stem cell transplantation (HSCT) through clinical research that aids the development of scientific
knowledge regarding this type of transplantation and new approaches in cell therapies that use HSC’s
and their derivatives.
202
PROFILES
Frenesius Kabi Deutschland GmbH
BOOTH N°318
Email: communication@frenesius-kabi.com
Phone: +49 6172 6860
Website: www.frenesius-kabi.com
Fresenius Kabi is a global health care company specializing in lifesaving medicines and technologies
for infusion, transfusion and clinical nutrition. The products and services help to care for critically and
chronically ill.
Product portfolio: I.V. generic drugs, infusion therapies, clinical nutrition and related medical devices,
products for whole blood and blood components collection and processing, transfusion medicine and
cell therapies
GAM FarmaSPONSOR
Email: amministrazione@gamfarma.it
Phone: +39 328 2134673
Website: www.gamfarma.it
GamFarma is an Italian company founded in 2011, that develops and markets nutritional
supplements, using natural products, dedicated to the management of side effects from cancer
treatments (e.g. diarrhea, oral mucositis , asthenia and nausea).
All products are registered and notified to the Ministry of Health in Italy and manufactured according
to G.M.P. EU.
GE Healthcare
BOOTH N°102
Email: isabela.cesa@ge.com
Phone: +44 1494542052
Website: www.ge.com
GE Healthcare Life Sciences delivers breakthroughs in drug discovery, biopharmaceutical
manufacturing and the latest in cellular technologies, so scientists and specialists around the world
discover new ways to predict, diagnose and treat disease. For more information about GE Healthcare
Life Sciences, visit our Website at www.gelifesciences.com.
Gentium
BOOTH N°205
Gentium (www.gentium.com), a Jazz Pharmaceuticals company (Nasdaq: JAZZ), is a
biopharmaceutical company that develops and manufactures treatments for conditions including
vascular diseases related to cancer and cancer treatments. Defitelio® (defibrotide) is approved in the
European Union (EU) for treatment of severe VOD in adults and children undergoing hematopoietic
stem cell transplantation.
203
Sponsors &
Exhibitors
Email: gentium@gentium.it
Phone: +39 031 5373 200
Website: www.gentium.com
PROFILES
Gilead Sciences
BOOTH N°204
Email: infocenter@gilead.com
Phone: + 44 208 587 2200
Website: www.gilead.com
Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and
commercializes innovative medicines in areas of unmet need. Gilead’s areas of focus include
infectious diseases (fungal infections, HIV/AIDS/hepatitis) and serious cardiovascular and respiratory
conditions. With each new discovery and experimental drug candidate, we seek to improve the care of
patients suffering from life-threatening diseases.
HEMASOFT
BOOTH N°217
Email: bruno.rousselin@hemasoft.com
Phone : +41 (0) 22 595 1268
Address : Route de Crassier 7. CH-1262,
Eysins, Switzerland
Website: www.hemasoft.com
Hemasoft is an International IT Company specialized in a Web-enabled software application
(e-Delphyn©) able to provide Cell Therapy Departments with the process automation, tracking and
audit features required and expected by regulatory bodies and accreditation institutions. E-Delphyn©
helps organizations streamlining their processes and tracking all steps from phlebotomy to
manufacturing, testing, storing and infusion.
Histogenics
BOOTH N°216
Email: nezih@histogenetics.com
Phone: +19147620300
Website: www.histogenetics.com
Histogenetics specializes in HLA Sequence based Typing services using NGS for blood stem cell
transplants. With proprietary state-of-the-art facilities Histogenetics serves clients globally.
Histogenetics provides fast high throughput high resolution molecular tissue typing services for
registries, donor centers, cord blood banks, transplant centers and HLA laboratories at a very
competitive price.
ICCBBA
BOOTH N°212
Email: iccbba@iccbba.org
Phone: +1-909-793-6516
Website: www.iccbba.org
ISBT 128 is the international information standard for blood and
transplant. It provides standard terminology, identification, labeling,
and information transfer of cellular therapy, blood, tissue and organ
products across international borders and disparate health care systems. The standard has been
designed to ensure the highest levels of accuracy, safety, and efficiency for the benefit of donors,
patients, and ISBT 128 licensed facilities worldwide.
204
PROFILES
Immudex
BOOTH N°003
Email: lb@immudex.com
Phone: +45 39179772
Website: www.immudex.com
Immudex develops and commercializes products for the quantitation, characterization, and
generation of antigen-specific T-cell responses for life science research, in vitro diagnostics and
vaccine development. All products are based on the proprietary and unique MHC Dextramer®
technology. Immudex also provides MHC Multimer and Elispot proficiency panel services worldwide.
Intergroupe Francophone du Myelome(IFM)SPONSOR
Email: adelineveau.ifm@gmail.com
Website: www.myelome.fr
The IFM (“Intergroupe Francophone du Myélome”) is a non-profit organization created in 1994.
It brings together clinicians and biologists from France, Belgium and Switzerland , with the aim to
improve the outcome of myeloma patients through basic, translational and clinical research. The main
goals of IFM are :
- The development of clinical trials to improve the treatment of patients with myeloma
- Evaluation of new active drugs in myeloma
- Support for researchers working in this field
- Informing patients and families about myeloma and treatment.
International Myeloma Workshop
BOOTH N°101
Email: imw2015@thetriumph.com
Phone: +39 051 4210559
Website: www.imw2015.it
The “15th International Myeloma Workshop” will be held in Rome at Auditorium Parco della Musica
on September 23-26, 2015. This meeting takes place every 2 years in different cities of the world and
counts about 3.000 people. The emerging advances in the biology and treatment of multiple myeloma
will be presented.
ITALFARMACO SpA.SPONSOR
Italfarmaco is an international pharmaceutical group with headquarters in Milan, focused on R&D,
manufacturing and commercialization of ethical products. In early 90s, the company has started a
process of international expansion. The Group has developed marketing expertise in several areas,
such as cardiovascular, immuno-oncology/supportive care, dermatology, gynaecology, orthopaedics
and CNS. Italfarmaco has many partnerships and agreements in place with primary pharmaceutical
companies.
205
Sponsors &
Exhibitors
Email: info@italfarmaco.com
Phone: +39-2-64431
Website: www.italfarmaco.com
PROFILES
JANSSEN-CILAG SpASPONSOR
Email: comunicazionejanssen@its.jnj.com
Phone: +39 0225101
Website: www.janssen-cilag.it
Janssen, the pharmaceutical company of Johnson & Johnson has a strong commitment on
innovation recognized by the WHO, which has included 4 molecules resulting from Janssen research
in the list of Essential Medicines for Human Kind.
The values of the J&J Credo are leading the company towards a single goal: develop innovative
medicines and integrated solutions for patients.
Kaneka Corporation
BOOTH N°223
Email: cornelia.fricke@kaneka.de
Phone: +4961969679725
Website: www.kaneka.co.jp/kaneka-e/
Kaneka Corporation is a producer of medical devices distributed worldwide. Kaneka Pharma Europe
N.V. is an independent subsidiary active in the European market. Kaneka Corporation has developed
innovative cell processing devices as medical devices for bone marrow, CellEffic BM and cord blood,
CellEffic CB which are efficient, safe and easy to use.
Kiadis PharmaSPONSOR
Email: info@kiadis.com
Phone: +31 20 3140 250
Website: www.kiadis.com
Kiadis Pharma is a biopharmaceutical company focused on the development of innovative and
potentially life-saving therapies for patients with late stage blood cancers and related disorders.
Kiadis Pharma’s lead product is ATIR™, a cell based orphan product enabling stem cell transplantations
from partially mismatched (haploidentical) family donors.
Lophius Biosciences GmbH
BOOTH N°002
Email: info@lophius.com
Phone: +49 941 / 6309 197 - 0
Website: www.lophius.com
With a long-time research experience Lophius Biosciences (Regensburg, Germany) is focusing on
the development and marketing of innovative T cell based research tools and diagnostic systems
for the early diagnosis and immunomonitoring in the fields of transplantation, infectious and
autoimmune diseases.
206
PROFILES
MACOPHARMA
BOOTH N°210
Email: contact@macopharma.com
Phone: +33 3 20 11 84 00
Website: www.macopharma.com
Macopharma is a leading worldwide manufacturer of medical devices for transfusion, infusion and
biotherapy. Investments in research and development as well as partnerships enable Macopharma
Biotherapy to provide in the fields of cell and tissue therapy, regenerative medicine and transplantation
worldwide high quality, GMP, single use, sterile, closed systems to collect, treat, expand and preserve
human regenerative cells, tissues and organs that consistently improve and secure cellular therapy
practices and clinical protocols
MAK-SYSTEM
BOOTH N°0 07
Email: c.glinkowski@mak-system.net
Phone: +33 1 48 63 27 27
Website: www.mak-system.com
MAK-SYSTEM International Group is a prominent medical information technology company,
providing web software solution globally to Cell Therapy Facilities, Cord Blood Banks, Tissue Banks,
Blood Banks and Transfusion Services.
MAK-YSTEM has more than 1,400 installations in over 60 countries uniquely positioned to provide
the most comprehensive combination of software functionality and technology to safeguard your
activities.
MARCELL
BOOTH N°221
Email: info@marcell.ch
Phone: +41 31 330 24 00
Website: www.marcell.ch/en/
Management And Resource System for Stem CELL therapy
The software solution MARCELL covers all phases of stem cell transplantation. MARCELL allows
you to carry out documentation and quality control according to the JACIE standards. Data is held
centrally so you can use it in all phases of stem cell transplantation and the creation of reports. On
top of that, MARCELL guides you through your process.
medac GmbH
BOOTH N°314
medac has specialised in the treatment of malignant diseases since its foundation in 1970. Now,
medac is one of the leading manufacturers of oncology products not only in Germany, but in many
international markets. medac offers both innovative and well proven therapeutic options in the fields
of Oncology, Hematology, Urology, Autoimmune Diseases and Fibrinolysis and is only one of a handful
of companies which also specialises in the field of Diagnostics.
207
Sponsors &
Exhibitors
Email: contact@medac.de
Phone: +49 4103 8006 0
Website: www.medac.de
PROFILES
Miltenyi Biotec GmbH
BOOTH N°308
Email: macsge@miltenyibiotec.de
Phone: +49 2204 83060
Website: www.miltenyibiotec.com
At Miltenyi Biotec, we are committed to advancing biomedical research
and cellular therapy. Our innovative tools support research at every level,
from basic research to clinical application. Our 25 years of expertise
includes immunology, stem cell biology, neuroscience, and cancer. Miltenyi Biotec has more than
1,400 employees in 25 countries.
MSD
BOOTH N°113
Email: nand.kumar@merck.com
Phone: + 39 06 361911
Website: www.MSD.com
Today’s MSD is working to help the world be well. Through our medicines, vaccines, biologic
therapies, and consumer and animal products, we work with customers and operate in more than 140
countries to deliver innovative health solutions. For more information, visit www.msd.com.
MVE Chart
BOOTH N°108
Email: customerservice.europe@chartindustries.com
Phone: +44 (0) 1344 403 100
Website: www.chartbiomed.com
MVE-Chart features a complete line of aluminum vapor shippers and
nitrogen handling equipment. We offer liquid and vapor stainless steel
freezers with 3,200-94,000 vial capacities. Our vapor units maintain -190
C at the top storage box and achieve the longest holding times and lowest
LN2 consumption of any comparable freezer.
Neovii Biotech GmbH
BOOTH N°209
Email: info@neoviibiotech.com
Phone: +49 89 898888-0
Website: www.neoviibiotech.com
Neovii Biotech GmbH is a globally operating company dedicated to delivering targeted
biopharmaceutical treatment options in transplantation medicine. A focal point of activity is the
development and commercialization of immunologically active therapeutics. For 30 years Neovii
Biotech has been manufacturing and commercializing ATG-Fresenius, a medicinal product for the
prevention and treatment of acute organ rejection after solid organ transplantation and for the
prevention of Graft-versus-Host-disease after stem cell transplantation.
208
PROFILES
Ontime Onboard Courier
BOOTH N°214
Email: flugplan@ontimecourier.com
Phone: +49-89-357373-20
Website: www.ontimecourier.com
With more than 13.500 HSC-transports successfully performed worldwide – Ontime Onboard
Courier is the expert for onboard transportation. Our experience on all 6 continents serving more
than 350 transplant centers guarantees the quality you are looking for. 24/7/365 – multi lingual
staff – online tracking – we cover all your needs. Flugplan@ontimecourier.com or +49-89-357373-20
– contact us to find out more!
OriGen Biomedical
BOOTH N°005
Email: b.sansegundo@origen.com
Phone: +1-512-474-7278
Website: www.origen.com
At OriGen Biomedical we manufacture a full range of cryopreservation and cell culture products.
We can create a custom product to meet your specific needs. We have CE-marked, sterile DMSO
solutions available in syringe and vial configurations. OriGen has cryopreservation and cell culture
bags available in a range of sizes.
PIERRE FABRE MÉDICAMENT
BOOTH N°211
Address: 45 Place Abel Gance
92654 Boulogne-Billancourt Cedex –
France
Phone: +33 (0)1 49 10 80 00
Website: www.pierre-fabre.com
Established in over 140 countries, Pierre Fabre Laboratories is a historical partner to healthcare
professionals. Along with Family Healthcare, Dermocosmetics and Neuropsychiatry, we have acquired
a real expertise in Haematology with Busilvex® (IV busulfan), and in Oncology with products such as
Navelbine® (vinorelbine) and Javlor® (vinflunine).
Remedy Informatics
BOOTH N°203
Remedy Informatics produces Comprehensive BMT™, the premier clinical informatics software
for blood and marrow transplantation central to the EBMT’s new registry system. Comprehensive
BMT offers robust tools and capabilities designed to help you identify trends, foster innovation and
collaboration, and streamline data capture and centre reporting.
209
Sponsors &
Exhibitors
Email: insight@remedyinformatics.com
Phone: + 1 855.736.3396, option 3
Website: www.remedyinformatics.com
PROFILES
SanofiSPONSOR
Website: www.sanofi.com
Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic
solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven
growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare,
emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN)
and in New York (NYSE: SNY).
Sanofi OncologySPONSOR
Website: www.sanofi.com
Sanofi Oncology is a global division of Sanofi based in Cambridge, Massachusetts and Vitry, France.
We are dedicated to translating science into effective therapeutics that address unmet medical needs
for cancer and organ transplant patients. We are building a renewed and diversified portfolio, driven
by the principles of innovation, personalization and patient access to medicines.
SIAD Healthcare Spa
BOOTH N°104
Email: liliana_andolfatto@siad.eu
Phone: 0039 02 45792257
Website: www.siadhealthcare.com
Public and private health have always looked for the experience of Siad Healthcare. This name is not
just a simple supplier of technology; in more than half a century, it has gained a unique experience.
Siad Healthcare became a referring partner for all of its customers in neurosurgery, in cardiosurgery,
in mini-invasive, plastic and reconstructive surgery, in haematology and transfusional medicine,
cryobiology, classified laboratories and medical gases distribution systems.
Takeda Pharmaceuticals International GmbH BOOTH N°315
Phone: +41 44 555 1000
Website: www.takeda.com
Takeda is a global company with its main focus on pharmaceuticals. As the largest pharmaceutical
company in Japan and 18th in Europe, Takeda is committed to strive towards better health for people
worldwide through leading innovation in medicine.
210
PROFILES
Terumo BCT
BOOTH N°208
EMAIL: info.emea@terumobct.com
PHONE: +32 2 715 05 90
WEBSITES: www.terumobct.com
www.terumobct.com/SpectraOptia
Terumo BCT is a global leader in blood component, therapeutic apheresis and cellular technologies.
We believe in the potential of blood. This belief inspires our innovation and strengthens our
collaboration with customers.
Teva Pharmaceuticals Europe B.V.
SPONSOR
WEBSITE: www.tevapharm.com
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic drugs
as well as innovative and specialty pharmaceuticals and active pharmaceutical
ingredients. Teva currently employs approximately 46,000 people around the
world and reached $20.3 billion in net revenues in 2012.
Therakos
BOOTH N°317
EMAIL: info@therakos.com
PHONE: +118 315 0810
WEBSITE: www.therakos.co.uk
Therakos is a leader in advancing the science of immune cell therapies. Therakos markets the world’s
only approved integrated systems for extracorporeal photopheresis which have a demonstrated track
record of efficacy and safety and have been used globally for more than 25 years.
Wisepress Medical Bookshop
BOOTH N°322
EMAIL: bookshop@wisepress.com
PHONE: +44 20 8715 1812
WEBSITE: www.wisepress.com
211
Sponsors &
Exhibitors
Wisepress are Europe’s principal conference bookseller. We exhibit the leading books, sample
journals and digital content relevant to this meeting. Books may be purchased at the booth, and we
offer a postal service. Visit our online bookshop for special offers and follow us on Twitter for the
latest news @WisepressBooks.
Prescribing information and licensed indications available at the booth
Submitted to AIFA on 23/01/2014

Annual Meeting

Transcription

Similar documents

Diapositiva 1

1119-21-Social

PERANTI PENCEGAHAN CETAK ROMPAK DI DALAM INDUSTRI

Natural Capital Accounting—List of Supporters

L`approccio neurochirurgico nelle lesioni midollari del

olinmun 2014

Europass Curriculum Vitae - MONALISA

Presentazione di PowerPoint

Biologi kertas 2 Ting 5 TOV Terengganu 2012

Diapositiva 1 - Terapia Intensiva dell`età Pediatrica (0

EDUPHARMA-Komunikasi Efektif Praktik Apoteker